```
=> d his

     (FILE 'HOME' ENTERED AT 11:04:04 ON 28 JUN 2006)

     FILE 'REGISTRY' ENTERED AT 11:04:18 ON 28 JUN 2006
L1             STRUCTURE UPLOADED
L2              50 S L1

     FILE 'HOME' ENTERED AT 11:10:43 ON 28 JUN 2006

     FILE 'REGISTRY' ENTERED AT 11:14:02 ON 28 JUN 2006
L3             STRUCTURE UPLOADED
L4              50 S L3
L5           13057 S L3 FULL
L6             STRUCTURE UPLOADED
L7            2438 SEARCH L6 SSS  SUB=L5 FULL

     FILE 'CAPLUS' ENTERED AT 11:23:11 ON 28 JUN 2006
L8             428 S L7
L9             185 S L8 AND THU/RL

=> d que l9 stat
L3             STR
```




```
G1 C,O,S,N


Structure attributes must be viewed using STN Express query preparation.
L5           13057 SEA FILE=REGISTRY SSS FUL L3
L6             STR
```



Structure attributes must be viewed using STN Express query preparation.
L7 2438 SEA FILE=REGISTRY SUB=L5 SSS FUL L6
L8 428 SEA FILE=CAPLUS ABB=ON PLU=ON L7
L9 185 SEA FILE=CAPLUS ABB=ON PLU=ON L8 AND THU/RL

=> d l9 1-185 bib abs hitstr

L9 ANSWER 1 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:577803 CAPLUS
TI Preparation of N-acylanthranilic acid derivatives or salts thereof as inhibitor for production of matrix metalloproteinase (MMP-13)
IN Yokotani, Junichi; Taniguchi, Yoichi; Hara, Eiji; Akitsu, Hitoshi; Tada, Yukie
PA Toyama Chemical Co., Ltd., Japan
SO PCT Int. Appl., 278 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006062093	A1	20060615	WO 2005-JP22367	20051206

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI JP 2004-353725 A 20041207
AB The title compds. [I; wherein R1 = H, a carboxy-protecting group; R2 = each (un)substituted Ph, cycloalkyl, or heterocyclic group; R3 = each (un)substituted Ph, cycloalkyl, cycloalkenyl, or monocyclic or bicyclic heterocyclic group; X1 = CO or SO2; X2 = a bond, each (un)substituted alkylene, alkenylene, or alkynylene; X3 = O, S, a bond; X4 = -X5-X6- or -X6-X5- (the left side bond is linked to R3) (wherein X5 = O, S, (un)protected NH, SO, SO2, a bond; X6 = each (un)substituted alkylene, alkenylene, or alkynylene)] or salts thereof are prepared These compds. have an MMP-13 production inhibitory activity and are hence useful as therapeutic agents for articular rheumatism, osteoarthritis, cancer, etc. Thus, Me 2-(benzoylamino)-4-bromobenzoate was coupled with benzofuran-2-boronic acid in the presence of polymer-supported Bis(acetato)bis(triphenylphosphine)palladium and Na2CO3 in N,N-dimethylacetamide at 90° for 11 h followed by saponification and acidification with 1.0 M aqueous HCl solution to give 2-(benzoylamino)-4-(3-methoxyphenyl)benzoic acid (II). II and 2-(benzoylamino)-4-((E)-2-(3-chlorophenyl)vinyl)benzoic acid inhibited the IL-1β-stimulated production of MMP-13 in human cartilage-derived SW1353 cells by 95 and 99%, resp., at 30 μM.
IT INDEXING IN PROGRESS
IT **22106-33-8**, 4-(1H-Pyrrol-1-yl)benzoic acid **61471-45-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N-acylanthranilic acid derivs. as inhibitors for production of matrix metalloproteinase (MMP-13))
RN 22106-33-8 CAPLUS

L9 ANSWER 1 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzoic acid, 4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 61471-45-2 CAPLUS
CN Benzoic acid, 3-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:493830 CAPLUS
DN 145:8166
TI Preparation of benzimidazoles as gonadotropin releasing hormone receptor antagonists for treating disorders associated with excessive GnRH receptor activity
IN Garrick, Lloyd Michael; Green, Daniel Michael; Jetter, James Winfield; Kao, Wenling; Kees, Kenneth Lewis; Pelletier, Jeffrey Claude; Rogers, John Francis
PA Wyeth, John, and Brother Ltd., USA
SO U.S. Pat. Appl. Publ., 72 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2006111355	A1	20060525	US 2005-286081	20051123
WO 2006058012	A2	20060601	WO 2005-US42338	20051121

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2004-630282P P 20041123
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to gonadotropin releasing hormone (GnRH) (also known as LH releasing hormone) receptor antagonists, processes for preparing them and to pharmaceutical compns. containing them. The antagonists are of general formula I wherein: A is cycloalkyl, aryl, heteroaryl, or diaryl substituted alkyl, each optionally substituted; B is aryl or heteroaryl, each optionally substituted; R1 is H, the tautomeric form, or optionally substituted alkyl; R2, R3, and R4 are, independently, H, optionally substituted alkyl, halogen, or OR1; and R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, and R16, are, independently, H, alkyl, alkenyl, or alkynyl, each alkyl, alkenyl, or alkynyl being optionally substituted. For example, II was prepared by reacting 4-(Dimethylamino)benzoic acid with the appropriate phenylenediamine (preparation given). All I tested in an in vitro assay involving COS cell membranes containing human GnRH receptors had IC50's between 1 and 10,000 nM.
IT **22106-33-8**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of benzimidazoles as gonadotropin releasing hormone receptor antagonists for treating disorders assocd. with excessive GnRH receptor activity)
RN 22106-33-8 CAPLUS
CN Benzoic acid, 4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



L9 ANSWER 3 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:471734 CAPLUS
DN 144:488692
TI Tricyclic guanidine derivatives as sodium-proton exchange inhibitors and their preparation, pharmaceutical compositions and use for treatment of various diseases
IN Lal, Bansi; Bal-Tembe, Swati; Ghosh, Usha; Jain, Arun Kumar; More, Tulsidas; Ghate, Anil; Trivedi, Jacqueline; Parikh, Sapna
PA Nicholas Piramal India Limited, India
SO PCT Int. Appl., 282 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006051476	A1	20060518	WO 2005-IB53653	20051108
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI IN 2004-MU1225	A	20041110		
US 2004-637208P	P	20041217		

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Guanidine derivs. having a condensed tricyclic ring of formula I, their preparation, pharmaceutical composition and use as sodium-proton exchange inhibitors
are disclosed. These derivs. are sodium-proton exchange inhibitors and are useful as medicaments for the treatment of, for example, organ disorders associated with ischemia and reperfusion, cardiac arrhythmia, cardiac hypertrophy, hypertension, cell proliferative disorders and diabetes. Compds. of formula I where in R1-R8 are independently H, halo, OH, hydroxyalkyl, formyl, alkoxy, cycloalkoxy, aryloxy, alkylthio, alkylcarbonyl, carboxy, alkylcarboxylate, alkyl, alkenyl, cycloalkyl, (un)substituted (hetero)aryl, aryloxycarbonyl, alkylaminoalkyl, aminocarbonyl, CN, No2, amidino, sulfonyl chloride, sulfonyl hydrazide, alkylsulfonyl, heterocyclylsulfonyl, heteroarylsulfonyl, sulfonamide, alkyl-NHSO2, arylalkyl, (un)substituted heterocyclyl, (un)substituted guanidino(carbonyl), NH2 and derivs., or N=R''', etc.; R''' is heterocyclyl, cycloalkyl, or alkyl; U is CO, CRaRb, O, NRa, S, SO, or SO2;
V is CRaRb or NRa; W is S, SO, or SO2; Ra is H, alkyl cycloalkyl, alkenyl,

L9 ANSWER 3 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
or arylalkyl; Rb is H alkyl, OH, ORa, or OCORa; and their stereoisomers, tautomers, mixts. thereof in all ratios, pharmaceutically acceptable salts, solvates, polymorphs, and prodrugs as well as the process for prepg. compds. of formula I are claimed. Example compd. II•MeSO3H were prepd. by nitration of compd. III to give the 4-chloro-6-methyl-2-nitro-10,10-dioxo-10,11-dihydro-5-oxa-10-λ6-thiadibenzo[a,d]cycloheptene-8-carboxylic acid, which was reduced to the corresponding amine, which reacted with guanidine to give example compd. II•MeSO3H. All the invention compds. were evaluated for their sodium-proton exchange inhibitory activity. From the assay it was detd. that compd. II•MeSO3H exhibited a IC50 value of 0.02 μM. Some of the invention compds. also exhibited potent anti-arrhythmic and anti-infarction activity against ischemia and reperfusion induced by cardiac injury in coronary artery ligated (CAL) rats. The compds. also showed significant cardioprotective effects in CAL rabbits.
IT 887508-19-2P 887508-21-6P 887509-87-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of tricyclic guanidine derivs. as sodium-proton
exchange inhibitors and their use for treatment of various diseases)
RN 887508-19-2 CAPLUS
CN 11H-Dibenzo[b,f][1,4]oxathiepin-8-carboxylic acid, 7-(1H-pyrrol-1-yl)-, 10,10-dioxide (9CI) (CA INDEX NAME)



RN 887508-21-6 CAPLUS
CN 11H-Dibenzo[b,f][1,4]oxathiepin-8-carboxylic acid, 4-methyl-7-(1H-pyrrol-1-yl)-, 10,10-dioxide (9CI) (CA INDEX NAME)



RN 887509-87-7 CAPLUS
CN Dibenzo[b,e][1,4]thiazepine-8-carboxylic acid, 5,11-dihydro-7-(1H-pyrrol-1-yl)-, 10,10-dioxide (9CI) (CA INDEX NAME)

L9 ANSWER 4 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:386429 CAPLUS
DN 144:432797
TI Preparation of diaryl substituted pyrazoles and analogs for nonsense suppression
IN Almstead, Neil; Karp, Gary M.; Wilde, Richard; Welch, Ellen; Campbell, Jeffrey A.; Ren, Hongyu; Chen, Guangming
PA PTC Therapeutics, Inc., USA
SO PCT Int. Appl., 286 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006044502	A2	20060427	WO 2005-US36761	20051013
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI US 2004-617633P	P	20041013		
US 2004-617634P	P	20041013		
US 2004-617653P	P	20041013		
US 2004-617655P	P	20041013		
US 2004-617670P	P	20041013		
US 2004-624170P	P	20041103		

GI



I

AB The present invention relates to methods, compds., and compns. for treating or preventing diseases associated with nonsense mutations in an mRNA
by administering the compds. I [A1 = C, CH, or N; V and X = N or C; W = N,
C or CH; wherein at least one of V, W, or X = N, and wherein if W = N, at least one of V or X is also N; Y and Z = N, CRa, CO, CS (Ra = H, Me, NH2);
R1 = carboxy, cyano, or carbonyl which is optionally substituted with alkoxy; R2 = absent or nitro; Ar1 = (un)substituted alkyl, aryl, 5-10 membered heterocyclyl; or Ar1 together with Ar2 form a ring; or Ar1 together with Ar3 form a ring; Ar2 is absent or together with Ar1 form a ring; Ar3 is absent or together with Ar1 form a ring; Ar4 is absent or is alkyl, alkoxy, thioalkyl, any of which together with A1 forms a 4-7

L9 ANSWER 4 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
membered carbocycle or heterocycle] or compns. comprising I. More particularly, the present invention relates to methods, compds., and compns. for suppressing premature translation termination assocd. with a nonsense mutation in an mRNA. Over 470 compds. I were prepd. E.g., a multi-step synthesis of 3-[1-(4-trifluoromethylphenyl)-1H-pyrrol-3-yl]benzoic acid, starting from 1-(triisopropylsilyl)pyrrole-3-boronic acid and Me 4-iodobenzoate, was given. Compds. I were tested for nonsense suppression activity from a cell-based luciferase reporter assay (data given).

IT **885016-17-1P 885016-39-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diaryl pyrazoles and analogs for suppressing premature translation termination associated with nonsense mutation in an mRNA and useful in treating and preventing diseases-associated with nonsense mutations in an mRNA)

RN 885016-17-1 CAPLUS
CN Benzoic acid, 3-[3-[4-(1-methylethyl)phenyl]-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 885016-39-7 CAPLUS
CN Benzoic acid, 4,4'-(1H-pyrrole-1,3-diyl)bis- (9CI) (CA INDEX NAME)



L9 ANSWER 5 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:367034 CAPLUS
DN 144:412543
TI Preparation of quinoxalines as B Raf inhibitors
IN Aquila, Brian; Dakin, Les; Deegan, Tracey; Ioannidis, Stephanos; Lee, Stephen; Lyne, Paul; Pontz, Timothy; Su, Mei
PA Astrazeneca AB, Swed.; Astrazeneca UK Ltd.
SO PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006040568	A1	20060420	WO 2005-GB3953	20051013

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2004-619373P P 20041015
GI



I

AB The title compds. I [A = carbocyclyl or heterocyclyl; R1 is a substituent on carbon and is selected from halo, nitro, cyano, etc.; n = 0-4; Z = CONH, NHCO, CH2NH; R2 = H, halo, nitro, etc.; R3 = halo, hydroxy, Me, methoxy or hydroxymethyl; X = NR18CO, NR19, NR20CH2; R4-R8 = H, halo, nitro, etc.; R18-R20 = H, alkyl, alkanoyl, etc.] which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity, were prepared Thus, amidation of N-(5-amino-2-methylphenyl)quinoxaline-6-carboxamide (preparation given) with 3-(methyllthio)benzoic acid afforded 73% N-(2-methyl-5-{[3-(methylthio)benzoyl]amino}phenyl)quinoxaline-6-carboxamide. The compds. I exhibited activity less than 30 μM when tested in B-Raf in vitro ELISA assay. The invention also relates to processes for the manufacture of compds.
I, to pharmaceutical compns. containing them and to their use in the manufacture of

L9 ANSWER 5 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
medicaments of use in the prodn. of an anti-cancer effect in a warm blooded animal such as man.

IT **26180-28-9**, 3-(2,5-Dimethyl-1H-pyrrol-1-yl)benzoic acid
61471-45-2, 3-(1H-Pyrrol-1-yl)benzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of quinoxalines as B Raf inhibitors for treating cancer)

RN 26180-28-9 CAPLUS
CN Benzoic acid, 3-(2,5-dimethyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 61471-45-2 CAPLUS
CN Benzoic acid, 3-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:361235 CAPLUS
DN 144:412361
TI Preparation of indole derivatives for treatment of Alzheimer's disease
IN Slade, Rachel; Klimova, Yevgeniya; Halter, Robert J.; Yungai, Ashantai J.;
Weiner, Warren S.; Walton, Ruth J.; Willardsen, Jon Adam; Anderson, Mark B.; Zavitz, Kenton
PA Myriad Genetics, Inc., USA
SO PCT Int. Appl., 300 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006041874	A2	20060420	WO 2005-US35747	20051004

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2004-615914P P 20041004
US 2004-616162P P 20041004
US 2005-660479P P 20050309
US 2005-660278P P 20050310
GI

L9 ANSWER 6 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


I


II


III

AB The invention provides novel indoles I and II [R1-R5 = independently H, OH, halo, CN, NO2, L-CO2H, L-CH:CHCO2H, optionally substituted alkyl, alkoxy, amino, L-CONH2, L-SO2(C1-3alkyl), L-SO2NH2, L-phosphono, L-tetrazolyl, etc.; R6-R10 = independently H, OH, halo, CN, NO2, optionally substituted alkyl, alkoxy, amino, CONH2, SO2-alkyl, SO2NH2, etc.; adjacent R6-R9 may form 4-7 membered, optionally substituted ring; R11 = optionally substituted Ph; L = optionally substituted (CH2)n-(CH2)n, (CH2)nCO(CH2)n, (CH2)nNH(CH2)n, (CH2)nO(CH2)n, (CH2)nS(CH2)n; each n = independently 0-8;] useful for the treatment of neurodegenerative disorders including Alzheimer's disease and dementia. Thus, condensation of phenacyl bromide with 1-(3,4-dihydro-2-naphthyl)pyrrolidine gave the expected 1-(2-oxo-2-phenylethyl)-3,4-dihydro-1H-naphthalen-2-one, which was condensed with substituted anilines RC6H4NH2 (R = 3-CO2H, 4-OH; 4-CH2CH2CO2H; 4-CH2CO2H; 3-OH; 4-OH; 3-CO2H; 3-CH2CO2H; 3-CH2CH2CO2H; 4-CH2CH2CH2CO2H) to give dihydrobenzindoles III.

IT **53597-27-6P 363607-41-4P 883895-48-5P**
883895-49-6P 883895-55-4P 883895-58-7P
883895-62-3P 883895-66-7P 883895-71-4P
883895-72-5P 883895-73-6P 883895-74-7P
883895-75-8P 883895-76-9P 883895-77-0P
883895-82-7P 883895-84-9P 883895-85-0P
883895-96-3P 883895-97-4P 883895-99-6P
883896-02-4P 883896-03-5P 883896-04-6P
883896-05-7P 883896-06-8P 883896-07-9P
883896-08-0P 883896-09-1P 883896-14-8P
883896-16-0P 883896-25-1P 883896-28-4P

L9 ANSWER 6 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
883896-29-5P 883896-30-8P 883896-32-0P
883896-36-4P 883896-37-5P 883896-38-6P
883896-39-7P 883896-40-0P 883896-41-1P
883896-42-2P 883896-43-3P 883896-44-4P
883896-45-5P 883896-47-7P 883896-49-9P
883896-50-2P 883896-52-4P 883896-54-6P
883896-55-7P 883896-57-9P 883896-59-1P
883896-60-4P 883896-61-5P 883896-62-6P
883896-63-7P 883896-64-8P 883896-65-9P
883896-66-0P 883896-67-1P 883896-68-2P
883896-72-8P 883896-73-9P 883896-74-0P
883896-76-2P 883896-77-3P 883896-79-5P
883896-80-8P 883896-81-9P 883896-82-0P
883896-83-1P 883896-85-3P 883896-86-4P
883896-89-7P 883896-90-0P 883896-91-1P
883896-92-2P 883896-93-3P 883896-96-6P
883896-97-7P 883896-99-9P 883897-01-6P
883897-03-8P 883897-04-9P 883897-06-1P
883897-09-4P 883897-11-8P 883897-12-9P
883897-13-0P 883897-16-3P 883897-17-4P
883897-18-5P 883897-19-6P 883897-21-0P
883897-23-2P 883897-25-4P 883897-27-6P
883897-29-8P 883897-32-3P 883897-33-4P
883897-39-0P 883897-40-3P 883897-48-1P
883897-50-5P 883897-52-7P 883897-69-6P
883897-79-8P 883897-83-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of indole derivs. for treatment of Alzheimer's disease)

RN 53597-27-6 CAPLUS
CN Benzoic acid, 5-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)



RN 363607-41-4 CAPLUS
CN Benzoic acid, 3-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)- (9CI) (CA INDEX NAME)



RN 883895-48-5 CAPLUS

L9 ANSWER 6 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzoic acid, 3-(2-phenyl-1H-indol-1-yl)- (9CI) (CA INDEX NAME)



RN 883895-49-6 CAPLUS
CN Benzoic acid, 3-[5-(1,1-dimethylethyl)-4,5,6,7-tetrahydro-2-phenyl-1H-indol-1-yl]- (9CI) (CA INDEX NAME)



RN 883895-55-4 CAPLUS
CN Benzoic acid, 3-(4,5,6,7-tetrahydro-2,5-diphenyl-1H-indol-1-yl)- (9CI) (CA INDEX NAME)



RN 883895-58-7 CAPLUS
CN Benzoic acid, 3-(2-phenyl-3H-benz[e]indol-3-yl)- (9CI) (CA INDEX NAME)



RN 883895-62-3 CAPLUS
CN Benzoic acid, 3-(4,5,6,7-tetrahydro-4-methyl-2-phenyl-1H-indol-1-yl)- (9CI) (CA INDEX NAME)

L9 ANSWER 6 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 883895-66-7 CAPLUS
CN Benzoic acid, 3-[2-(3-thienyl)-3H-benz[e]indol-3-yl]- (9CI) (CA INDEX NAME)



RN 883895-71-4 CAPLUS
CN Benzoic acid, 3-[4,5-dihydro-2-(3-phenyl-5-isoxazolyl)-3H-benz[e]indol-3-yl]- (9CI) (CA INDEX NAME)



RN 883895-72-5 CAPLUS
CN Benzoic acid, 3-[2-(3-pyridinyl)-3H-benz[e]indol-3-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 6 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 883895-73-6 CAPLUS
CN Benzoic acid, 3-[4,5-dihydro-2-(3-pyridinyl)-3H-benz[e]indol-3-yl]- (9CI) (CA INDEX NAME)



RN 883895-74-7 CAPLUS
CN Benzoic acid, 3-[2-(2-pyridinyl)-3H-benz[e]indol-3-yl]- (9CI) (CA INDEX NAME)



RN 883895-75-8 CAPLUS
CN Benzoic acid, 3-[4,5-dihydro-2-(2-pyridinyl)-3H-benz[e]indol-3-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 6 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 883895-76-9 CAPLUS
CN Benzoic acid, 3-[2-(2-benzofuranyl)-3H-benz[e]indol-3-yl]- (9CI) (CA INDEX NAME)



RN 883895-77-0 CAPLUS
CN Benzoic acid, 3-[2-(2-benzofuranyl)-4,5-dihydro-3H-benz[e]indol-3-yl]- (9CI) (CA INDEX NAME)



RN 883895-82-7 CAPLUS
CN Benzoic acid, 3-[2-(4-carboxyphenyl)-4,5-dihydro-3H-benz[e]indol-3-yl]- (9CI) (CA INDEX NAME)



L9 ANSWER 6 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 883895-84-9 CAPLUS
CN Benzoic acid, 3-[4,5-dihydro-2-(2-methoxyphenyl)-3H-benz[e]indol-3-yl]- (9CI) (CA INDEX NAME)



RN 883895-85-0 CAPLUS
CN Benzoic acid, 3-[2-(2-methoxyphenyl)-3H-benz[e]indol-3-yl]- (9CI) (CA INDEX NAME)



RN 883895-96-3 CAPLUS
CN Benzoic acid, 3-[5-(1,1-dimethylpropyl)-4,5,6,7-tetrahydro-2-phenyl-1H-indol-1-yl]- (9CI) (CA INDEX NAME)



RN 883895-97-4 CAPLUS
CN Benzoic acid, 3-[4,5,6,7-tetrahydro-2-phenyl-5-(trifluoromethyl)-1H-indol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 6 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 883895-99-6 CAPLUS
CN Benzoic acid, 3-(5-ethyl-4,5,6,7-tetrahydro-2-phenyl-1H-indol-1-yl)-(9CI)
(CA INDEX NAME)



RN 883896-02-4 CAPLUS
CN 1H-Indole-5-carboxylic acid, 1-(3-carboxyphenyl)-4,5,6,7-tetrahydro-2-phenyl-, 5-ethyl ester (9CI) (CA INDEX NAME)



RN 883896-03-5 CAPLUS
CN Benzoic acid, 3-[5-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-4,5,6,7-tetrahydro-2-phenyl-1H-indol-1-yl]- (9CI) (CA INDEX NAME)



RN 883896-04-6 CAPLUS
CN Benzoic acid, 3-[4,5-dihydro-2-(4-methoxyphenyl)-3H-benz[e]indol-3-yl]-(9CI) (CA INDEX NAME)

L9 ANSWER 6 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 883896-08-0 CAPLUS
CN Benzoic acid, 3-[2-(4-chlorophenyl)-4,5-dihydro-3H-benz[e]indol-3-yl]-(9CI) (CA INDEX NAME)



RN 883896-09-1 CAPLUS
CN Benzoic acid, 3-[2-(3-chlorophenyl)-4,5-dihydro-3H-benz[e]indol-3-yl]-(9CI) (CA INDEX NAME)



RN 883896-14-8 CAPLUS
CN Benzoic acid, 3-(4,5,6,7-tetrahydro-6,6-dimethyl-2-phenyl-1H-indol-1-yl)-(9CI) (CA INDEX NAME)



RN 883896-16-0 CAPLUS
CN Benzoic acid,
3-[(6R)-4,5,6,7-tetrahydro-6-methyl-2-phenyl-1H-indol-1-yl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 6 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 883896-05-7 CAPLUS
CN Benzoic acid, 3-[2-(4-methoxyphenyl)-3H-benz[e]indol-3-yl]- (9CI) (CA INDEX NAME)



RN 883896-06-8 CAPLUS
CN Benzoic acid, 3-[2-(2,4-dimethoxyphenyl)-3H-benz[e]indol-3-yl]- (9CI) (CA
INDEX NAME)



RN 883896-07-9 CAPLUS
CN 1H-Indole-5-carboxylic acid, 1-(3-carboxyphenyl)-4,5,6,7-tetrahydro-2-phenyl- (9CI) (CA INDEX NAME)

L9 ANSWER 6 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 883896-25-1 CAPLUS
CN Benzoic acid, 3-(4,5,6,7-tetrahydro-2-phenyl-5-propyl-1H-indol-1-yl)-(9CI) (CA INDEX NAME)



RN 883896-28-4 CAPLUS
CN Benzoic acid, 3-[2-phenyl-5-(trifluoromethyl)-1H-indol-1-yl]- (9CI) (CA INDEX NAME)



RN 883896-29-5 CAPLUS
CN Benzoic acid, 3-(5-ethyl-2-phenyl-1H-indol-1-yl)- (9CI) (CA INDEX NAME)



RN 883896-30-8 CAPLUS
CN Benzoic acid, 3-(6-methyl-2-phenyl-1H-indol-1-yl)- (9CI) (CA INDEX NAME)



L9 ANSWER 6 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 883896-32-0 CAPLUS
CN Benzoic acid, 3-(4,5,6,7-tetrahydro-5-hydroxy-2-phenyl-1H-indol-1-yl)- (9CI) (CA INDEX NAME)



RN 883896-36-4 CAPLUS
CN Benzoic acid, 3-[2-(3-methoxyphenyl)-3H-benz[e]indol-3-yl]- (9CI) (CA INDEX NAME)



RN 883896-37-5 CAPLUS
CN Benzoic acid, 3-[2-(3-hydroxyphenyl)-3H-benz[e]indol-3-yl]- (9CI) (CA INDEX NAME)



RN 883896-38-6 CAPLUS
CN Benzoic acid, 3-[2-(4-fluorophenyl)-3H-benz[e]indol-3-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 6 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 883896-39-7 CAPLUS
CN Benzoic acid, 3-[2-[3,5-bis(trifluoromethyl)phenyl]-3H-benz[e]indol-3-yl]- (9CI) (CA INDEX NAME)



RN 883896-40-0 CAPLUS
CN Benzoic acid, 3-[2-(3-chlorophenyl)-3H-benz[e]indol-3-yl]- (9CI) (CA INDEX NAME)



RN 883896-41-1 CAPLUS
CN Benzoic acid, 3-[2-[4-(trifluoromethyl)phenyl]-3H-benz[e]indol-3-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 6 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 883896-42-2 CAPLUS
CN Benzoic acid, 3-[4,5,6,7-tetrahydro-2-phenyl-4-(trifluoromethyl)-1H-indol-1-yl]- (9CI) (CA INDEX NAME)



RN 883896-43-3 CAPLUS
CN Benzoic acid, 3-[4,5,6,7-tetrahydro-2-phenyl-6-(trifluoromethyl)-1H-indol-1-yl]- (9CI) (CA INDEX NAME)



RN 883896-44-4 CAPLUS
CN Benzoic acid, 3-[4-[4-(ethoxycarbonyl)phenyl]-4,5,6,7-tetrahydro-2-phenyl-1H-indol-1-yl]- (9CI) (CA INDEX NAME)



L9 ANSWER 6 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 883896-45-5 CAPLUS
CN Benzoic acid, 3-(6-[4-(ethoxycarbonyl)phenyl]-4,5,6,7-tetrahydro-2-phenyl-1H-indol-1-yl]- (9CI) (CA INDEX NAME)



RN 883896-47-7 CAPLUS
CN Benzoic acid, 3-[2-(3-phenyl-5-isoxazolyl)-3H-benz[e]indol-3-yl]- (9CI) (CA INDEX NAME)



RN 883896-49-9 CAPLUS
CN Benzoic acid, 3-[2-(2-benzofuranyl)-4,5,6,7-tetrahydro-5-(trifluoromethyl)-1H-indol-1-yl]- (9CI) (CA INDEX NAME)



RN 883896-50-2 CAPLUS
CN Benzoic acid, 3-[2-(3,4-dichlorophenyl)-4,5,6,7-tetrahydro-5-(trifluoromethyl)-1H-indol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 6 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 883896-52-4 CAPLUS
CN Benzoic acid, 3-[2-(3,4-dichlorophenyl)-3H-benz[e]indol-3-yl]- (9CI) (CA INDEX NAME)



RN 883896-54-6 CAPLUS
CN Benzoic acid, 3-(4,5,6,7-tetrahydro-5-oxo-2-phenyl-1H-indol-1-yl)- (9CI) (CA INDEX NAME)



RN 883896-55-7 CAPLUS
CN Benzoic acid, 3-(1',4',6',7'-tetrahydro-2'-phenylspiro[1,3-dioxolane-2,5'-[5H]indol]-1'-yl)- (9CI) (CA INDEX NAME)

L9 ANSWER 6 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 883896-61-5 CAPLUS
CN Benzoic acid, 3-(5-cyclohexyl-4,5,6,7-tetrahydro-2-phenyl-1H-indol-1-yl)- (9CI) (CA INDEX NAME)



RN 883896-62-6 CAPLUS
CN 2-Furancarboxylic acid, 5-[1-(3-carboxyphenyl)-4,5,6,7-tetrahydro-2-phenyl-1H-indol-4-yl]-, 2-ethyl ester (9CI) (CA INDEX NAME)



RN 883896-63-7 CAPLUS
CN 2-Furancarboxylic acid, 5-[1-(3-carboxyphenyl)-4,5,6,7-tetrahydro-2-phenyl-1H-indol-6-yl]-, 2-ethyl ester (9CI) (CA INDEX NAME)

L9 ANSWER 6 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 883896-57-9 CAPLUS
CN Benzoic acid, 3-[2-(4-chlorophenyl)-3H-benz[e]indol-3-yl]- (9CI) (CA INDEX NAME)



RN 883896-59-1 CAPLUS
CN Benzoic acid, 2-[3-(3-carboxyphenyl)-3H-benz[e]indol-2-yl]-, 1-methyl ester (9CI) (CA INDEX NAME)



RN 883896-60-4 CAPLUS
CN Benzoic acid, 3-[2-(2-chlorophenyl)-3H-benz[e]indol-3-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 6 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 883896-64-8 CAPLUS
CN Benzoic acid, 3-[2-(3,4-dichlorophenyl)-4,5,6,7-tetrahydro-4-(trifluoromethyl)-1H-indol-1-yl]- (9CI) (CA INDEX NAME)



RN 883896-65-9 CAPLUS
CN Benzoic acid, 3-[2-(3,4-dichlorophenyl)-4,5,6,7-tetrahydro-6-(trifluoromethyl)-1H-indol-1-yl]- (9CI) (CA INDEX NAME)



RN 883896-66-0 CAPLUS
CN Benzoic acid, 3-[2-[3-(trifluoromethyl)phenyl]-3H-benz[e]indol-3-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 6 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 883896-67-1 CAPLUS
CN Benzoic acid, 3-[2-[4-(trifluoromethoxy)phenyl]-3H-benz[e]indol-3-yl]- (9CI) (CA INDEX NAME)



RN 883896-68-2 CAPLUS
CN Benzoic acid, 3-[2-(4-cyanophenyl)-3H-benz[e]indol-3-yl]- (9CI) (CA INDEX NAME)



RN 883896-72-8 CAPLUS
CN Benzoic acid, 3-(4,5,6,7-tetrahydro-5-methoxy-2-phenyl-1H-indol-1-yl)- (9CI) (CA INDEX NAME)

L9 ANSWER 6 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 883896-73-9 CAPLUS
CN Benzoic acid, 3-[5-(1,1-dimethylpropyl)-4,5,6,7-tetrahydro-2-phenyl-1H-indol-1-yl]-4-hydroxy- (9CI) (CA INDEX NAME)



RN 883896-74-0 CAPLUS
CN Benzoic acid, 2-chloro-5-[5-(1,1-dimethylpropyl)-4,5,6,7-tetrahydro-2-phenyl-1H-indol-1-yl]- (9CI) (CA INDEX NAME)



RN 883896-76-2 CAPLUS
CN Benzoic acid, 3-(6-ethyl-4,5,6,7-tetrahydro-2-phenyl-1H-indol-1-yl)- (9CI) (CA INDEX NAME)



RN 883896-77-3 CAPLUS
CN Benzoic acid, 3-[2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-3H-benz[e]indol-3-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 6 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 883896-79-5 CAPLUS
CN Benzoic acid, 3-[2-[4-(1-pyrrolidinyl)phenyl]-3H-benz[e]indol-3-yl]- (9CI) (CA INDEX NAME)



RN 883896-80-8 CAPLUS
CN Benzoic acid, 3-[2-(3,4-dichlorophenyl)-5-(1,1-dimethylethyl)-4,5,6,7-tetrahydro-1H-indol-1-yl]- (9CI) (CA INDEX NAME)



RN 883896-81-9 CAPLUS
CN Benzoic acid, 3-[2-(2,5-dichlorophenyl)-3H-benz[e]indol-3-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 6 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 883896-82-0 CAPLUS
CN Benzoic acid, 5-[2-(2-benzofuranyl)-3H-benz[e]indol-3-yl]-2-chloro- (9CI) (CA INDEX NAME)





RN 883896-83-1 CAPLUS
CN Benzoic acid, 3-[2-(2-benzofuranyl)-3H-benz[e]indol-3-yl]-4-hydroxy- (9CI) (CA INDEX NAME)

PAGE 1-A





L9 ANSWER 6 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



RN 883896-85-3 CAPLUS
CN Benzoic acid, 3-[5-(1,1-dimethylethyl)-4,5,6,7-tetrahydro-2-[4-(trifluoromethyl)phenyl]-1H-indol-1-yl]- (9CI) (CA INDEX NAME)



RN 883896-86-4 CAPLUS
CN Benzoic acid, 3-[4,5,6,7-tetrahydro-2-phenyl-5-(phenylmethoxy)-1H-indol-1-yl]- (9CI) (CA INDEX NAME)



RN 883896-89-7 CAPLUS
CN Benzoic acid, 3-[2-(2-benzofuranyl)-1-[(dimethylamino)methyl]-3H-benz[e]indol-3-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 6 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 883896-90-0 CAPLUS
CN Benzoic acid, 3-[4-(3-cyanopropyl)-4,5,6,7-tetrahydro-2-phenyl-1H-indol-1-yl]- (9CI) (CA INDEX NAME)



RN 883896-91-1 CAPLUS
CN Benzoic acid, 3-[6-(3-cyanopropyl)-4,5,6,7-tetrahydro-2-phenyl-1H-indol-1-yl]- (9CI) (CA INDEX NAME)



RN 883896-92-2 CAPLUS
CN Benzoic acid, 3-[2-(3,4-dimethoxyphenyl)-4,5,6,7-tetrahydro-5-(trifluoromethyl)-1H-indol-1-yl]- (9CI) (CA INDEX NAME)



L9 ANSWER 6 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 883896-93-3 CAPLUS
CN Benzoic acid, 3-[2-(2,4-dimethoxyphenyl)-4,5,6,7-tetrahydro-5-(trifluoromethyl)-1H-indol-1-yl]- (9CI) (CA INDEX NAME)



RN 883896-96-6 CAPLUS
CN Benzoic acid, 3-[4,5,6,7-tetrahydro-2-[4-(4-morpholinyl)phenyl]-5-(trifluoromethyl)-1H-indol-1-yl]- (9CI) (CA INDEX NAME)



RN 883896-97-7 CAPLUS
CN Benzoic acid, 3-[4,5,6,7-tetrahydro-5-(trifluoromethyl)-2-(2,3,4-trimethoxyphenyl)-1H-indol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 6 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 883896-99-9 CAPLUS
CN Benzoic acid, 3-[3-[(dimethylamino)methyl]-5-(1,1-dimethylethyl)-4,5,6,7-tetrahydro-2-phenyl-1H-indol-1-yl]- (9CI) (CA INDEX NAME)



RN 883897-01-6 CAPLUS
CN Benzoic acid, 2-chloro-5-[2-(4-chlorophenyl)-3H-benz[e]indol-3-yl]- (9CI) (CA INDEX NAME)



RN 883897-03-8 CAPLUS
CN Benzoic acid, 3-[5-(diethylamino)-4,5,6,7-tetrahydro-2-phenyl-1H-indol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 6 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 883897-04-9 CAPLUS
CN Benzoic acid, 3-[4,5,6,7-tetrahydro-5-(4-morpholinyl)-2-phenyl-1H-indol-1-yl]- (9CI) (CA INDEX NAME)



RN 883897-06-1 CAPLUS
CN Benzoic acid, 3-[4,5,6,7-tetrahydro-2-phenyl-5-(1-pyrrolidinyl)-1H-indol-1-yl]- (9CI) (CA INDEX NAME)



RN 883897-09-4 CAPLUS
CN Benzoic acid, 3-[2-(4-chlorophenyl)-5-(1,1-dimethylpropyl)-4,5,6,7-tetrahydro-1H-indol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 6 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 883897-11-8 CAPLUS
CN Benzoic acid, 3-[5-(1,1-dimethylpropyl)-4,5,6,7-tetrahydro-2-[3-(trifluoromethyl)phenyl]-1H-indol-1-yl]- (9CI) (CA INDEX NAME)



RN 883897-12-9 CAPLUS
CN Benzoic acid, 3-[5-(1,1-dimethylpropyl)-2-(4-fluorophenyl)-4,5,6,7-tetrahydro-1H-indol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 6 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 883897-13-0 CAPLUS
CN Benzoic acid, 3-[5-(1,1-dimethylpropyl)-4,5,6,7-tetrahydro-2-[4-(trifluoromethyl)phenyl]-1H-indol-1-yl]- (9CI) (CA INDEX NAME)



RN 883897-16-3 CAPLUS
CN Benzoic acid, 3-[2-(3-chlorophenyl)-5-(1,1-dimethylpropyl)-4,5,6,7-tetrahydro-1H-indol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 6 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 883897-17-4 CAPLUS
CN Benzoic acid, 3-[2-(3,4-dichlorophenyl)-5-(1,1-dimethylpropyl)-4,5,6,7-tetrahydro-1H-indol-1-yl]- (9CI) (CA INDEX NAME)



RN 883897-18-5 CAPLUS
CN Benzoic acid, 3-[2-(1,1-dimethylethyl)-5-(1,1-dimethylpropyl)-4,5,6,7-tetrahydro-1H-indol-1-yl]- (9CI) (CA INDEX NAME)



RN 883897-19-6 CAPLUS
CN Benzoic acid, 3-[2-phenyl-5-(phenylmethoxy)-1H-indol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 6 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 883897-21-0 CAPLUS
CN Benzoic acid, 3-[4,5,6,7-tetrahydro-2-(4-nitrophenyl)-5-(trifluoromethyl)-1H-indol-1-yl]- (9CI) (CA INDEX NAME)



RN 883897-23-2 CAPLUS
CN Benzoic acid, 3-[4,5-dihydro-2-(3-methoxyphenyl)-3H-benz[e]indol-3-yl]- (9CI) (CA INDEX NAME)



RN 883897-25-4 CAPLUS
CN Benzoic acid, 3-[2-(4-hydroxyphenyl)-3H-benz[e]indol-3-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 6 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 883897-33-4 CAPLUS
CN Benzoic acid, 3-[4,5-dihydro-2-(4-methylphenyl)-3H-benz[e]indol-3-yl]- (9CI) (CA INDEX NAME)



RN 883897-39-0 CAPLUS
CN Benzoic acid, 3-[2-(1,3-benzodioxol-5-yl)-4,5-dihydro-3H-benz[e]indol-3-yl]- (9CI) (CA INDEX NAME)



RN 883897-40-3 CAPLUS
CN Benzoic acid, 3-[2-(1,3-benzodioxol-5-yl)-3H-benz[e]indol-3-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 6 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 883897-27-6 CAPLUS
CN Benzoic acid, 3-amino-5-[4,5,6,7-tetrahydro-2-phenyl-5-(trifluoromethyl)-1H-indol-1-yl]- (9CI) (CA INDEX NAME)



RN 883897-29-8 CAPLUS
CN Benzoic acid, 3-[2-(4-aminophenyl)-4,5,6,7-tetrahydro-5-(trifluoromethyl)-1H-indol-1-yl]- (9CI) (CA INDEX NAME)



RN 883897-32-3 CAPLUS
CN Benzoic acid, 3-[2-(2,4-dimethoxyphenyl)-4,5-dihydro-3H-benz[e]indol-3-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 6 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 883897-48-1 CAPLUS
CN Benzoic acid, 3-[4,5-dihydro-2-(4-pyridinyl)-3H-benz[e]indol-3-yl]- (9CI) (CA INDEX NAME)



RN 883897-50-5 CAPLUS
CN Benzoic acid, 3-[2-(4-pyridinyl)-3H-benz[e]indol-3-yl]- (9CI) (CA INDEX NAME)



RN 883897-52-7 CAPLUS
CN Benzoic acid, 3-[2-(5-methyl-3-phenyl-4-isoxazolyl)-3H-benz[e]indol-3-yl]- (9CI) (CA INDEX NAME)



L9 ANSWER 6 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 883897-69-6 CAPLUS
CN Benzoic acid, 3-[2-(2-benzofuranyl)-5-(1,1-dimethylpropyl)-4,5,6,7-tetrahydro-1H-indol-1-yl]- (9CI) (CA INDEX NAME)



RN 883897-79-8 CAPLUS
CN Benzoic acid, 3-[2-[5-(2,4-dichlorophenyl)-2-furanyl]-3H-benz[e]indol-3-yl]- (9CI) (CA INDEX NAME)



RN 883897-83-4 CAPLUS
CN Benzoic acid, 3-[4,5,6,7-tetrahydro-2-phenyl-6-(2-pyridinyl)-1H-indol-1-yl]- (9CI) (CA INDEX NAME)



L9 ANSWER 7 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
pharmaceutically acceptable salts, derivs., tautomers, or solvates thereof were prepd. as tubulin inhibitors for the treatment of proliferative diseases or cancer (no data). For example, 4-amino-3,5-dichlorobenzoic acid was reacted with 1-(3-chlorophenyl)-piperazine in DMF at 50 °C in the presence of TBTU to give II (47 %). The title compds. showed inhibitory activity with IC50 < 10 μM in vitro cytotoxicity assay. Formulations as tablets, coated tablets, capsules, or ampoules were described.

IT 10333-68-3, 2-(1-Pyrrolyl)-benzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of arylpiperazine derivs. as tubulin inhibitors for treatment of proliferation or cancer)

RN 10333-68-3 CAPLUS
CN Benzoic acid, 2-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:335893 CAPLUS
DN 144:390943
TI Preparation of arylpiperazine derivatives as tubulin inhibitors for treatment of proliferation or cancer
IN Betzemeier, Bodo; Krist, Bernd; McConnell, Darryl; Steurer, Steffen; Impagnatiello, Maria; Weyer-Czernilofsky, Ulrike; Hilberg, Frank; Brueckner, Ralph; Daiimann, Georg; Heckel, Armin; Kley, Joerg; Lehmann-Lintz, Thorsten; Roth, Gerald
PA Boehringer Ingelheim International G.m.b.H., Germany
SO Eur. Pat. Appl., 55 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 1645556	A1	20060412	EP 2004-23926	20041007
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRAI EP 2004-23926		20041007		

OS MARPAT 144:390943
GI



I



II

AB The title arylpiperazine derivs. I [wherein A = mono- or bicyclic aryl; R1 and R2 = independently H, halo, CN, (un)substituted alkyl, alkoxy, etc.; R3 = H, halo, CN, alkyl, or alkoxy; or R2 and R3 = (un)substituted -O-(CH2)p-O- ring; R4 and R5 = independently H or alkyl; R6-R10 = independently H, halo, NO2, CN, (un)substituted alkyl, NH2, alkoxy, etc.; X and Y = independently CH, CF, or N; n and p = independently 1 or 2], or

L9 ANSWER 8 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:332235 CAPLUS
DN 144:350539
TI Preparation of pyrrolecarboxamide derivatives as mineralocorticoid receptor antagonists for use against cancer and other disorders
IN Canne Bannen, Lynne; Chen, Jeff; Dalrymple, Lisa Esther; Flatt, Brenton T.; Forsyth, Timothy Patrick; Gu, Xiao-Hu; Mac, Morrison B.; Mann, Larry W.; Mann, Grace; Martin, Richard; Mohan, Raju; Murphy, Brett; Nyman, Michael Charles; Stevens, William C., Jr.; Wang, Tie-Lin; Wong, Yong; Wu, Jason H.
PA Exelixis, Inc., USA
SO PCT Int. Appl., 477 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006012642	A2	20060202	WO 2005-US26916	20050730
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI US 2004-592439P	P	20040730		
US 2004-592469P	P	20040730		

OS MARPAT 144:350539
GI



I

AB Pyrrolecarboxamide derivs. (shown as I; other Markush structures for pyrrolecarboxamides are defined in the claims; variables defined below; e.g. 1-[4-fluoro-2-(trifluoromethyl)phenyl]-2,5-dimethyl-1H-pyrrole-3-carboxylic acid N-[4-(sulfamoyl)phenyl]amide (II)), compns. and methods for modulating the activity of receptors are provided. In particular compds. and compns. are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of ≥1 symptoms of disease or disorder directly or indirectly related to the activity of the receptors. Semiquant. IC50 values for antagonist activity of 23 examples of I are tabulated and compared to the activity of the Spironolactone control. For I: R1 and R2 = H, halo, cyano, or (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl, or heterocyclylalkyl, or -OR9, -SR9, -N(R9)2, -C(O)OR9 or -C(O)N(R9)2; R3 =

L9 ANSWER 8 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
H, halo, cyano, (un)substituted alkyl, (un)substituted alkenyl or (un)substituted alkynyl; R4 is H, -C(O)R9, -S(O)2R9, or (un)substituted alkyl, alkenyl or alkynyl, or R4 is (un)substituted cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl; R6 is H or (un)substituted alkyl; R7 is (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl; addnl. details are given in the claims. Although the methods of prepn. are not claimed, prepns. and/or characterization data for many examples of I are included. For example, II was prepd. in 5 steps (50, 37, 62, 64, and 66 % yields, resp.) starting with prepn. of 1-[4-fluoro-2-(trifluoromethyl)phenyl]-2,5-dimethyl-1H-pyrrole from 4-fluoro-2-(trifluoromethyl)aniline and 2,5-hexanedione, followed by prepn. of the following intermediates: 1-(4-fluoro-2-trifluoromethylphenyl)-2,5-dimethyl-1H-pyrrole-3-carboxaldehyde, 1-[4-fluoro-2-(trifluoromethyl)phenyl]-2,5-dimethyl-1H-pyrrole-3-carboxylic acid, and 1-[4-fluoro-2-(trifluoromethyl)phenyl]-2,5-dimethyl-1H-pyrrole-3-carbonyl chloride and finally amide formation with sulfanilamide.

IT **880779-34-0P**, 2-[3-[(4-Methylsulfonylphenyl)carbamoyl]-2,5-dimethylpyrrol-1-yl]benzoic acid
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of pyrrolecarboxamide derivs. as mineralocorticoid receptor antagonists for use against cancer and other disorders)

RN 880779-34-0 CAPLUS
CN Benzoic acid, 2-[2,5-dimethyl-3-[[[4-(methylsulfonyl)phenyl]amino]carbonyl]-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



L9 ANSWER 8 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L9 ANSWER 9 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:315138 CAPLUS
DN 144:480399
TI Discovery of novel biaryl heterocyclic EP1 receptor antagonists
AU Hall, Adrian; Bit, Rino A.; Brown, Susan H.; Chaignot, Helene M.; Chessell, Iain P.; Coleman, Tanya; Giblin, Gerard M. P.; Hurst, David N.; Kilford, Ian R.; Lewell, Xiao Q.; Michel, Anton D.; Mohamed, Shiyam; Naylor, Alan; Novelli, Riccardo; Skinner, Lee; Spalding, David J.; Tang, Sac P.; Wilson, Richard J.
CS Neurology and Gastrointestinal Centre of Excellence for Drug Discovery, GlaxoSmithKline, Essex, CM19 5AW, UK
SO Bioorganic & Medicinal Chemistry Letters (2006), 16(10), 2666-2671
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier B.V.
DT Journal
LA English
AB We describe the generation of novel EP1 receptor antagonists by investigation of thiophene isosteres. In addition, we disclose preliminary in vitro and in vivo DMPK for selected compds.

IT **632621-54-6P 632621-55-7P 854195-37-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(Discovery of novel biaryl heterocyclic EP1 receptor antagonists)

RN 632621-54-6 CAPLUS
CN Benzoic acid, 3-[2-[5-chloro-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632621-55-7 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



L9 ANSWER 9 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 854195-37-2 CAPLUS
CN Benzoic acid, 3-[2-[5-chloro-2-(phenylmethoxy)phenyl]-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RE.CNT 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 10 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:273658 CAPLUS
DN 144:331457
TI Preparation of substituted pyrazolo[1,5-a]pyrimidines and methods of their
use as antiproliferative agents
IN Wang, Yanong Daniel; Gopalsamy, Ariamala; Honores, Erick Eduardo; Jennings, Lee Dalton; Johnson, Steven Lawrence; Powell, Dennis William; Sum, Fuk-Wah; Tsou, Hwei-Ru; Wu, Biqi; Zhang, Nan
PA USA
SO U.S. Pat. Appl. Publ., 83 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2006063784	A1	20060323	US 2005-221846	20050909
WO 2006033795	A2	20060330	WO 2005-US31087	20050901

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2004-610550P P 20040917
OS MARPAT 144:331457
GI

L9 ANSWER 10 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB The invention is related to novel methods of use of pyrazolo[1,5-a]pyrimidines I [R1 = H, CN, halo, CHO, CO2H, etc.; R2-R4 = H, CF3, alkyl;
R5 = (un)substituted hetero/aryl], and their therapeutically acceptable salts and prodrugs, as antiproliferative agents, particularly antitumor agents, in mammals, including humans. The use of pyrazolpyrimidines I in regulating the expression of p21 in cells, and the preparation of certain I are
given. Thus, reacting (3-Amino-1H-pyrazol-4-yl)(thien-2-yl)methanone (preparation given) with 3-(Dimethylamino)-1-(2-thienyl)-2-propen-1-one (preparation
given) gave pyrazolopyrimidine II. In a cytotoxicity test against 80S14 (p21-deficient) cells, II had an IC50 in the range of 1-10 μM.
IT 22106-33-8, 4-(1H-Pyrrol-1-yl)benzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of substituted pyrazolo[1,5-a]pyrimidines as antitumor agents)
RN 22106-33-8 CAPLUS
CN Benzoic acid, 4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)

L9 ANSWER 10 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 11 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:273618 CAPLUS
DN 144:312112
TI Preparation of substituted pyrazolo[1,5-a]pyrimidines as antiproliferative
agents
IN Wang, Yanong Daniel; Gopalsamy, Ariamala; Powell, Dennis William; Tsou, Hwei-Ru; Zhang, Nan
PA USA
SO U.S. Pat. Appl. Publ., 84 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2006063785	A1	20060323	US 2005-221847	20050909
WO 2006033796	A1	20060330	WO 2005-US31088	20050901

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2004-610520P P 20040917
OS MARPAT 144:312112
GI



I II

AB This invention relates to novel pyrazolo[1,5-a]pyrimidine compds. I (wherein R1 = H, cyano, halogen, carbamoyl, formyl, carboxy, C(O)O-alkyl, C(O)O-cycloalkyl, C(O)cycloalkyl, R6, C(O)R6, and C(S)R6; R6 = (un)substituted, aryl or heteroaryl; R2, R3, and R4 = H, CF3, or alkyl;
R5
= (un)substituted aryl or heteroaryl) and the therapeutically acceptable salts thereof. These compds. are useful as anti-proliferative agents in mammals, including humans. The compds., their use in regulating the expression of p21 in cells, as well as a method of preparation are claimed.

L9 ANSWER 11 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
For example, II is prepd. from (3-amino-1H-pyrazol-4-yl)-2-thienylmethanone and 3-(dimethylamino)-1-[3-(cyclopentyloxy)phenyl]-2-propen-1-one, which in turn was prepd. from 3-cyclopentyloxyacetophenone and DMF-di-Me acetal. In a cytotoxicity test against 80S14 (p21-deficient) cells, II had an IC50 in the range of 1-10 μM.
IT 22106-33-8, 4-(1H-Pyrrol-1-yl)benzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of substituted pyrazolo[1,5-a]pyrimidines as antiproliferative agents)
RN 22106-33-8 CAPLUS
CN Benzoic acid, 4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



L9 ANSWER 12 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 12 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:266231 CAPLUS
DN 144:460309
TI Quantitative Structure-Activity Relationship Studies on Inhibition of HERG Potassium Channels
AU Yoshida, Katsumi; Niwa, Tomoko
CS Discovery Research Laboratories, Nippon Shinyaku Co. Ltd., 14 Nishinosho-Monguchi-cho, Kisshoin, Minami-ku, Kyoto, 601-8550, Japan
SO Journal of Chemical Information and Modeling (2006), 46(3), 1371-1378
CODEN: JCISD8; ISSN: 1549-9596
PB American Chemical Society
DT Journal
LA English
AB The human ether-a-go-go-related gene (HERG) protein forms the ion channel responsible for the rapidly acting delayed rectifier potassium current, IKr, and its blockade is a significant contributor to prolongation of the QT interval. Using descriptors which have clear physicochem. meanings and are familiar to medicinal chemists, we have carried out 2D-quant. structure-activity relationship (2D-QSAR) studies on 104 HERG channel blockers with diverse structures collected from the literature, and we have formulated interpretable models to guide chemical-modification studies and virtual screening. Statistically significant descriptors were selected by a genetic algorithm, and the final model included the octanol/water partition coefficient, topol. polar surface area, diameter, summed surface area of atoms with partial charges from -0.25 to -0.20, and an indicator variable representing the exptl. conditions. The statistics were r = 0.839, r2 = 0.704, q2 = 0.671, s = 0.763, and F = 46.6. The correspondence of the mol. determinants derived from the 2D-QSAR models with the 3D structural characteristics of the putative binding site in a homol.-modeled HERG channel is also discussed.
IT 572913-76-9, BMCL 131829-05
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(QSAR of HERG potassium channel blockers)
RN 572913-76-9 CAPLUS
CN Benzoic acid, 4-[5-chloro-3-[1-[2-(2-oxo-1-imidazolidinyl)ethyl]-4-piperidinyl]-1H-indol-1-yl]- (9CI) (CA INDEX NAME)



RE.CNT 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD

L9 ANSWER 13 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:218210 CAPLUS
DN 144:274307
TI Preparation of hydroxyamides, particularly N-hydroxyacrylamides, as histone deacetylase inhibitors
IN Ishibashi, Naoki; Sawada, Yuki; Urano, Yasuharu; Satoh, Shigeki; Inoue, Yoshikazu; Eikyu, Yoshiteru; Mukoyoshi, Koichiro; Kamijo, Kazunori; Shirai, Fumiyuki; Takasugi, Hisashi
PA Astellas Pharma Inc., Japan
SO U.S. Pat. Appl. Publ., 142 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2006052599	A1	20060309	US 2005-199453	20050809
PRAI EP 2004-904487	A	20040809		
EP 2004-907228	A	20041220		

OS MARPAT 144:274307
GI



II

AB Title compds. R1-X-N(R2)-Y-Z-CO-NH-OH [I; R1 = H, (un)substituted lower alk(en/yn)yl, cyclo(lower)alkyl, cyclo(higher)alkyl, cyclo(lower)alkyl(lower)alkyl, cyclo(higher)alkyl(lower)alkyl, cyclo(lower)alkenyl(lower)alkyl, aryl-fused cyclo(lower)alkyl, lower alkoxy, acyl, aryl, ar(lower)alkoxy, ar(lower)alkyl, heteroar(lower)alkyl, amino, heteroaryl, heterocyclyl or heterocyclyl(lower)alkyl; R2 = H, lower alkyl; X = hetero/arylene, aryl-fused/hetero/cycloalkylene; Y = (un)substituted hetero/arylene; Z = (un)substituted lower alkenylene; and their salts] were prepared as histone deacetylase (HDAC) inhibitors. E.g., a multi-step synthesis starting from Me 6-chloronicotinate and 1-benzyl-3-aminopyrrolidine, is given for II•2HCl. Selected I displayed HDAC inhibitory activity (IC50 < 10 nM). Selected I exhibited T-cell growth inhibitory activity (IC50 < 25 nM).
IT 22106-33-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of hydroxyamides as histone deacetylase inhibitors)
RN 22106-33-8 CAPLUS
CN Benzoic acid, 4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)

L9 ANSWER 13 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 14 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:193420 CAPLUS
DN 144:274129
TI Preparation of 1-(hetero)aroyl-2-(pyrrolidin-1-ylmethyl)pyrrolidine histamine H3 receptor agents and therapeutic uses
IN Finley, Don Richard; Finn, Terry Patrick; Hipskind, Philip Arthur; Hornback, William Joseph; Jesudason, Cynthia Darshini; Takakuwa, Takako
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 123 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006023462	A1	20060302	WO 2005-US29032	20050815
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI US 2004-603628P	P	20040823		

OS MARPAT 144:274129
GI



I



II

L9 ANSWER 14 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
AB The present invention provides 1-(hetero)aroyl-2-(pyrrolidin-1-ylmethyl)pyrrolidines (shown as I; variables defined below; e.g. (S)-[4-[4-(pyridin-3-yl)thiazol-2-yl]phenyl][2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl]methanone dihydrochloride (free base shown as II)) or a pharmaceutically acceptable salt thereof, having histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compds. In another embodiment, the invention discloses pharmaceutical compns. comprising compds. I as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. Although the methods of preparation are not claimed, prepns. and/or characterization data for 57 examples of I are included. For example, II was prepared by converting sodium 4-[4-(pyridin-3-yl)thiazol-2-yl]benzoate to the acid chloride and then condensing it with (S)-(+)-1-[(2-pyrrolidinyl)methyl]pyrrolidine in the presence of pyridine. For I: X = C (substituted with H or the optional substituents indicated herein), or N; R1 = -HET ((un)substituted on C, independently, 1-3 times with R2, and optionally once substituted on N with R3), or benzo-fused heterocycle ((un)substituted on C, independently, 1-3 times with R2, and optionally once substituted on N with R3); R2 = at each occurrence -H, -halogen, -(C1-C7) alkyl ((un)substituted with 1-3 halogens), -CN, -C(O)R7, -C(O)OR7, et al. R3 = at each occurrence -H, -(C1-C7) alkyl ((un)substituted with 1-3 halogens), -SO2R7, -C(O)R7, -C(O)NR7R8, or -C(O)OR7; R4 and R5 = -H, -OH, -halogen, -(C1-C3)alkyl ((un)substituted with 1-3 halogens), or -OR9, provided that when X is N, then R4 and R5 are not attached to X; R6 = -H, -halo, -(C1-C3) alkyl ((un)substituted with 1-3 halogens), -NH2, -NR7R8, -OH, or -OR7; R7 and R8 = -H, -Ph, -(C1-C7) alkyl ((un)substituted with 1-3 halogens); or R7 and R8 combine with the atom to which they are attached to form a 4 to 7 membered ring; R9 is -H, -halo, -(C1-C3) alkyl ((un)substituted with 1-3 halogens), or -OR7. All compds. set forth in the examples exhibit affinity for the H3 receptor >1 μM in the H3R binding assay; e.g. Ki = 3.1 nM for II·2HCl.
IT 15898-26-7, 4-(2,5-Dimethylpyrrol-1-yl)benzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 1-(hetero)aroyl-2-(pyrrolidin-1-ylmethyl)pyrrolidine histamine H3 receptor agents and therapeutic uses)
RN 15898-26-7 CAPLUS
CN Benzoic acid, 4-(2,5-dimethyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 15 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:192166 CAPLUS
DN 144:260823
TI Compositions containing 5-amino-2-hydroxybenzoic acid and a reducing sugar
IN Kaczanowski, Matthew John; Williams, Thomas Daniel; Trombley, Kurt Franklin; Redman-Furey, Nancy Lee
PA The Procter & Gamble Company, USA
SO U.S. Pat. Appl. Publ., 12 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2006046973	A1	20060302	US 2005-218132	20050901
WO 2006028831	A2	20060316	WO 2005-US30907	20050831
WO 2006028831	A3	20060601		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI US 2004-606386P	P	20040901		

AB Compns. comprising 5-amino-2-hydroxybenzoic acid (5-amino salicylic acid, mesalamine) and a reducing sugar, e.g., lactose, undergo the Maillard and other chemical reactions and produce, in the case of lactose, a degradant 5-[2-Formyl-5-(hydroxymethyl)-1H-pyrrol-1-yl]-2-hydroxybenzoic acid. Inventors have developed means to contain and/or reduce the formation of degradants of 5-amino-2-hydroxybenzoic acid.
IT 876903-48-9
RL: FMU (Formation, unclassified); FORM (Formation, nonpreparative)
(stable compns. containing 5-amino-2-hydroxybenzoic acid and a reducing sugar)
RN 876903-48-9 CAPLUS
CN Benzoic acid, 5-[2-formyl-5-(hydroxymethyl)-1H-pyrrol-1-yl]-2-hydroxy- (9CI) (CA INDEX NAME)



L9 ANSWER 16 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:152557 CAPLUS
DN 144:233098
TI Preparation of hydroxyamides, particularly N-hydroxyacrylamides, as histone deacetylase inhibitors
IN Ishibashi, Naoki; Sawada, Yuki; Urano, Yasuharu; Satoh, Shigeki; Inoue, Yoshikazu; Eikyu, Yoshiteru; Mukoyoshi, Koichiro; Kamijo, Kazunori; Shirai, Fumiyuki; Takasugi, Hisashi
PA Astellas Pharma Inc., Japan
SO PCT Int. Appl., 426 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006016680	A1	20060216	WO 2005-JP14862	20050808
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI AU 2004-904487	A	20040809		
AU 2004-907228	A	20041220		

OS MARPAT 144:233098
GI



II

AB Title compds. R1-X-N(R2)-Y-Z-CO-NH-OH [I; R1 = H, (un)substituted lower alk(en/yn)yl, cyclo(lower)alkyl, cyclo(higher)alkyl, cyclo(lower)alkyl(lower)alkyl, cyclo(higher)alkyl(lower)alkyl, cyclo(lower)alkenyl(lower)alkyl, aryl-fused cyclo(lower)alkyl, lower alkoxy, acyl, aryl, ar(lower)alkoxy, ar(lower)alkyl, heteroar(lower)alkyl, amino, heteroaryl, heterocyclyl or heterocyclyl(lower)alkyl; R2 = H, lower alkyl; X = hetero/arylene, aryl-fused/hetero/cycloalkylene; Y = (un)substituted hetero/arylene; Z = (un)substituted lower alkenylene; and their salts] were prepared as histone deacetylase (HDAC) inhibitors. E.g.,

L9 ANSWER 16 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
a multi-step synthesis starting from Me 6-chloronicotinate and 1-benzyl-3-aminopyrrolidine, is given for II•2HCl. Selected I displayed HDAC inhibitory activity (IC50 < 10 nM). Selected I exhibited T-cell growth inhibitory activity (IC50 < 25 nM).
IT 22106-33-8, 4-(1H-Pyrrol-1-yl)benzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of hydroxyamides as histone deacetylase inhibitors)
RN 22106-33-8 CAPLUS
CN Benzoic acid, 4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 17 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:149623 CAPLUS
DN 144:226279
TI Use of immune cell specific conjugates for treatment of inflammatory diseases of the gastrointestinal tract
IN Mercep, Mladen; Mesic, Milan; Tomaskovic, Linda; Markovic, Stribor
PA Pliva-Istrazivacki Institut d.o.o., Croatia
SO U.S. Pat. Appl. Publ., 40 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2006035845	A1	20060216	US 2005-201685	20050810
WO 2006018698	A2	20060223	WO 2005-IB2406	20050810
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI US 2004-601087P	P	20040812		
US 2004-603315P	P	20040819		

OS MARPAT 144:226279
AB The present invention is directed to methods for the prevention and treatment of inflammatory diseases, disorders, and conditions of gastrointestinal tract by administering to a patient in need of such treatment, conjugate compds. of Formula VII (M-L-T) having low oral-bioavailability, or pharmaceutically acceptable salts, prodrugs, or solvate thereof: wherein M represents a macrolide subunit possessing the property of accumulation in inflammatory cells, T represents an anti-inflammatory subunit that can be a steroid or nonsteroid (nonsteroidal moiety) derived from a non-steroid drug with anti-inflammatory, analgesic and/or antipyretic activity (NSAID) and L represents a linker covalently linking M and T. The present disclosure is also directed to pharmaceutical compns. containing conjugate compds. of Formula VII having low oral-bioavailability.
IT 53597-27-6D, Fendosal, conjugates with macrolides
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of immune cell specific conjugates of macrolides linked to an anti-inflammatory subunit with low bioavailability for treatment of inflammatory diseases of gastrointestinal tract)
RN 53597-27-6 CAPLUS
CN Benzoic acid, 5-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)

L9 ANSWER 17 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 18 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:100738 CAPLUS
DN 144:198849
TI Novel dosage form comprising modified-release and immediate-release active ingredients
IN Vaya, Navin; Karan, Rajesh Singh; Sadanand, Sunil; Gupta, Vinod Kumar
PA India
SO U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S. Ser. No. 630,446.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006024365	A1	20060202	US 2005-134633	20050519
	US 2004096499	A1	20040520	US 2003-630446	20030729
PRAI	IN 2002-MU697	A	20020805		
	IN 2002-MU699	A	20020805		
	IN 2003-MU80	A	20030122		
	IN 2003-MU82	A	20030122		
	US 2003-630446	A2	20030729		

AB A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form. Tablets containing 10 mg sodium pravastatin and 1000 mg niacin were prepared The release of sodium pravastatin after 24 h was 67.7%, and the release of niacin after 1 h was 84.1%.
IT 53597-27-6, Fendosal
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel dosage form comprising modified-release and immediate-release active ingredients)
RN 53597-27-6 CAPLUS
CN Benzoic acid, 5-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)



L9 ANSWER 19 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:100022 CAPLUS
DN 144:164251
TI Indole derivatives and their pharmaceutical compositions and methods for treatment of thrombosis
IN Deng, Hongfeng; Lin, Jian; Guo, Zihong; Meyers, Harold V.; Abdel-Meguid, Sherin S.; Babine, Robert E.
PA Daiamed, Inc., USA
SO PCT Int. Appl., 166 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006012504	A2	20060202	WO 2005-US26022	20050722
	WO 2006012504	A3	20060518		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	US 2004-590718P	P	20040723		

OS MARPAT 144:164251
GI

L9 ANSWER 19 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB The invention provides compds. of formula I, pharmaceutical compns., and methods for the treatment of thromboembolic disorders, such as, for example, arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, or thromboembolic disorders in the chambers of the heart. Compds. of formula I wherein W is N or CR6, where R6 is H, halo, OH, (un)substituted C1-6 alkyl, C2-6 alkynyl, C1-6 alkoxy, or C2-6 alkoxyalkyl, etc.; X1 is (H,H) or NR7, where R7 is H, C1-6 alkyl, OH, NH2, NO2, CO2R7a, where R7a is C1-6 alkyl, or R7R7a together forms a 5- to 6-membered ring, etc.; Y is NH or O; R1 is (un)substituted C2-7 alkanoyl, C1-6 alkyl, C2-6 alkenyl, C1-6 alkoxy, or C2-12 alkoxyalkyl, etc.; R2 is H, OH, (un)substituted C1-6 alkyl, C2-6 alkenyl, C1-6 alkoxy, C7-16 aralkoxy, CF3, halo, amidino, N-hydroxyamidino, or guanidino, etc.; R3 is H, or C1-6 alkyl, or R3R5 or R3R7 together form a 5- to 6-membered ring, etc.; R4 is H, (un)substituted C2-7 alkanoyl, C1-6 (amino)alkyl, C2-6 alkenyl, C2-12 alkoxyalkyl, C2-12 alkylsulfonyl, C6 or C10 arum, C7-16 arylalkyl, C7 or C11 aroyl, C1-6 azidoalkyl, carboxaldehyde, carboxamide, etc.; R5 is H, (un)substituted C1-6 alkyl, C2-6 alkenyl, C1-6 alkoxy, carboxamide, C3-8 cycloalkyl, Oh, NO2, CN, C1-6 thioalkoxy, or C1--4 perfluoroalkyl(oxy), etc.; and the pharmaceutically acceptable salts, solvates, active metabolites, or prodrug thereof are claimed in this invention. The compds. in this invention were tested in vitro for their activity against factor XIa, factor Xa and thrombin. The inhibition data (IC50) were determined from the assay. Invention compound II showed IC50 values of 0.87 μM for factor XIa, 82 μM for factor Xa, and 4.3 μM for thrombin.
IT 874757-38-7 874757-42-3
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

L9 ANSWER 19 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(indole derivs. and their methods for treatment of thrombosis)
RN 874757-38-7 CAPLUS
CN Benzoic acid, 2-[3-(aminoiminomethyl)-1H-indol-1-yl]-4-bromo- (9CI) (CA INDEX NAME)



RN 874757-42-3 CAPLUS
CN [1,1'-Biphenyl]-3,4'-dicarboxylic acid, 3'-[3-(aminoiminomethyl)-1H-indol-1-yl]- (9CI) (CA INDEX NAME)



L9 ANSWER 20 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:75243 CAPLUS
DN 144:150384
TI Preparation of 1,4-disubstituted naphthalenes as inhibitors of p38 MAP kinase
IN Ashwell, Mark Antony; Liu, Yanbin; Ali, Syed; Hill, Jason; Wrona, Woj
PA Arqule, Inc., USA
SO PCT Int. Appl., 261 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006010082	A1	20060126	WO 2005-US24441	20050708
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI US 2004-585862P	P	20040708		

OS MARPAT 144:150384
GI



AB In general, the present invention relates to 1,4-disubstituted naphthalenes (shown as I; X is O, NR, CH2, or a bond; R is H or alkyl; R' is H or alkyl; m = 0-2; n is 0, 1, or 2; p is 0, 1, 2, 3, or 4; Ar is aryl; Het is heterocyclic group; Y1 = halogen, alkyl, nitro, hydroxy, and alkyloxy; and Y2 = halogen, alkyl, nitro, hydroxy, and alkyloxy; e.g. 2-(morpholin-4-yl)-N-[4-[2-(morpholin-4-yl)ethoxy]naphthalen-1-yl]isonicotinamide (shown as II)) capable of inhibiting p38 MAP kinase, methods for inhibiting p38 MAP kinase in vivo or in vitro, diagnostics for detg. activity in the treatment of p38 MAP kinase and/or cytokine-assocd. conditions and methods for treating conditions assocd. with p38 MAP kinase activity or cytokine activity. Although the methods of prepn. are not claimed, prepns. and/or characterization data for hundreds of examples of I are included. For example, II was prepd. from morpholine and 2-chloro-N-[4-[2-(morpholin-4-yl)ethoxy]naphthalen-1-yl]isonicotinamide, which was prepd. (51 %) from 2-chloroisonicotinoyl chloride and [4-[2-(morpholin-4-yl)ethoxy]naphthalen-1-yl]amine, which was prepd. (81.3 %) by redn. of 4-[2-(4-nitro-1-naphthalenyloxy)ethyl]morpholine, which was prepd. (92.6 %) from 4-nitro-1-hydroxynaphthalene and 4-(2-chloroethyl)morpholine hydrochloride. Pharmacol. activity is tabulated for >400 examples of I.

IT 61471-45-2, 3-(Pyrrol-1-yl)benzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N-(4-substituted naphthalen-1-yl)carboxamides as inhibitors of p38 MAP kinase)

RN 61471-45-2 CAPLUS
CN Benzoic acid, 3-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 21 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:75092 CAPLUS
DN 144:170792
TI Preparation of trisubstituted nitrogen modulators, particularly N,N-dibenzylarylsulfonamide inhibitors, of tyrosine phosphatases for treating metabolic disorders, autoimmune diseases and neoplasm
IN Semple, Joseph E.; Rideout, Darryl; Nutt, Ruth F.; Shernderovich, Mark; Wang, Jing; Mylvaganam, Shankari; Wu, Feiyue; Tsai, Chung-Ying; Yalamoori, Venkatachalapathi; Loweth, Colin J.
PA Cengent Therapeutics, Inc., USA
SO PCT Int. Appl., 238 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006009876	A2	20060126	WO 2005-US21540	20050617
WO 2006009876	A3	20060330		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006135773	A1	20060622	US 2005-156230	20050617
PRAI US 2004-581251P	P	20040617		
US 2004-634200P	P	20041207		
US 2004-638419P	P	20041222		

OS MARPAT 144:170792
GI





AB The invention is related to the preparation of trisubstituted nitrogen compds. I [L1-L3 = independently N-C single bond (G1, G2, or G3 are directly bonded to N by a single bond), alkylene, sulfonyl, amido, etc.; G1-G3 = alkyl, aryl, cyanobiaryl, etc., optionally substituted with carboxy, phosphonato, phosphonatoalkyl, phosphonatohaloalkyl, amido, etc.], and their pharmaceutically acceptable derivs., including N,N-dibenzylarylsulfonamides. The invention is also related to the use of compds. I, and their compns., for modulating the activity of protein tyrosine phosphatases, especially PTP-1B. Thus, reacting (bromodifluoromethyl)phosphonic acid di-Et ester with bis(4-iodobenzyl)carbamic acid tert-Bu ester (preparation given), followed by reaction with 2-chlorobenzenesulfonyl chloride and ester hydrolysis gave phosphonic acid II. In a pNPP assay, selected I displayed IC50 values of less than 99 nM for the inhibition of PTP-1B. I are useful for treating metabolic disorders, autoimmune diseases and neoplasm.

IT 340225-87-8P, 4-[3-[2-Cyano-2-[(naphthalen-2-yl)carbamoyl]vinyl]-2,5-dimethylpyrrol-1-yl]benzoic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of N,N-dibenzylarylsulfonamide inhibitors of tyrosine phosphatases for treating metabolic disorders, autoimmune diseases and neoplasm)

RN 340225-87-8 CAPLUS
CN Benzoic acid, 4-[3-[2-cyano-3-(2-naphthalenylamino)-3-oxo-1-propenyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 21 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 22 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:54922 CAPLUS
DN 144:150646
TI Preparation of novel ligands with protamine extensions for the HisB10 Zn2+
sites of the R-state insulin hexamer and their use in pharmaceutical preparations comprising insulin
IN Olsen, Helle Birk; Kaarsholm, Niels Christian; Madsen, Peter; Balschmidt, Per
PA Novo Nordisk A/S, Den.
SO PCT Int. Appl., 408 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006005683	A1	20060119	WO 2005-EP53070	20050629
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI DK 2004-1091	A	20040709		

OS MARPAT 144:150646
AB The invention provides novel pharmaceutical prepns. comprising (1) insulin; (2) zinc ions; and (3) ligands of formula CGr-Lnk-Frg-Protamine (I; CGr = a chemical group which binds reversibly to HisB10 Zn2+ site of insulin hexamer selected from carboxylates, phenolates, benzotriazoles, tetrazoles, thiazolidinediones, etc.; Lnk = a linker selected from a valence bond, -B1-B2-SO2-, -B1-B2-NH-, -B1-B2-CO-, -B1-B2-CH2-; B1 = a valence bond, O, S, NH and derivs.; B2 = a valence bond, (un)substituted alk(en/yn)ylene, hetero/arylene, etc.; Frg = fragment containing 0-5 neutral α- or β-amino acids; including acid or base addition salts, and any optical isomers or mixture of optical isomers, racemates, and tautomers) which bind reversibly to HisB10 Zn2+ sites of the R-state insulin hexamer and which are extended by covalent attachment to protamine. About 1000 prepns. for CGr derivs., e.g. CGr-carboxylic acids and derivs., are given.
Eight peptidic ligands I were prepared from salmon protamine sulfate and either 4-[[4-[(2,4-Dioxothiazolidin-5-ylidene)methyl]naphthalen-1-yl]oxy]butyric acid 2,5-dioxopyrrolidin-1-yl ester or 5-[[6-(5-Cyano-1H-[1,2,3]triazol-4-yl)naphthalen-2-yl]oxy]pentanoic acid 2,5-dioxopyrrolidin-1-yl ester. A reduction in plasma glucose level after s.c. injection of a preparation containing 0.6 mM A21G, B28D insulin, 0.3 mM Zn2+, 30 mM PhOH, 1.6% glycerol, 0.3 mM 4-[[4-[(2,4-Dioxothiazolidin-5-

L9 ANSWER 22 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
ylidene)methyl]naphthalen-1-yl]oxy]butyrylprotamine was obsd. The resulting prepns. are capable of prolonging the action of insulin prepn. and are useful for treating Type 1 or Type 2 diabetes.
IT 52034-38-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of ligands with protamine extensions for HisB10 Zn2+ sites of R-state insulin hexamer and their use in pharmaceutical prepns. comprising insulin)
RN 52034-38-5 CAPLUS
CN Benzoic acid, 4-(3-formyl-2,5-dimethyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



IT 333410-16-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of ligands with protamine extensions for HisB10 Zn2+ sites of R-state insulin hexamer and their use in pharmaceutical prepns. comprising insulin)
RN 333410-16-5 CAPLUS
CN Benzoic acid, 4-[3-[(2,4-dioxo-5-thiazolidinylidene)methyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

L9 ANSWER 22 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 23 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1354760 CAPLUS
DN 144:81226
TI A method for preventing gastrointestinal side-effects of a drug or food product
IN Christgau, Stephan; Hansen, Christian; Nilsson, Henrik
PA Osteologix A/S, Den.
SO PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005123098	A2	20051229	WO 2005-DK405	20050617

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI DK 2004-949 A 20040617
AB Methods of alleviating, reducing and/or preventing gastrointestinal (GI) side effects induced by a therapeutically and/or prophylactically active pharmaceutical substance or a food product in an animal including a mammal, the method comprising administration of one or more strontium containing compds. Methods wherein the therapeutically and/or prophylactically active substance or food product responsible for/associated with the GI side effects is administered together with the one or more strontium containing compds.
IT 53597-27-6, Fendosal
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method for preventing gastrointestinal side-effects of drug or food product)
RN 53597-27-6 CAPLUS
CN Benzoic acid, 5-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)



L9 ANSWER 23 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L9 ANSWER 24 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1354741 CAPLUS
DN 144:94351
TI A method of improving treatments in rheumatic and arthritic diseases using strontium salts
IN Christgau, Stephan; Hansen, Christian; Nilsson, Henrik
PA Osteologix A/S, Den.
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 8

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005123193	A2	20051229	WO 2005-DK404	20050617
WO 2005123193	A3	20060302		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2006122274	A1	20060608	US 2005-269289	20051107
PRAI DK 2004-950	A	20040617		
DK 2003-691	A	20030507		
DK 2003-932	A	20030620		
DK 2003-1820	A	20031209		
US 2003-528442P	P	20031209		
WO 2004-DK328	A2	20040506		
WO 2005-DK140	A2	20050228		
WO 2005-DK401	A2	20050617		
WO 2005-DK404	A2	20050617		

AB Improved treatments of joint diseases, such as, e.g. osteoarthritis and rheumatoid arthritis, and pain, comprise a strontium-containing compound administered alone or in combination with one or more second therapeutically and/or prophylactically active substances. The second active substance is selected from the group consisting of bisphosphonates, glucosamine, pallitative agents, analgesic agents, disease modifying anti-rheumatic compds. (DMARDs), selective estrogen receptor modulators (SERMs), aromatase inhibitors, non-steroidal anti-inflammatory agents (NSAIDs), COX-2 inhibitors, COX-3 inhibitors, opioids, inhibitors/antagonists of IL-1, inhibitors/antagonists of TNF-α, inhibitors of matrix metallo-proteinases (MMPs), cathepsin K inhibitors, inhibitors/antagonists of RANK-ligand, statins, glucocorticoids, chondroitin sulfate, NMDA receptor antagonists, inhibitors of interleukin-I converting enzyme, Calcitonin gene related peptide antagonists, glycine antagonists, vanilloid receptor antagonists, inhibitors of inducible nitric oxide synthetase (iNOS), N-acetylcholine receptor agonists, neurokinin antagonists, neuroleptic agents, PAR2 receptor antagonists and anabolic growth factors acting on joint tissue components. Pharmaceutical compns. comprising a strontium-containing compound and a second therapeutically and/or prophylactically active substance as defined above are also described. Thus, a tablet formulation to be administrated one to two times daily contained alendronate 10 mg, strontium malonate 200 mg, lactose 100 mg, corn starch (for mixing) 15 mg, corn starch (for paste) 15 mg, and magnesium stearate 10 mg.
IT 53597-27-6, Fendosal
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral combination of strontium salt and other agents for improvement in treatment of arthritic diseases and associated pain)
RN 53597-27-6 CAPLUS
CN Benzoic acid, 5-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)



L9 ANSWER 24 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L9 ANSWER 25 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1220346 CAPLUS
DN 143:477978
TI Preparation of substituted pyrrolo[2,3-d]pyrimidines as inducers of keratinocyte differentiation
IN Hong, Jiyong; Gray, Nathanael S.; Schultz, Peter
PA IRM LLC, Bermuda
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005107760	A1	20051117	WO 2005-US15118	20050429

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2004-567346P P 20040430
OS MARPAT 143:477978
GI


I


II

AB The invention provides compds. I [n = 0-2; W = NR4, S, O, SO, SO2 (wherein R4 = H, alkyl); R1 = arylalkyl, heteroarylalkyl, cycloalkylalkyl, etc.; R2 = arylalkyl, heteroarylalkyl, cycloalkylalkyl, etc.; R3 = halo, OH, XSR5, etc. (X = a bond, alkylene; R5 = H, alkyl, cycloalkylalkyl)], pharmaceutical compns. comprising such compds. and methods of using such compds. to induce undifferentiated keratinocytes to differentiate into terminally differentiated keratinocytes. The invention further provides compds. for the treatment of diseases or disorders associated with casein kinase II (CK2), TANK-binding kinase 1 (TBK1) and NIMA-related kinase 9 (NEK9). Over 200 compds. I were prepd. E.g., a 4-step synthesis of II, starting from 5-bromo-2,4-dichloropyrimidine, was given.

IT **863597-39-1P 863597-75-5P 863597-89-1P**
863598-02-1P 863598-06-5P 863599-10-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted pyrrolo[2,3-d]pyrimidines as inducers of keratinocyte differentiation)

RN 863597-39-1 CAPLUS
CN Benzoic acid, 4-[2-[(5-methoxy-2-methylphenyl)amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 863597-75-5 CAPLUS
CN Benzoic acid, 3-[5-chloro-2-[(3,4,5-trimethoxyphenyl)amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 863597-89-1 CAPLUS
CN Benzoic acid, 3-[2-[(3,4,5-trimethoxyphenyl)amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 863598-02-1 CAPLUS
CN Benzoic acid, 2-amino-5-[2-[(3,4,5-trimethoxyphenyl)amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 863598-06-5 CAPLUS
CN Benzoic acid, 2-(acetylamino)-5-[2-[(3,4,5-trimethoxyphenyl)amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 863599-10-4 CAPLUS
CN Benzoic acid, 2-[2-[(3,4,5-trimethoxyphenyl)amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 26 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:1046388 CAPLUS

DN 143:398889

TI Lead Validation and SAR Development via Chemical Similarity Searching; Application to Compounds Targeting the pY+3 Site of the SH2 Domain of p56lck

AU Macias, Alba T.; Mia, Md. Younus; Xia, Guanjun; Hayashi, Jun; MacKerell, Alexander D., Jr.

CS Department of Pharmaceutical Sciences, University of Maryland, Baltimore, MD, 21201, USA

SO Journal of Chemical Information and Modeling (2005), 45(6), 1759-1766
CODEN: JCISD8; ISSN: 1549-9596

PB American Chemical Society

DT Journal

LA English

AB Compound selection based on chemical similarity has been used to validate active "parent" compds. identified via database searching as viable lead compds. and to obtain initial structure-activity relationships for those leads. Twelve parent compds. that have inhibitory activity against the SH2 domain of the p56 T-cell tyrosine kinase (Lck) are the focus of this study. Lck is involved in the T-cell mediated immune response, and inhibitors of Lck protein-protein interactions could potentially be used to develop novel immunosuppressants. Similarity searches for each parent compound were performed using 2D structural fingerprints on a database containing 1 300 000 com. available compds. The inhibitory activity of the selected compds. was assessed using enzyme immunoassay (EIA). In general, the most active parent compds. yield the most high activity similar compds.; however, in two cases low activity parent compds. (i.e.inhibitory activity < 25% at 100 μM) yielded multiple similar compds. with activities > 60%. Such compds. may, therefore, be considered as viable lead compds. for optimization. Structure-activity relationships were explored by examining both ligand structures and their computed bound conformations to the protein. Functional groups common to the active compds. as well as key amino acid residues that form hydrogen bonds with the active compds. were identified. This information will act as the basis for the rational optimization of the lead compds.

IT 430471-60-6 431982-96-6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lead validation and SAR development via chemical similarity searching; application to compds. targeting pY+3 site of p56lck SH2 domain)

RN 430471-60-6 CAPLUS

CN Benzoic acid, 4-[2,5-dimethyl-3-[[3-[2-[(4-methylphenyl)amino]-2-oxoethyl]-2,4-dioxo-5-thiazolidinylidene]methyl]-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 26 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 431982-96-6 CAPLUS

CN Benzoic acid, 3-[2,5-dimethyl-3-[[3-[2-[(4-methylphenyl)amino]-2-oxoethyl]-2,4-dioxo-5-thiazolidinylidene]methyl]-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 26 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 27 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:962258 CAPLUS

DN 143:266947

TI Preparation of pyrrolopyrimidines and their analogs as protein kinase inhibitors

IN Choi, Ha-Soon; Wang, Zhicheng; Gray, Nathanael Schiander; Gu, Xiang-Ju; He, Xiaohui; He, Yun; Jiang, Tao; Liu, Yi; Richmond, Wendy; Sim, Taebo; Yang, Kunyong

PA IRM LLC, Bermuda

SO PCT Int. Appl., 63 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005080393	A1	20050901	WO 2005-US4630	20050214
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI US 2004-544944P	P	20040214		

OS MARPAT 143:266947

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention provides a novel class of compds. I-V [n = 0-2; m = 0-3; W = NR4, S, O, SO, SO2 (wherein R4 = H, alkyl); R1 = (un)substituted (hetero)arylakyl, (hetero)cycloalkyl; R2 = (un)substituted (hetero)arylakyl, (hetero)cycloalkyl; R3 = halo, OH, XSR5, etc. (X = a bond, alkylene; R5 = H, alkyl, cycloalkylalkyl)], pharmaceutical compns. comprising such compds. and methods of using such compds. to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the FAK, Abl, BCR-Abl, PDGF-R, c-Kit, NPM-ALK, Flt-3, JAK2 and c-Met kinases. Over 200 compds. I-V were prepared and characterized. The preparation of the compds. I is illustrated in examples. E.g., synthesis of I [R1 = 3,4,6-(MeO)3C6H2; R2 = 2-pyridyl; R3 = H; W = NH], starting from 5-bromo-2,4-dichloropyrimidine, was given. The compds. I-V were tested against various kinases. For example, they inhibit the enzyme activity by 50% (IC50), in a concentration of from 0.001 to 0.5 μM, especially from 0.01 to 0.1 μM.

IT 863597-39-1P 863597-75-5P 863597-89-1P 863598-02-1P 863598-06-5P 863599-10-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

L9 ANSWER 27 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(Uses)
(prepn of pyrrolopyrimidines and their analogs as protein kinase inhibitors)
RN 863597-39-1 CAPLUS
CN Benzoic acid, 4-[2-[(5-methoxy-2-methylphenyl)amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 863597-75-5 CAPLUS
CN Benzoic acid, 3-[5-chloro-2-[(3,4,5-trimethoxyphenyl)amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 863597-89-1 CAPLUS
CN Benzoic acid, 3-[2-[(3,4,5-trimethoxyphenyl)amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 863598-02-1 CAPLUS

L9 ANSWER 27 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzoic acid, 2-amino-5-[2-[(3,4,5-trimethoxyphenyl)amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 863598-06-5 CAPLUS
CN Benzoic acid, 2-(acetylamino)-5-[2-[(3,4,5-trimethoxyphenyl)amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 863599-10-4 CAPLUS
CN Benzoic acid, 2-[2-[(3,4,5-trimethoxyphenyl)amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 28 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:961905 CAPLUS
DN 143:260403
TI Protein kinase inhibitors and methods for identifying same
IN Lawrence, David S.
PA Albert Einstein College of Medicine of Yeshiva University, USA
SO PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005079300	A2	20050901	WO 2005-US4410	20050214
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI US 2004-544376P	P	20040213		

OS MARPAT 143:260403
AB Inhibitors of protein kinase C (PKC)α, PKCδ and PKCζ are provided which are selective for those PKC isotypes. Combinatorial libraries for identifying protein kinases are also provided, as are methods of identifying protein kinases using those libraries. Addnl., methods of treating a mammal having a deleterious condition, where the condition is dependent on a protein kinase for induction or severity, are provided. Methods of inhibiting protein kinases are also provided.
IT 22106-33-8D, conjugates with consensus peptides
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(protein kinase C inhibitors and methods for identifying same for disease treatment)
RN 22106-33-8 CAPLUS
CN Benzoic acid, 4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



L9 ANSWER 29 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:902714 CAPLUS
DN 143:235463
TI Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
IN Proehl, Gerald T.; Olmstead, Kay; Hall, Warren
PA Santarus, Inc., USA
SO PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005076987	A2	20050825	WO 2005-US3791	20050204
WO 2005076987	A3	20060608		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005249806	A1	20051110	US 2005-51260	20050204
PRAI US 2004-543636P	P	20040210		

AB Pharmaceutical compns. comprising a proton pump inhibitor, one or more buffering agent and a nonsteroidal anti-inflammatory drug are described. Methods are described for treating gastric acid-related disorders and treating inflammatory disorders, using pharmaceutical compns. comprising a proton pump inhibitor, a buffering agent, and a nonsteroidal anti-inflammatory drug. For example, a powder for suspension formulation contained omeprazole 20 mg, ibuprofen 400 mg, sodium bicarbonate 1895 mg, Xylitol 300 (sweetener) 2000 mg, sucrose (sweetener) 1750 mg, sucralose (sweetener) 125 mg, xanthan gum 17 mg, peach flavor 47 mg, and peppermint 26 mg.
IT 53597-27-6, Fendosal
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of proton pump inhibitor, buffering agent, and NSAID agent
for treatment of gastric acid-related disorders and inflammation)
RN 53597-27-6 CAPLUS
CN Benzoic acid, 5-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)



L9 ANSWER 29 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L9 ANSWER 30 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:823544 CAPLUS
DN 143:206470
TI Amphiphilic macromolecules for treating diseases
IN Uhrich, Kathryn E.; Moghe, Prabhas
PA Rutgers, the State University, USA
SO PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005074887	A2	20050818	WO 2005-US2900	20050131
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI US 2004-540765P	P	20040130		
US 2004-540867P	P	20040130		

AB Biomedical uses of amphiphilic macromols. include the use of such macromols. in the form of nanoparticle formulations for the sequestration and/or removal of LDL, and for the treatment and prevention of atherosclerosis and atherosclerotic development. The invention also provides the use of amphiphilic macromol. encapsulates for treating diseases including cancer and inflammation, as well as targeted amphiphilic macromols. and their use in therapy. Cellular uptake and intracellular retention of amphiphilic scorpion-like macromols. (AScMs) was demonstrated in vitro using human umbilical vein endothelial cells (HUVEC). AScMs were shown to be rapidly internalized into the HUVEC. Cellular uptake was shown to be time- and AScM concentration-dependent, and the micelles were mainly localized in the cytoplasm. Interactions between LDL and AScMs were confirmed using both dynamic light scattering and transmission electron microscopy. LDL-AScM complexes of about 60-90 nm in size were detected and visualized, which demonstrated that LDL may be sequestered by the anionic AScMs.
IT 53597-27-6, Fendosal
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as antiinflammatory compound associated with targeting amphiphilic macromol.; amphiphilic macromols. for removing LDL, treating and preventing atherosclerosis and treating cancer and inflammation)
RN 53597-27-6 CAPLUS
CN Benzoic acid, 5-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)

L9 ANSWER 30 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 31 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:696779 CAPLUS
DN 143:179636
TI Lipid-based dispersions for drug delivery
IN Hu, Ning; Jensen, Gerard M.; Yang, Stephanie; Su-ming, Chiang
PA Gilead Sciences, Inc., USA
SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005070465	A2	20050804	WO 2005-US1149	20050114
WO 2005070465	A3	20060413		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005238705	A1	20051027	US 2005-35755	20050114
PRAI US 2004-536459P	P	20040114		

AB The invention provides lipid-based dispersion comprising comprising, phosphatidylcholine, an anionic phospholipid, up to 1% cholesterol by weight of total lipids, and a therapeutic agent, wherein the mean particle size measured by dynamic light scattering is <100 nm. The invention also provides pharmaceutical compns. comprising such a dispersion as well as methods of producing a therapeutic effect in a mammal comprising administering an effective amount of such a dispersion.
Soy-phosphatidylcholine, DSPG, and propofol were dissolved in a 1:1 mixture of methanol and chloroform at a molar ratio of Soy-PC:DSPG of 1:0.4 and a weight ratio of (Soy-PC + DSPG):propofol of 10:1. Solvents were removed by evaporation and the films were then hydrated in 9% sucrose at desired drug concns. and sonicated to form liposomes.
IT 53597-27-6, Fendosal
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lipid-based dispersions for drug delivery)
RN 53597-27-6 CAPLUS
CN Benzoic acid, 5-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)

L9 ANSWER 31 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 32 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:600367 CAPLUS
DN 143:318346
TI Development and exploitation of CK2 inhibitors
AU Sarno, Stefania; Ruzzene, Maria; Frascella, Pietrogiulio; Pagano, Mario A.; Meggio, Flavio; Zambon, Alfonso; Mazzorana, Marco; Di Maira, Giovanni; Lucchini, Vittorio; Pinna, Lorenzo A.
CS Dipartimento di Chimica Biologica, Universita' di Padova, Padua, Italy
SO Molecular and Cellular Biochemistry (2005), 274(1&2), 69-76
CODEN: MCBIB8; ISSN: 0300-8177
PB Springer
DT Journal
LA English
AB A number of quite specific and fairly potent inhibitors of protein kinase CK2, belonging to the classes of condensed polyphenolic compds., tetrabromobenzimidazole/triazole derivs. and indoloquinazolines are available to date. The structural basis for their selectivity is provided by a hydrophobic pocket adjacent to the ATP/GTP binding site, which in CK2 is smaller than in the majority of other protein kinases due to the presence of a number of residues whose bulky side chains are generally replaced by smaller ones. Consequently a doubly substituted CK2 mutant V66A,I174A is much less sensitive than CK2 wild type to these classes of inhibitors. The most efficient inhibitors both in terms of potency and selectivity are 4,5,6,7-tetrabromo-1H-benzotriazole, TBB (Ki = 0.4 μM), the TBB derivative 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole, DMAT (Ki = 0.040 μM), the emodin related coumarinic compound 8-hydroxy-4-methyl-9-nitrobenzo[g]chromen-2-one, NBC (Ki = 0.22 μM) and the indoloquinazoline derivative ([5-oxo-5,6-dihydroindolo-(1,2a)quinazolin-7-yl]acetic acid), IQA (Ki = 0.17 μM). These inhibitors are cell permeable as judged from ability to block CK2 in living cells and they have been successfully employed, either alone or in combination with CK2 mutants refractory to inhibition, to dissect signaling pathways affected by CK2 and to identify the endogenous substrates of this pleiotropic kinase. By blocking CK2 these inhibitors display a remarkable pro-apoptotic efficacy on a number of tumor derived cell lines, a property which can be exploited in perspective to develop antineoplastic drugs.
IT 865357-23-9
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(structure-activity relationship studies, development and exploitation of CK2 inhibitors)
RN 865357-23-9 CAPLUS
CN 1H-Indole-3-acetic acid, 2-amino-1-(2-carboxyphenyl)- (9CI) (CA INDEX NAME)

L9 ANSWER 32 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 33 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:572457 CAPLUS
DN 143:90985
TI Identification of active-site inhibitors of glycosyltransferases using a generalizable high-throughput screen
IN Kahne, Suzanne Walker; Kahne, Daniel
PA USA
SO U.S. Pat. Appl. Publ., 26 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2005142629	A1	20050630	US 2003-748335	20031230
PRAI US 2003-748335		20031230		

OS MARPAT 143:90985
AB A method is described for identifying a compound that modulates the ability of a glycosyltransferase to bind a substrate, comprising combining a glycosyltransferase, a labeled substrate, and a compound, in a reaction vessel, under conditions known to be suitable for the glycosyltransferase to bind the labeled substrate, measuring an amount of labeled substrate bound to the glycosyltransferase, and comparing the amount to a standardized amount to identify a relative increase or decrease in substrate bound glycosyltransferase, thereby identifying a compound that modulates the ability of the glycosyltransferase to bind the substrate. A composition comprising an effective amount of a compound that inhibits the ability of a glycosyltransferase to bind a substrate, in a pharmaceutically acceptable carrier, is also provided. The invention further provides methods for controlling the growth of bacteria using the compds. of the invention. Compds. of the invention include e.g. 5-(4-tert-butylbenzylidene)-3-(4-methylpiperidin-1-ylmethyl)-2-thioxothiazolidin-4-one. Preparation of a fluoresceinated UDP-N-acetylglucosamine analog is included.
IT 347385-19-7 347385-19-7D, stereoisomers and salts
347387-81-9 347387-81-9D, stereoisomers and salts
347389-31-5 347389-31-5D, stereoisomers and salts
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(glycosyltransferases inhibitor screening and use for controlling growth of bacteria)
RN 347385-19-7 CAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-[3-[[1-(2-fluorophenyl)tetrahydro-4,6-dioxo-2-thioxo-5(2H)-pyrimidinylidene]methyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 33 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 347385-19-7 CAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-[3-[[1-(2-fluorophenyl)tetrahydro-4,6-dioxo-2-thioxo-5(2H)-pyrimidinylidene]methyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 347387-81-9 CAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-[3-[[1-(3-chlorophenyl)tetrahydro-4,6-dioxo-2-thioxo-5(2H)-pyrimidinylidene]methyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 33 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 347389-31-5 CAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-[3-[[1-(4-chlorophenyl)tetrahydro-4,6-dioxo-2-thioxo-5(2H)-pyrimidinylidene]methyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



L9 ANSWER 33 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 347387-81-9 CAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-[3-[[1-(3-chlorophenyl)tetrahydro-4,6-dioxo-2-thioxo-5(2H)-pyrimidinylidene]methyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 347389-31-5 CAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-[3-[[1-(4-chlorophenyl)tetrahydro-4,6-dioxo-2-thioxo-5(2H)-pyrimidinylidene]methyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 34 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:523415 CAPLUS
DN 143:59814
TI Preparation of aryl-substituted pyrroles as prostanoid EP1 inhibitors useful for treating inflammation
IN Giblin, Gerard Martin Paul; Hall, Adrian; Healy, Mark Patrick; Lewell, Xiao Qing; Miller, Neil Derek; Novelli, Riccardo; King, Francis David; Naylor, Alan
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005054191	A1	20050616	WO 2004-EP13744	20041130
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI GB 2003-28024	A	20031203		

OS MARPAT 143:59814
GI



AB Title compds. I [A = aryl, heterocyclyl, etc.; B = Ph, pyridyl; Z = O, SO0-2; R1 = carboxy, CN, alkoxy, etc.; R2a-2b = H, halo, alkyl, etc.; Rx = alkyl, etc.; R8 = H, Cl, CF3, etc.; R9 = halo, H, CF3, alkyl] are prepared
For instance, 6-[2-(5-Chloro-2-benzyloxyphenyl)-5-methylpyrrol-1-yl]picolinic is prepared via the metalation/carboxylation of 6-[2-(5-chloro-2-benzyloxyphenyl)-5-methylpyrrol-1-yl]-2-bromopyridine. Compds. of the invention have an antagonist pIC50 = 6.0 to 9.0 at EP1 receptors and pIC50 < 6.0 at EP3 receptors. I are useful in the treatment
of inflammatory disorders.
IT **854195-23-6P**, 3-[2-(5-Chloro-2-hydroxyphenyl)-5-trifluoromethylpyrrol-1-yl]benzoic acid

L9 ANSWER 34 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of aryl-substituted pyrroles as prostanoid EP1 inhibitors useful for treating inflammation)
RN 854195-23-6 CAPLUS
CN Benzoic acid, 3-[2-(5-chloro-2-hydroxyphenyl)-5-(trifluoromethyl)-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



IT 632622-01-6P, 3-[2-[5-Chloro-2-(2,4-difluorobenzyloxy)phenyl]-5-methylpyrrol-1-yl]-6-methylbenzoic acid 632624-11-4P,

4-[2-[5-Trifluoromethyl-2-(2,4-difluorobenzyloxy)phenyl]-5-methylpyrrol-1-yl]-6-methylbenzoic acid 632624-18-1P, 3-[2-[5-Chloro-2-(2-fluoro-4-bromobenzyloxy)phenyl]-5-methylpyrrol-1-yl]-6-methylbenzoic acid 632624-32-9P, 3-[2-[5-Chloro-2-(2,6-difluorobenzyloxy)phenyl]-5-methylpyrrol-1-yl]-6-methylbenzoic acid 854192-21-5P, 3-[2-(5-Bromo-2-methoxyphenyl)-5-methylpyrrol-1-yl]-6-methylbenzoic acid 854192-76-0P, 3-[2-[5-Chloro-2-(2,4-dimethylbenzyloxy)phenyl]-5-methylpyrrol-1-yl]-6-methylbenzoic acid 854192-78-2P, 3-[2-[5-Chloro-2-(2,6-dichlorobenzyloxy)phenyl]-5-methylpyrrol-1-yl]-6-methylbenzoic acid 854192-80-6P, 3-[2-[5-Chloro-2-(3,4-difluorobenzyloxy)phenyl]-5-methylpyrrol-1-yl]-6-methylbenzoic acid 854192-82-8P, 3-[2-[5-Chloro-2-(2-fluoro-4-trifluoromethylbenzyloxy)phenyl]-5-methylpyrrol-1-yl]-6-methylbenzoic acid 854192-84-0P, 3-[2-[5-Chloro-2-(2-methylbenzyloxy)phenyl]-5-methylpyrrol-1-yl]-6-methylbenzoic acid 854192-86-2P,

3-[2-[5-Chloro-2-(4-trifluoromethylbenzyloxy)phenyl]-5-methylpyrrol-1-yl]-6-methylbenzoic acid 854192-88-4P, 3-[2-[5-Chloro-2-(2,5-difluorobenzyloxy)phenyl]-5-methylpyrrol-1-yl]-6-methylbenzoic acid 854192-90-8P, 3-[2-[5-Chloro-2-(2-chlorobenzyloxy)phenyl]-5-methylpyrrol-1-yl]-6-methylbenzoic acid 854192-92-0P,

3-[2-[5-Chloro-2-(2,3,6-trifluorobenzyloxy)phenyl]-5-methylpyrrol-1-yl]-6-methylbenzoic acid 854192-94-2P, 3-[2-[5-Chloro-2-(2-chloro-6-fluorobenzyloxy)phenyl]-5-methylpyrrol-1-yl]-6-methylbenzoic acid 854192-96-4P, 3-[2-[5-Chloro-2-(2-fluoro-4-chlorobenzyloxy)phenyl]-5-methylpyrrol-1-yl]-6-methylbenzoic acid 854192-98-6P,

3-[2-[5-Chloro-2-(2-chloro-4-fluorobenzyloxy)phenyl]-5-methylpyrrol-1-yl]-6-methylbenzoic acid 854193-01-4P, 3-[2-[5-Chloro-2-(2-

L9 ANSWER 34 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
fluorobenzyloxy)phenyl]-5-methylpyrrol-1-yl]-6-methylbenzoic acid 854193-03-6P, 3-[2-[5-Chloro-2-(4-chlorobenzyloxy)phenyl]-5-methylpyrrol-1-yl]-6-methylbenzoic acid 854193-05-8P, 3-[2-[5-Chloro-2-(2,4-dichlorobenzyloxy)phenyl]-5-methylpyrrol-1-yl]-6-methylbenzoic acid 854193-21-0P, 3-[2-(5-Bromo-2-hydroxyphenyl)-5-methylpyrrol-1-yl]-6-methylbenzoic acid 854194-77-7P, 3-[2-(5-Chloro-2-isobutoxyphenyl)-5-methylpyrrol-1-yl]-6-methylbenzoic acid sodium salt 854194-81-3P, 3-[2-(5-Chloro-2-isobutoxyphenyl)-5-methylpyrrol-1-yl]benzoic acid sodium salt 854194-83-5P, 3-[2-(5-Bromo-2-isobutoxyphenyl)-5-methylpyrrol-1-yl]benzoic acid sodium salt 854194-85-7P, 3-[2-(5-Bromo-2-isobutoxyphenyl)-5-methylpyrrol-1-yl]-6-methylbenzoic acid sodium salt 854194-87-9P, 3-[2-(5-Chloro-2-cyclopentylmethoxyphenyl)-5-methylpyrrol-1-yl]benzoic acid sodium salt 854194-89-1P, 3-[2-(5-Chloro-2-cyclopentylmethoxyphenyl)-5-methylpyrrol-1-yl]-6-methylbenzoic acid sodium
salt 854194-91-5P, 3-[2-(5-Bromo-2-cyclopentylmethoxyphenyl)-5-methylpyrrol-1-yl]benzoic acid sodium salt 854194-93-7P, 3-[2-(5-Bromo-2-cyclopentylmethoxyphenyl)-5-methylpyrrol-1-yl]-6-methylbenzoic acid sodium salt 854194-95-9P, 3-[2-(5-Chloro-2-isobutoxyphenyl)-5-methylpyrrol-1-yl]-6-fluorobenzoic acid sodium salt 854194-97-1P, 3-[2-(5-Bromo-2-isobutoxyphenyl)-5-methylpyrrol-1-yl]-6-fluorobenzoic acid sodium salt 854194-99-3P, 3-[2-(5-Bromo-2-cyclopentylmethoxyphenyl)-5-methylpyrrol-1-yl]-6-fluorobenzoic acid sodium salt 854195-01-0P, 3-[2-(5-Chloro-2-cyclopentylmethoxyphenyl)-5-methylpyrrol-1-yl]-6-fluorobenzoic acid sodium salt 854195-25-8P,

3-[2-[5-Chloro-2-(2,4-difluorobenzyloxy)phenyl]-5-trifluoromethylpyrrol-1-yl]benzoic acid 854195-27-0P, 3-[2-[5-Chloro-2-(4-fluorobenzyloxy)phenyl]-5-trifluoromethylpyrrol-1-yl]benzoic acid 854195-29-2P, 3-[2-[5-Chloro-2-(2,6-difluorobenzyloxy)phenyl]-5-trifluoromethylpyrrol-1-yl]benzoic acid 854195-31-6P, 3-[2-[5-Chloro-2-(2-fluorobenzyloxy)phenyl]-5-trifluoromethylpyrrol-1-yl]benzoic acid 854195-33-8P, 3-[2-(5-Bromo-2-isobutoxyphenyl)-5-methylpyrrol-1-yl]-6-methylbenzoic acid 854195-35-0P, 3-[2-(2-Benzyloxyphenyl)pyrrol-1-yl]benzoic acid 854195-37-2P, 3-[2-(5-Chloro-2-benzyloxyphenyl)pyrrol-1-yl]benzoic acid 854195-39-4P, 3-[2-(5-Chloro-2-isobutyloxyphenyl)pyrrol-1-yl]-6-fluorobenzoic acid sodium salt 854195-41-8P, 3-[2-(5-Bromo-2-isobutyloxyphenyl)pyrrol-1-yl]-6-fluorobenzoic acid 854195-56-5P, 3-[2-(5-Chloro-2-benzyloxyphenyl)-5-chloropyrrol-1-yl]benzoic acid sodium salt
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of aryl-substituted pyrroles as prostanoid EP1 inhibitors useful for treating inflammation)
RN 632622-01-6 CAPLUS
CN Benzoic acid, 5-[2-[5-chloro-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)

L9 ANSWER 34 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632624-11-4 CAPLUS
CN Benzoic acid, 4-[2-[2-[(2,4-difluorophenyl)methoxy]-5-(trifluoromethyl)phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 632624-18-1 CAPLUS
CN Benzoic acid,
5-[2-[2-[(4-bromo-2-fluorophenyl)methoxy]-5-chlorophenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)

L9 ANSWER 34 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632624-32-9 CAPLUS
CN Benzoic acid, 5-[2-[5-chloro-2-[(2,6-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 854192-21-5 CAPLUS
CN Benzoic acid, 5-[2-(5-bromo-2-methoxyphenyl)-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)



L9 ANSWER 34 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 854192-76-0 CAPLUS
CN Benzoic acid, 5-[2-[5-chloro-2-[(2,4-dimethylphenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 854192-78-2 CAPLUS
CN Benzoic acid, 5-[2-[5-chloro-2-[(2,6-dichlorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 854192-80-6 CAPLUS
CN Benzoic acid, 5-[2-[5-chloro-2-[(3,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)

L9 ANSWER 34 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 854192-86-2 CAPLUS
CN Benzoic acid, 5-[2-[5-chloro-2-[[4-(trifluoromethyl)phenyl]methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 854192-88-4 CAPLUS
CN Benzoic acid, 5-[2-[5-chloro-2-[(2,5-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)

L9 ANSWER 34 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 854192-82-8 CAPLUS
CN Benzoic acid, 5-[2-[5-chloro-2-[[2-fluoro-4-(trifluoromethyl)phenyl]methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 854192-84-0 CAPLUS
CN Benzoic acid, 5-[2-[5-chloro-2-[(2-methylphenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)

L9 ANSWER 34 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 854192-90-8 CAPLUS
CN Benzoic acid, 5-[2-[5-chloro-2-[(2-chlorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 854192-92-0 CAPLUS
CN Benzoic acid, 5-[2-[5-chloro-2-[(2,3,6-trifluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)

L9 ANSWER 34 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 854192-94-2 CAPLUS
CN Benzoic acid,
5-[2-[5-chloro-2-[(2-chloro-6-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 854192-96-4 CAPLUS
CN Benzoic acid,
5-[2-[5-chloro-2-[(4-chloro-2-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)

L9 ANSWER 34 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 854193-03-6 CAPLUS
CN Benzoic acid, 5-[2-[5-chloro-2-[(4-chlorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 854193-05-8 CAPLUS
CN Benzoic acid, 5-[2-[5-chloro-2-[(2,4-dichlorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)



L9 ANSWER 34 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 854192-98-6 CAPLUS
CN Benzoic acid,
5-[2-[5-chloro-2-[(2-chloro-4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 854193-01-4 CAPLUS
CN Benzoic acid, 5-[2-[5-chloro-2-[(2-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)

L9 ANSWER 34 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 854193-21-8 CAPLUS
CN Benzoic acid, 5-[2-(5-bromo-2-hydroxyphenyl)-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 854194-77-7 CAPLUS
CN Benzoic acid,
5-[2-[5-chloro-2-(2-methylpropoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 854194-81-3 CAPLUS
CN Benzoic acid,
3-[2-[5-chloro-2-(2-methylpropoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]-, sodium salt (9CI) (CA INDEX NAME)

L9 ANSWER 34 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na

RN 854194-83-5 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-(2-methylpropoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 854194-85-7 CAPLUS
CN Benzoic acid, 5-[2-[5-bromo-2-(2-methylpropoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl-, sodium salt (9CI) (CA INDEX NAME)

L9 ANSWER 34 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na

RN 854194-87-9 CAPLUS
CN Benzoic acid, 3-[2-[5-chloro-2-(cyclopentylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 854194-89-1 CAPLUS
CN Benzoic acid, 5-[2-[5-chloro-2-(cyclopentylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl-, sodium salt (9CI) (CA INDEX NAME)

L9 ANSWER 34 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na

RN 854194-91-5 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-(cyclopentylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 854194-93-7 CAPLUS
CN Benzoic acid, 5-[2-[5-bromo-2-(cyclopentylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl-, sodium salt (9CI) (CA INDEX NAME)

L9 ANSWER 34 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na

RN 854194-95-9 CAPLUS
CN Benzoic acid, 5-[2-[5-chloro-2-(2-methylpropoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]-2-fluoro-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 854194-97-1 CAPLUS
CN Benzoic acid, 5-[2-[5-bromo-2-(2-methylpropoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]-2-fluoro-, sodium salt (9CI) (CA INDEX NAME)

L9 ANSWER 34 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na

RN 854194-99-3 CAPLUS
CN Benzoic acid, 5-[2-[5-bromo-2-(cyclopentylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]-2-fluoro-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 854195-01-0 CAPLUS
CN Benzoic acid, 5-[2-[5-chloro-2-(cyclopentylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]-2-fluoro-, sodium salt (9CI) (CA INDEX NAME)

L9 ANSWER 34 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na

RN 854195-25-8 CAPLUS
CN Benzoic acid, 3-[2-[5-chloro-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-(trifluoromethyl)-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 854195-27-0 CAPLUS
CN Benzoic acid, 3-[2-[5-chloro-2-[(4-fluorophenyl)methoxy]phenyl]-5-(trifluoromethyl)-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 34 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 854195-29-2 CAPLUS
CN Benzoic acid, 3-[2-[5-chloro-2-[(2,6-difluorophenyl)methoxy]phenyl]-5-(trifluoromethyl)-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 854195-31-6 CAPLUS
CN Benzoic acid, 3-[2-[5-chloro-2-[(2-fluorophenyl)methoxy]phenyl]-5-(trifluoromethyl)-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 854195-33-8 CAPLUS
CN Benzoic acid, 5-[2-[5-bromo-2-(2-methylpropoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)

L9 ANSWER 34 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 854195-35-0 CAPLUS
CN Benzoic acid, 3-[2-[2-(phenylmethoxy)phenyl]-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 854195-37-2 CAPLUS
CN Benzoic acid, 3-[2-[5-chloro-2-(phenylmethoxy)phenyl]-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 854195-39-4 CAPLUS
CN Benzoic acid, 5-[2-[5-chloro-2-(2-methylpropoxy)phenyl]-1H-pyrrol-1-yl]-2-fluoro-, sodium salt (9CI) (CA INDEX NAME)

L9 ANSWER 34 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na

RN 854195-41-8 CAPLUS
CN Benzoic acid, 5-[2-[5-bromo-2-(2-methylpropoxy)phenyl]-1H-pyrrol-1-yl]-2-fluoro- (9CI) (CA INDEX NAME)



RN 854195-56-5 CAPLUS
CN Benzoic acid, 3-[2-chloro-5-[5-chloro-2-(phenylmethoxy)phenyl]-1H-pyrrol-1-yl]-, sodium salt (9CI) (CA INDEX NAME)

L9 ANSWER 34 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 35 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:490281 CAPLUS
DN 143:48056
TI Novel nanoparticulate nimesulide compositions
IN Bosch, H. William; Wertz, Christian F.
PA Elan Pharma International Ltd., Ire.
SO PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005051356	A1	20050609	WO 2003-US32731	20031031
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003303744	A1	20050617	AU 2003-303744	20031031
PRAI WO 2003-US32731	A	20031031		

AB The present invention provides nanoparticulate nimesulide compns. The compns. preferably comprise nimesulide and at least one surface stabilizer adsorbed on or associated with the surface of the nimesulide particles. The nanoparticulate nimesulide particles preferably have an effective average particle size of less than about 2000 nm. The invention also provides methods of making and using nanoparticulate nimesulide compns. An aqueous solution of 1% (weight/weight) Plasdone S-630 was combined with 4.25 g of nimesulide (5% weight/weight) and stirred for 1 h at 4200 rpm with chilled water (10°) recirculated through the milling chamber. The process yielded a colloidal dispersion of nimesulide with a mean particle size of 150 nm, a D50 of 124 nm, a D90 of 256 nm, and a D95 of 293 nm.

IT 53597-27-6, Fendosal
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel nanoparticulate nimesulide compns.)

RN 53597-27-6 CAPLUS
CN Benzoic acid, 5-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

L9 ANSWER 35 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 36 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:369133 CAPLUS
DN 142:435774
TI Compositions treatment of chronic inflammatory diseases
IN Shapiro, Howard K.
PA USA
SO U.S. Pat. Appl. Publ., 44 pp., Cont.-in-part of U.S. Ser. No. 610,073, abandoned.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005090553	A1	20050428	US 2004-924945	20040824
PRAI	US 1992-906909	B2	19920630		
	US 1994-241603	B2	19940511		
	US 1997-814291	B2	19970310		
	US 2000-610073	B2	20000705		

OS MARPAT 142:435774
AB This invention defines novel compns. that can be used for clin. treatment of a class of chronic inflammatory diseases. Increased generation of carbonyl substances, aldehydes and ketones, occurs at sites of chronic inflammation and is common to the etiologies of all of the clin. disorders addressed herein. Such carbonyl substances are cytotoxic and addnl. serve to perpetuate and disseminate the inflammatory process. This invention defines use of compns., the orally administered required primary agents of which are primary amine derivs. of benzoic acid capable of reacting with the carbonyl substances. P-Aminobenzoic acid (or PABA) is an example of the required primary agent of the present invention. PABA has a small mol. weight, is water soluble, has a primary amine group which reacts with carbonyl-containing substances and is tolerated by the body in relatively high dosages for extended periods. The method of the present invention includes administration of a composition comprising: (1) an orally consumed primary agent; (2) a previously known medicament co-agent recognized as effective to treat a chronic inflammatory disease addressed herein administered to the mammalian subject via the oral route, other systemic routes of administration or via the topical route; and (3) optionally 1 or more addnl. orally consumed co-agent selected from the group consisting of antioxidants, vitamins, metabolites at risk of depletion, sulfhydryl co-agents, co-agents which may facilitate glutathione activity and nonabsorbable primary amine polymeric co-agents, so as to produce an additive or synergistic physiol. effect of an anti-inflammatory nature.
IT 53597-27-6, Fendosal
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. treatment of chronic inflammatory diseases)
RN 53597-27-6 CAPLUS
CN Benzoic acid, 5-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)

L9 ANSWER 36 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 37 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:347016 CAPLUS
DN 142:411252
TI Preparation of azabicyclooctane derivatives as CXCR3 antagonists
IN Habashita, Hiromu; Suzuki, Ryo; Shibayama, Shiro; Tanihiro, Tatsuya; Kaneko, Yousuke; Egashira, Hiromu; Nishiyama, Eiji; Yamatsuta, Katsura; Fujita, Setsuko
PA Ono Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 171 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005035534	A1	20050421	WO 2004-JP14864	20041007
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	JP 2003-349033	A	20031008		
	JP 2004-266040	A	20040913		

OS MARPAT 142:411252
GI



I

AB Title compds. I [ring A = (un)substituted heterobicycle, heterotricycle; ring B = (un)substituted cycle; Y = bond, spacer] were prepared For example, 1,3,3-trimethyl-6-(2-naphthoyl)-6-azabicyclo[3.2.1]octane (II) was prepared from 1,3,3-trimethyl-6-azabicyclo[3.2.1]octane. In 11β-HSD1 inhibition assays, the IC50 value of compound II was 29 nM. Compds. I are claimed useful for the treatment of inflammation, allergy, etc. Formulations are given.
IT 850366-02-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of azabicyclooctane derivs. as CXCR3 antagonists for treatment of treatment of inflammation, allery, etc.)
RN 850366-02-8 CAPLUS
CN Benzoic acid, 4-[2,5-dimethyl-3-[(1,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-yl)methyl]-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 37 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 38 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:300395 CAPLUS
DN 142:355054
TI Preparation of amide derivatives as inhibitors of histone deacetylase
IN Moradei, Oscar; Paquin, Isabelle; Leit, Silvana; Frechette, Sylvie; Vaisburg, Arkadii; Besterman, Jeffrey M.; Tessier, Pierre; Mallais, Tammy C.
PA Methylgene, Inc., Can.
SO PCT Int. Appl., 559 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005030705	A1	20050407	WO 2004-US31591	20040924
	WO 2005030705	C2	20060420		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004276337	A1	20050407	AU 2004-276337	20040924
	EP 1663953	A1	20060607	EP 2004-789074	20040924
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,				

HR
PRAI US 2003-505884P P 20030924
US 2003-532973P P 20031229
US 2004-561082P P 20040409
WO 2004-US31591 W 20040924
OS MARPAT 142:355054
GI

L9 ANSWER 38 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB Title compds. I [Ar1 = (un)saturated-, (un)substituted-mono or fused poly-cyclic hydrocarbyl optionally containing 1-4 heteroatoms per ring; R1 = (un)substituted-mono-, -bi-, -tri-cyclic-aryl or -heteroaryl; R2, R3, and R4 independently = H, halo, amino, etc.; R5 and R6 independently = H, alkyl, aryl, etc.; x = 0-1; Y = any pharmaceutically acceptable chemical moiety consisting of 1 to 50 atoms with provisions] and their pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of histone deacetylase. Thus, e.g., II was prepared by Suzuki coupling of 2-bromo-2-nitro-phenylamine (preparation given) with 2-thiopheneboronic acid followed by carbonylation with 4-[3,4-dimethoxy-(phenylamino)-methyl]benzoic acid (preparation given) and subsequent reduction The inhibitory capability of I towards antiproliferative activity of histone deacetylase enzyme was evaluated using 3-[4,5-dimethylthiazol-2-yl-2,5-diphenyltetrazolium] bromide (MTT) assay and it revealed that certain compds. of the invention had MTT IC 50 values in the range of below 1 up to 20 μM. I as histone deacetylase inhibitors should prove useful in the treatment of diseases such as, but not limited to, cell proliferative disease, protozoal disease, and fungal disease.
IT **15898-26-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

L9 ANSWER 38 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(prepn. of amide derivs. as inhibitors of histone deacetylase)
RN 15898-26-7 CAPLUS
CN Benzoic acid, 4-(2,5-dimethyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 39 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:300394 CAPLUS
DN 142:373563
TI Preparation of amide derivatives as inhibitors of histone deacetylase
IN Moradei, Oscar; Paquin, Isabelle; Leit, Silvana; Frechette, Sylvie; Vaisburg, Arkadii; Besterman, Jeffrey M.; Tessier, Pierre; Mallais, Tammy C.
PA Methylgene, Inc., Can.
SO PCT Int. Appl., 389 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005030704	A1	20050407	WO 2004-US31590	20040924
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2003-505884P P 20030924
US 2003-532973P P 20031229
US 2004-561082P P 20040409
OS MARPAT 142:373563
GI

L9 ANSWER 39 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB Title compds. I [Ar1 = (un)saturated-, (un)substituted-mono or fused poly-cyclic hydrocarbyl optionally containing 1-4 heteroatoms per ring; R1 = (un)substituted-mono-, -bi-, -tri-cyclic-aryl or -heteroaryl; R2, R3, and R4 independently = H, halo, amino, etc.; R5 and R6 independently = H, alkyl, aryl, etc.; x = 0-1; Y = any pharmaceutically acceptable chemical moiety consisting of 1 to 50 atoms with provisions] and their pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of histone deacetylase. Thus, e.g., II was prepared by Suzuki coupling of 2-bromo-2-nitro-phenylamine (preparation given) with 2-thiopheneboronic acid followed by carbonylation with 4-[3,4-dimethoxy-(phenylamino)-methyl]benzoic acid (preparation given) and subsequent reduction The inhibitory capability of I towards antiproliferative activity of histone deacetylase enzyme was evaluated using 3-[4,5-dimethylthiazol-2-yl-2,5-diphenyltetrazolium] bromide (MTT) assay and it revealed that certain compds. of the invention had MTT IC 50 values in the range of below 1 up to 20 μM. I as histone deacetylase inhibitors should prove useful in the treatment of diseases such as, but not limited to, cell proliferative disease, protozoal disease, and fungal disease.

IT **15898-26-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

L9 ANSWER 39 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(prepn. of amide derivs. as inhibitors of histone deacetylase)

RN 15898-26-7 CAPLUS

CN Benzoic acid, 4-(2,5-dimethyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 40 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:281773 CAPLUS

DN 142:341906

TI Diclofenac compositions for the treatment of skin disorders

IN Arkin, Moshe; Zeevi, Amira; Cherkez, Stephen; Asculai, Eilon; Abu-gnim, Chalil; Yosha, Ido; Arnon, Michal; Ohayon-Tsahor, Hila; Chen, Oren; Fridler, Galia

PA Agis Industries 1983 Ltd., Israel

SO PCT Int. Appl., 77 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005027977	A2	20050331	WO 2004-IL883	20040922
WO 2005027977	A3	20051208		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005137164	A1	20050623	US 2004-946560	20040922
PRAI US 2003-503883P	P	20030922		

AB Novel NSAID pharmaceutical comps. and methods for the treatment of skin disease and disorders such as actinic keratosis are disclosed. Thus, a topical gel contained diclofenac sodium 3.00, benzyl alc. 1.00, methoxy PEG 20.00, Methocel 2.20, Transcutol 10.00, and water 63.80%.

IT **53597-27-6**, Fendosal
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(diclofenac comps. for treatment of skin disorders)

RN 53597-27-6 CAPLUS

CN Benzoic acid, 5-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)



L9 ANSWER 41 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:177818 CAPLUS

DN 142:266765

TI Penetrating pharmaceutical foam

IN Tamarkin, Dov; Friedman, Doron; Eini, Meir

PA Foamix Ltd., Israel

SO PCT Int. Appl., 68 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005018530	A2	20050303	WO 2004-IB2965	20040820
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004266502	A1	20050303	AU 2004-266502	20040820
CA 2536482	AA	20050303	CA 2004-2536482	20040820
US 2005074414	A1	20050407	US 2004-922358	20040820
US 2005075407	A1	20050407	US 2004-922555	20040820
EP 1663148	A2	20060607	EP 2004-769356	20040820
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
PRAI US 2003-497648P	P	20030825		
WO 2004-IB2965	W	20040820		

AB The invention relates to an alc.-free cosmetic or pharmaceutical foam carrier comprising water, a hydrophobic solvent, a surfactant and a gelling agent. The foam carrier further comprises active agents and excipients with therapeutic properties having enhanced skin penetration. Thus, a foam composition contained lidocaine 4.00 and lactic acid 10.00%.

IT **53597-27-6**, Fendosal
RL: COS (Cosmetic use); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(penetrating pharmaceutical foam)

RN 53597-27-6 CAPLUS

CN Benzoic acid, 5-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)



L9 ANSWER 42 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:158669 CAPLUS
DN 142:261536
TI Preparation of imidazopyridine derivatives as melanin-concentrating hormone
receptor antagonists
IN Kishino, Hiroyuki; Moriya, Minoru; Sakamoto, Toshihiro; Takahashi, Hidekazu; Sakuraba, Shunji; Suzuki, Takao; Kanatani, Akio
PA Banyu Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005016928	A1	20050224	WO 2004-JP11945	20040813
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004265189	A1	20050224	AU 2004-265189	20040813
CA 2535416	AA	20050224	CA 2004-2535416	20040813
EP 1657242	A1	20060517	EP 2004-771906	20040813
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
PRAI JP 2003-207632	A	20030815		
WO 2004-JP11945	W	20040813		

OS MARPAT 142:261536
GI

L9 ANSWER 42 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB Title compds. I [R1, R2 = H, halo, etc., further detail on R1, R2 is given; R3 = H, halo, etc.; R4 = H, alkyl; W = single bond, etc.; Ar = optionally substituted aromatic ring, etc. with R7; R7 = halo, etc.] were prepared For example, Pd-catalyzed hydrogenation of 2-isopropyl-6-nitroimidazo[1,2-a]pyridine hydrobromide followed by HATU-mediated acylation with 4'-fluoro-1,1'-biphenyl-4-carboxylic acid afforded compound
II. In MCH (Melanin Concentrating Hormone) binding inhibition assays, the IC50
value of compound II was 3.1 nM. Compds. I are claimed useful for the treatment of obesity, diabetes, etc.
IT 22106-33-8, 4-(1H-Pyrrol-1-yl)benzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of imidazopyridine derivs. as melanin-concentrating hormone receptor
antagonists for treatment of obesity, diabetes, etc.)
RN 22106-33-8 CAPLUS
CN Benzoic acid, 4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



L9 ANSWER 42 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 43 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:100389 CAPLUS
DN 142:198061
TI New antibiotic compounds, in particular thioxothiazolidinone derivatives, their pharmaceutical compositions containing them and their uses
IN Leonetti, Jean Paul; Andre, Estelle
PA Centre National De La Recherche Scientifique CNRS, Fr.
SO Fr. Demande, 86 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI FR 2858324	A1	20050204	FR 2003-9395	20030730
WO 2005020990	A1	20050310	WO 2004-FR1951	20040722
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1653954	A1	20060510	EP 2004-767752	20040722
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
PRAI FR 2003-9395	A	20030730		
WO 2004-FR1951	W	20040722		

OS MARPAT 142:198061
GI



I



II

AB The invention is related to pharmaceutical compns. containing at least one

L9 ANSWER 43 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
compd. of formula I as active substance in combination with a pharmaceutically acceptable component and their use as antibiotics [X, Y = independently O, S, NH and derivs.; Ra = (un)substituted alk(en)yl; A = (un)substituted 5-6-membered heterocycle selected from thiophene, furan, pyrrole, pyrazole, 1,2,4-thiadiazole, etc.]. For example, II was prepd., in 3 steps, by reacting DL-Methionine Me ester with thiophosgene, followed by cyclocondensation with Me thioglycolate, and condensation with 5-(4-Nitrophenyl)furan-2-carboxaldehyde. II displayed a minimal inhibitory concn. (MIC) of 4 μg/mL against Staphylococcus aureus. I inhibited the complexation of RNA polymerase with sigma-70. I were toxic at 100 μg/mL. Thus, I and their compns. are useful as antibacterial agents.

IT **366464-92-8P 425668-25-3P**
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(antibacterial agent; preparation and pharmaceutical compns. of thioxothiazolidinones and related compds. useful as antibiotics)

RN 366464-92-8 CAPLUS
CN Benzoic acid, 3-[2,5-dimethyl-3-[[4-oxo-3-(2-propenyl)-2-thioxo-5-thiazolidinylidene]methyl]-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 425668-25-3 CAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-[2,5-dimethyl-3-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 43 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 44 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:17015 CAPLUS
DN 142:120515
TI Dispersible formulations containing anti-inflammatory agents and other active ingredients for infusion
IN Britten, Nancy Jean; Waldron, Niki Ann; Watts, Jeffrey L.; Hallberg, John Walter; Burns, John W.
PA USA
SO U.S. Pat. Appl. Publ., 22 pp., Cont.-in-part of U.S. Ser. No. 803,146.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2005004098	A1	20050106	US 2004-909050	20040730
US 2004235803	A1	20041125	US 2004-803146	20040317
AU 2004258745	A1	20050203	AU 2004-258745	20040719
CA 2533101	AA	20050203	CA 2004-2533101	20040719
WO 2005009436	A1	20050203	WO 2004-IB2461	20040719
WO 2005009436	C1	20050506		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1651210	A1	20060503	EP 2004-744112	20040719
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
PRAI US 2003-456325P	P	20030320		
US 2003-492121P	P	20030731		
US 2004-803146	A2	20040317		
WO 2004-IB2461	W	20040719		

OS MARPAT 142:120515
AB A method is provided for treatment and/or prevention of an inflammatory condition in a fluid-containing organ having a natural exterior orifice, such as the udder of a milk-producing animal or an ear of a subject. The invention also relates to a dispersible pharmaceutical composition suitable for infusion into the organ according to the method of the invention, and a process for preparing such a composition For example, a suspension to be administered by intramammary infusion was prepared containing parecoxib 100 mg/mL, Labrafil M-1944CS 50 mg/mL, microcryst. wax 70 mg/mL,, and cottonseed oil q.s.

IT **53597-27-6**, Fendosal
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(dispersible formulation containing anti-inflammatory agents and other active ingredients for infusion)

RN 53597-27-6 CAPLUS
CN Benzoic acid, 5-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)

L9 ANSWER 44 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 45 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:927010 CAPLUS
DN 141:376382
TI Pin1-modulating compounds and methods of use for the treatment of Pin1-associated diseases, including cancer
IN Bao, Lere; Kimzey, Amy
PA Pintex Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 189 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004093803	A2	20041104	WO 2004-US11957	20040416

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-463271P P 20030416
OS MARPAT 141:376382
AB The invention is directed to modulators, e.g., inhibitors, of Pin1 and Pin1-related proteins and the use of such modulators for treatment of Pin1 associated states, e.g., for the treatment of cancer. The present invention aims to provide photochemotherapeutic compds. with increased specificity as compared with known agents.
IT **676654-28-7**
RL: PAC (Pharmacological activity); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(Pin1-modulating compds. for treatment of Pin1-associated diseases, including cancer)
RN 676654-28-7 CAPLUS
CN 3-Thiazolidinebutanoic acid, 5-[[1-(4-carboxyphenyl)-2,5-dihydroxy-1H-pyrrol-3-yl]methylene]-4-oxo-2-thioxo- (9CI) (CA INDEX NAME)

L9 ANSWER 45 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 46 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:905621 CAPLUS
DN 141:360656
TI Opioid inhibitors of ABC drug transporters in microbial cells, and use with antimicrobial compounds for the treatment of microbial infections
IN Schoenhard, Grant L.
PA USA
SO U.S. Pat. Appl. Publ., 69 pp., Cont.-in-part of U.S. Ser. No. 107.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004214848	A1	20041028	US 2002-159212	20020530
US 2003130171	A1	20030710	US 2001-107	20011030
PRAI US 2001-107	A2	20011030		

OS MARPAT 141:360656
AB The present invention relates to microbial infections, including those involving multidrug resistance and, in particular, to opioid compds. that are inhibitors of drug transporters of the ABC protein superfamily. The invention relates to methods of treating microbial infections using anti-microbial agents and opioid inhibitors of such transporters. The invention also relates to methods for selecting or identifying compds. for the ability to inhibit drug transporter proteins and to methods of inhibiting drug transporter proteins. The invention concerns the new use of opioid receptor antagonists in the treatment of microbial infections, including multidrug resistant microbial infections.
IT **432492-45-0**
RL: PRP (Properties)
(opioid inhibitors of ABC drug transporters in microbial cells, and use with antimicrobial compds. for treatment of microbial infections)
RN 432492-45-0 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-(3-carboxy-2,4,6-trimethylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



L9 ANSWER 47 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:878364 CAPLUS
DN 141:366035
TI Preparation of hydroxynaphthyl amides as Vanilloid receptor 1 inhibitors
IN Besidski, Yevgeni; Rotticci, Didier; Johnstone, Shawn
PA Astrazeneca Ab, Swed.
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004089877	A1	20041021	WO 2004-SE573	20040413

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI SE 2003-1120 A 20030414
SE 2004-102 A 20040119
OS MARPAT 141:366035
GI



I

AB Title compds. represented by the formula I [wherein R1 = R3 = H; R2 = methylamino(alkyl), (un)substituted (hetero)arylalkyl; R4, R5 = independently H, halo, nitro, CHO, carbonylalkyl; and pharmaceutically acceptable salts, solvates or solvates salts thereof] were prepared as Vanilloid receptor 1 (VR1) inhibitors. For example, reaction of 4-methoxybenzyl alc. with 7-hydroxy-1-naphthyl isocyanate gave I (R1 = R3 = R4 = R5 = H, R2 = 4-MeOC6H4CH2) in 74% yield. I (R1 = R3 = R4 = R5 = H, R2 = 3,4-F2C6H4CH2NH, 4-Me3CC6H4NH, 4-F3COC6H4) were tested for human VR1 inhibition in hVR1 FLIPR (fluorometric Image Plate Reader) screening assay with IC50 values of 60-200 nM. Thus, the title compound and their pharmaceutical compns. are useful as VR1 inhibitors for the treatment of VR1-mediated disorders, such as acute and chronic neuropathic and inflammatory pain (no data).
IT **22106-33-8**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of hydroxynaphthyl amides as Vanilloid receptor 1 inhibitors)

L9 ANSWER 47 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 22106-33-8 CAPLUS
CN Benzoic acid, 4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 48 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
IT 53597-27-6, Fendosal
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dispersible pharmaceutical composition for treatment of mastitis and otic disorders)
RN 53597-27-6 CAPLUS
CN Benzoic acid, 5-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 48 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:802738 CAPLUS
DN 141:301477
TI Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
IN Britten, Nancy J.; Burns, John W.; Hallberg, John W.; Waldron, Niki A.; Watts, Jeffrey L.
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004082719	A1	20040930	WO 2004-IB802	20040310
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004222518	A1	20040930	AU 2004-222518	20040310
	CA 2519589	AA	20040930	CA 2004-2519589	20040310
	EP 1608406	A1	20051228	EP 2004-719029	20040310
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004008559	A	20060321	BR 2004-8559	20040310
	CN 1761486	A	20060419	CN 2004-80007551	20040310
	NO 2005004777	A	20051017	NO 2005-4777	20051017
PRAI	US 2003-456201P	P	20030320		
	WO 2004-IB802	A	20040310		

AB A method is provided for treatment of an infective condition in a fluid-containing organ having a natural exterior orifice, such as the udder of a milk producing animal or an ear. The method comprises administering an antibacterial agent to the organ via the exterior orifice and administering in combination therapy with the antibacterial agent a second agent that is an anti-inflammatory agent, an analgesic and/or an antipyretic. The antibacterial agent and, optionally, the second agent, are administered as a pharmaceutical composition further comprising a vehicle that comprises an amphipathic oil that is water dispersible and ethanol insol., microcryst. wax and a pharmaceutically acceptable non-aqueous carrier.
Also provided is such a composition comprising the antibacterial agent and the second agent. The composition is readily dispersible in the fluid of the fluid-containing organ. A suspension to be administered by intramammary infusion was contained ceftiofur hydrochloride (micronized) 12.5 mg/mL, Labrafil M-1944CS 50 mg/mL, microcryst. wax 100 mg/mL, cottonseed oil q.s.

L9 ANSWER 49 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:802681 CAPLUS
DN 141:301462
TI Dispersible formulations of an anti-inflammatory agent
IN Britten, Nancy J.; Burns, John W.; Hallberg, John W.; Waldron, Niki A.; Watts, Jeffrey L.
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004082588	A2	20040930	WO 2004-IB826	20040310
	WO 2004082588	A3	20041223		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004222523	A1	20040930	AU 2004-222523	20040310
	CA 2519125	AA	20040930	CA 2004-2519125	20040310
	EP 1608407	A2	20051228	EP 2004-719030	20040310
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004008556	A	20060321	BR 2004-8556	20040310
	CN 1761487	A	20060419	CN 2004-80007593	20040310
	NO 2005004260	A	20051212	NO 2005-4260	20050915
PRAI	US 2003-456325P	P	20030320		
	WO 2004-IB826	A	20040310		

AB A method is provided for treatment of an inflammatory condition in a fluid-containing organ having a natural exterior orifice, such as the udder of a milk producing animal or an ear. The method comprises administering, to the organ via the exterior orifice, a pharmaceutical composition comprising an anti-inflammatory agent and a vehicle that comprises an amphipathic oil that is water dispersible and ethanol insol., microcryst. wax and a pharmaceutically acceptable non-aqueous carrier. Also provided is such a composition comprising the anti-inflammatory agent. The composition is readily dispersible in the fluid of the fluid-containing organ. Thus, a suspension to be administered by intramammary infusion comprised parecoxib 100, Labrafil M-1944CS 50, and microcryst. wax 70 mg/mL, and cottonseed oil qs.
IT 53597-27-6, Fendosal
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dispersible formulations of anti-inflammatory agent)
RN 53597-27-6 CAPLUS
CN Benzoic acid, 5-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)

L9 ANSWER 49 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 50 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:780555 CAPLUS
DN 141:301423
TI Preparation of high-affinity ligands for crystalline formulations of NPH-insulin
IN Balschmidt, Per; Olsen, Helle Birk; Kaarsholm, Niels C.; Madsen, Peter; Jakobsen, Palle; Ludvigsen, Svend; Schluckebier, Gerd; Steensgaard, Dorte Bjerre; Petersen, Anders Klarskov
PA Novo Nordisk A/S, Den.
SO PCT Int. Appl., 394 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004080481	A1	20040923	WO 2004-DK160	20040312
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1605967	A1	20051221	EP 2004-719932	20040312
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
PRAI	DK 2003-383	A	20030313		
	US 2003-455341P	P	20030317		
	WO 2004-DK160	W	20040312		

OS MARPAT 141:301423
AB This invention relates to NPH-insulin (crystalline prepns.) that are prepared in the presence of certain high-affinity ligands for the HisB10-Zn2+, sites of the R-state insulin hexamer. Preparation of NPH-insulin in the presence of high-affinity ligand results in crystalline NPH-insulin suspensions that are absorbed more slowly from subcutis than regular NPH-insulin. Hence the resulting action profile is longer and the spike is less pronounced than observed with regular NPH-insulin. Thus, 1H-benzotriazole-5-carboxylic acid phenylamide was prepared by the reaction of benzotriazole-5-carboxylic acid with aniline in the presence of EDAC in DMF. A formulation contained a ligand-incorporated NPH insulin and.
IT **333410-16-5P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of high-affinity ligands for crystalline formulations of NPH-insulin)
RN 333410-16-5 CAPLUS
CN Benzoic acid, 4-[3-[(2,4-dioxo-5-thiazolidinylidene)methyl]-2,5-dimethyl-

L9 ANSWER 50 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 51 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:780554 CAPLUS
DN 141:301422
TI Preparation of heterocyclic ligands for acid-stabilized insulin analogs
IN Ostergaard, Soren; Olsen, Helle Birk; Kaarsholm, Niels C.; Madsen, Peter; Jakobsen, Palle; Ludvigsen, Svend; Schluckebier, Gerd; Steensgaard, Dorte Bjerre; Petersen, Anders Klarskov
PA Novo Nordisk A/S, Den.
SO PCT Int. Appl., 473 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004080480	A1	20040923	WO 2004-DK158	20040311
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004218808	A1	20040923	AU 2004-218808	20040311
	CA 2522818	AA	20040923	CA 2004-2522818	20040311
	EP 1610812	A1	20060104	EP 2004-719368	20040311
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004008229	A	20060221	BR 2004-8229	20040311
	CN 1787833	A	20060614	CN 2004-80012690	20040311
	US 2006069013	A1	20060330	US 2005-227760	20050912
	NO 2005004555	A	20051117	NO 2005-4555	20051004
PRAI	DK 2003-365	A	20030311		
	US 2003-455400P	P	20030317		
	WO 2004-DK158	A	20040311		

OS MARPAT 141:301422
AB Novel ligands for the His-B10 Zn2+ sites of the R-state insulin hexamer that are capable of prolonging the action of insulin prepns. are disclosed. A mixture of 4-aminobenzonitrile, sodium azide and ammonium chloride in DMF was heated at 125° for 16 h. The cooled mixture was filtered and the filtrate was concentrated to give 5-(4-aminophenyl)-2H-tetrazole. This was used as the ligand for His-B10 Zn2+ sites of the R-state insulin hexamer.
IT **333410-16-5P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic ligands for acid-stabilized insulin analogs)
RN 333410-16-5 CAPLUS
CN Benzoic acid, 4-[3-[(2,4-dioxo-5-thiazolidinylidene)methyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 51 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 52 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:580668 CAPLUS
DN 141:123652
TI Preparation of 7H-pyrrolo[2,3-d]pyrimidines for use in pharmaceutical compositions as corticotropin-releasing factor (CRF) antagonists
IN Chen, Yuhpyng Liang
PA Pfizer Inc., USA
SO U.S., 25 pp., Cont.-in-part of U.S. Ser. No. 991,764, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6765008	B1	20040720	US 1995-448539	19950614
	WO 9413676	A1	19940623	WO 1993-US10715	19931112
	W: AU, BR, CA, CZ, JP, KR, NO, NZ, PL, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	IL 119461	A1	20000229	IL 1993-119461	19931206
	IL 119462	A1	20000229	IL 1993-119462	19931206
PRAI	US 1992-991764	B2	19921217		
	WO 1993-US10715	W	19931112		
	IL 1993-107897	A3	19931206		

OS MARPAT 141:123652
GI



I II

AB 7H-Pyrrolo[2,3-d]pyrimidine derivs., such as I [R3 = H, OH, SH, NH2, halogen, alkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, etc.; R4 = alkyl, alkylamino, acyl, alkyoxy, etc.; R5, R6 = H, NH2, CN, alkyl, halogen, alkoxy, alkylamino, carboxy, carboxamide, etc.; R7 = aryl, heteroaryl, etc.], were prepared for therapeutic uses as CRF receptor antagonists for the treatment of inflammation, stress, anxiety and related diseases and disorders. These compds. were claimed for use in the treatment of gastrointestinal disorders, inflammatory disorders, mental, neural and central nervous system diseases and disorders, fertility disfunctions, cancer, HIV infection, stress-induced depression, fatigue syndrome, stress-induced psychotic episodes, irritable bowel syndrome,

L9 ANSWER 52 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Crohn's disease, spastic or irritable colon, arthritis, asthma, pain, immune dysfunction, headache, pain, neurodegenerative diseases, Alzheimer's disease, eating disorders, anorexia nervosa, drug addiction, drug and alc. withdrawal symptoms and stress-induced psychotic episodes. Thus, 7H-pyrrolo[2,3-d]pyrimidine II [R4 = N(Et)Bu] was prepd. in 81% yield via an amination reaction of the corresponding chloride II (R4 = Cl) with N-ethylbutylamine. The prepd. 7H-pyrrolo[2,3-d]pyrimidines were tested for CRF receptor binding activity, and drug delivery compns. were discussed.
IT **157285-55-7P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 7H-pyrrolo[2,3-d]pyrimidines for use in pharmaceutical compns. as corticotropin-releasing factor antagonists)
RN 157285-55-7 CAPLUS
CN Benzoic acid, 4-[4-(butylethylamino)-2,5-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 53 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:550870 CAPLUS
DN 141:106476
TI Preparation of heterocyclic compounds as ligands for stabilizing insulin compositions
IN Kaarsholm, Niels Christian; Madsen, Peter; Schlein, Morten; Olsen, Helle Birk; Havelund, Svend; Steensgaard, Dorte Bjerre; Ludvigsen, Svend; Jakobsen, Palle; Petersen, Anders Klarskov; Schluckebier, Gerd
PA Novo Nordisk A/S, Den.
SO PCT Int. Appl., 432 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004056347	A2	20040708	WO 2003-DK931	20031222
	WO 2004056347	A3	20040812		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003291972	A1	20040714	AU 2003-291972	20031222
	EP 1585541	A2	20051019	EP 2003-767488	20031222
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2005065066	A1	20050324	US 2004-825995	20040416
PRAI	DK 2002-1991	A	20021220		
	US 2003-439382P	P	20030110		
	WO 2003-DK931	W	20031222		

OS MARPAT 141:106476
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention provides pharmaceutical compns. comprising insulin and novel ligands for the His B10 Zn2+ sites of the R-state insulin hexamer. The ligands belong to different subclasses of compds., e.g., benzotriazoles, 3-hydroxy-2-naphthoic acids, salicylic acids, tetrazoles, thiazolidinediones, 5-mercaptotetrazoles, or 4-cyano-1,2,3-triazoles. Methods for preparing the various classes of ligands included amidation, condensation, and coupling reactions. Compds. of the invention I-IX were evaluated for affinity to the zinc site with Kd values ranging from 3-3,879 nM. Addnl., I-IX were evaluated for retention of fast absorption characteristics of formulations stabilized by addition of ligands and chemical stability of insulin formulations. The resulting prepns. have improved phys. and chemical stability.
IT **333410-16-5P**
RL: MOA (Modifier or additive use); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES

L9 ANSWER 53 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(Uses)
(prepn. of heterocyclic zinc-binding ligands for use as stabilizing agents for insulin compns.)
RN 333410-16-5 CAPLUS
CN Benzoic acid, 4-[3-[(2,4-dioxo-5-thiazolidinylidene)methyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



IT 52034-38-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of heterocyclic zinc-binding ligands for use as stabilizing agents for insulin compns.)
RN 52034-38-5 CAPLUS
CN Benzoic acid, 4-(3-formyl-2,5-dimethyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



L9 ANSWER 54 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:546486 CAPLUS
DN 141:106470
TI Preparation of 5-chlorobenzimidazoles and related compounds as blood-coagulation factor Xa inhibitors.
IN Priepke, Henning; Pfau, Roland; Gerlach, Kai; Gillard, James; Bauer, Eckhart; Wienen, Wolfgang; Handschuh, Sandra; Nar, Herbert
PA Boehringer Ingelheim Pharma GmbH & Co. Kg, Germany; Dahmann, Georg
SO PCT Int. Appl., 502 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004056784	A1	20040708	WO 2003-EP14195	20031213
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10259407	A1	20040701	DE 2002-10259407	20021219
	DE 10335545	A1	20050602	DE 2003-10335545	20030802
	CA 2510846	AA	20040708	CA 2003-2510846	20031213
	AU 2003292239	A1	20040714	AU 2003-292239	20031213
	EP 1575925	A1	20050921	EP 2003-767800	20031213
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006514987	T2	20060518	JP 2005-502541	20031213
PRAI	DE 2002-10259407	A	20021219		
	DE 2003-10335545	A	20030802		
	WO 2003-EP14195	W	20031213		

OS MARPAT 141:106470
GI

L9 ANSWER 54 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I II



III

AB Title compds. I (R1 = amino, alkylamino, cycloalkylamino, etc.; R2 = H, halo, alkyl, etc.; R3 = H, alkyl; R4 = H, alkenyl, alkynyl, etc.; R5 = H, alkyl; A = carbonylamino, aminocarbonyl, with provisos; B = (un)substituted benzimidazol, 4-azabenzimidazol, 1-azanaphthalene, etc.] and their formulations and pharmaceutically acceptable salts were prepared
For example, coupling of 3-methyl-4-(2,5-dihydropyrrol-1-ylcarbonyl)benzoic acid and amine II, e.g., prepared from 4-chloro-o-phenylenediamine in 6-steps, afforded chlorobenzimidazole III. Compds. I were claimed useful as antithrombotic agents.
IT 720000-41-9, 4-(4-Oxo-4,5,6,7-tetrahydroindol-1-yl)benzoic acid
720000-44-2, 3-Chloro-4-(4,5,6,7-tetrahydroindol-1-yl)benzoic acid
720000-56-6 720000-57-7, 4-(4-Oxo-4,5-dihydropyrrol-[3,2-c]pyridin-1-yl)-3-trifluoromethylbenzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 5-chlorobenzimidazoles and related compds. as blood-coagulation factor Xa inhibitors)
RN 720000-41-9 CAPLUS
CN Benzoic acid, 4-(4,5,6,7-tetrahydro-4-oxo-1H-indol-1-yl)- (9CI) (CA INDEX NAME)



RN 720000-44-2 CAPLUS
CN Benzoic acid, 3-chloro-4-(4,5,6,7-tetrahydro-1H-indol-1-yl)- (9CI) (CA INDEX NAME)

L9 ANSWER 54 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 720000-56-6 CAPLUS
CN Benzoic acid, 4-[2-[(dimethylamino)methyl]-1H-indol-1-yl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 720000-57-7 CAPLUS
CN Benzoic acid, 4-(4,5-dihydro-4-oxo-1H-pyrrolo[3,2-c]pyridin-1-yl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 55 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:467690 CAPLUS
DN 141:17579
TI Substituted N-phenylpyrrole compounds for inhibition of HIV infection by blocking HIV entry
IN Jiang, Shibo; Debnath, Asim Kumar
PA New York Blood Center, USA
SO PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004047730	A2	20040610	WO 2003-US36359	20031112
	WO 2004047730	A3	20040916		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003294275	A1	20040618	AU 2003-294275	20031112
	EP 1567491	A2	20050831	EP 2003-789757	20031112
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2004116427	A1	20040617	US 2003-706027	20031113
PRAI	US 2002-428055P	P	20021121		
	WO 2003-US36359	W	20031112		

OS MARPAT 141:17579
GI


I


II

AB A group of compds. that inhibit HIV replication by blocking HIV entry was identified. Two representative compds., designated NB-2 (I) and NB-64 (II), inhibited HIV replication (p24 production) with IC50 values < 0.5 μg/mL. It was proved that NB-2 and NB-64 are HIV entry inhibitors by

L9 ANSWER 55 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

targeting the HIV gp41 since: (1) they inhibited HIV-mediated cell fusion;
(2) they inhibited HIV replication only when they were added to the cells less than one hour after virus addn.; (3) they did not block the gp120-CD4
binding; (4) they did not interact with the co-receptor CXCR4 since they failed to block anti-CXCR4 antibody binding to CXCR4-expressing cells; (5)
they blocked the formation of the gp41 core that is detected by sandwich enzyme linked immunosorbent assay (ELISA) using a conformation-specific Mab NC-1; (6) they inhibited the formation of the gp41 six-helix bundle revealed by fluorescence native-polyacrylamide gel electrophoresis (FN-PAGE); and (7) they blocked binding of D-peptide to the hydrophobic cavity within gp41 coiled coil domain, modeled by peptide IQN17. These results suggested that NB-2 and NB-64 may interact with the hydrophobic cavity and block the formation of the fusion-active gp41 coiled coil domain, resulting in inhibition of HIV-1 mediated membrane fusion and virus entry.

IT **53242-68-5**, NB 64 **674782-30-0**, NB 2
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(N-phenylpyrrole derivs. for inhibition of HIV infection)

RN 53242-68-5 CAPLUS
CN Benzoic acid, 2-chloro-5-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 674782-30-0 CAPLUS
CN Benzoic acid, 4-(2,5-dimethyl-1H-pyrrol-1-yl)-2-hydroxy- (9CI) (CA INDEX NAME)



L9 ANSWER 56 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:419905 CAPLUS
DN 141:218293
TI Identification of Selective Inhibitors for the Glycosyltransferase MurG via High-Throughput Screening
AU Hu, Yanan; Helm, Jeremiah S.; Chen, Lan; Ginsberg, Cindy; Gross, Benjamin;
Kraybill, Brian; Tiyanont, Kittichoat; Fang, Xiao; Wu, Tao; Walker, Suzanne
CS Department of Chemistry, Princeton University, Princeton, NJ, 08544, USA
SO Chemistry & Biology (2004), 11(5), 703-711
CODEN: CBOLE2; ISSN: 1074-5521
PB Cell Press
DT Journal
LA English
AB Nucleotide-glycosyltransferases (NDP-Gtfs) play key roles in a wide range of biol. processes. It is difficult to probe the roles of individual glycosyltransferases or their products because, with few exceptions, selective glycosyltransferase inhibitors do not exist. Here, the authors investigate a high-throughput approach to identify glycosyltransferase inhibitors based on a fluorescent donor displacement assay. The authors have applied the screen to E. coli MurG, an enzyme that is both a potential antibiotic target and a paradigm for a large family of glycosyltransferases. The authors show that the compds. identified in the
donor-displacement screen of MurG are selective for MurG over other enzymes that use similar or identical substrates, including structurally related enzymes. The donor displacement assay described here should be adaptable to many other NDP-Gtfs and represents a new strategy to identify
selective NDP-Gtf inhibitors.

IT **347385-19-7** **347389-31-5**
RL: PAC (Pharmacological activity); BIOL (Biological study)
(identification of selective inhibitors for glycosyltransferase MurG via high-throughput screening)

RN 347385-19-7 CAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-[3-[[1-(2-fluorophenyl)tetrahydro-4,6-dioxo-2-thioxo-5(2H)-pyrimidinylidene]methyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



L9 ANSWER 56 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 347389-31-5 CAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-[3-[[1-(4-chlorophenyl)tetrahydro-4,6-dioxo-2-thioxo-5(2H)-pyrimidinylidene]methyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



IT 347387-81-9
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(identification of selective inhibitors for glycosyltransferase MurG via high-throughput screening)
RN 347387-81-9 CAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-[3-[[1-(3-chlorophenyl)tetrahydro-4,6-dioxo-2-thioxo-5(2H)-pyrimidinylidene]methyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



L9 ANSWER 56 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 57 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:392451 CAPLUS
DN 140:395537
TI New formulations of injectable particles for intra-articular injection containing therapeutic compositions
IN Giroux, Karen; Butz, Robert F.
PA Polymerix Corporation, USA
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004039355	A1	20040513	WO 2003-US34183	20031028
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2503841	AA	20040513	CA 2003-2503841	20031028
	AU 2003287235	A1	20040525	AU 2003-287235	20031028
	EP 1556011	A1	20050727	EP 2003-781417	20031028
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1717224	A	20060104	CN 2003-80104152	20031028
	JP 2006508941	T2	20060316	JP 2004-548530	20031028
PRAI	US 2002-421888P	P	20021028		
	WO 2003-US34183	W	20031028		

AB The present invention provides new formulations of injectable particles (e.g. microspheres) useful for intra-articular (i.a.) injection. The formulations are made of biocompatible polymers that biodegrade to generate NSAIDs, ad are useful for treating inflamed joints, thus providing safe, long-lasting relief of joint pain and swelling. In one embodiment, the present invention provides an injectable particle, comprising a biodegradable polymer comprising an agent selected from the group consisting of an NSAID, a COX-2 inhibitor, an anesthetic and a narcotic analgesic. Injectable mcirosppheres containing salicylic acid were prepared and their efficacy in reducing joint swelling and serum ovalbumin antibody was shown in rabbits.
IT 53597-27-6, Fendosal
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(new formulations of injectable particles for intra-articular injection containing therapeutic compns.)
RN 53597-27-6 CAPLUS
CN Benzoic acid, 5-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)

L9 ANSWER 57 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 58 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:354923 CAPLUS

DN 140:375196

TI Preparation of substituted piperazines, [1,4]diazepines, and 2,5-diazabicyclo[2.2.1]heptanes as histamine H1 and/or H3 antagonists or histamine H3 reverse antagonists

IN Ancliff, Rachael; Eldred, Colin David; Fogden, Yvonne C.; Hancock, Ashley Paul; Heightman, Thomas Daniel; Hobbs, Heather; Hodgson, Simon Teanby; Lindon, Matthew J.; Wilson, David Matthew

PA Glaxo Group Limited, UK

SO PCT Int. Appl., 140 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004035556	A1	20040429	WO 2003-EP11423	20031014
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2502249	AA	20040429	CA 2003-2502249	20031014
	AU 2003280380	A1	20040504	AU 2003-280380	20031014
	BR 2003015283	A	20050830	BR 2003-15283	20031014
	EP 1567511	A1	20050831	EP 2003-772221	20031014
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1726201	A	20060125	CN 2003-80106014	20031014
	JP 2006508935	T2	20060316	JP 2004-544241	20031014
	NO 2005001689	A	20050707	NO 2005-1689	20050405
	US 2006025404	A1	20060202	US 2005-531758	20050414
PRAI	GB 2002-24084	A	20021016		
	WO 2003-EP11423	W	20031014		

OS MARPAT 140:375196

GI

L9 ANSWER 58 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I II III

AB The title compds. [I; R1 = H, alkyl, alkoxy, etc.; Z = a bond, CO, (un)substituted CONH, SO2; p = 1-2; m, n, r = 0-2; R2 = halo, alkyl, alkoxy, etc.; R3 = (CH2)qNR11R12, II (wherein q = 2-4; R11, R12 = alkyl, cycloalkyl; NR11R12 = heterocyclyl; R13 = H, alkyl, cycloalkyl, etc.; R14 = halo, alkyl, haloalkyl, etc.; f, k = 0-2; g = 0-2; h = 0-3, such that g and h cannot both be 0); R4 = H, alkyl such that when r = 2, two R4 groups may instead be linked to form CH2, (CH2)2, (CH2)3; with the provisos], useful in the treatment of neurodegenerative disorders including Alzheimer's disease, and inflammatory diseases of the upper respiratory tract, were prepared Thus, reacting 1-[4-(3-piperidin-1-ylpropoxy)benzyl]piperazine.3HCl (preparation given) with benzoic acid afforded 77% III which was tested in the histamine H3 functional antagonist assay and showed pKb of > 6.5. The pharmaceutical composition comprising the compound I is claimed.

IT 22106-33-8, 4-(1H-Pyrrol-1-yl)benzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of substituted piperazines, [1,4]diazepines, and 2,5-diazabicyclo[2.2.1]heptanes as histamine H1 and/or H3 antagonists or histamine H3 reverse antagonists)

RN 22106-33-8 CAPLUS

CN Benzoic acid, 4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)

L9 ANSWER 58 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 59 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:333850 CAPLUS

DN 140:355836

TI High-mannose oligosaccharide cluster conjugated with immunogenic protein for use as HIV vaccines

IN Wang, Lai-xi

PA University of Maryland Biotechnology Institute Off. of Research Admin./ Tech. Dev., USA

SO PCT Int. Appl., 68 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004033663	A2	20040422	WO 2003-US32496	20031014
	WO 2004033663	A3	20060316		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2504755	AA	20040422	CA 2003-2504755	20031014
	AU 2003282821	A1	20040504	AU 2003-282821	20031014
	EP 1572963	A2	20050914	EP 2003-774819	20031014
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2005244424	A1	20051103	US 2005-531124	20050630
PRAI	US 2002-417764P	P	20021011		
	WO 2003-US32496	W	20031014		

AB The present invention relates to a constructed oligosaccharide cluster, optionally bonded to an immunogenic protein, that can be administered to a subject to induce an immune response for increasing production of 2G12 and/or used in assays as reactive sites for determining compds. that inactivate and/or bind the high-mannose oligosaccharide cluster. The high-mannose oligosaccharide cluster comprises ≥2 high-mannose oligosaccharides attached a scaffolding framework of monosaccharide, cyclic peptide, cyclic organic compound or 11-bis-maleimidetetraethyleneglycol. The high-mannose oligosaccharide that mimics high-mannose N-glycan of HIV-1 gp120 comprises Man9, Man8, Man7, Man6, Man5 or a combination thereof. The high-mannose oligosaccharide of the invention is derived from soybean agglutinin or chemical synthesized. The immunogenic protein is keyhole limpet hemocyanin, tetanus toxoid, diphtheria toxoid, bovine serum albumin, ovalbumin, thyroglobulin, myoglobin, cholera toxin β-subunit, Ig. and/or tuberculosis purified protein derivative Compns. comprising these clusters, methods of using these clusters and compns. are disclosed.

IT 674782-30-0, NB 2
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

L9 ANSWER 59 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(high-mannose oligosaccharide cluster conjugated with immunogenic protein for use as HIV vaccines)
RN 674782-30-0 CAPLUS
CN Benzoic acid, 4-(2,5-dimethyl-1H-pyrrol-1-yl)-2-hydroxy- (9CI) (CA INDEX NAME)



L9 ANSWER 60 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:291950 CAPLUS
DN 140:315042
TI Pin1-modulating compounds and methods of use for the treatment of Pin1-associated diseases, including cancer
IN Mckee, Timothy D.; Suto, Robert K.; Tibbitts, Thomas; Sowadski, Janusz
PA Pintex Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 166 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004028535	A1	20040408	WO 2003-US6675	20030303
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003225669	A1	20040419	AU 2003-225669	20030303
US 2004214872	A1	20041028	US 2003-379408	20030303
EP 1551396	A1	20050713	EP 2003-798653	20030303
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI US 2002-414077P	P	20020926		
WO 2003-US6675	W	20030303		

OS MARPAT 140:315042
AB The invention is directed to modulators, e.g., inhibitors, of Pin1 and Pin1-related proteins and the use of such modulators for treatment of Pin1 associated states, e.g., for the treatment of cancer. Synthetic methods are included.
IT **676654-28-7**
RL: PAC (Pharmacological activity); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(Pin1-modulating compds. for treatment of Pin1-associated diseases, including cancer)
RN 676654-28-7 CAPLUS
CN 3-Thiazolidinebutanoic acid, 5-[[1-(4-carboxyphenyl)-2,5-dihydroxy-1H-pyrrol-3-yl]methylene]-4-oxo-2-thioxo- (9CI) (CA INDEX NAME)

L9 ANSWER 60 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 61 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:267336 CAPLUS
DN 140:303699
TI Preparation of triazaspiro[5.5]undecane derivatives as chemokine receptor CCR5 antagonists and drugs comprising the same as the active ingredients
IN Takaoka, Yoshikazu; Nishizawa, Rena; Shibayama, Shiro; Sagawa, Kenji; Matsuo, Masayoshi
PA Ono Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 288 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004026873	A1	20040401	WO 2003-JP11834	20030917
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2497903	AA	20040401	CA 2003-2497903	20030917
AU 2003272879	A1	20040408	AU 2003-272879	20030917
EP 1541574	A1	20050615	EP 2003-753933	20030917
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003014304	A	20050726	BR 2003-14304	20030917
CN 1688577	A	20051026	CN 2003-824386	20030917
US 2005267114	A1	20051201	US 2005-527435	20050311
NO 2005001379	A	20050617	NO 2005-1379	20050316
ZA 2005002222	A	20050930	ZA 2005-2222	20050316
PRAI JP 2002-270849	A	20020918		
WO 2003-JP11834	W	20030917		

OS MARPAT 140:303699
GI



AB The title compds. [I; R1 = (a) each (un)substituted and partially or completely saturated C3-15 mono-, di-, or tricarbocyclic aryl or 3- to 15-membered mono-, di-, or triheterocyclic aryl latter containing heteroatoms selected from 1-4 N atoms, 1 or 2 O atoms, and/or 1 or 2 S atoms, or (b) C1-8 alkyl, C2-4 alkenyl, or C2-4 alkynyl each substituted by 1-3 substituents selected from each (un)substituted HO, acyl, NH2, CONH2, acylamino, sulfonylamino, :NH, and :NOH; R2 = H, C1-8 alkyl, C2-8 alkenyl,

L9 ANSWER 61 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

C2-8 alkynyl, each (un)substituted Ph, pyridinyl, or C3-8 cycloalkyl, group (b); R3, R4 = (i) H, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, or (ii) C1-8 alkyl, C2-8 alkenyl, or C2-8 alkynyl each substituted by 1-5 substituents selected from group (a), HO, and tetrahydropyran-4-ylidene], quaternary ammonium salts, N-oxides, or salts thereof are prepd. These compds. are useful in preventing and/or treating various inflammatory diseases (asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis, etc.), immune diseases (autoimmune disease, transplant rejection, immune suppression, psoriasis, multiple sclerosis, etc.), infection with human immunodeficiency virus (acquired immune deficiency syndrome), allergic diseases (atopic dermatitis, urticaria, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis, etc.), ischemic reperfusion injury, acute respiratory distress syndrome, shock accompanying bacterial infection, diabetes, cancer metastasis, etc. (no data). They are improved in bioavailability when administered orally, metabolic stability, liver or systemic clearance, or affinity for chemokine receptor CCR compared to prior art compds. and exhibit very low toxicity. Thus, 1-benzyl-4-piperidone, (2R,3R)-2-(tert-butoxycarbonylamino)-3-cyclohexyl-3-hydroxypropanoic acid, n-butylamine, and 2-(morpholin-4-yl)ethyl isocyanide were stirred in MeOH at 50° overnight to give, after workup, 1-benzyl-4-[2-(morpholin-4-yl)ethylaminocarbonyl]-4-[N-butyl-N-[(2R,3R)-2-amino-3-hydroxy-3-cyclohexylpropanoyl]amino]piperidine which was stirred in AcOH at 70° for 1 h to give, after workup, (3R)-1-butyl-2,5-dioxo-3-[(1R)-1-hydroxy-1-cyclohexylmethyl]-9-phenylmethyl-1,4,9-triazaspiro[5.5]undecane (II). A tablet and an ampule formulation contg. specific compd. I were described.

IT **676450-75-2P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of triazaspiro[5.5]undecane derivs. as chemokine receptor CCR5 antagonists and drugs)

RN 676450-75-2 CAPLUS

CN Benzoic acid, 4-[3-[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-2,5-dimethyl-1H-pyrrol-1-yl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 61 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 62 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:252478 CAPLUS

DN 140:264479

TI G1-phase arresting compounds for inducing increased levels of β-chemokines

IN Redfield, Robert R.; Amoroso, Anthony; Davis, Charles E.; Heredia, Alonsa

PA University of Maryland Biotechnology, USA

SO PCT Int. Appl., 76 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004024683	A2	20040325	WO 2003-US28697	20030912
WO 2004024683	A3	20040701		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2498934	AA	20040325	CA 2003-2498934	20030912
AU 2003266152	A1	20040430	AU 2003-266152	20030912
EP 1545539	A2	20050629	EP 2003-795698	20030912
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2006099170	A1	20060511	US 2005-527904	20050707
PRAI US 2002-410714P	P	20020913		
WO 2003-US28697	W	20030912		

AB The present invention relates to methods for inducing increased levels and availability of β-chemokines by administering to a subject at least 1 G1-phase arresting compound, wherein the increased levels and availability of β-chemokines block chemokine/viral receptors thereby preventing or treating viral infections. The secretion of the β-chemokines by peripheral blood mononuclear cells in response to the activation started before lymphocytes entered the DNA synthesis phase of the cell cycle (S phase), reaches a peak by day 3 or 7 and then declined to low levels. The antivial activity is due the presence of the β-chemokines RANTES, and MIP proteins.

IT **674782-30-0**

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(G1-phase arresting compds. for inducing increased levels of β-chemokines)

RN 674782-30-0 CAPLUS

CN Benzoic acid, 4-(2,5-dimethyl-1H-pyrrol-1-yl)-2-hydroxy- (9CI) (CA INDEX NAME)

L9 ANSWER 62 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 63 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:182845 CAPLUS
DN 140:217519
TI Preparation of quinoline derivatives as TGFβ inhibitors
IN Shimizu, Kiyoshi; Shimizu, Toshiyuki; Kimura, Kaname; Kawakami, Kazuki; Nakoji, Masayoshi
PA Kirin Beer Kabushiki Kaisha, Japan
SO PCT Int. Appl., 628 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004018430	A1	20040304	WO 2003-JP10647	20030822
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003257666	A1	20040311	AU 2003-257666	20030822
	EP 1548008	A1	20050629	EP 2003-792805	20030822
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1688549	A	20051026	CN 2003-824397	20030822
	US 2006111375	A1	20060525	US 2005-525087	20050223
PRAI	JP 2002-244028	A	20020823		
	WO 2003-JP10647	W	20030822		

OS MARPAT 140:217519
GI



I

AB The title compds. I [wherein X = CH or N; Z = O, NH, S, or CO; R and R' = independently H, halo, (un)substituted alkyl, alkenyl, NH2, CONH2, OH, or heterocyclyl; A = (un)substituted Ph or (hetero)cyclyl] or pharmaceutically acceptable salts, or solvates thereof are prepared as transforming growth factor (TGF) β inhibitors. For example, 4-chloro-6,7-dimethoxyquinoline was reacted with 2-benzylphenol in 1,2-dichlorobenzene to give 4-(2-benzylphenoxy)-6,7-dimethoxyquinoline (10%). Some of compds. I inhibited 100% of human TGFβ at 10 μM.
IT 53242-70-9
RL: RCT (Reactant); RACT (Reactant or reagent)

L9 ANSWER 63 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(prepn. of quinoline derivs. as TGFβ inhibitors)
RN 53242-70-9 CAPLUS
CN Benzoic acid, 2-hydroxy-5-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 64 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:41217 CAPLUS
DN 140:111135
TI Preparation of nitrosated nonsteroidal antiinflammatory compounds
IN Earl, Richard A.; Ezawa, Maiko; Fang, Xinqin; Garvey, David S.; Gaston, Ricky D.; Khanapure, Subhash P.; Letts, Gordon L.; Lin, Chia-En; Ranatunge, Ramani R.; Richardson, Stewart K.; Schroeder, Joseph D.; Stevenson, Cheri A.; Wey, Shiow-Jyi
PA Nitromed, Inc., USA
SO PCT Int. Appl., 145 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004004648	A2	20040115	WO 2003-US21026	20030703
	WO 2004004648	A3	20041028		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2491127	AA	20040115	CA 2003-2491127	20030703
	AU 2003247792	A1	20040123	AU 2003-247792	20030703
	US 2004024057	A1	20040205	US 2003-612014	20030703
	EP 1539729	A2	20050615	EP 2003-763193	20030703
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005539089	T2	20051222	JP 2004-562619	20030703
	US 2005222243	A1	20051006	US 2005-134358	20050523
PRAI	US 2002-393111P	P	20020703		
	US 2002-397979P	P	20020724		
	US 2002-418353P	P	20021016		
	US 2003-449798P	P	20030226		
	US 2003-456182P	P	20030321		
	US 2003-612014	A3	20030703		
	WO 2003-US21026	W	20030703		

OS MARPAT 140:111135
GI



II

AB Title compds. RnRmHC-CO-X [Rm = H, alkyl; Rn = 4-((thiophen-2-yl)carbonyl)phenyl, 3-(benzoyl)phenyl, etc.; X = Y-alkyl-aryl, etc.; Y = O, S; I] are prepared For instance, naproxen is coupled to 2,2'-thiodiethanol (CH2Cl2, DMAP, EDCI) and treated with Ac2O/HNO3 at 0° to give II. I are nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) used alone or are combined with one compd. that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase. The invention provides methods for treating inflammation, pain, fever, gastrointestinal disorders, etc.
IT 53597-27-6D, Fendosal, nitrosated derivs.
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination pharmaceutical; preparation of naproxen-derived nitrosated antiinflammatory compds.)
RN 53597-27-6 CAPLUS
CN Benzoic acid, 5-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)



L9 ANSWER 65 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:20650 CAPLUS
DN 140:77035
TI Preparation of (4-hydroxypiperidin-1-yl)arylcarboxamides as interleukin-4 production inhibitors for treatment of allergic diseases
IN Naito, Youichiro; Ushio, Hiroyuki; Hoshino, Yukio; Kagoshima, Masahiko; Oshita, Kouichi; Kataoka, Hirotoshi; Chiba, Kenji
PA Mitsubishi Pharma Corporation, Japan
SO PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004002948	A1	20040108	WO 2002-JP6606	20020628
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002313309	A1	20040119	AU 2002-313309	20020628
PRAI WO 2002-JP6606	A	20020628		

OS MARPAT 140:77035
GI



I



II

AB The title arylcarboxamides I [wherein R1 = halo, alkyl, alkoxy, NO2, OH, (un)substituted amino, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, or cycloalkenyl; ring Q = (un)substituted benzene, cyclohexane, pyridine, pyrazine, pyridazine, furan, thiophene, oxazole, thiazole, or imidazole; R2 = H, alkyl, hydroxyalkyl, acyloxyalkyl, hydroxycarbonylalkyl, alkoxycarbonylalkyl, or (un)substituted aminoalkyl; Z = CH or N; R3 = halo, CN, NO2,NH2, alkyl, alkoxy, CO2H, alkoxycarbonyl, carbamoyl, alkenyl, alkynyl, or haloalkyl; R4 = H, halo, CN, or NO2; R5 = alkyl, hydroxyalkyl, hydroxycarbonylalkyl, alkoxy, haloalkoxy, aryloxy, cycloalkyloxy, hydroxyalkoxy, hydroxycarbonylalkoxy, SH, alkylthio,

L9 ANSWER 65 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
hydroxyalkylthio, hydroxycarbonylalkylthio, (un)substituted aminoalkyl, aminoalkoxy, aminoalkylthio, OH, or NH2) or pharmaceutically acceptable salts thereof are prepd. For example, the compd. II was prepd. in a multi-step synthesis. II showed IC50 of 0.049 μM against interleukin-4 prodn. in rat. The compds. I are highly effective in inhibiting interleukin-4 prodn. in type-2 helper T cells, and are useful for the treatment of allergic diseases (no data). Formulations contg. I as an active ingredient were also described.
IT 22106-33-8, 4-(1-Pyrrolyl)benzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of (hydroxypiperidinyl)arylcarboxamides for treatment of allergic diseases)
RN 22106-33-8 CAPLUS
CN Benzoic acid, 4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 66 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:991345 CAPLUS
DN 140:42216
TI Preparation of phenol or phenyl acetate derivatives for treatment of allergic diseases
IN Muto, Susumu; Itai, Akiko
PA Institute of Medicinal Molecular Design. Inc., Japan
SO PCT Int. Appl., 418 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003103665	A1	20031218	WO 2003-JP7120	20030605
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2488367	AA	20031218	CA 2003-2488367	20030605
AU 2003242103	A1	20031222	AU 2003-242103	20030605
EP 1514544	A1	20050316	EP 2003-730831	20030605
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1658872	A	20050824	CN 2003-812926	20030605
US 2006122243	A1	20060608	US 2005-515623	20050620
PRAI JP 2002-165148	A	20020606		
WO 2003-JP7120	W	20030605		

OS MARPAT 140:42216
GI



I

AB The title compds. I [wherein X = a connecting group; A = H or acetyl; E = (un)substituted aryl or heteroaryl; ring Z = (un)substituted arene or heteroarene] and pharmaceutically acceptable salts, hydrates, and solvates thereof are prepared for the treatment of allergic diseases, endometriosis, and/or hysteromyoma (no data). A total of .apprx.500 I including N-phenylhydroxybenzamides (N-phenylsalicylamide), N-heterocyclylhydroxybenzamides, N-phenylhydroxycarbazolecarboxamides, N-phenylhydroxynaphthalenecarboxamides, N-phenylhydroxypyridinecarboxamides, N-phenylhydroxyquinoxalinecarboxamide, and N-phenylhydroxyindolecarboxamide were prepared The compds. I exhibited inhibitory activities against IgE production, cell proliferation, and cell degranulation.

L9 ANSWER 66 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
IT 53242-70-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of phenol or Ph acetate derivs. for treatment of allergic diseases)
RN 53242-70-9 CAPLUS
CN Benzoic acid, 2-hydroxy-5-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 67 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:991339 CAPLUS
DN 140:42204
TI Preparation of immunity-related protein kinase inhibitors
IN Muto, Susumu; Itai, Akiko
PA Institute of Medicinal Molecular Design. Inc., Japan
SO PCT Int. Appl., 401 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003103658	A1	20031218	WO 2003-JP7130	20030605
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2487900	AA	20031218	CA 2003-2487900	20030605
	AU 2003242131	A1	20031222	AU 2003-242131	20030605
	EP 1510210	A1	20050302	EP 2003-730840	20030605
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1658854	A	20050824	CN 2003-812919	20030605
	US 2006019958	A1	20060126	US 2005-515343	20050801
PRAI	JP 2002-164525	A	20020605		
	WO 2003-JP7130	W	20030605		

OS MARPAT 140:42204
GI



I

AB The title compds. I [X is a connecting group whose main chain has 2 to 5 atoms and which may have a substituent; A is hydrogen or acetyl; E is optionally substituted aryl or optionally substituted heteroaryl; and Z is arene which may have a substituent in addition to the groups represented by the general formulas O-A (wherein A is as defined above) and X-E (wherein X and E are as defined above) or heteroarene which may have a substituent

L9 ANSWER 67 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
in addn. to the groups represented by the general formulas O-A (wherein A is as defined above) and X-E (wherein X and E are as defined above)] are prepd. Compds. of this invention in vitro at 1 μg/mL gave 90% to 92.6% inhibition of NF-κB activation.
IT 53242-70-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of immunity-related protein kinase inhibitors)
RN 53242-70-9 CAPLUS
CN Benzoic acid, 2-hydroxy-5-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 68 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:991338 CAPLUS
DN 140:42203
TI Preparation of hydroxybenzamide, naphthalenecarboxamide, and hydroxyheterocyclecarboxamide derivatives for preventive and/or therapeutic drugs for neurodegenerative diseases and epilepsy
IN Muto, Susumu; Itai, Akiko
PA Institute of Medicinal Molecular Design. Inc., Japan
SO PCT Int. Appl., 278 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003103657	A1	20031218	WO 2003-JP7128	20030605
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2488979	AA	20031218	CA 2003-2488979	20030605
	AU 2003242124	A1	20031222	AU 2003-242124	20030605
	EP 1555018	A1	20050720	EP 2003-730838	20030605
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1658858	A	20050824	CN 2003-813557	20030605
	US 2006035944	A1	20060216	US 2005-516293	20050810
PRAI	JP 2002-169640	A	20020611		
	WO 2003-JP7128	W	20030605		

OS MARPAT 140:42203
GI



I

AB Disclosed are preventive and/or therapeutic drugs for (1) neurodegenerative diseases including Alzheimer's disease and (2) epilepsy, which contain as the active ingredient substances selected from the group consisting of compds. represented by the general formula (I), pharmacol. acceptable salts thereof, and hydrates and solvates of both [wherein A is hydrogen or acetyl; E is 2,5- or 3,5-disubstituted Ph or an optionally substituted monocyclic or fused-polycyclic heteroaryl group (exclusive of (1) fused -polycyclic heteroaryl whose benzene ring is bonded directly to the -CONH- group, (2) unsubstituted thiazol-2-yl, and (3) unsubstituted benzothiazol-2-yl); and Z is arene which may have a substituent in addition

L9 ANSWER 68 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
to the groups represented by the general formulas: -O-A (wherein A is as defined above) and -CONH-E (wherein E is as defined above) or heteroarene which may have a substituent in addn. to the groups represented by the general formulas: -O-A (wherein A is as defined above) and -CONH-E (wherein E is as defined above)]. These compds. I are effective for the prevention and/or treatment of Alzheimer's disease and (2) epilepsy based on the simultaneous inhibition of activated protein 1 (AP-1) and transcription factor NF-κB activation. The compds. I including N-phenylhydroxybenzamide (N-phenylsalicylamide), N-phenylhydroxynaphthalenecarboxamide, N-heterocyclylsalicylamide, N-phenylpyridinecarboxamide, N-phenylhydroxythiophenecarboxamide, N-phenylquinoxalinecarboxamide, and N-phenylindolecarboxamide derivs. exhibited the inhibition of (1) TNF-α-stimulated activation of NF-κB in HepG2 cells, (2) TNF-α-stimulated activation of Hela cells, and (3) the activation of AP-1 in HepG2 cells transfected with MEKK-1 expression plasmid. In an Alzheimer's model animal assay, N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide inhibited the memory formation failure in rats injected with human β-amyloid to the hippocampus.
IT 53242-70-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of hydroxybenzamide, naphthalenecarboxamide, and hydroxyheterocyclecarboxamide preventive and/or therapeutic drugs for Alzheimer's disease and epilepsy)
RN 53242-70-9 CAPLUS
CN Benzoic acid, 2-hydroxy-5-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 69 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:991336 CAPLUS
DN 140:42202
TI Preparation of hydroxybenzamide, naphthalenecarboxamide, and hydroxyheterocyclecarboxamide derivatives as anticancer agents
IN Muto, Susumu; Itai, Akiko
PA Institute of Medicinal Molecular Design. Inc., Japan
SO PCT Int. Appl., 265 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003103655	A1	20031218	WO 2003-JP7121	20030605
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2488974	AA	20031218	CA 2003-2488974	20030605
	AU 2003242108	A1	20031222	AU 2003-242108	20030605
	EP 1535610	A1	20050601	EP 2003-730832	20030605
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1658856	A	20050824	CN 2003-813312	20030605
	US 2006014811	A1	20060119	US 2005-516292	20050705
PRAI	JP 2002-168332	A	20020610		
	WO 2003-JP7121	W	20030605		

OS MARPAT 140:42202
GI



I

AB Disclosed are drugs for the prevention and/or treatment of cancer, which contain as the active ingredient substances selected from the group consisting of compds. represented by the general formula (I), pharmacol. acceptable salts thereof, and hydrates and solvates of both [wherein A is hydrogen or acetyl; E is 2,5- or 3,5-disubstituted Ph or an optionally substituted monocyclic or fused-polycyclic heteroaryl group (exclusive of (1) fused -polycyclic heteroaryl whose benzene ring is bonded directly to the -CONH- group, (2) unsubstituted thiazol-2-yl, and (3) unsubstituted

L9 ANSWER 69 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
benzothiazol-2-yl); and Z is arene which may have a substituent in addn. to the groups represented by the general formulas: -O-A (wherein A is as defined above) and -CONH-E (wherein E is as defined above) or heteroarene which may have a substituent in addn. to the groups represented by the general formulas: -O-A (wherein A is as defined above) and -CONH-E (wherein E is as defined above)]. The compds. I including N-phenylhydroxybenzamide (N-phenylsalicylamide), N-phenylhydroxynaphthalenecarboxamide, N-heterocyclylsalicylamide, N-phenylpyridinecarboxamide, N-phenylhydroxythiophenecarboxamide, N-phenylquinoxalinecarboxamide, and N-phenylindolecarboxamide derivs. in vitro inhibited the proliferation of Jurkat, MIA PACA-2, RD, HepG2, and A549 human cancer cells. N-[3,5-bis(trifluoromethyl)phenyl]-4-chloro-2-hydroxybenzamide in vitro inhibited the proliferation of B16 melanoma, HT-1080 fibrosarcoma, NB-1 neuroblastoma, and HMC-1-8 breast cancer cells and in vivo metastasis of B16 melanoma in mice.
IT 53242-70-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of hydroxybenzamide, naphthalenecarboxamide, and hydroxyheterocyclecarboxamide derivs. as anticancer agents)
RN 53242-70-9 CAPLUS
CN Benzoic acid, 2-hydroxy-5-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 70 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:991335 CAPLUS
DN 140:42201
TI Preparation of hydroxybenzamide, naphthalenecarboxamide, and hydroxyheterocyclecarboxamide derivatives as transcription factor NF-κB activation inhibitors
IN Muto, Susumu; Itai, Akiko
PA Institute of Medicinal Molecular Design. Inc., Japan
SO PCT Int. Appl., 286 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003103654	A1	20031218	WO 2003-JP7119	20030605
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2489091	AA	20031218	CA 2003-2489091	20030605
	AU 2003242098	A1	20031222	AU 2003-242098	20030605
	EP 1535609	A1	20050601	EP 2003-730830	20030605
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1658857	A	20050824	CN 2003-813313	20030605
	US 2006089395	A1	20060427	US 2005-516294	20050912
PRAI	JP 2002-168924	A	20020610		
	WO 2003-JP7119	W	20030605		

OS MARPAT 140:42201
GI



I

AB Disclosed are drugs having an inhibitory activity against transcription factor NF-κB activation, which contain as the active ingredient substances selected from the group consisting of compds. represented by the general formula (I), pharmacol. acceptable salts thereof, and hydrates and solvates of both [wherein A is hydrogen or acetyl; E is 2,5- or 3,5-disubstituted Ph or an optionally substituted monocyclic or fused-polycyclic heteroaryl group (exclusive of (1) fused -polycyclic heteroaryl whose benzene ring is bonded directly to the -CONH- group, (2) unsubstituted thiazol-2-yl, and (3) unsubstituted benzothiazol-2-yl); and Z is arene which may have a substituent in addition to the groups represented

L9 ANSWER 70 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
by the general formulas: -O-A (wherein A is as defined above) and -CONH-E (wherein E is as defined above) or heteroarene which may have a substituent in addn. to the groups represented by the general formulas: -O-A (wherein A is as defined above) and -CONH-E (wherein E is as defined above)]. Also disclosed are (1) inhibitors against prodn. and release of inflammatory mediators and immunosuppressants and (2) drugs for prevention and/or treatment of chronic articular rheumatism. The compds. I including N-phenylhydroxybenzamide (N-phenylsalicylamide), N-phenylhydroxynaphthalenecarboxamide, N-heterocyclylsalicylamide, N-phenylpyridinecarboxamide, N-phenylhydroxythiophenecarboxamide, N-phenylquinoxalinecarboxamide, and N-phenylindolecarboxamide derivs. exhibited the inhibition of (1) TNF-α-stimulated activation of NF-κB (2) TNF-α-stimulated prodn. of IL-6, IL-8, and PGE2 in human synoviocyte (RA-pos.) cells, (3) collagen-induced inflammation in mice, (4) myocardial ischemic reperfusion disorder in rats, and (5) proliferation of smooth muscle cells of normal coronary artery blood vessel. Some com. available compds. were selected as NF-κB inhibitors (ligands) by virtual screening using a three-dimensional database automated retrieval software based on a protein structure of NF-κB. The activity of the selected compds. were confirmed by reporter assay for inhibition of TNF-α-stimulated activation of NF-κB and an assay for inhibition of NF-α-stimulated prodn. of inflammatory mediators.
IT 53242-70-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of hydroxybenzamide, naphthalenecarboxamide, and hydroxyheterocyclecarboxamide derivs. as transcription factor NF-κB activation inhibitors)
RN 53242-70-9 CAPLUS
CN Benzoic acid, 2-hydroxy-5-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)

RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 71 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:991330 CAPLUS
DN 140:27850
TI Preparation of phenol or phenyl acetate derivatives as therapeutic drugs for prevention or treatment of diabetes and/or diabetes complications
IN Muto, Susumu; Itai, Akiko
PA Institute of Medicinal Molecular Design. Inc., Japan
SO PCT Int. Appl., 396 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003103648	A1	20031218	WO 2003-JP7131	20030605
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2488342	AA	20031218	CA 2003-2488342	20030605
	AU 2003242137	A1	20031222	AU 2003-242137	20030605
	EP 1510207	A1	20050302	EP 2003-730841	20030605
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1658850	A	20050824	CN 2003-812943	20030605
	US 2006111409	A1	20060525	US 2005-515341	20050713
PRAI	JP 2002-164524	A	20020605		
	WO 2003-JP7131	W	20030605		

OS MARPAT 140:27850
GI



I

AB Disclosed are medicines for the prevention and/or treatment of diabetes and/or diabetes complications, containing as the active ingredient substances selected from the group consisting of compds. represented by the general formula (I) and pharmacol. acceptable salts thereof, and hydrates and solvates of both (wherein X is a connecting group whose main chain has 2 to 5 carbon atoms and which may have a substituent; A is hydrogen or acetyl; E is optionally substituted aryl or optionally substituted

L9 ANSWER 71 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
heteroaryl; and the ring Z is arene which may have a substituent in addn. to the groups represented by the general formulas: -O-A and -X-E, or heteroarene which may have a substituent in addn. to the groups represented by the general formulas: -O-A and -X-E). Also disclosed are medicines possessing insulin-resistance improving, hyperinsulinemia improving, and/or hyperglycemia improving activity. A total of .apprx.500 I including N-phenylhydroxybenzamides (N-phenylsalicylamide), N-heterocyclylhydroxybenzamides, N-phenylhydroxycarbazolecarboxamides, N-phenylhydroxynaphthalenecarboxamides, N-phenylhydroxypyridinecarboxamide s, N-phenylhydroxyquinoxalinecarboxamide, and N-phenylhydroxyindolecarboxamide were prepd. The compds. I improve insulin resistance by specifically inhibiting IKK-β (I κB kinase β).
IT 53242-70-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of phenol or Ph acetate derivs. as therapeutic drugs for prevention or treatment of diabetes and/or diabetes complications)
RN 53242-70-9 CAPLUS
CN Benzoic acid, 2-hydroxy-5-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 72 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:991329 CAPLUS
DN 140:27849
TI Preparation of phenol or phenyl acetate derivatives as inhibitors against the activation of activator protein-1 (AP-1) and nuclear factor of activated T-cells (NFAT)
IN Muto, Susumu; Itai, Akiko
PA Institute of Medicinal Molecular Design. Inc., Japan
SO PCT Int. Appl., 401 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003103647	A1	20031218	WO 2003-JP7129	20030605
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2487891	AA	20031218	CA 2003-2487891	20030605
	AU 2003242127	A1	20031222	AU 2003-242127	20030605
	EP 1512396	A1	20050309	EP 2003-730839	20030605
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1658849	A	20050824	CN 2003-812942	20030605
	US 2006100257	A1	20060511	US 2005-515342	20050915
PRAI	JP 2002-164526	A	20020605		
	WO 2003-JP7129	W	20030605		

OS MARPAT 140:27849
GI



I

AB Disclosed are medicines for inhibiting the activation of AP-1 or NFAT, containing as the active ingredient substances selected from the group consisting of compds. represented by the general formula (I) and pharmacol. acceptable salts thereof, and hydrates and solvates of both (wherein X is a connecting group whose main chain has 2 to 5 carbon atoms and which may have a substituent; A is hydrogen or acetyl; E is optionally substituted aryl or optionally substituted heteroaryl; and the ring Z is arene which may have a substituent in addition to the groups represented by the general formulas: -O-A and -X-E, or heteroarene which may have a

L9 ANSWER 72 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
substituent in addn. to the groups represented by the general formulas: -O-A and -X-E). A total of .apprx.500 I including N-phenylhydroxybenzamides (N-phenylsalicylamide), N-heterocyclylhydroxybenzamides, N-phenylhydroxycarbazolecarboxamides, N-phenylhydroxynaphthalenecarboxamides, N-phenylhydroxypyridinecarboxamide s, N-phenylhydroxyquinoxalinecarboxamide, and N-phenylhydroxyindolecarboxamide were prepd. The compds. I can exhibit the inhibitory activity against releasing inflammatory cytokines, inflammatory activity, immunosuppressant activity, and antiallergic activity based on inhibiting the activation of AP-1 or NFAT.
IT 53242-70-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of phenol or Ph acetate derivs. as inhibitors against activation of activator protein-1 (AP-1) and nuclear factor of activated T-cells (NFAT))
RN 53242-70-9 CAPLUS
CN Benzoic acid, 2-hydroxy-5-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:972053 CAPLUS
DN 140:27757
TI Preparation of pyrroles for the treatment of prostaglandin mediated diseases
IN Giblin, Gerard Martin Paul; Hall, Adrian; Healy, Mark Patrick; Lewell, Xiao Qing; Miller, Neil Derek; Novelli, Riccardo
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 275 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003101959	A1	20031211	WO 2003-EP5790	20030530
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003238455	A1	20031219	AU 2003-238455	20030530
EP 1509499	A1	20050302	EP 2003-732522	20030530
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005532347	T2	20051027	JP 2004-509653	20030530
PRAI GB 2002-12785	A	20020531		
WO 2003-EP5790	W	20030530		

OS MARPAT 140:27757
GI



AB The title compds. [I; A = (un)substituted aryl, 5-6 membered heterocyclyl, bicyclic heterocyclyl; R1 = CO2H, CN, CH2CO2H, alkyl, etc.; R2, R3 = H, halo, alkyl, alkoxy, etc.; R4 = (un)substituted alkyl wherein 1 or 2 of the non-terminal carbon atoms may optionally be replaced by a O, (un)substituted NH, SOn (n = 0-2); R5, R6 = H, CF3, alkyl] which bind with

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632621-69-3 CAPLUS
CN Benzoic acid, 3-[2-[2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632621-70-6 CAPLUS
CN Benzoic acid, 3-[2-[2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632621-71-7 CAPLUS
CN Benzoic acid, 3-[2-[2-[(4-chlorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
high affinity to the EP1 receptors, and are useful in medicine, in particular in the treatment of prostaglandin mediated diseases such as pain, inflammatory, immunol., bone, neurodegenerative or renal disorder, were prepd. Prepn. of 394 compds. I is described in detail. E.g., a 3-step synthesis of 3-[2-(2-benzyloxyphenyl)-5-methylpyrrol-1-yl]benzoic acid (starting from 2-benzyloxybenzaldehyde and Me vinyl ketone), was given. The exemplified compds. I had an antagonist pIC50 of 7.0-9.5 at EP1 receptors and pIC50 of < 6.0 at EP3 receptors. The pharmaceutical compn. comprising the title compd. I is claimed.
IT **632621-53-5P 632621-54-6P 632621-68-2P**
632621-69-3P 632621-70-6P 632621-71-7P
632621-76-2P 632621-77-3P 632622-12-9P
632623-39-3P 632625-02-6P 632625-38-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrroles for the treatment of prostaglandin mediated diseases)
RN 632621-53-5 CAPLUS
CN Benzoic acid, 3-[2-methyl-5-[2-(phenylmethoxy)phenyl]-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632621-54-6 CAPLUS
CN Benzoic acid, 3-[2-[5-chloro-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632621-68-2 CAPLUS
CN Benzoic acid, 3-[2-[2-[(2-chloro-4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
1-yl]- (9CI) (CA INDEX NAME)



RN 632621-76-2 CAPLUS
CN Benzoic acid, 3-[2-[5-chloro-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632621-77-3 CAPLUS
CN Benzoic acid, 3-[2-[5-chloro-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632622-12-9 CAPLUS
CN Benzoic acid, 3-(acetylamino)-5-[2-[5-bromo-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632623-39-3 CAPLUS
CN Benzoic acid,
5-[2-[5-bromo-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 632625-02-6 CAPLUS
CN Benzoic acid,
3-amino-5-[2-[5-chloro-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632625-38-8 CAPLUS
CN Benzoic acid,
4-[2-[5-chloro-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

yl]- (9CI) (CA INDEX NAME)



IT 632621-55-7P 632621-56-8P 632621-57-9P
632621-60-4P 632621-61-5P 632621-62-6P
632621-63-7P 632621-64-8P 632621-65-9P
632621-66-0P 632621-67-1P 632621-72-8P
632621-73-9P 632621-74-0P 632621-75-1P
632621-91-1P 632621-92-2P 632621-93-3P
632621-94-4P 632621-95-5P 632621-96-6P
632621-97-7P 632621-98-8P 632621-99-9P
632622-00-5P 632622-01-6P 632622-02-7P
632622-03-8P 632622-04-9P 632622-05-0P
632622-06-1P 632622-07-2P 632622-08-3P
632622-09-4P 632622-10-7P 632622-11-8P
632622-13-0P 632622-14-1P 632622-15-2P
632622-16-3P 632622-17-4P 632622-18-5P
632622-19-6P 632622-20-9P 632622-21-0P
632622-22-1P 632622-23-2P 632622-24-3P
632622-25-4P 632622-26-5P 632622-27-6P
632622-28-7P 632622-29-8P 632622-30-1P
632622-31-2P 632622-87-8P 632622-88-9P
632622-89-0P 632622-90-3P 632622-91-4P
632622-92-5P 632622-93-6P 632622-94-7P
632622-95-8P 632622-96-9P 632622-97-0P
632622-98-1P 632622-99-2P 632623-00-8P
632623-01-9P 632623-02-0P 632623-03-1P
632623-04-2P 632623-05-3P 632623-06-4P
632623-07-5P 632623-08-6P 632623-09-7P
632623-10-0P 632623-11-1P 632623-12-2P
632623-13-3P 632623-14-4P 632623-15-5P
632623-16-6P 632623-17-7P 632623-18-8P
632623-19-9P 632623-20-2P 632623-21-3P
632623-22-4P 632623-23-5P 632623-24-6P
632623-25-7P 632623-26-8P 632623-27-9P
632623-28-0P 632623-29-1P 632623-30-4P
632623-31-5P 632623-32-6P 632623-34-8P
632623-35-9P 632623-36-0P 632623-37-1P
632623-38-2P 632623-40-6P 632623-41-7P
632623-42-8P 632623-43-9P 632623-44-0P
632623-45-1P 632623-46-2P 632623-47-3P
632623-48-4P 632623-49-5P 632623-50-8P
632623-51-9P 632623-52-0P 632623-53-1P

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

632623-54-2P 632623-55-3P 632623-56-4P
632623-57-5P 632623-58-6P 632623-59-7P
632623-60-0P 632623-61-1P 632623-62-2P
632623-63-3P 632623-64-4P 632623-65-5P
632623-66-6P 632623-67-7P 632623-68-8P
632623-69-9P 632623-70-2P 632623-71-3P
632623-72-4P 632623-73-5P 632623-74-6P
632623-75-7P 632623-76-8P 632623-77-9P
632623-78-0P 632623-79-1P 632623-80-4P
632623-81-5P 632623-82-6P 632623-83-7P
632623-84-8P 632623-91-7P 632623-92-8P
632623-93-9P 632623-94-0P 632623-95-1P
632623-96-2P 632623-97-3P 632623-98-4P
632623-99-5P 632624-00-1P 632624-01-2P
632624-02-3P 632624-03-4P 632624-04-5P
632624-05-6P 632624-06-7P 632624-07-8P
632624-08-9P 632624-09-0P 632624-10-3P
632624-11-4P 632624-12-5P 632624-13-6P
632624-14-7P 632624-15-8P 632624-16-9P
632624-17-0P 632624-18-1P 632624-19-2P
632624-20-5P 632624-21-6P 632624-22-7P
632624-23-8P 632624-24-9P 632624-25-0P
632624-26-1P 632624-27-2P 632624-28-3P
632624-29-4P 632624-30-7P 632624-31-8P
632624-32-9P 632624-33-0P 632624-34-1P
632624-35-2P 632624-36-3P 632624-37-4P
632624-38-5P 632624-39-6P 632624-40-9P
632624-41-0P 632624-42-1P 632624-43-2P
632624-44-3P 632624-45-4P 632624-46-5P
632624-47-6P 632624-48-7P 632624-49-8P
632624-50-1P 632624-51-2P 632624-52-3P
632624-53-4P 632624-54-5P 632624-55-6P
632624-56-7P 632624-57-8P 632624-58-9P
632624-59-0P 632624-60-3P 632624-61-4P
632624-62-5P 632624-63-6P 632624-64-7P
632624-65-8P 632624-66-9P 632624-67-0P
632624-68-1P 632624-69-2P 632624-70-5P
632624-71-6P 632624-72-7P 632624-73-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrroles for the treatment of prostaglandin mediated diseases)

RN 632621-55-7 CAPLUS
CN Benzoic acid,
3-[2-[5-bromo-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 632621-56-8 CAPLUS
CN Benzoic acid, 3-[2-methyl-5-[4-(phenylmethoxy)[1,1'-biphenyl]-3-yl]-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632621-57-9 CAPLUS
CN Benzoic acid, 3-[2-[5-chloro-2-(cyclohexylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632621-60-4 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(4-methoxyphenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632621-61-5 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(3,4-dichlorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632621-62-6 CAPLUS
CN Benzoic acid,
3-[2-[5-bromo-2-[(2-chloro-4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632621-63-7 CAPLUS
CN Benzoic acid,
3-[2-[5-bromo-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 632621-64-8 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632621-65-9 CAPLUS
CN Benzoic acid,
3-[2-[5-bromo-2-[(4-chlorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632621-66-0 CAPLUS
CN Benzoic acid,
3-[2-[2-[(4-methoxyphenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632621-67-1 CAPLUS
CN Benzoic acid, 3-[2-[2-[(3,4-dichlorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632621-72-8 CAPLUS
CN Benzoic acid,
3-[2-[5-chloro-2-[(4-methoxyphenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632621-73-9 CAPLUS
CN Benzoic acid, 3-[2-[5-chloro-2-[(4-chlorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632621-74-0 CAPLUS
CN Benzoic acid, 3-[2-[5-chloro-2-[(3,4-dichlorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632621-75-1 CAPLUS
CN Benzoic acid,
3-[2-[5-chloro-2-[(2-chloro-4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632621-91-1 CAPLUS
CN Benzoic acid,
2-chloro-5-[2-[5-chloro-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632621-92-2 CAPLUS
CN Benzoic acid, 3-bromo-5-[2-[5-chloro-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632621-93-3 CAPLUS
CN Benzoic acid, 3-(acetylamino)-5-[2-[5-chloro-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632621-94-4 CAPLUS
CN Benzoic acid, 3-[2-[5-chloro-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN Benzoic acid, 3-[2-[5-chloro-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-4-fluoro- (9CI) (CA INDEX NAME)



RN 632621-98-8 CAPLUS
CN Benzoic acid, 5-[2-[5-chloro-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 632621-99-9 CAPLUS
CN Benzoic acid, 2-chloro-5-[2-[5-chloro-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632621-95-5 CAPLUS
CN 1-Naphthalenecarboxylic acid, 3-[2-[5-chloro-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632621-96-6 CAPLUS
CN Benzoic acid, 5-[2-[5-chloro-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-fluoro- (9CI) (CA INDEX NAME)



RN 632621-97-7 CAPLUS

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 632622-00-5 CAPLUS
CN Benzoic acid, 3-[2-[5-chloro-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2,5,6-trifluoro- (9CI) (CA INDEX NAME)



RN 632622-01-6 CAPLUS
CN Benzoic acid, 5-[2-[5-chloro-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 632622-02-7 CAPLUS
CN Benzoic acid, 5-[2-[5-chloro-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-fluoro- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632622-03-8 CAPLUS
CN 1-Naphthalenecarboxylic acid, 3-[2-[5-chloro-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632622-04-9 CAPLUS
CN Benzoic acid, 3-[2-[5-chloro-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 632622-05-0 CAPLUS
CN Benzoic acid, 3-[2-[5-chloro-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-4-fluoro- (9CI) (CA INDEX NAME)



RN 632622-06-1 CAPLUS
CN Benzoic acid, 3-(acetylamino)-5-[2-[5-chloro-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632622-07-2 CAPLUS
CN Benzoic acid, 2-chloro-5-[2-[5-chloro-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632622-08-3 CAPLUS
CN Benzoic acid, 3-[2-[5-chloro-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2,5,6-trifluoro- (9CI) (CA INDEX NAME)



RN 632622-09-4 CAPLUS
CN Benzoic acid, 5-[2-[5-bromo-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-chloro- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632622-10-7 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-4-chloro- (9CI) (CA INDEX NAME)



RN 632622-11-8 CAPLUS
CN 1-Naphthalenecarboxylic acid, 3-[2-[5-bromo-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632622-13-0 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632622-14-1 CAPLUS
CN Benzoic acid, 5-[2-[5-bromo-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-fluoro- (9CI) (CA INDEX NAME)



RN 632622-15-2 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-4-fluoro- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632622-16-3 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2,5,6-trifluoro- (9CI) (CA INDEX NAME)



RN 632622-17-4 CAPLUS
CN Benzoic acid, 3-amino-5-[2-[5-bromo-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632622-18-5 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-5-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 632622-19-6 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-(cyclohexylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632622-20-9 CAPLUS
CN Benzoic acid, 3-[2-methyl-5-[5-(methylsulfonyl)-2-(phenylmethoxy)phenyl]-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632622-21-0 CAPLUS
CN Benzoic acid, 3-[2-[2-[(4-chlorophenyl)methoxy]-5-(methylsulfonyl)phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632622-22-1 CAPLUS
CN Benzoic acid, 3-[2-[2-[(4-fluorophenyl)methoxy]-5-(methylsulfonyl)phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632622-23-2 CAPLUS
CN Benzoic acid, 3-[2-[2-[(2-chloro-4-fluorophenyl)methoxy]-5-(methylsulfonyl)phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632622-24-3 CAPLUS
CN Benzoic acid, 3-[2-[2-[(2,4-difluorophenyl)methoxy]-5-(methylsulfonyl)phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632622-25-4 CAPLUS
CN Benzoic acid, 3-[2-methyl-5-[2-(phenylmethoxy)-5-(trifluoromethyl)phenyl]-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632622-26-5 CAPLUS
CN Benzoic acid, 3-[2-[2-[(4-chlorophenyl)methoxy]-5-(trifluoromethyl)phenyl]-

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632622-27-6 CAPLUS
CN Benzoic acid, 3-[2-[2-[(4-fluorophenyl)methoxy]-5-(trifluoromethyl)phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632622-28-7 CAPLUS
CN Benzoic acid, 3-[2-[2-[(2-chloro-4-fluorophenyl)methoxy]-5-(trifluoromethyl)phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 632622-29-8 CAPLUS
CN Benzoic acid, 3-[2-[2-[(2,4-difluorophenyl)methoxy]-5-(trifluoromethyl)phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632622-30-1 CAPLUS
CN Benzoic acid, 3-[2-[2-(cyclohexylmethoxy)-5-(trifluoromethyl)phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632622-31-2 CAPLUS
CN Benzoic acid, 3-[2-[2-[(4-methoxyphenyl)methoxy]-5-(trifluoromethyl)phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632622-87-8 CAPLUS
CN Benzoic acid, 3-[2-[2-([1,1'-biphenyl]-4-ylmethoxy)-5-bromophenyl]-5-

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632622-88-9 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(2-bromo-4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632622-89-0 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(3-chloro-4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632622-90-3 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(4-bromo-2-fluorophenyl)methoxy]phenyl]-5-

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632622-91-4 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(3,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632622-92-5 CAPLUS
CN Benzoic acid,
3-[2-[5-bromo-2-[[4-(trifluoromethoxy)phenyl]methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632622-96-9 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(3-methoxyphenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632622-97-0 CAPLUS
CN Benzoic acid,
3-[2-[5-bromo-2-[(3-fluoro-4-methoxyphenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632622-98-1 CAPLUS
CN Benzoic acid,
3-[2-[5-bromo-2-[[3-(difluoromethoxy)phenyl]methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632622-93-6 CAPLUS
CN Benzoic acid, 3-[2-[2-(2,1,3-benzoxadiazol-5-ylmethoxy)-5-bromophenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632622-94-7 CAPLUS
CN Benzoic acid,
3-[2-[5-bromo-2-[(4-bromophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632622-95-8 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(3,5-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632622-99-2 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(2,3-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632623-00-8 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(2,6-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632623-01-9 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-(2-naphthalenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632623-02-0 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(4-methylphenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632623-03-1 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(3,5-dichlorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632623-04-2 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(2,3,6-trifluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632623-05-3 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(2,4,6-trifluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632623-06-4 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(2-methylphenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632623-07-5 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(2-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632623-08-6 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(2-chlorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632623-09-7 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(2,6-dichlorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632623-10-0 CAPLUS
CN Benzoic acid, 3-[2-[2-[[2,4-bis(trifluoromethyl)phenyl]methoxy]-5-bromophenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632623-11-1 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(2,5-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632623-12-2 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[[4-(trifluoromethyl)phenyl]methoxy]phenyl]-

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632623-13-3 CAPLUS
CN Benzoic acid,
3-[2-[5-bromo-2-[(2-chloro-6-fluorophenyl)methoxy]phenyl]-5-
methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632623-14-4 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(3,4,5-trifluorophenyl)methoxy]phenyl]-5-
methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632623-15-5 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(2-bromo-5-fluorophenyl)methoxy]phenyl]-5-
methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632623-16-6 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(2,4-dichloro-5-
fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX
NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632623-17-7 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(2,4,5-trifluorophenyl)methoxy]phenyl]-5-
methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632623-18-8 CAPLUS
CN Benzoic acid,
3-[2-[5-bromo-2-[[2-fluoro-4-(trifluoromethyl)phenyl]methoxy
]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632623-19-9 CAPLUS
CN Benzoic acid,
3-[2-[5-bromo-2-[(5-fluoro-2-methylphenyl)methoxy]phenyl]-5-
methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632623-20-2 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(2,3,4-trifluorophenyl)methoxy]phenyl]-5-
methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632623-21-3 CAPLUS
CN Benzoic acid,
3-[2-[5-bromo-2-[[2-fluoro-6-(trifluoromethyl)phenyl]methoxy
]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632623-22-4 CAPLUS

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzoic acid,
3-[2-[5-bromo-2-[(2-bromophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632623-23-5 CAPLUS
CN Benzoic acid,
3-[2-[5-bromo-2-[(3-chlorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632623-24-6 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(2,4-dichlorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632623-25-7 CAPLUS
CN Benzoic acid, 2-(acetylamino)-5-[2-[5-bromo-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632623-26-8 CAPLUS
CN Benzoic acid,
5-[2-[5-bromo-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]-2-(difluoromethoxy)- (9CI) (CA INDEX NAME)



RN 632623-27-9 CAPLUS
CN Benzoic acid, 3-amino-5-[2-[5-bromo-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632623-28-0 CAPLUS
CN Benzoic acid,
3-[2-[5-bromo-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]-5-(ethylamino)- (9CI) (CA INDEX NAME)



RN 632623-29-1 CAPLUS
CN Benzoic acid,
3-[2-[5-bromo-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]-5-(1,1-dioxido-2-isothiazolidinyl)- (9CI) (CA INDEX NAME)



RN 632623-30-4 CAPLUS
CN Benzoic acid,
3-[2-[5-bromo-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]-5-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632623-31-5 CAPLUS
CN Benzoic acid,
3-[2-[5-bromo-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]-5-(2-oxo-1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 632623-32-6 CAPLUS
CN Benzoic acid, 3-amino-5-[2-[5-bromo-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 632623-34-8 CAPLUS
CN Benzoic acid,
3-[2-[5-bromo-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632623-35-9 CAPLUS
CN Benzoic acid,
5-[2-[5-bromo-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]-2-chloro- (9CI) (CA INDEX NAME)



RN 632623-36-0 CAPLUS
CN Benzoic acid, 3-(acetylamino)-5-[2-[5-bromo-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632623-37-1 CAPLUS
CN Benzoic acid,
5-[2-[5-bromo-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632623-38-2 CAPLUS
CN Benzoic acid,
5-[2-[5-bromo-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]-2-fluoro- (9CI) (CA INDEX NAME)



RN 632623-40-6 CAPLUS
CN Benzoic acid,
5-[2-[5-bromo-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 632623-41-7 CAPLUS
CN 1-Naphthalenecarboxylic acid, 3-[2-[5-bromo-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632623-42-8 CAPLUS
CN Benzoic acid,
3-[2-[5-bromo-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]-4-fluoro- (9CI) (CA INDEX NAME)



RN 632623-43-9 CAPLUS
CN Benzoic acid,
3-[2-[5-bromo-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]-5-(propylamino)- (9CI) (CA INDEX NAME)



RN 632623-44-0 CAPLUS
CN Benzoic acid, 5-[2-[5-bromo-2-[(2,4,6-trifluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-(difluoromethoxy)- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632623-45-1 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(2,4,6-trifluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 632623-46-2 CAPLUS
CN Benzoic acid, 3-amino-5-[2-[5-bromo-2-[(2,4,6-trifluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 632623-47-3 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(2,4,6-trifluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-5-(1,1-dioxido-2-isothiazolidinyl)- (9CI) (CA INDEX NAME)



RN 632623-48-4 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(2,4,6-trifluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-5-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 632623-49-5 CAPLUS
CN Benzoic acid, 3-amino-5-[2-[5-bromo-2-[(2,4,6-trifluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632623-50-8 CAPLUS
CN Benzoic acid, 5-[2-[5-bromo-2-[(2,4,6-trifluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-fluoro- (9CI) (CA INDEX NAME)



RN 632623-51-9 CAPLUS
CN Benzoic acid, 5-[2-[5-bromo-2-[(2,4,6-trifluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-hydroxy- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632623-52-0 CAPLUS
CN 1-Naphthalenecarboxylic acid, 3-[2-[5-bromo-2-[(2,4,6-trifluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632623-53-1 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(2,4,6-trifluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-4-fluoro- (9CI) (CA INDEX NAME)



RN 632623-54-2 CAPLUS
CN Benzoic acid, 5-[2-[5-bromo-2-[(2,4,6-trifluorophenyl)methoxy]phenyl]-5-

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
methyl-1H-pyrrol-1-yl]-2-chloro- (9CI) (CA INDEX NAME)



RN 632623-55-3 CAPLUS
CN Benzoic acid, 3-(acetylamino)-5-[2-[5-bromo-2-[(2,4,6-trifluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632623-56-4 CAPLUS
CN Benzoic acid, 5-[2-[5-bromo-2-[(2,4,6-trifluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632623-57-5 CAPLUS
CN Benzoic acid,
5-[2-[5-bromo-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-chloro- (9CI) (CA INDEX NAME)



RN 632623-58-6 CAPLUS
CN Benzoic acid,
5-[2-[5-bromo-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-fluoro- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632623-59-7 CAPLUS
CN Benzoic acid,
5-[2-[5-bromo-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 632623-60-0 CAPLUS
CN Benzoic acid,
5-[2-[5-bromo-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-hydroxy- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632623-61-1 CAPLUS
CN Benzoic acid, 3-(acetylamino)-5-[2-[5-bromo-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632623-62-2 CAPLUS
CN 1-Naphthalenecarboxylic acid, 3-[2-[5-bromo-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632623-63-3 CAPLUS
CN Benzoic acid,
3-[2-[5-bromo-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-4-fluoro- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632623-64-4 CAPLUS
CN Benzoic acid, 2-(acetylamino)-5-[2-[5-bromo-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632623-65-5 CAPLUS
CN Benzoic acid,
5-[2-[5-bromo-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-(difluoromethoxy)- (9CI) (CA INDEX NAME)



L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 632623-66-6 CAPLUS
CN Benzoic acid,
3-[2-[5-bromo-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 632623-67-7 CAPLUS
CN Benzoic acid, 3-amino-5-[2-[5-bromo-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632623-68-8 CAPLUS
CN Benzoic acid,
3-[2-[5-bromo-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-5-(1,1-dioxido-2-isothiazolidinyl)- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632623-69-9 CAPLUS
CN Benzoic acid,
3-[2-[5-bromo-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-5-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 632623-70-2 CAPLUS
CN Benzoic acid,
3-[2-[5-bromo-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-5-(2-oxo-1-piperidinyl)- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632623-71-3 CAPLUS
CN Benzoic acid, 3-amino-5-[2-[5-bromo-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 632623-72-4 CAPLUS
CN Benzoic acid,
2-chloro-5-[2-[5-fluoro-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632623-73-5 CAPLUS
CN Benzoic acid,
2-fluoro-5-[2-[5-fluoro-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632623-74-6 CAPLUS
CN Benzoic acid, 5-[2-[5-fluoro-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)



L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 632623-75-7 CAPLUS
CN Benzoic acid, 5-[2-[5-fluoro-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 632623-76-8 CAPLUS
CN Benzoic acid, 3-(acetylamino)-5-[2-[5-fluoro-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632623-77-9 CAPLUS
CN 1-Naphthalenecarboxylic acid, 3-[2-[5-fluoro-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632623-78-0 CAPLUS
CN Benzoic acid, 4-fluoro-3-[2-[5-fluoro-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632623-79-1 CAPLUS
CN Benzoic acid, 2-(difluoromethoxy)-5-[2-[5-fluoro-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 632623-80-4 CAPLUS
CN Benzoic acid, 3-[2-[5-fluoro-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 632623-81-5 CAPLUS
CN Benzoic acid, 3-(1,1-dioxido-2-isothiazolidinyl)-5-[2-[5-fluoro-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632623-82-6 CAPLUS
CN Benzoic acid, 3-[2-[5-fluoro-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-5-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 632623-83-7 CAPLUS
CN Benzoic acid, 3-amino-5-[2-[5-fluoro-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 632623-84-8 CAPLUS
CN Benzoic acid, 5-[2-[2-[(2,4-difluorophenyl)methoxy]-5-fluorophenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 632623-91-7 CAPLUS
CN Benzoic acid, 2-chloro-5-[2-[2-[(4-fluorophenyl)methoxy]-5-(trifluoromethyl)phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632623-92-8 CAPLUS
CN Benzoic acid, 2-fluoro-5-[2-[2-[(4-fluorophenyl)methoxy]-5-(trifluoromethyl)phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632623-93-9 CAPLUS
CN Benzoic acid, 4-fluoro-3-[2-[2-[(4-fluorophenyl)methoxy]-5-(trifluoromethyl)phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632623-97-3 CAPLUS
CN Benzoic acid, 3-[2-[2-[(4-fluorophenyl)methoxy]-5-(trifluoromethyl)phenyl]-5-methyl-1H-pyrrol-1-yl]-5-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 632623-98-4 CAPLUS
CN Benzoic acid, 3-[2-[2-[(4-fluorophenyl)methoxy]-5-(trifluoromethyl)phenyl]-5-methyl-1H-pyrrol-1-yl]-5-(2-oxo-1-piperidinyl)- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 632623-94-0 CAPLUS
CN Benzoic acid, 5-[2-[2-[(4-fluorophenyl)methoxy]-5-(trifluoromethyl)phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 632623-95-1 CAPLUS
CN Benzoic acid, 3-(acetylamino)-5-[2-[2-[(4-fluorophenyl)methoxy]-5-(trifluoromethyl)phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632623-96-2 CAPLUS
CN Benzoic acid, 3-(1,1-dioxido-2-isothiazolidinyl)-5-[2-[2-[(4-fluorophenyl)methoxy]-5-(trifluoromethyl)phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632623-99-5 CAPLUS
CN Benzoic acid, 3-amino-5-[2-[2-[(4-fluorophenyl)methoxy]-5-(trifluoromethyl)phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 632624-00-1 CAPLUS
CN Benzoic acid, 2-chloro-5-[2-methyl-5-[2-(phenylmethoxy)-5-(trifluoromethyl)phenyl]-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632624-01-2 CAPLUS
CN Benzoic acid, 4-fluoro-3-[2-methyl-5-[2-(phenylmethoxy)-5-(trifluoromethyl)phenyl]-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632624-02-3 CAPLUS
CN Benzoic acid, 3-[2-methyl-5-[2-(phenylmethoxy)-5-(trifluoromethyl)phenyl]-1H-pyrrol-1-yl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 632624-03-4 CAPLUS
CN Benzoic acid, 3-amino-2-methyl-5-[2-methyl-5-[2-(phenylmethoxy)-5-(trifluoromethyl)phenyl]-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632624-06-7 CAPLUS
CN Benzoic acid, 3-[2-[2-[(2,4-difluorophenyl)methoxy]-5-(trifluoromethyl)phenyl]-5-methyl-1H-pyrrol-1-yl]-4-fluoro- (9CI) (CA INDEX NAME)



RN 632624-07-8 CAPLUS
CN Benzoic acid, 3-(acetylamino)-5-[2-[2-[(2,4-difluorophenyl)methoxy]-5-(trifluoromethyl)phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632624-08-9 CAPLUS

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632624-04-5 CAPLUS
CN Benzoic acid, 2-chloro-5-[2-[2-[(2,4-difluorophenyl)methoxy]-5-(trifluoromethyl)phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632624-05-6 CAPLUS
CN Benzoic acid, 5-[2-[2-[(2,4-difluorophenyl)methoxy]-5-(trifluoromethyl)phenyl]-5-methyl-1H-pyrrol-1-yl]-2-fluoro- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzoic acid, 3-[2-[2-[(2,4-difluorophenyl)methoxy]-5-(trifluoromethyl)phenyl]-5-methyl-1H-pyrrol-1-yl]-5-(1,1-dioxido-2-isothiazolidinyl)- (9CI) (CA INDEX NAME)



RN 632624-09-0 CAPLUS
CN Benzoic acid, 3-[2-[2-[(2,4-difluorophenyl)methoxy]-5-(trifluoromethyl)phenyl]-5-methyl-1H-pyrrol-1-yl]-5-(2-oxo-1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 632624-10-3 CAPLUS
CN Benzoic acid, 3-[2-[2-[(2,4-difluorophenyl)methoxy]-5-(trifluoromethyl)phenyl]-5-methyl-1H-pyrrol-1-yl]-5-[(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632624-11-4 CAPLUS
CN Benzoic acid, 4-[2-[[2,4-difluorophenyl)methoxy]-5-(trifluoromethyl)phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 632624-12-5 CAPLUS
CN Benzoic acid, 3-[2-[2-[(4-bromo-2-fluorophenyl)methoxy]-5-chlorophenyl]-5-methyl-1H-pyrrol-1-yl]-5-hydroxy- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632624-13-6 CAPLUS
CN Benzoic acid, 5-[2-[2-[(4-bromo-2-fluorophenyl)methoxy]-5-chlorophenyl]-5-methyl-1H-pyrrol-1-yl]-2-chloro- (9CI) (CA INDEX NAME)



RN 632624-14-7 CAPLUS
CN Benzoic acid, 5-[2-[2-[(4-bromo-2-fluorophenyl)methoxy]-5-chlorophenyl]-5-methyl-1H-pyrrol-1-yl]-2-fluoro- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632624-15-8 CAPLUS
CN Benzoic acid, 3-[2-[2-[(4-bromo-2-fluorophenyl)methoxy]-5-chlorophenyl]-5-methyl-1H-pyrrol-1-yl]-4-fluoro- (9CI) (CA INDEX NAME)



RN 632624-16-9 CAPLUS
CN Benzoic acid, 3-(acetylamino)-5-[2-[2-[(4-bromo-2-fluorophenyl)methoxy]-5-chlorophenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 632624-17-0 CAPLUS
CN 1-Naphthalenecarboxylic acid, 3-[2-[2-[(4-bromo-2-fluorophenyl)methoxy]-5-chlorophenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632624-18-1 CAPLUS
CN Benzoic acid, 5-[2-[2-[(4-bromo-2-fluorophenyl)methoxy]-5-chlorophenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 632624-19-2 CAPLUS
CN Benzoic acid, 5-[2-[2-[(4-bromo-2-fluorophenyl)methoxy]-5-chlorophenyl]-5-methyl-1H-pyrrol-1-yl]-2-hydroxy- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632624-20-5 CAPLUS
CN Benzoic acid, 3-bromo-5-[2-[2-[(4-bromo-2-fluorophenyl)methoxy]-5-chlorophenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632624-21-6 CAPLUS
CN Benzoic acid, 3-amino-5-[2-[2-[(4-bromo-2-fluorophenyl)methoxy]-5-chlorophenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632624-22-7 CAPLUS
CN Benzoic acid, 2-(acetylamino)-5-[2-[2-[(4-bromo-2-fluorophenyl)methoxy]-5-chlorophenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632624-23-8 CAPLUS
CN Benzoic acid, 3-[2-[2-[(4-bromo-2-fluorophenyl)methoxy]-5-chlorophenyl]-5-methyl-1H-pyrrol-1-yl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632624-24-9 CAPLUS
CN Benzoic acid, 3-[2-[2-[(4-bromo-2-fluorophenyl)methoxy]-5-chlorophenyl]-5-methyl-1H-pyrrol-1-yl]-5-(1,1-dioxido-2-isothiazolidinyl)- (9CI) (CA INDEX NAME)



RN 632624-25-0 CAPLUS
CN Benzoic acid, 3-[2-[5-chloro-2-[(2,6-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-5-hydroxy- (9CI) (CA INDEX NAME)



RN 632624-26-1 CAPLUS

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzoic acid, 5-[2-[5-chloro-2-[(2,6-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 632624-27-2 CAPLUS
CN Benzoic acid, 2-chloro-5-[2-[5-chloro-2-[(2,6-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632624-28-3 CAPLUS
CN Benzoic acid, 5-[2-[5-chloro-2-[(2,6-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-fluoro- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632624-29-4 CAPLUS
CN Benzoic acid, 3-(acetylamino)-5-[2-[5-chloro-2-[(2,6-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632624-30-7 CAPLUS
CN 1-Naphthalenecarboxylic acid, 3-[2-[5-chloro-2-[(2,6-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632624-31-8 CAPLUS
CN Benzoic acid, 3-[2-[5-chloro-2-[(2,6-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-4-fluoro- (9CI) (CA INDEX NAME)



RN 632624-32-9 CAPLUS
CN Benzoic acid, 5-[2-[5-chloro-2-[(2,6-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)



L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 632624-33-0 CAPLUS
CN Benzoic acid, 3-bromo-5-[2-[5-chloro-2-[(2,6-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632624-34-1 CAPLUS
CN Benzoic acid, 3-amino-5-[2-[5-chloro-2-[(2,6-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632624-35-2 CAPLUS
CN Benzoic acid, 2-(acetylamino)-5-[2-[5-chloro-2-[(2,6-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632624-36-3 CAPLUS
CN Benzoic acid, 3-[2-[5-chloro-2-[(2,6-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 632624-37-4 CAPLUS
CN Benzoic acid, 3-[2-[5-chloro-2-[(2,6-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-5-(1,1-dioxido-2-isothiazolidinyl)- (9CI) (CA INDEX NAME)



L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 632624-38-5 CAPLUS
CN Benzoic acid, 2-chloro-5-[2-[5-chloro-2-[(2,3-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632624-39-6 CAPLUS
CN Benzoic acid, 5-[2-[5-chloro-2-[(2,3-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-fluoro- (9CI) (CA INDEX NAME)



RN 632624-40-9 CAPLUS
CN Benzoic acid, 3-(acetylamino)-5-[2-[5-chloro-2-[(2,3-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzoic acid, 5-[2-[5-chloro-2-[(2,3-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 632624-44-3 CAPLUS
CN Benzoic acid, 3-bromo-5-[2-[5-chloro-2-[(2,3-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632624-45-4 CAPLUS
CN Benzoic acid, 3-amino-5-[2-[5-chloro-2-[(2,3-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632624-41-0 CAPLUS
CN 1-Naphthalenecarboxylic acid, 3-[2-[5-chloro-2-[(2,3-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632624-42-1 CAPLUS
CN Benzoic acid, 3-[2-[5-chloro-2-[(2,3-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-4-fluoro- (9CI) (CA INDEX NAME)



RN 632624-43-2 CAPLUS

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632624-46-5 CAPLUS
CN Benzoic acid, 2-(acetylamino)-5-[2-[5-chloro-2-[(2,3-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632624-47-6 CAPLUS
CN Benzoic acid, 3-[2-[5-chloro-2-[(2,3-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 632624-48-7 CAPLUS
CN Benzoic acid, 3-[2-[5-chloro-2-[(2,3-difluorophenyl)methoxy]phenyl]-5-

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
methyl-1H-pyrrol-1-yl]-5-(1,1-dioxido-2-isothiazolidinyl)- (9CI) (CA INDEX NAME)



RN 632624-49-8 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-5-[(1-oxopropyl)amino]- (9CI) (CA INDEX NAME)



RN 632624-50-1 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-5-[(1-oxobutyl)amino]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632624-51-2 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(2,4-difluorophenyl]methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-5-[(methoxyacetyl)amino]- (9CI) (CA INDEX NAME)



RN 632624-52-3 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(2,4-difluorophenyl]methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-5-[(2-thienylacetyl)amino]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632624-53-4 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-5-[(2-methyl-1-oxopropyl)amino]- (9CI) (CA INDEX NAME)



RN 632624-54-5 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-5-[(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632624-55-6 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-5-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 632624-56-7 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-5-(ethylamino)- (9CI) (CA INDEX NAME)



RN 632624-57-8 CAPLUS
CN Benzoic acid, 3-[2-[5-chloro-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
methyl-1H-pyrrol-1-yl]-5-(ethylamino)- (9CI) (CA INDEX NAME)



RN 632624-58-9 CAPLUS
CN Benzoic acid, 3-(acetylmethylamino)-5-[2-[5-bromo-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632624-59-0 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-5-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632624-60-3 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-5-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 632624-61-4 CAPLUS
CN Benzoic acid, 5-[2-[5-bromo-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-hydroxy- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632624-62-5 CAPLUS
CN Benzoic acid, 5-[2-[5-bromo-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 632624-63-6 CAPLUS
CN Benzoic acid, 2-(acetylamino)-5-[2-[5-bromo-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632624-64-7 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-5-(1,1-dioxido-2-isothiazolidinyl)- (9CI) (CA INDEX NAME)



RN 632624-65-8 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-5-(2-oxo-1-piperidinyl)- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632624-66-9 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-5-(methylamino)- (9CI) (CA INDEX NAME)



RN 632624-67-0 CAPLUS
CN Benzoic acid, 3-[2-[5-chloro-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-5-(methylamino)- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632624-68-1 CAPLUS
CN Benzoic acid, 3-[2-[5-chloro-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-5-(methylamino)- (9CI) (CA INDEX NAME)



RN 632624-69-2 CAPLUS
CN Benzoic acid, 3-[2-[5-chloro-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-5-[(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)



L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 632624-70-5 CAPLUS
CN Benzoic acid, 3-chloro-5-[2-[5-chloro-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632624-71-6 CAPLUS
CN Benzoic acid,
3-chloro-5-[2-[5-chloro-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632624-72-7 CAPLUS
CN Benzoic acid,
3-bromo-5-[2-[5-chloro-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632624-73-8 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-5-chloro- (9CI) (CA INDEX NAME)



IT 632624-74-9P 632624-75-0P 632624-76-1P
632624-77-2P 632624-78-3P 632624-79-4P
632624-80-7P 632624-81-8P 632624-82-9P
632624-83-0P 632624-84-1P 632624-85-2P
632624-86-3P 632624-87-4P 632624-88-5P
632624-89-6P 632624-90-9P 632624-91-0P
632624-92-1P 632624-93-2P 632624-94-3P
632624-95-4P 632624-96-5P 632624-97-6P
632624-98-7P 632624-99-8P 632625-00-4P
632625-01-5P 632625-03-7P 632625-04-8P
632625-05-9P 632625-06-0P 632625-07-1P
632625-08-2P 632625-09-3P 632625-10-6P
632625-22-0P 632625-26-4P 632625-27-5P
632625-28-6P 632625-29-7P 632625-37-7P
632625-39-9P 632628-24-1P 632628-25-2P
632628-26-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrroles for the treatment of prostaglandin mediated diseases)

RN 632624-74-9 CAPLUS
CN Benzoic acid,
3-bromo-5-[2-[5-chloro-2-[(4-fluorophenyl)methoxy]phenyl]-5-

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632624-75-0 CAPLUS
CN Benzoic acid, 3-[2-[5-chloro-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-5-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 632624-76-1 CAPLUS
CN Benzoic acid, 3-[2-[5-chloro-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-5-(4-morpholinyl)- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632624-77-2 CAPLUS
CN Benzoic acid,
3-[2-[5-chloro-2-(phenylmethoxy)phenyl]-5-ethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632624-78-3 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-(phenylmethoxy)phenyl]-5-ethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 632624-79-4 CAPLUS
CN Benzoic acid, 3-[2-[2-[(4-fluorophenyl)methoxy]-5-methylphenyl]-5-methyl-1H-pyrrol-1-yl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 632624-80-7 CAPLUS
CN Benzoic acid, 2-(difluoromethoxy)-5-[2-[2-[(4-fluorophenyl)methoxy]-5-methylphenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632624-81-8 CAPLUS
CN Benzoic acid, 3-[2-[2-[(4-fluorophenyl)methoxy]-5-methylphenyl]-5-methyl-1H-pyrrol-1-yl]-5-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 632624-82-9 CAPLUS
CN Benzoic acid, 3-[2-[2-[(4-fluorophenyl)methoxy]-5-methylphenyl]-5-methyl-1H-pyrrol-1-yl]-5-(2-oxo-1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 632624-83-0 CAPLUS
CN Benzoic acid, 3-(1,1-dioxido-2-isothiazolidinyl)-5-[2-[2-[(4-fluorophenyl)methoxy]-5-methylphenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA
INDEX NAME)



RN 632624-84-1 CAPLUS
CN Benzoic acid, 2-(acetylamino)-5-[2-[2-[(4-fluorophenyl)methoxy]-5-methylphenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632624-85-2 CAPLUS
CN Benzoic acid,
3-amino-5-[2-[2-[(4-fluorophenyl)methoxy]-5-methylphenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632624-86-3 CAPLUS
CN Benzoic acid,
3-amino-5-[2-[2-[(4-fluorophenyl)methoxy]-5-methylphenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632624-87-4 CAPLUS
CN Benzoic acid, 5-[2-[2-[(4-fluorophenyl)methoxy]-5-methylphenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 632624-88-5 CAPLUS
CN Benzoic acid,
2-fluoro-5-[2-[2-[(4-fluorophenyl)methoxy]-5-methylphenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632624-89-6 CAPLUS
CN Benzoic acid,
2-chloro-5-[2-[2-[(4-fluorophenyl)methoxy]-5-methylphenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632624-90-9 CAPLUS
CN 1-Naphthalenecarboxylic acid, 3-[2-[2-[(4-fluorophenyl)methoxy]-5-methylphenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632624-91-0 CAPLUS
CN Benzoic acid, 3-(acetylamino)-5-[2-[2-[(4-fluorophenyl)methoxy]-5-methylphenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632624-92-1 CAPLUS
CN Benzoic acid,
3-[2-[5-chloro-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 632624-93-2 CAPLUS
CN Benzoic acid,
5-[2-[5-chloro-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]-2-(difluoromethoxy)- (9CI) (CA INDEX NAME)



RN 632624-94-3 CAPLUS
CN Benzoic acid,
3-[2-[5-chloro-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]-5-(2-oxo-1-piperidinyl)- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632624-95-4 CAPLUS
CN Benzoic acid, 2-(acetylamino)-5-[2-[5-chloro-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632624-96-5 CAPLUS
CN Benzoic acid,
3-amino-5-[2-[5-chloro-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 632624-97-6 CAPLUS
CN Benzoic acid,
5-[2-[5-chloro-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]-2-fluoro- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632624-98-7 CAPLUS
CN Benzoic acid, 3-(acetylamino)-5-[2-[5-chloro-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632624-99-8 CAPLUS
CN 1-Naphthalenecarboxylic acid, 3-[2-[5-chloro-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632625-00-4 CAPLUS
CN Benzoic acid,
3-[2-[5-chloro-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]-4-fluoro- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632625-01-5 CAPLUS
CN Benzoic acid,
5-[2-[5-chloro-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 632625-03-7 CAPLUS
CN Benzoic acid,
3-[2-[5-chloro-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]-5-[(methoxycarbonyl)amino]- (9CI) (CA INDEX NAME)



RN 632625-04-8 CAPLUS
CN Benzoic acid,
5-[2-[5-chloro-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]-2-hydroxy- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632625-05-9 CAPLUS
CN 1H-Indole-4-carboxylic acid, 6-[2-[5-chloro-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632625-06-0 CAPLUS
CN Benzoic acid,
3-[2-[5-chloro-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]-5-[(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 632625-07-1 CAPLUS
CN Benzoic acid,
3-[2-[5-chloro-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]-5-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632625-08-2 CAPLUS
CN Benzoic acid, 3-[2-[5-chloro-2-[(tetrahydro-2H-pyran-4-yl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632625-09-3 CAPLUS
CN Benzoic acid, 3-[2-[5-chloro-2-[(tetrahydro-3-furanyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632625-10-6 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(5-methyl-3-isoxazolyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632625-22-0 CAPLUS
CN Benzoic acid, 5-[2-[5-bromo-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 632625-26-4 CAPLUS
CN Benzoic acid, 2-fluoro-5-[2-methyl-5-[2-(phenylmethoxy)-5-(trifluoromethyl)phenyl]-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632625-27-5 CAPLUS
CN Benzoic acid, 3-(acetylamino)-5-[2-methyl-5-[2-(phenylmethoxy)-5-(trifluoromethyl)phenyl]-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632625-28-6 CAPLUS
CN Benzoic acid, 3-amino-5-[2-[5-fluoro-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632625-29-7 CAPLUS
CN Benzoic acid, 5-[2-[5-bromo-2-[(2,4-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-2-(difluoromethoxy)- (9CI) (CA INDEX NAME)



RN 632625-37-7 CAPLUS
CN Benzoic acid, 4-[2-methyl-5-[2-(phenylmethoxy)phenyl]-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632625-39-9 CAPLUS
CN Benzoic acid, 4-[2-[5-bromo-2-(phenylmethoxy)phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632628-24-1 CAPLUS
CN Benzoic acid, 3-[2-[5-bromo-2-[(2,3,5-trifluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 632628-25-2 CAPLUS
CN Benzoic acid, 3-[2-[5-chloro-2-[(2,3-difluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-5-hydroxy- (9CI) (CA INDEX NAME)

L9 ANSWER 73 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 632628-26-3 CAPLUS
CN Benzoic acid, 3-[2-[5-chloro-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1H-pyrrol-1-yl]-5-(1,1-dioxido-2-isothiazolidinyl)- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 74 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:928905 CAPLUS
DN 141:167192
TI Bone-targeted Src kinase inhibitors: novel pyrrolo- and pyrazolopyrimidine
analogues. [Erratum to document cited in CA139:285654]
AU Sundaramoorthi, Raji; Shakespeare, William C.; Keenan, Terence P.; Metcalf, Chester A., III; Wang, Yihan; Mani, Ukti; Merry, Taylor; Liu, Shuangying; Bohacek, Regine S.; Narula, Surinder S.; Dalgarno, David C.; Van Schravendijk, Marie Rose; Violette, Shelia M.; Liou, Shuenn; Adams, Susan; Ram, Mary K.; Keats, Jeffrey A.; Weigle, Manfred; Sawyer, Tomi K.
CS ARIAN Pharmaceuticals, Inc., Cambridge, MA, 02139-4234, USA
SO Bioorganic & Medicinal Chemistry Letters (2003), 13(24), 4519
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science B.V.
DT Journal
LA English
AB The names of authors Taylor Merry, Marie Rose Van Schravendijk, Manfred Weigle, and Shelia M. Violette, Chester A. Metcalf, III, were given incorrectly. The author list has been corrected
IT 344891-90-3 344891-91-4
RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(synthesis and activity of pyrrolo- and pyrazolopyrimidine analogs as bone-targeting Src kinase inhibitors (Erratum))
RN 344891-90-3 CAPLUS
CN Benzoic acid, 4-[4-amino-5-(3-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 344891-91-4 CAPLUS
CN Benzoic acid, 3-[4-amino-5-(3-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 74 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 75 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:855743 CAPLUS
DN 139:335104
TI Gelsolin as a prognostic marker of atherosclerotic diseases
IN Stossel, Thomas P.
PA The Brigham and Women's Hospital, Inc., USA
SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003088811	A2	20031030	WO 2003-US11722	20030416
	WO 2003088811	A3	20040226		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003226401	A1	20031103	AU 2003-226401	20030416
PRAI	US 2002-373043P	P	20020416		
	WO 2003-US11722	W	20030416		

AB This invention involves the using blood gelsolin levels as a diagnostic test to determine the risk of atherosclerotic diseases such as myocardial infarction, stroke, and peripheral ischemic cardiovascular disease, particularly among subjects with no signs or symptoms of current disease and among nonsmokers. Further, this invention involves the new use of a diagnostic test to assist physicians in determining which subjects at risk will
preferentially benefit from certain treatments designed either to prevent first or recurrent myocardial infarctions and strokes, or to treat acute and chronic cardiovascular disorders.
IT 53597-27-6, Pendosal
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gelsolin as prognostic marker of atherosclerotic diseases)
RN 53597-27-6 CAPLUS
CN Benzoic acid, 5-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)



L9 ANSWER 76 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:796665 CAPLUS
DN 139:307607
TI Preparation of substituted biaryl amides as C5a receptor modulators
IN Gao, Yang; Hutchison, Alan; Peterson, John; Pringle, Wallace; Thurkauf, Andrew; Yoon, Taeyoung; Zhao, He
PA Neurogen Corporation, USA
SO PCT Int. Appl., 144 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003082826	A1	20031009	WO 2003-US9045	20030325
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2479928	AA	20031009	CA 2003-2479928	20030325
	AU 2003225971	A1	20031013	AU 2003-225971	20030325
	EP 1487796	A1	20041222	EP 2003-745585	20030325
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006502095	T2	20060119	JP 2003-580294	20030325
	US 2004048913	A1	20040311	US 2003-401270	20030327
	US 6858637	B2	20050222		
	US 2005096358	A1	20050505	US 2004-994224	20041119
PRAI	US 2002-368462P	P	20020328		
	US 2002-372150P	P	20021204		
	WO 2003-US9045	W	20030325		
	US 2003-401270	A1	20030327		

OS MARPAT 139:307607
GI



I

AB The title compds. ArlCONR1R2 [Ar1 = (un)substituted Ph, 9H-fluorenyl, naphthyl, heteroaryl; R1 = (un)substituted cycloalkyl, (cycloalkyl)alkyl, (heteroaryl)alkyl, etc.; R2 = alkyl, cycloalkyl, aryl, etc.] which are ligands that may be used to modulate C5a receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathol. C5a receptor activation in humans, domesticated companion animals and livestock animals, were prepared and formulated. Thus, treating 2-iodobenzoic acid with 1,1'-carbonyldiimidazole followed by addition of N-(3,4-methylenedioxybenzyl)-N-benzylamine, and coupling of the resulting intermediate with 4-trifluoromethylphenylboronic acid in the presence of Pd(PPh3)4 afforded I. Preferred compds. exhibit IC50 values of less than 1 μM in the assay for C5a receptor mediated chemotaxis. Pharmaceutical compns. and methods for using them to treat such mentioned above disorders are provided, as are methods for using such ligands for receptor localization studies.

IT **10333-68-3**, 2-(Pyrrol-1-yl)benzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of biaryl amides as C5a receptor modulators)

RN 10333-68-3 CAPLUS
CN Benzoic acid, 2-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 77 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:719458 CAPLUS
DN 139:255327
TI Pin1-modulating compounds and methods of use thereof
IN Mckee, Timothy D.; Suto, Robert K.; Tibbitts, Thomas; Sowadski, Janusz
PA Pintex Pharmaceutical, Inc., USA
SO PCT Int. Appl., 230 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003074497	A1	20030912	WO 2003-US306674	20030303
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	WO 2003074497	A1	20030912	WO 2003-XA306674	20030303
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003225668	A1	20030916	AU 2003-225668	20030303
	US 2005049267	A1	20050303	US 2003-379410	20030303
PRAI	US 2002-361246P	P	20020301		
	WO 2003-US6674	A	20030303		

OS MARPAT 139:255327
GI



I

AB The invention is directed to modulators, e.g., inhibitors, of Pin 1 and Pin 1-related proteins and the use of such modulators for treatment of Pin 1 associated states, e.g., for the treatment of cancer. This method includes administering to the subject an effective amt. of a Pin1-modulating compd. of formula I (the dashed line to R1 indicates a single or a double bond; n or m are independently 0 or 1; X1, X2, and X3 are each independently O, S, or NR2; Y1, and Y2 are each independently O, S, or NR3; R1, R2 and R3 are each independently substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, hydrogen, acyl, or any combination thereof; Z1 and Z2 are each independently CH2, CH, or N). In a second embodiment, the invention pertains, at least in part, to a method for treating cyclin D1 overexpression in a subject. [This abstr. record is one of two records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.].

IT **600666-50-0** **600693-33-2**
RL: PAC (Pharmacological activity); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(Pin1-modulating compds. for treatment of disease states such as cancer in combination with other agents in relation to cyclin D1 overexpression)

RN 600666-50-0 CAPLUS
CN Benzoic acid, 4-[2,5-dimethyl-3-[[tetrahydro-4,6-dioxo-1-(4-phenoxyphenyl)-2-thioxo-5(2H)-pyrimidinylidene]methyl]-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 600693-33-2 CAPLUS
CN Benzoic acid, 4-[3-[[tetrahydro-4,6-dioxo-1-(2-propenyl)-2-thioxo-5(2H)-pyrimidinylidene]methyl]-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 77 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:719265 CAPLUS
DN 139:240337
TI Pin1 peptidyl prolyl isomerase-modulating compounds and methods of use in the treatment of cancer and other Pin1-associated conditions
IN Mckee, Timothy D.; Suto, Robert K.
PA Pintex Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003073999	A2	20030912	WO 2003-US6399	20030303
	WO 2003073999	A3	20031231		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003217870	A1	20030916	AU 2003-217870	20030303
	US 2004180889	A1	20040916	US 2003-379404	20030303
PRAI	US 2002-361231P	P	20020301		
	WO 2003-US6399	W	20030303		

OS MARPAT 139:240337
GI



AB The invention discloses modulators, e.g., inhibitors of Pin1 and Pin1-related proteins, and the use of such modulators for treatment of Pin1-associated states, e.g., for the treatment of cancer. Compds. of the invention include I [dashed lines = single or double bonds; G1 = CH, N; G2, G3 = H, N, CH2, CH, NH; R1, R2, R3, R3', R4, R4', X1-X5 = H, acyl,

L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(un)substituted alkyl, etc.]. Detn. of Pin1 overexpression in a variety of tumor types is also presented.
IT 15898-26-7 15898-26-7D, derivs. 26165-62-8 26165-62-8D, derivs. 26180-27-8 26180-27-8D, derivs. 26180-29-0 26180-29-0D, derivs. 26180-30-3 26180-30-3D, derivs. 52034-38-5 52034-38-5D, derivs. 83141-00-8 83141-00-8D, derivs. 92028-57-4 92028-57-4D, derivs. 247225-32-7 247225-32-7D, derivs. 292058-56-1 292058-56-1D, derivs. 292058-57-2 292058-57-2D, derivs. 313483-13-5 313483-13-5D, derivs. 313701-78-9 313701-78-9D, derivs. 313701-79-0 313701-79-0D, derivs. 313701-80-3 313701-80-3D, derivs. 313701-92-7 313701-92-7D, derivs. 328267-09-0 328267-09-0D, derivs. 330946-35-5 330946-35-5D, derivs. 340225-87-8 340225-87-8D, derivs. 340226-01-9 340226-01-9D, derivs. 340227-74-9 340227-74-9D, derivs. 340228-71-9 340228-71-9D, derivs. 340228-76-4 340228-76-4D, derivs. 340229-48-3 340229-48-3D, derivs. 340230-27-5 340230-27-5D, derivs. 340232-46-4 340232-46-4D, derivs. 340303-17-5 340303-17-5D, derivs. 340303-22-2 340303-22-2D, derivs. 340307-05-3 340307-05-3D, derivs. 340307-16-6 340307-16-6D, derivs. 340308-97-6 340308-97-6D, derivs. 340309-41-3 340309-41-3D, derivs. 340311-70-8 340311-70-8D, derivs. 340312-91-6 340312-91-6D, derivs. 340315-24-4 340315-24-4D, derivs. 346711-96-4 346711-96-4D, derivs. 347393-96-8 347393-96-8D, derivs. 354157-32-7 354157-32-7D, derivs. 354157-51-0 354157-51-0D, derivs. 354775-16-9 354775-16-9D, derivs. 423725-15-9 423725-15-9D, derivs. 423740-90-3 423740-90-3D, derivs. 500728-27-8 500728-27-8D, derivs. 500728-32-5 500728-32-5D, derivs. 596790-72-6 596790-72-6D, derivs. 596790-73-7 596790-73-7D, derivs. 596790-74-8 596790-74-8D, derivs. 596790-76-0 596790-76-0D, derivs. 596790-81-7 596790-81-7D, derivs. 596790-82-8 596790-82-8D, derivs. 596790-87-3 596790-87-3D, derivs. 596790-88-4 596790-88-4D, derivs. 596790-89-5 596790-89-5D, derivs. 596790-90-8 596790-90-8D, derivs. 674782-30-0 674782-30-0D, derivs.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Pin1 peptidyl prolyl isomerase-modulating compds. for treatment of cancer and other Pin1-associated conditions)
RN 15898-26-7 CAPLUS
CN Benzoic acid, 4-(2,5-dimethyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)

L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 15898-26-7 CAPLUS
CN Benzoic acid, 4-(2,5-dimethyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 26165-62-8 CAPLUS
CN Benzoic acid, 4-chloro-3-(2,5-dimethyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 26165-62-8 CAPLUS
CN Benzoic acid, 4-chloro-3-(2,5-dimethyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 26180-27-8 CAPLUS

L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzoic acid, 2-(2-methyl-5-phenyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 26180-27-8 CAPLUS
CN Benzoic acid, 2-(2-methyl-5-phenyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 26180-29-0 CAPLUS
CN Benzoic acid, 3-(2-methyl-5-phenyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 26180-29-0 CAPLUS
CN Benzoic acid, 3-(2-methyl-5-phenyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)

L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 26180-30-3 CAPLUS
CN Benzoic acid, 4-(2-methyl-5-phenyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 26180-30-3 CAPLUS
CN Benzoic acid, 4-(2-methyl-5-phenyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 52034-38-5 CAPLUS
CN Benzoic acid, 4-(3-formyl-2,5-dimethyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)

L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 52034-38-5 CAPLUS
CN Benzoic acid, 4-(3-formyl-2,5-dimethyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 83141-00-8 CAPLUS
CN Benzoic acid, 3-(2,5-dimethyl-1H-pyrrol-1-yl)-2-methyl- (9CI) (CA INDEX NAME)



RN 83141-00-8 CAPLUS
CN Benzoic acid, 3-(2,5-dimethyl-1H-pyrrol-1-yl)-2-methyl- (9CI) (CA INDEX NAME)

L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 92028-57-4 CAPLUS
CN Benzoic acid, 2-(2,5-dimethyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 92028-57-4 CAPLUS
CN Benzoic acid, 2-(2,5-dimethyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 247225-32-7 CAPLUS
CN Benzoic acid, 2-chloro-5-(2,5-dimethyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 247225-32-7 CAPLUS
CN Benzoic acid, 2-chloro-5-(2,5-dimethyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)

L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 292058-56-1 CAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-(2,5-dimethyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 292058-56-1 CAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-(2,5-dimethyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 292058-57-2 CAPLUS
CN Benzoic acid, 5-chloro-2-(2,5-dimethyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)

L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 292058-57-2 CAPLUS
CN Benzoic acid, 5-chloro-2-(2,5-dimethyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 313483-13-5 CAPLUS
CN Benzoic acid, 2-hydroxy-5-(2-methyl-5-phenyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 313483-13-5 CAPLUS
CN Benzoic acid, 2-hydroxy-5-(2-methyl-5-phenyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)

L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 313701-78-9 CAPLUS
CN Benzoic acid, 3-(2,5-dimethyl-1H-pyrrol-1-yl)-4-methyl- (9CI) (CA INDEX NAME)



RN 313701-78-9 CAPLUS
CN Benzoic acid, 3-(2,5-dimethyl-1H-pyrrol-1-yl)-4-methyl- (9CI) (CA INDEX NAME)



RN 313701-79-0 CAPLUS
CN Benzoic acid, 2-chloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 313701-79-0 CAPLUS
CN Benzoic acid, 2-chloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 313701-80-3 CAPLUS
CN 1,2-Benzenedicarboxylic acid, 4-(2,5-dimethyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 313701-80-3 CAPLUS
CN 1,2-Benzenedicarboxylic acid, 4-(2,5-dimethyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 313701-92-7 CAPLUS
CN Benzoic acid, 5-(2,5-dimethyl-1H-pyrrol-1-yl)-2-hydroxy- (9CI) (CA INDEX NAME)

L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 313701-92-7 CAPLUS
CN Benzoic acid, 5-(2,5-dimethyl-1H-pyrrol-1-yl)-2-hydroxy- (9CI) (CA INDEX NAME)



RN 328267-09-0 CAPLUS
CN Benzoic acid, 5-[2-(4-bromophenyl)-4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo-1H-indol-1-yl]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 328267-09-0 CAPLUS
CN Benzoic acid, 5-[2-(4-bromophenyl)-4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo-1H-indol-1-yl]-2-hydroxy- (9CI) (CA INDEX NAME)

L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 340225-87-8 CAPLUS
CN Benzoic acid,
4-[3-[2-cyano-3-(2-naphthalenylamino)-3-oxo-1-propenyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 340226-01-9 CAPLUS
CN Benzoic acid, 3-[3-[[2-(acetylamino)-4-oxo-5(4H)-thiazolylidene]methyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 340226-01-9 CAPLUS
CN Benzoic acid, 3-[3-[[2-(acetylamino)-4-oxo-5(4H)-thiazolylidene]methyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)





RN 330946-35-5 CAPLUS
CN Benzoic acid, 2-chloro-5-(2-methyl-5-phenyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 330946-35-5 CAPLUS
CN Benzoic acid, 2-chloro-5-(2-methyl-5-phenyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 340225-87-8 CAPLUS
CN Benzoic acid,
4-[3-[2-cyano-3-(2-naphthalenylamino)-3-oxo-1-propenyl]-2,5-

L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 340227-74-9 CAPLUS
CN Benzoic acid, 4-[3-[2-cyano-3-[(4-methoxyphenyl)amino]-3-oxo-1-propenyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



RN 340227-74-9 CAPLUS
CN Benzoic acid, 4-[3-[2-cyano-3-[(4-methoxyphenyl)amino]-3-oxo-1-propenyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 340228-71-9 CAPLUS
CN Benzoic acid, 4-[3-[2-cyano-3-[(4-fluorophenyl)amino]-3-oxo-1-propenyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 340228-71-9 CAPLUS
CN Benzoic acid, 4-[3-[2-cyano-3-[(4-fluorophenyl)amino]-3-oxo-1-propenyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 340228-76-4 CAPLUS
CN Benzoic acid, 4-[3-[3-[(4-chlorophenyl)amino]-2-cyano-3-oxo-1-propenyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 340228-76-4 CAPLUS
CN Benzoic acid, 4-[3-[3-[(4-chlorophenyl)amino]-2-cyano-3-oxo-1-propenyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 340229-48-3 CAPLUS
CN Benzoic acid,
3-[3-[2-cyano-3-(2-naphthalenylamino)-3-oxo-1-propenyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 340232-46-4 CAPLUS
CN Benzoic acid, 2-(2,5-dimethyl-1H-pyrrol-1-yl)-4,5-dimethoxy- (9CI) (CA INDEX NAME)



RN 340232-46-4 CAPLUS
CN Benzoic acid, 2-(2,5-dimethyl-1H-pyrrol-1-yl)-4,5-dimethoxy- (9CI) (CA INDEX NAME)



L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 340229-48-3 CAPLUS
CN Benzoic acid,
3-[3-[2-cyano-3-(2-naphthalenylamino)-3-oxo-1-propenyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 340230-27-5 CAPLUS
CN Benzoic acid, 3-[3-[3-[(4-chlorophenyl)amino]-2-cyano-3-oxo-1-propenyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 340230-27-5 CAPLUS
CN Benzoic acid, 3-[3-[3-[(4-chlorophenyl)amino]-2-cyano-3-oxo-1-propenyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 340303-17-5 CAPLUS
CN Benzoic acid, 4-[3-[2-cyano-3-[(2-methylphenyl)amino]-3-oxo-1-propenyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 340303-17-5 CAPLUS
CN Benzoic acid, 4-[3-[2-cyano-3-[(2-methylphenyl)amino]-3-oxo-1-propenyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 340303-22-2 CAPLUS
CN Benzoic acid, 3-[3-[2-cyano-3-[(3-methylphenyl)amino]-3-oxo-1-propenyl]-

L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 340303-22-2 CAPLUS
CN Benzoic acid, 3-[3-[2-cyano-3-[(3-methylphenyl)amino]-3-oxo-1-propenyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 340307-05-3 CAPLUS
CN Benzoic acid, 4-[3-[2-cyano-3-[(3-methylphenyl)amino]-3-oxo-1-propenyl]-

L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 340307-05-3 CAPLUS
CN Benzoic acid, 4-[3-[2-cyano-3-[(3-methylphenyl)amino]-3-oxo-1-propenyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 340307-16-6 CAPLUS
CN Benzoic acid, 3-[3-[2-cyano-3-[(3-ethoxyphenyl)amino]-3-oxo-1-propenyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 340307-16-6 CAPLUS
CN Benzoic acid, 3-[3-[2-cyano-3-[(3-ethoxyphenyl)amino]-3-oxo-1-propenyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 340308-97-6 CAPLUS
CN Benzoic acid, 3-[3-[2-cyano-3-[(2-methylphenyl)amino]-3-oxo-1-propenyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 340308-97-6 CAPLUS
CN Benzoic acid, 3-[3-[2-cyano-3-[(2-methylphenyl)amino]-3-oxo-1-propenyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 340309-41-3 CAPLUS
CN Benzoic acid, 2-(2,5-dimethyl-1H-pyrrol-1-yl)-5-hydroxy- (9CI) (CA INDEX NAME)



RN 340309-41-3 CAPLUS
CN Benzoic acid, 2-(2,5-dimethyl-1H-pyrrol-1-yl)-5-hydroxy- (9CI) (CA INDEX NAME)

L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 340312-91-6 CAPLUS
CN Benzoic acid, 4-(2,5-dimethyl-1H-pyrrol-1-yl)-3-methyl- (9CI) (CA INDEX NAME)



RN 340315-24-4 CAPLUS
CN Benzoic acid, 3-(2,5-dimethyl-1H-pyrrol-1-yl)-4-hydroxy- (9CI) (CA INDEX NAME)



RN 340315-24-4 CAPLUS
CN Benzoic acid, 3-(2,5-dimethyl-1H-pyrrol-1-yl)-4-hydroxy- (9CI) (CA INDEX NAME)



L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 340311-70-8 CAPLUS
CN Benzoic acid, 5-bromo-2-(2,5-dimethyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 340311-70-8 CAPLUS
CN Benzoic acid, 5-bromo-2-(2,5-dimethyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 340312-91-6 CAPLUS
CN Benzoic acid, 4-(2,5-dimethyl-1H-pyrrol-1-yl)-3-methyl- (9CI) (CA INDEX NAME)

L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 346711-96-4 CAPLUS
CN Benzoic acid, 4-[2,5-dimethyl-3-[[(5-nitro-2-pyridinyl)hydrazono]methyl]-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 346711-96-4 CAPLUS
CN Benzoic acid, 4-[2,5-dimethyl-3-[[(5-nitro-2-pyridinyl)hydrazono]methyl]-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 347393-96-8 CAPLUS
CN Benzoic acid, 4-[3-[[2-(acetylamino)-4-oxo-5(4H)-thiazolylidene]methyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 347393-96-8 CAPLUS
CN Benzoic acid, 4-[3-[[2-(acetylamino)-4-oxo-5(4H)-thiazolylidene]methyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 354157-32-7 CAPLUS
CN Benzoic acid, 3-[3-[2-cyano-3-oxo-3-(phenylamino)-1-propenyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 354157-32-7 CAPLUS
CN Benzoic acid, 3-[3-[2-cyano-3-oxo-3-(phenylamino)-1-propenyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 354157-51-0 CAPLUS
CN Benzoic acid, 3-[3-[2-cyano-3-[(4-methoxyphenyl)amino]-3-oxo-1-propenyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 354157-51-0 CAPLUS
CN Benzoic acid, 3-[3-[2-cyano-3-[(4-methoxyphenyl)amino]-3-oxo-1-propenyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 354775-16-9 CAPLUS
CN Benzoic acid, 4-[3-[(hydroxyimino)methyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 354775-16-9 CAPLUS
CN Benzoic acid, 4-[3-[(hydroxyimino)methyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 423725-15-9 CAPLUS
CN Benzoic acid, 4-[3-[2-cyano-3-oxo-3-[(phenylmethyl)amino]-1-propenyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 423725-15-9 CAPLUS
CN Benzoic acid, 4-[3-[2-cyano-3-oxo-3-[(phenylmethyl)amino]-1-propenyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 423740-90-3 CAPLUS
CN Benzeneacetic acid, 3-(trifluoromethyl)-, [[1-(3-carboxyphenyl)-2,5-dimethyl-1H-pyrrol-3-yl]methylene]hydrazide (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 423740-90-3 CAPLUS
CN Benzeneacetic acid, 3-(trifluoromethyl)-, [[1-(3-carboxyphenyl)-2,5-

L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
dimethyl-1H-pyrrol-3-yl]methylene]hydrazide (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 500728-27-8 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-(4-carboxyphenyl)-2,5-dimethyl- (9CI) (CA
INDEX NAME)

L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 500728-27-8 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-(4-carboxyphenyl)-2,5-dimethyl- (9CI) (CA
INDEX NAME)



RN 500728-32-5 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-(4-carboxyphenyl)-2,5-dimethyl-, 3-ethyl ester (9CI) (CA INDEX NAME)



RN 500728-32-5 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-(4-carboxyphenyl)-2,5-dimethyl-, 3-ethyl ester (9CI) (CA INDEX NAME)

L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 596790-72-6 CAPLUS
CN Benzoic acid, 5-(2,5-dimethyl-1H-pyrrol-1-yl)-2-hydroxy-4-methyl- (9CI) (CA INDEX NAME)



RN 596790-72-6 CAPLUS
CN Benzoic acid, 5-(2,5-dimethyl-1H-pyrrol-1-yl)-2-hydroxy-4-methyl- (9CI) (CA INDEX NAME)



RN 596790-73-7 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 2-(2,5-dimethyl-1H-pyrrol-1-yl)-, 1-methyl ester (9CI) (CA INDEX NAME)

L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 596790-73-7 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 2-(2,5-dimethyl-1H-pyrrol-1-yl)-, 1-methyl ester (9CI) (CA INDEX NAME)



RN 596790-74-8 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 2-(2,5-dimethyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 596790-74-8 CAPLUS
CN 1,4-Benzenedicarboxylic acid, 2-(2,5-dimethyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)

L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 596790-76-0 CAPLUS
CN Benzoic acid, 5-chloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)-2-hydroxy- (9CI) (CA INDEX NAME)



RN 596790-76-0 CAPLUS
CN Benzoic acid, 5-chloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)-2-hydroxy- (9CI) (CA INDEX NAME)



RN 596790-81-7 CAPLUS
CN Benzoic acid, 4-(2-ethyl-5-methyl-1H-pyrrol-1-yl)-2-hydroxy- (9CI) (CA INDEX NAME)

L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 596790-81-7 CAPLUS
CN Benzoic acid, 4-(2-ethyl-5-methyl-1H-pyrrol-1-yl)-2-hydroxy- (9CI) (CA INDEX NAME)



RN 596790-82-8 CAPLUS
CN Benzoic acid, 2-hydroxy-4-[2-methyl-5-(2-methylpropyl)-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 596790-82-8 CAPLUS
CN Benzoic acid, 2-hydroxy-4-[2-methyl-5-(2-methylpropyl)-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 596790-87-3 CAPLUS
CN Benzoic acid, 4-(3-cyano-2,5-dimethyl-1H-pyrrol-1-yl)-2-hydroxy- (9CI) (CA INDEX NAME)



RN 596790-87-3 CAPLUS
CN Benzoic acid, 4-(3-cyano-2,5-dimethyl-1H-pyrrol-1-yl)-2-hydroxy- (9CI) (CA INDEX NAME)



RN 596790-88-4 CAPLUS
CN Benzoic acid, 2-hydroxy-4-[3-[(hydroxyimino)methyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 596790-88-4 CAPLUS
CN Benzoic acid,
2-hydroxy-4-[3-[(hydroxyimino)methyl]-2,5-dimethyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 596790-89-5 CAPLUS
CN Benzoic acid, 4-(3-formyl-2,5-dimethyl-1H-pyrrol-1-yl)-2-hydroxy- (9CI) (CA INDEX NAME)



RN 596790-89-5 CAPLUS
CN Benzoic acid, 4-(3-formyl-2,5-dimethyl-1H-pyrrol-1-yl)-2-hydroxy- (9CI)

L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 674782-30-0 CAPLUS
CN Benzoic acid, 4-(2,5-dimethyl-1H-pyrrol-1-yl)-2-hydroxy- (9CI) (CA INDEX NAME)



L9 ANSWER 78 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(CA INDEX NAME)



RN 596790-90-8 CAPLUS
CN Benzoic acid, 4-(2,5-dimethyl-1H-pyrrol-1-yl)-2-hydroxy-5-methyl- (9CI) (CA INDEX NAME)



RN 596790-90-8 CAPLUS
CN Benzoic acid, 4-(2,5-dimethyl-1H-pyrrol-1-yl)-2-hydroxy-5-methyl- (9CI) (CA INDEX NAME)



RN 674782-30-0 CAPLUS
CN Benzoic acid, 4-(2,5-dimethyl-1H-pyrrol-1-yl)-2-hydroxy- (9CI) (CA INDEX NAME)

L9 ANSWER 79 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:665546 CAPLUS
DN 139:285654
TI Bone-Targeted Src kinase inhibitors: novel pyrrolo- and pyrazolopyrimidine analogues
AU Sundaramoorthi, Raji; Shakespeare, William C.; Keenan, Terence P.; Metcalf, Chester A.; Wang, Yihan; Mani, Ukti; Taylor, Merry; Liu, Shuangying; Bohacek, Regine S.; Narula, Surinder S.; Dalgarno, David C.; Van Schravandijk, Marie Rose; Violette, Sheila M.; Liou, Shuenn; Adams, Susan; Ram, Mary K.; Keats, Jeffrey A.; Weigele, Manfred; Sawyer, Tomi K.
CS ARIAD Pharmaceuticals, Inc., Cambridge, MA, 02139-4234, USA
SO Bioorganic & Medicinal Chemistry Letters (2003), 13(18), 3063-3066
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science B.V.
DT Journal
LA English
OS CASREACT 139:285654
AB Src tyrosine kinase is a therapeutic target for bone diseases that has been validated by gene knockout studies. Furthermore, in vitro cellular studies implicate that Src has a pos. regulatory role in osteoclasts and a neg. regulatory role in osteoblasts. The potential use of Src inhibitors for osteoporosis therapy has been previously shown by novel bone-targeted ligands of the Src SH2 (e.g., AP22408) and non-bone-targeted, ATP-based inhibitors of Src kinase. Significant to this study, compds. 2-12 exemplify novel analogs of known pyrrolopyrimidine and pyrazolopyrimidine template-based Src kinase inhibitors that incorporate bone-targeting group modifications designed to provide tissue (bone) selectivity and diminished side effects. Accordingly, we report here the structure-based design, synthetic chemical and biol. testing of these compds. and proof-of-concept studies thereof.
IT **344891-90-3 344891-91-4**
RL: PAC (Pharmacological activity); RCT (Reactant); **THU (Therapeutic use)**; BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(synthesis and activity of pyrrolo- and pyrazolopyrimidine analogs as bone-targeting Src kinase inhibitors)
RN 344891-90-3 CAPLUS
CN Benzoic acid,
4-[4-amino-5-(3-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



L9 ANSWER 79 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 344891-91-4 CAPLUS
CN Benzoic acid, 3-[4-amino-5-(3-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 80 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:633448 CAPLUS
DN 139:185666
TI Coated pharmaceutical tablets with speckled appearance
IN Martino, Alice C.; Noack, Robert M.; Pierman, Steven A.
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003066030	A2	20030814	WO 2003-US3837	20030206
	WO 2003066030	A3	20031016		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2474921	AA	20030814	CA 2003-2474921	20030206
	AU 2003210930	A1	20030902	AU 2003-210930	20030206
	US 2003180357	A1	20030925	US 2003-359939	20030206
	EP 1480624	A2	20041201	EP 2003-737712	20030206
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003007593	A	20050201	BR 2003-7593	20030206
	JP 2005517693	T2	20050616	JP 2003-565454	20030206
	CN 1630512	A	20050622	CN 2003-803580	20030206
	RU 2273473	C2	20060410	RU 2004-124065	20030206
	ZA 2004005556	A	20050810	ZA 2004-5556	20040713
	NO 2004003716	A	20040906	NO 2004-3716	20040906
PRAI	US 2002-355705P	P	20020207		
	WO 2003-US3837	W	20030206		

OS MARPAT 139:185666
AB A pharmaceutical tablet is provide comprising a core and a coating adherent thereto, wherein (a) the core comprises solid particles of a water-soluble dye distributed in a matrix and (b) the coating comprises gellan gum. The tablet is suitable for peroral or intraoral administration, for example for delivery of a drug contained in the core of the tablet to a subject. The tablet has a speckled appearance that renders the tablet readily identifiable.
IT 53597-27-6, Fendosal
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(active ingredients for coated pharmaceutical tablets with speckled appearance)
RN 53597-27-6 CAPLUS
CN Benzoic acid, 5-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)

L9 ANSWER 80 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 81 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:633447 CAPLUS
DN 139:185665
TI Pharmaceutical dosage form for mucosal delivery
IN Martino, Alice C.; Pierman, Steven A.; Noack, Robert M.; Britten, Nancy
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003066029	A2	20030814	WO 2003-US3836	20030206
	WO 2003066029	A3	20031016		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2474190	AA	20030814	CA 2003-2474190	20030206
	AU 2003215110	A1	20030902	AU 2003-215110	20030206
	US 2003235617	A1	20031225	US 2003-360167	20030206
	EP 1471890	A2	20041103	EP 2003-710927	20030206
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003007473	A	20041109	BR 2003-7473	20030206
	CN 1627938	A	20050615	CN 2003-803419	20030206
	JP 2005519924	T2	20050707	JP 2003-565453	20030206
	ZA 2004005614	A	20050627	ZA 2004-5614	20040714
	NO 2004003723	A	20040906	NO 2004-3723	20040906
PRAI	US 2002-355703P	P	20020207		
	WO 2003-US3836	W	20030206		

OS MARPAT 139:185665
AB A pharmaceutical tablet is provided comprising an intraorally disintegratable core and an excipient coating adherent thereto, wherein the coating comprises gellan gum. The tablet is suitable for intraoral administration, for example for delivery of a drug contained in the core of the tablet to a subject, at least in part by absorption of the drug via
oral mucosa of the subject.
IT 53597-27-6, Fendosal
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(active ingredients for coated sublingual tablets)
RN 53597-27-6 CAPLUS
CN Benzoic acid, 5-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)

L9 ANSWER 81 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 82 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:590833 CAPLUS

DN 139:149629

TI Preparation of amidoimidazo[4,5-c]quinolines as immune response modifiers

IN Coleman, Patrick L.; Crooks, Stephen L.; Griesgraber, George W.; Lindstrom, Kyle J.; Merrill, Bryon A.; Rice, Michael J.

PA 3M Innovative Properties Co., USA

SO U.S. Pat. Appl. Publ., 85 pp., Cont.-in-part of U.S. 6,451,810. CODEN: USXXCO

DT Patent

LA English

FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003144283	A1	20030731	US 2001-27218	20011221
	US 6756382	B2	20040629		
	US 6451810	B1	20020917	US 2000-589580	20000607
	TR 200103574	T2	20020821	TR 2001-3574	20000608
	EP 1438958	A1	20040721	EP 2004-4588	20000608
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, CY				
	EP 1642580	A1	20060405	EP 2005-21837	20000608
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	ZA 2001009854	A	20030228	ZA 2001-9854	20011129
	ZA 2001009857	A	20030228	ZA 2001-9857	20011129
	ZA 2001009861	A	20030228	ZA 2001-9861	20011129
	US 2004029877	A1	20040212	US 2001-27272	20011221
	US 6800624	B2	20041005		
	US 2004204438	A1	20041014	US 2004-826836	20040416
	US 7030131	B2	20060418		
	US 2004229897	A1	20041118	US 2004-848893	20040519
	US 2006106052	A1	20060518	US 2006-275699	20060125
PRAI	US 1999-138365P	P	19990610		
	US 2000-589580	A2	20000607		
	US 2000-589216	A	20000607		
	US 2000-589236	A	20000607		
	EP 2000-938205	A3	20000608		
	EP 2000-938211	A3	20000608		
	US 2001-166321	A1	20010615		
	US 2001-27218	A1	20011221		
	US 2001-27272	A1	20011221		
	US 2004-826836	A3	20040416		

OS MARPAT 139:149629

GI

L9 ANSWER 82 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Title compds. I [wherein R1 = alkyl-NR3COR4; R3 = independently H, alkyl or (un)substituted alkyl(hetero)aryl; R4 = alkyl or (un)substituted (hetero)aryl; R2 = H, alkenyl, (un)substituted alkyl or (hetero)aryl, etc.; R = independently alkyl, alkoxy, halo, CF3; n = 0-4; and their pharmaceutically acceptable salts] were prepared as immune response modifiers. For example, II was prepared by acylation of 1-(4-aminobutyl)-1H-imidazo[4,5-c]quinolin-4-amine with benzoyl chloride in pyridine. II induced interferon α and TNFα at concns. of 0.37 μM and 10 μM, resp., in human cells. Thus, I and their pharmaceutical compns. are useful for the treatment of a variety of conditions including viral diseases and neoplastic diseases (no data).

IT 22106-33-8, 4-(1-Pyrrolyl)benzoic acid

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of (amido)imidazo[4,5-c]quinolines as immune response modifiers)

RN 22106-33-8 CAPLUS

CN Benzoic acid, 4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RE.CNT 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 83 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:551494 CAPLUS

DN 139:101027

TI Preparation of mercaptoethyl indolecarboxylic acids as NAALAdase inhibitors for treating and diagnosing glutamate abnormalities, neurological and other disorders

IN Tsukamoto, Takashi; Grella, Brian; Majer, Pavel

PA Guilford Pharmaceuticals Inc., USA

SO PCT Int. Appl., 173 pp. CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003057670	A2	20030717	WO 2002-US37617	20021219
	WO 2003057670	A3	20031106		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002357003	A1	20030724	AU 2002-357003	20021219
	US 2005080128	A1	20050414	US 2003-500319	20021219
PRAI	US 2001-342764P	P	20011228		
	WO 2002-US37617	W	20021219		

OS MARPAT 139:101027

GI



AB This invention relates to new indoles (shown as I; variables defined below; e.g. 3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid), pharmaceutical compns. and diagnostic kits comprising such compds., and methods of using such compds. for inhibiting NAALADase enzyme activity, detecting diseases where NAALAdase levels are altered, affecting neuronal activity, effecting TGF-β activity, inhibiting angiogenesis, and treating glutamate abnormalities, neuropathy, pain, compulsive disorders, prostate diseases, cancers and glaucoma. IC50 values are tabulated for inhibition of NAALAdase by 12 examples of I. Many pharmacol. and therapeutic test results are reported for the following 6 compds. that are not covered by I: 2-[[(2,3,4,5,6-pentafluorobenzyl)hydroxyphosphinyl]methyl]pentanedioic acid, 2-(3-sulfanylpropyl)pentanedioic acid, 2-(phosphonomethyl)pentanedioic acid, 2-(2-sulfanylethyl)pentanedioic

L9 ANSWER 83 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
acid, 3-carboxy-α-(3-mercaptopropyl)benzenepropanoic acid and 3-carboxy-5-(1,1-dimethylethyl)-α-(3-mercaptopropyl)benzenepropanoic acid. For I: A1, A2, A3 and A4 = H, C1-C9 alkyl, C2-C9 alkenyl, C2-C9 alkynyl, aryl, heteroaryl, carbocycle, heterocycle, C1-C9 alkoxy, C2-C9 alkenyloxy, phenoxy, benzyloxy, hydroxy, halo, nitro, cyano, isocyano, -COOR6, - COR6, -NR6R7, -SR6, -SOR6, -SO2R6, -SO2(OR6), -C(O)NR6R7, -C(O)NR6 (CH2)nCOOH, -NR6C(O)R7 or -(CH2)nCOOH, or any adjacent two of A1, A2, A3 and A4 form with the benzene ring a fused ring that is (un)satd., arom. or nonarom., and carbocyclic or heterocyclic, said heterocyclic ring contg. 1 or 2 O, N and/or S heteroatom(s); n is 1-3; R, R1, R2, R3, R4, R5, R6, R7 = H, carboxy, C1-C9 alkyl, C2-C9 alkenyl, C2-C9 alkynyl, aryl, heteroaryl, carbocycle or heterocycle; and said alkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocycle, heterocycle, alkoxy, alkenyloxy, phenoxy, benzyloxy and fused ring (un)substituted with ≥1 substituent(s). Although the methods of prepn. are not claimed, 13 example prepns. are included.

IT **560131-56-8P**, 1-(3-Carboxyphenyl)-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid **560131-65-9P**, 1-[3-Carboxy-5-(1,1-dimethylethyl)phenyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid
RL: DGN (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate and diagnosis agent; preparation of mercaptoethyl indolecarboxylic acids as NAALAdase inhibitors for treating and diagnosing glutamate abnormalities and neurol. and other disorders)

RN 560131-56-8 CAPLUS
CN 1H-Indole-2-carboxylic acid, 1-(3-carboxyphenyl)-3-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)





RN 560131-65-9 CAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[3-carboxy-5-(1,1-dimethylethyl)phenyl]-3-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)

L9 ANSWER 83 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)





IT **560131-58-0P**, 3-Carboxymethyl-1-(3-carboxyphenyl)-1H-indole-2-carboxylic acid **560131-59-1P**, 1-(3-Carboxyphenyl)-3-[(ethoxycarbonyl)methyl]-1H-indole-2-carboxylic acid **560131-60-4P**, 1-(3-Carboxyphenyl)-3-(2-hydroxyethyl)-1H-indole-2-carboxylic acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of mercaptoethyl indolecarboxylic acids as NAALAdase inhibitors for treating and diagnosing glutamate abnormalities and neurol. and other disorders)

RN 560131-58-0 CAPLUS
CN 1H-Indole-3-acetic acid, 2-carboxy-1-(3-carboxyphenyl)- (9CI) (CA INDEX NAME)





RN 560131-59-1 CAPLUS
CN 1H-Indole-3-acetic acid, 2-carboxy-1-(3-carboxyphenyl)-, α-ethyl ester (9CI) (CA INDEX NAME)

L9 ANSWER 83 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)





RN 560131-60-4 CAPLUS
CN 1H-Indole-2-carboxylic acid, 1-(3-carboxyphenyl)-3-(2-hydroxyethyl)- (9CI)
(CA INDEX NAME)





L9 ANSWER 84 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:396858 CAPLUS
DN 138:401620
TI Preparation of 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivatives for treatment of central diabetes insipidus and/or night pollakisuria
IN Koshio, Hiroyuki; Tsukamoto, Isaei; Kuramochi, Takahiro; Akamatsu, Seijiro; Saitoh, Chikashi
PA Yamanouchi Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003042181	A1	20030522	WO 2002-JP11842	20021113
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2464069	AA	20030522	CA 2002-2464069	20021113
	EP 1445253	A1	20040811	EP 2002-781759	20021113
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002014224	A	20040921	BR 2002-14224	20021113
	CN 1585752	A	20050223	CN 2002-822604	20021113
	RU 2268882	C1	20060127	RU 2004-118063	20021113
	ZA 2004003189	A	20050428	ZA 2004-3189	20040428
	US 2005004103	A1	20050106	US 2004-495494	20040513
	NO 2004002497	A	20040721	NO 2004-2497	20040615
PRAI	JP 2001-350909	A	20011116		
	JP 2002-252931	A	20020830		
	WO 2002-JP11842	W	20021113		

OS MARPAT 138:401620
GI

L9 ANSWER 84 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I II

AB The title compds. I [wherein R1 = OH, alkoxy, or (un)substituted amino; R2 = halo or (un)substituted alkyl; R3 and R4 = independently H, alkyl, halo, (un)substituted cyclic amino, or aromatic cyclic amino; R5 = H, alkyl, or halo] and pharmaceutically acceptable salts thereof, which have excellent arginine vasopressin V2 activity and are useful for the treatment of central diabetes insipidus and/or night pollakisuria, are prepared For example, the compound II was prepared in a multi-step synthesis. II showed Ki of 5.6 nM against human vasopressin V2 receptor.

IT **232275-65-9P 313701-79-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of benzazepine derivs. for treatment of central diabetes insipidus and/or night pollakisuria)

RN 232275-65-9 CAPLUS
CN Benzoic acid, 2-chloro-4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 313701-79-0 CAPLUS
CN Benzoic acid, 2-chloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX

L9 ANSWER 84 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
NAME)



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 85 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:377132 CAPLUS
DN 138:367144
TI Soluble CD40L (CD154) as a prognostic marker of atherosclerotic diseases
IN Schoenbeck, Uwe; Ridker, Paul M.; Libby, Peter
PA The Brigham and Women's Hospital, Inc., USA
SO PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003040691	A2	20030515	WO 2002-US35505	20021105
	WO 2003040691	A3	20031113		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2464531	AA	20030515	CA 2002-2464531	20021105
	US 2003152566	A1	20030814	US 2002-288253	20021105
	EP 1451577	A2	20040901	EP 2002-780578	20021105
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	CN 1613012	A	20050504	CN 2002-826711	20021105
	JP 2005515407	T2	20050526	JP 2003-542897	20021105
PRAI	US 2001-338841P	P	20011105		
	WO 2002-US35505	W	20021105		

AB The invention involves the new use of a diagnostic test to determine the risk of atherosclerotic diseases, e.g. myocardial infarction and stroke, particularly among individuals with no signs or symptoms of current disease and among nonsmokers. Further, the invention involves the new use of a diagnostic test to assist physicians in determining which individuals at risk will preferentially benefit from certain treatments designed either to prevent first or recurrent myocardial infarctions and strokes, or to treat acute and chronic cardiovascular disorders. Methods for treatment are also described.

IT **53597-27-6**, Fendosal
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(soluble CD40L as prognostic marker of atherosclerotic diseases, and use in therapeutic agent assessment)

RN 53597-27-6 CAPLUS
CN Benzoic acid, 5-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)

L9 ANSWER 85 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 86 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:376832 CAPLUS
DN 138:368895
TI Preparation of triazole derivatives as cyclooxygenase inhibitors
IN Aoki, Satoshi; Nakagawa, Toshiya; Konishi, Nobukiyo; Nakamura, Katsuya; Omori, Hiroki; Kubota, Ariyoshi; Hashimoto, Norio
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003040110	A1	20030515	WO 2002-JP11314	20021030
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2465757	AA	20030515	CA 2002-2465757	20021030
	JP 2004521964	T2	20040722	JP 2003-542156	20021030
	EP 1442026	A1	20040804	EP 2002-779943	20021030
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	CN 1612865	A	20050504	CN 2002-826900	20021030
	US 2003191155	A1	20031009	US 2003-344416	20030219
	US 6927230	B2	20050809		
PRAI	AU 2001-8782	A	20011109		
	WO 2002-JP11314	W	20021030		

OS MARPAT 138:368895
GI





I II

AB Title compds. I [wherein R1 = (un)substituted alkyl; R2 = alkyl, alkoxy, CN, or 1H-pyrrol-1-yl; R3 = alkyl, alkoxy, or CN; X = O, S, SO, or SO2; Y and Z = independently CH or N; m = 0-1; and pharmaceutically acceptable

L9 ANSWER 86 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
salts thereof] were prepd. as cyclooxygenase (COX) inhibitors. For example, 4-methoxyphenylhydrazine•HCl was coupled with trifluoroacetamidine in the presence of TEA in MeOH to give 2,2,2-trifluoro-N'-(4-methoxyphenyl)ethanehydrazonamide (quant.). Cycloaddn. with 4-methoxybenzoyl chloride using pyridine in dioxane provided 1,5-bis(4-methoxyphenyl)-3-(trifluoromethyl)-1H-1,2,4-triazole II (48.6%). In a whole blood assay, the latter showed selective inhibition against COX-1 compared to COX-2 with IC50 values of < 0.01 μM and > 0.1 μM, resp. II displayed analgesic activity at a dose of 3.2 mg/kg in rats with arthritis induced by injection of Mycobacterium tuberculosis. In addn., II inhibited platelet aggregation in platelet-rich human plasma with an IC50 value of < 0.02 μM. Thus, I are useful for the treatment and/or prevention of inflammatory conditions, various pains, collagen diseases, autoimmune diseases, various immunity diseases, thrombosis, cancer, or neurodegenerative diseases (no data).
IT **22106-33-8**, 4-(1H-Pyrrol-1-yl)benzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of triazole derivs. as cyclooxygenase inhibitors for treatment of inflammatory conditions and pain)
RN 22106-33-8 CAPLUS
CN Benzoic acid, 4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 87 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:356260 CAPLUS
DN 138:362654
TI Opioid inhibitors of ABC drug transporters in cancer cells, and use in cancer treatment
IN Schoenhard, Grant L.
PA Pain Therapeutics, Inc., USA
SO PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003037340	A1	20030508	WO 2002-US17092	20020530
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003144312	A1	20030731	US 2001-3215	20011030
PRAI	US 2001-3215	A	20011030		

OS MARPAT 138:362654
AB The invention discloses opioid compds. that are inhibitors of drug transporters of the ABC protein superfamily. The invention provides methods of treating cancer using antitumor agents and opioid inhibitors of such transporters. The invention also provides methods for selecting or designing compds. for the ability to inhibit drug transporter proteins and to methods of inhibiting drug transporter proteins. The invention discloses the use of opioid receptor antagonists in the treatment of a cancer patient who has developed a resistance to a therapeutically active substance.
IT **432492-45-0**
RL: PRP (Properties)
(opioid inhibitors of ABC drug transporters in cancer cells, and use in cancer treatment)
RN 432492-45-0 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-(3-carboxy-2,4,6-trimethylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)

L9 ANSWER 87 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 88 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:356232 CAPLUS
DN 138:362635
TI Opioid inhibitors of ABC drug transporters in microbial cells, and use with antimicrobial compounds for the treatment of microbial infections
IN Schoenhard, Grant L.
PA Pain Therapeutics, Inc., USA
SO PCT Int. Appl., 131 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003037310	A2	20030508	WO 2002-US17153	20020531
WO 2003037310	A3	20030918		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003130171	A1	20030710	US 2001-107	20011030
PRAI US 2001-107	A	20011030		

OS MARPAT 138:362635
AB The invention relates to microbial infections, including those involving multidrug resistance and, in particular, to opioid compds. that are inhibitors of drug transporters of the ABC protein superfamily. The invention provides methods of treating microbial infections using antimicrobial agents and opioid inhibitors of such transporters. The invention also provides methods for selecting or identifying compds. for the ability to inhibit drug transporter proteins, as well as methods for inhibiting drug transporter proteins. The invention discloses the use of opioid receptor antagonists in the treatment of microbial infections, including multidrug-resistant microbial infections.
IT 432492-45-0
RL: PRP (Properties)
(opioid inhibitors of ABC drug transporters in microbial cells, and use
with antimicrobial compds. for treatment of microbial infections)
RN 432492-45-0 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-(3-carboxy-2,4,6-trimethylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)

L9 ANSWER 88 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 89 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:326047 CAPLUS
DN 139:143357
TI Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches
AU Pearlstein, Robert A.; Vaz, Roy J.; Kang, Jiesheng; Chen, Xiao-Liang; Preobrazhenskaya, Maria; Shchekotikhin, Andrey E.; Korolev, Alexander M.; Lysenkova, Ludmila N.; Miroshnikova, Olga V.; Hendrix, James; Rampe, David
CS Aventis Pharmaceuticals, Bridgewater, NJ, 08876, USA
SO Bioorganic & Medicinal Chemistry Letters (2003), 13(10), 1829-1835
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science B.V.
DT Journal
LA English
OS CASREACT 139:143357
AB A data set consisting of twenty-two sertindole analogs and ten structurally diverse inhibitors, spanning a wide range in potency, was analyzed using CoMSiA. A homol. model of HERG was constructed from the crystal structure of the open MthK potassium channel. A complementary relationship between our CoMSiA and homol. models is apparent when the long inhibitor axis is oriented parallel to the longitudinal axis of the pore, with the tail region pointed toward the selectivity filter. The key elements of the pharmacophore, the CoMSiA and the homol. model are: (1) The hydrophobic feature optimally consists of an aromatic group that is capable of engaging in π-stacking with a Phe656 side chain. Optionally, a second aromatic or hydrophobic group present in some inhibitors may contact an addnl. Phe656 side chain. (2) The basic nitrogen appears to undergo a π-cation interaction with Tyr652. (3) The pore diameter (12 A+), and depth of the selectivity loop relative to the intracellular opening, act as constraints on the conformation-dependent inhibitor dimensions.
IT 572913-76-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homol. modeling approaches and sertindole analogs)
RN 572913-76-9 CAPLUS
CN Benzoic acid, 4-[5-chloro-3-[1-[2-(2-oxo-1-imidazolidinyl)ethyl]-4-piperidinyl]-1H-indol-1-yl]- (9CI) (CA INDEX NAME)



RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD

L9 ANSWER 89 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 90 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:319701 CAPLUS
DN 138:337840
TI Preparation of 5'-acylamino-1,1'-biphenyl-4-carboxamides as p38 kinase inhibitors
IN Angell, Richard Martyn; Aston, Nicola Mary; Bamborough, Paul; Bamford, Mark James; Cockerill, George Stuart; Flack, Stephen Sean; Laine, Dramane Ibrahim; Merrick, Suzanne Joy; Smith, Kathryn Jane; Walker, Ann Louise
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003032971	A1	20030424	WO 2002-EP11576	20021016
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002346929	A1	20030428	AU 2002-346929	20021016
	EP 1435934	A1	20040714	EP 2002-782931	20021016
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2005511531	T2	20050428	JP 2003-535775	20021016
	US 2004242868	A1	20041202	US 2004-492605	20040415
PRAI	GB 2001-24939	A	20011017		
	WO 2002-EP11576	W	20021016		

OS MARPAT 138:337840
GI



I II

L9 ANSWER 90 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

AB The title compds. [I; when m = 0-4, R1 = alkyl, cycloalkyl, alkenyl, etc.; when m = 2-4, R1 addnl. = alkoxy, OH, etc.; R2 = H, alkyl, (CH2)ncycloalkyl; R3 = NHCOR6 (wherein R6 = H, alkyl, alkoxy, etc.); U = Me, halo; W = Me, Cl; X, Y = H, Me, halo; m = 0-4; n = 0-1; s = 0-2], useful as pharmaceuticals, particularly as p38 kinase inhibitors, were prepared E.g., a 6-step synthesis of the nicotinamide II, starting with 3-bromo-4-methylaniline, was given.
IT **26180-28-9**, 3-(2,5-Dimethylpyrrol-1-yl)benzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 5'-acylamino-1,1'-biphenyl-4-carboxamides as p38 kinase inhibitors)
RN 26180-28-9 CAPLUS
CN Benzoic acid, 3-(2,5-dimethyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 91 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:49279 CAPLUS
DN 139:159420
TI Discrimination and selection of new potential antibacterial compounds using simple topological descriptors
AU Murcia-Soler, Miguel; Perez-Gimenez, Facundo; Garcia-March, Francisco J.; Salabert-Salvador, M. Teresa; Diaz-Villanueva, Wladimiro; Medina-Casamayor, Piedad
CS Faculty of Pharmacy, Department of Physical Chemistry, Universitat de Valencia, Valencia, Spain
SO Journal of Molecular Graphics & Modelling (2003), 21(5), 375-390
CODEN: JMGMFI; ISSN: 1093-3263
PB Elsevier Science Inc.
DT Journal
LA English
AB The aim of the work was to discriminate between antibacterial and non-antibacterial drugs by topol. methods and to select new potential antibacterial agents from among new structures. The method used for antibacterial activity selection was a linear discriminant anal. (LDA). It is possible to obtain a QSAR interpretation of the information contained in the discriminant function. We make use of the pharmacol. distribution diagrams (PDDs) as a visualizing technique for the identification and selection of new antibacterial agents.
IT **53597-27-6**, Fendosal
RL: PAC (Pharmacological activity); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(discrimination and selection of new potential antibacterial compds. using simple topol. descriptors)
RN 53597-27-6 CAPLUS
CN Benzoic acid, 5-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 92 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:5718 CAPLUS
DN 138:56075
TI Preparation of phosphorus-substituted pyrazolo- and pyrrolopyrimidines as therapeutic agents
IN Shakespeare, William C.; Sawyer, Tomi K.; Metcalf, Chester A., III; Wang, Yihan; Bohacek, Regine; Sundaramoorthi, Rajeswari
PA Ariad Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 165 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003000187	A2	20030103	WO 2002-US19632	20020621
	WO 2003000187	A3	20040805		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003114467	A1	20030619	US 2002-177563	20020621
	EP 1463742	A2	20041006	EP 2002-742237	20020621
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI	US 2001-299924P	P	20010621		
	WO 2002-US19632	W	20020621		

OS MARPAT 138:56075
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Phosphorus-substituted pyrazolo- and pyrrolopyrimidines [e.g, I; wherein W = CR4, N; R1, R3, independently = H, aliphatic, heteroaliph., aryl, heteroaryl, alkylaryl, alkylheteroaryl; R2, R4, independently = H, aliphatic, heteroaliph., aryl, heteroaryl, halo, cyano, alkylcarbonyl, etc.; at least one of R1, R2, R3 or R4 is a phosphorus-containing moiety] were prepared For example, compound (II) was prepared according to the invention. The prepared compds. are useful as, inter alia, anticancer agents, antiproliferative agents, and agents for the treatment of osteoporosis (no data).
IT **344891-90-3** **344891-91-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of phosphorus-substituted pyrazolo- and pyrrolopyrimidines as therapeutic agents)
RN 344891-90-3 CAPLUS
CN Benzoic acid, 4-[4-amino-5-(3-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-

L9 ANSWER 92 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
yl]- (9CI) (CA INDEX NAME)



RN 344891-91-4 CAPLUS
CN Benzoic acid,
3-[4-amino-5-(3-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



L9 ANSWER 93 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 93 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:900790 CAPLUS
DN 137:384757
TI Preparation of N-[(hydroxypiperidinyl)phenyl]benzamides as pharmaceuticals
for treatment of atopic dermatitis, asthma, and allergic rhinitis
IN Naito, Yoichiro; Ushio, Hiroyuki; Hoshino, Yukio; Kakoshima, Masahiko; Oshita, Koichi; Kataoka, Hirotoshi; Chiba, Kenji
PA Mitsubishi Pharma Corporation, Japan
SO Jpn. Kokai Tokkyo Koho, 29 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2002338537	A2	20021127	JP 2001-146915	20010516
PRAI	JP 2001-146915		20010516		

OS MARPAT 137:384757
GI



AB Amides I [R1 = halo, alkyl, alkoxy, NO2, amino, etc.; ring Q = (un)substituted benzene, cyclohexane, heterocyclic aromatic ring; R2 = H, alkyl, hydroxyalkyl, acyloxyalkyl, aminoalkyl, etc.; Z = CH, N; R3 = halo, cyano, NO2, amino, alkyl, alkoxy, CO2H, etc.; R4 = H, halo, cyano, NO2; R5 = alkyl, hydroxyalkyl, hydroxycarbonylalkyl, substituted aminoalkyl, OH, alkoxy, etc.] or their pharmaceutically acceptable salts are prepared The compds. are useful for inhibitors of interleukin 4 production from type 2 helper T cell. 5-Amino-2-(4-hydroxypiperidin-1-yl)benzonitrile (5 g) was reacted with 4-iodobenzoic acid in the presence of 1-hydroxybenzotriazole monohydrate and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride in DMF at room temperature for 2 days to give 9.3 g N-[3-cyano-4-(4-hydroxypiperidin-1-yl)phenyl]-4-benzamide. The compds. controlled ovalbumin-induced edema in mice.
IT 22106-33-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of [(hydroxypiperidinyl)phenyl]benzamides as pharmaceuticals
for treatment of atopic dermatitis, asthma, and allergic rhinitis)
RN 22106-33-8 CAPLUS
CN Benzoic acid, 4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)

L9 ANSWER 94 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:869567 CAPLUS
DN 137:370356
TI Preparation and use of bombesin receptor antagonists for treatment of sexual dysfunction in males and females
IN Gonzalez, Maria Isabel; Higginbottom, Michael; Stock, Herman Thijs; Pritchard, Martyn Clive; Pinnock, Robert Denham; Van der Graaf, Pieter Hadewijn; Naylor, Alisdair Mark; Wayman, Christopher Peter
PA UK
SO U.S. Pat. Appl. Publ., 105 pp., Cont.-in-part of U.S. Pat. Appl. 2002 58,606.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002169101	A1	20021114	US 2001-999284	20011115
	US 2002058606	A1	20020516	US 2001-759777	20010112
	ZA 2003003249	A	20040623	ZA 2003-3249	20030425
PRAI	US 1999-133355P	P	19990510		
	WO 2000-GB1787	W	20000510		
	US 2000-700165	A2	20001109		
	US 2001-759777	A2	20010112		
	GB 2001-9910	A	20010423		
	GB 2001-11037	A	20010504		

OS MARPAT 137:370356
GI



AB Bombesin receptor antagonists have been found to be useful in the treatment of sexual dysfunction in both males and females. They may be selective BB1 antagonists or mixed BB1/BB2 antagonists. Combinations are disclosed of bombesin receptor antagonists with a range of other active compds., for example PDE5 inhibitors, NEP inhibitors and lasofoxifene. Preparation of bombesin receptor antagonists consisting of α-Me tryptophane (e.g., I) or α-methylphenylalanine derivs. was given. In tests on sexually-dysfunctional male rats, it was concluded that I had a stimulatory effect, at the level of sexual desire, performance, and anorgasmy. In tests on sexually-dysfunctional female rats, it was concluded that I had a stimulatory effect on proceptivity, which was unaffected by repeated administration.
IT 10333-68-3, 2-Pyrrol-1-ylbenzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of in the preparation of bombesin receptor antagonists for treatment of sexual dysfunction)
RN 10333-68-3 CAPLUS

L9 ANSWER 94 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzoic acid, 2-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



L9 ANSWER 95 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
1-(tert-butoxycarbonyl)piperazine afforded VI [R = 4-tert-butoxycarbonylpiperazin-1-yl] which showed 56% inhibition of binding to membranes of CHO cell line stably transfected with human oxytocin receptor
at 100 nM vs. 2% and 13% inhibition of binding to membranes of CHO cell line stably transfected with human vasopressin V1a and V2 receptor subtypes, resp. The compds. I are also useful in enhancing fertility rates, enhancing survival rates and synchronizing estrus in farm animals, and may be useful in the prevention and treatment of dysfunctions of the oxytocin system in the central nervous system including obsessive compulsive disorder (OCD) and neuropsychiatric disorders.
IT **473264-27-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tricyclic diazepines as tocolytic oxytocin receptor antagonists)
RN 473264-27-6 CAPLUS
CN Benzoic acid, 4-(2,5-dimethyl-1H-pyrrol-1-yl)-3,5-dimethyl- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 95 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:814136 CAPLUS
DN 137:310939
TI Preparation of tricyclic diazepines as tocolytic oxytocin receptor antagonists
IN Failli, Amedeo Arturo; Shumsky, Jay Scott; Caggiano, Thomas Joseph; Sabatucci, Joseph Peter; Memoli, Kevin Anthony; Trybulski, Eugene John
PA Wyeth, John and Brother Ltd., USA
SO PCT Int. Appl., 220 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002083678	A1	20021024	WO 2002-US11527	20020411
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003008863	A1	20030109	US 2002-119971	20020410
	CA 2443490	AA	20021024	CA 2002-2443490	20020411
	EP 1377586	A1	20040107	EP 2002-731343	20020411
	EP 1377586	B1	20060322		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	CN 1501932	A	20040602	CN 2002-808039	20020411
	JP 2004526768	T2	20040902	JP 2002-581433	20020411
	BR 2002009014	A	20050111	BR 2002-9014	20020411
	AT 321047	E	20060415	AT 2002-731343	20020411
PRAI	US 2001-283264P	P	20010412		
	WO 2002-US11527	W	20020411		

OS MARPAT 137:310939
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; ring containing Z = II, III; R1, R2 = H, alkyl, halo,
CN, etc.; R3 = H, alkyl, alkoxy, etc.; R4 = BC (wherein B = IV, V; C = (un)substituted Ph, 1-naphthyl, 1-pyrrolyl, etc.; A = CH, N; R5-R7 = H, alkyl, alkoxy, etc.); R = OH, NR11R12, (un)substituted 4-oxopiperidin-1-yl, etc. (R11, R12 = H, alkyl, cycloalkyl, etc.)}, useful
for the treatment and/or prevention and/or suppression of disorders which may be remedied or alleviated by oxytocin antagonist activity, including treatment of preterm labor, dysmenorrhea, endometritis, and for suppressing labor prior to Caesarian delivery, were prepared Thus, amidation of VI [R = OH] (multi-step synthesis given) with

L9 ANSWER 96 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:695935 CAPLUS
DN 137:232447
TI Preparation of hydrazones for use in the treatment of microbial infections
IN Burri, Kaspar; Hoffner, Johannes; Islam, Khalid; Mukhija, Seema
PA Arpida A.-G., Switz.
SO PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002070464	A2	20020912	WO 2002-EP474	20020118
	WO 2002070464	A3	20040122		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1404644	A2	20040407	EP 2002-722025	20020118
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004525118	T2	20040819	JP 2002-569785	20020118
	US 2004110963	A1	20040610	US 2003-466810	20031121
PRAI	WO 2001-EP636	W	20010122		
	WO 2002-EP474	W	20020118		

OS MARPAT 137:232447
GI



I

AB Novel hydrazones [I; wherein R1 = alkyl-carbonylamino, formylamino, amino,
OH; R2 = H, OH, lower alkyl, F, Cl; R3 = H, Me, Et, i-Pr; R4 = aryl, optionally substituted arylmethyl, indoyl methyl; R5, R6, independently = H, OH, lower alkyl, lower alkoxy, F, Cl, amino; R7 = H, lower alkyl] were prepared For example, benzoic acid hydrazide and 2,5-dihydroxybenzaldehyde
are reacted to give N'-(2,5-dihydroxybenzylidene)-benzohydrazide, which inhibited bacterial phosphotransferase activity (IC50 = 15 μM). The prepared compds. are useful in the treatment of microbial infections.
IT **458549-91-2P**

L9 ANSWER 96 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of hydrazones for use in treatment of microbial infections)
RN 458549-91-2 CAPLUS
CN Benzoic acid, 3-chloro-2-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



L9 ANSWER 97 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RL: COS (Cosmetic use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(UV filter stabilizer; prepn. of quinoxaline derivs. for use as as UV filter stabilizers in cosmetic and pharmaceutical formulations)
RN 457625-59-1 CAPLUS
CN Benzoic acid, 4-(2-phenyl-1H-pyrrolo[2,3-b]quinoxalin-1-yl)- (9CI) (CA INDEX NAME)



L9 ANSWER 97 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:695646 CAPLUS
DN 137:232671
TI Quinoxaline derivatives for use as as photostable UV filters
IN Pfluecker, Frank; Schwarz, Michael; Scholz, Volker; Neunhoeffer, Hans
PA Merck Patent G.m.b.H., Germany
SO Ger. Offen., 40 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 10111728	A1	20020912	DE 2001-10111728	20010309
	WO 2002072583	A1	20020919	WO 2002-EP1402	20020211
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1373270	A1	20040102	EP 2002-716759	20020211
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2004102446	A1	20040527	US 2003-471101	20030908
PRAI	DE 2001-10111728	A	20010309		
	WO 2002-EP1402	W	20020211		

OS MARPAT 137:232671
GI



I



II

AB The present invention concerns the use of quinoxaline derivs., e.g., I (X = N, CR3; A = X1 - X3, X1 - X4; X1, X2, X3, X4 = :N, NR4, CR5R6, C(:O), :CR; R, R1, R2, R3 = H, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkoxy, cycloalkenyl, bicycloalkyl; R4 = H, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkoxy, cycloalkenyl, bicycloalkyl; R5, R6 = H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, bicycloalkyl, (CR'R")n-Ar, (CR'R")n-Het; R', R" = H, C1-4-alkyl; Ar = (un)substituted aromatic; Het = (un)substituted heteroarom.; n = 0 - 4) and II, as photostable UV filters, in particular in cosmetic and pharmaceutical prepns. to the protection the human epidermis or human hair against UV-RADIATION, particularly within the range of 280-400 Nm.
IT 457625-59-1P

L9 ANSWER 98 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:644193 CAPLUS
DN 138:265118
TI A Quick Diversity-Oriented Amide-Forming Reaction to Optimize P-Subsite Residues of HIV Protease Inhibitors
AU Brik, Ashraf; Lin, Ying-Chuan; Elder, John; Wong, Chi-Huey
CS Department of Chemistry, The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA, 9203, USA
SO Chemistry & Biology (2002), 9(8), 891-896
CODEN: CBOLE2; ISSN: 1074-5521
PB Cell Press
DT Journal
LA English
OS CASREACT 138:265118
AB We report a new simple method that allows rapid preparation in solution of a
library of compds. for in situ high-throughput screening to identify new inhibitors of HIV-1 protease. The method is based on the amide-forming reaction of a C2-sym. diamino diol core with various carboxylic acids, followed by a direct assay of the inhibition activity without product isolation. Sixty-two compds. were made and screened in less than 1 h. The utility of this method is demonstrated by the identification of new P3-P3' residues that convert a transition state analog core from a poor binding mol. (1, Ki > 2 μM) to a potent inhibitor (AB1, Ki = 2 nM) against the wild-type, and the inhibition activities against resistant mutants are better than those of two existing drugs. This method reduces the time required for synthesis and testing of a large number of characterized inhibitors and should find useful applications in other enzyme systems.
IT 53242-70-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(drug design, structure-activity relationship and high throughput screening to identify new HIV protease inhibitors)
RN 53242-70-9 CAPLUS
CN Benzoic acid, 2-hydroxy-5-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 99 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:595343 CAPLUS
DN 137:150228
TI Antiinflammatory compositions and methods for therapy through enhanced tissue regeneration
IN Uhrich, Kathryn E.; Macedo, Braz
PA Rutgers, The State University of New Jersey, USA
SO U.S. Pat. Appl. Publ., 17 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002106345	A1	20020808	US 2000-732516	20001207
	US 6685928	B2	20040203		
PRAI	US 1999-304190P	P	19991207		
	US 1999-455861	A	19991207		

AB The invention provides methods of promoting healing through enhanced regeneration of tissue (e.g. hard tissue or soft tissue) by contacting the tissue or the surrounding tissue with an antiinflammatory agent, preferably in a controlled-release form, e.g. by dispersing the agent through a polymer matrix, appending the agent to a polymer backbone, or incorporating the agent directly into a biodegradable polymer backbone. These methods are useful in a variety of dental and orthopedic applications. Expts. are presented which demonstrate that implantation of a film comprising an aromatic polyanhydride that hydrolyzes to form a therapeutically useful salicylate resulted in less swelling in tissues adjacent to the film and a decrease in the d. of inflammatory cells as compared to other polyanhydride films. Preparation of e.g. poly[1,6-bis(o-carboxyphenoxy) hexane] is described.
IT 53597-27-6D, Fendosal, polymer backbone-incorporated
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiinflammatory compns. and methods for therapy through enhanced tissue regeneration)
RN 53597-27-6 CAPLUS
CN Benzoic acid, 5-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)



L9 ANSWER 100 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:576581 CAPLUS
DN 138:147428
TI Characterization and comparative evaluation of a novel PAI-1 inhibitor
AU Gils, Ann; Stassen, Jean-Marie; Nar, Herbert; Kley, Joerg T.; Wienen, Wolfgang; Ries, Uwe J.; Declerck, Paul J.
CS Laboratory for Pharmaceutical Biology and Phytopharmacology, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Louvain, B-3000, Belg.
SO Thrombosis and Haemostasis (2002), 88(1), 137-143
CODEN: THHADQ; ISSN: 0340-6245
PB Schattauer GmbH
DT Journal
LA English
AB Plasminogen activator inhibitor-1 (PAI-1), the primary physiol. inhibitor of both tissue-type plasminogen activator and urokinase-type plasminogen activator in plasma, is a well established risk factor in thrombotic diseases. Reduction of active PAI-1 levels may lead to a decreased tendency of thrombosis. Compds. that can suppress pharmacol. active PAI-1 levels are therefore considered as putative drugs. In the present study, we describe the PAI-1 neutralizing properties and mechanism of a newly selected compound (i.e. fendosal, HP129) in comparison to four previously reported compds. (i.e. AR-H029953XX, XR1853, XR5118 and the peptide TVASS) using different assays. The inhibitory effect of these compds. on active PAI-1 was analyzed by a plasmin-coupled chromogenic assay (Coaset t-PA), direct chromogenic assays (t-PA, u-PA) and quantification of complex formation by ELISA, SDS-PAGE and surface plasmon resonance. Comparative evaluation of the obtained IC50 values reveals large differences [i.e. IC50 of 15 μM (HP129) vs. >1000 μM (XR5118) determined at 37° using SDS-PAGE] between the compds. studied. Importantly, the relative potency of the various compds. is also dependent on the method used (10 to 170-fold differences in IC50 values). Characterization of the PAI-1 forms (i.e. active, non-reactive and substrate) generated upon inactivation reveals that the newly described compound HP129 induces a unique pathway (i.e. active to non-reactive conversion via substrate-behaving intermediate) of inactivation compared to the other compds. Taken together, these data strongly suggest that the various compds. act through different mechanisms. In addition, the results stress the necessity for a careful selection of the method used for the evaluation of PAI-1 inhibitors, preferably requiring a panel of screening methods.
IT 53597-27-6, HP 129
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(characterization and comparative evaluation of a novel PAI-1 inhibitor)
RN 53597-27-6 CAPLUS
CN Benzoic acid, 5-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)

L9 ANSWER 100 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 101 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:576360 CAPLUS
DN 138:231345
TI A small-molecule inhibitor of the ribonucleolytic activity of human angiogenin that possesses antitumor activity
AU Kao, Richard Y. T.; Jenkins, Jeremy L.; Olson, Karen A.; Key, Marc E.; Fett, James W.; Shapiro, Robert
CS Center for Biochemical and Biophysical Sciences and Medicine, Harvard Medical School, Cambridge, MA, 02139, USA
SO Proceedings of the National Academy of Sciences of the United States of America (2002), 99(15), 10066-10071
CODEN: PNASA6; ISSN: 0027-8424
PB National Academy of Sciences
DT Journal
LA English
AB The results of previous preclin. and clin. studies have identified angiogenin (ANG) as a potentially important target for anticancer therapy. Here the authors report the design and implementation of a high-throughput screening assay to identify small mols. that bind to the ribonucleolytic active site of ANG, which is critically involved in the induction of angiogenesis by this protein. Screening of 18,310 compds. from the National Cancer Institute (NCI) Diversity Set and ChemBridge DIVERSet yielded 15 hits that inhibit the enzymic activity of ANG with Ki values <100 μM. One of these, NCI compound 65828 [8-amino-5-(4'-hydroxybiphenyl-4-ylazo)naphthalene-2-sulfonate; Ki = 81 μM], was selected for more detailed studies. Minor changes in ANG or ligand structure markedly reduced potency, demonstrating that inhibition reflects active-site rather than nonspecific binding: these observations are consistent with a computationally generated model of the ANG·65828 complex. Local treatment with modest doses of 65828 significantly delayed the formation of s.c. tumors from two distinct human cancer cell types in athymic mice. ANG is the likely target involved because (i) a 65828 analog with much lower potency against the enzymic activity of ANG failed to exert any antitumor effect, (ii) tumors from 65828-treated mice had fewer interior blood vessels than those from control mice, and (ii) 65828 appears to have no direct effect on the tumor cells. The authors' findings provide considerable support for the targeting of the enzymic active site of ANG as a strategy for developing new anticancer drugs.
IT 26180-28-9
RL: PAC (Pharmacological activity); BIOL (Biological study)
(small-mol. inhibitor of ribonucleolytic activity of human angiogenin that possesses antitumor activity in human cells)
RN 26180-28-9 CAPLUS
CN Benzoic acid, 3-(2,5-dimethyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



L9 ANSWER 101 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 102 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:505411 CAPLUS
DN 137:78769
TI Preparation of N-arylcarbonyl- and heteroarylcarbonyl benzenesulfonamide inhibitors of Bcl-Xl and Bcl-2 as promoters of apoptosis
IN Augeri, David J.; Baumeister, Steven A.; Bruncko, Milan; Dickman, Daniel A.; Ding, Hong; Dinges, Jurgen; Fesik, Stephen W.; Hajduk, Philip J.; Kunzer, Aaron R.; McClellan, William; Nettesheim, David G.; Oost, Thorsten; Petros, Andrew M.; Rosenberg, Saul H.; Wang, Shen; Thomas, Sheela A.; Wang, Xilu; Wendt, Michael D.
PA Abbott Laboratories, USA
SO U.S. Pat. Appl. Publ., 126 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002086887	A1	20020704	US 2001-957276	20010920
	US 6720338	B2	20040413		
	US 2004192681	A1	20040930	US 2004-820097	20040407
PRAI	US 2000-233866P	P	20000920		
	US 2001-957276	A3	20010920		

OS MARPAT 137:78769
GI



I



II

AB N-aryl- and N-heteroarylcarbonyl benzenesulfonamides I [A = (un)substituted Ph, 5- or 6-membered heterocyclic ring with 1-3 N, O, or S atoms; R1 = alkyl, haloalkyl, NO2, NR6R7; R2, R3 = H, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, etc.; R4 = aryl, arylalkenyl, arylalkoxy, cycloalkenyl, cycloalkyl, halo, heterocyclyl, heterocyclyloxy; R5 = H, alkyl, halo; R6, R7 = H, alkenyl, alkoxyalkyl, alkoxycarbonylalkyl, alkyl, heterocyclyl, etc.; R6R7N = imidazolyl, morpholinyl, piperazinyl,

L9 ANSWER 102 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
piperidinyl, pyrrolidinyl, etc.] are prepd. Over 500 I are prepd. E.g., N-biphenylcarbonyl benzenesulfonamide II was prepd. by Pd-catalyzed coupling of 4-FC6H4B(OH)2 and 4-BrC6H4CO2Me, hydrolysis of the ester with LiOH, acylation of 4-chloro-3-nitrobenzenesulfonamide with the resulting acid in the presence of EDCI and DMAP, and nucleophilic arom. substitution of the chlorobenzenesulfonamide with 2,2-dimethylcyclopentylamine. Compds. of the invention inhibit Bcl-Xl with IC50 values between 0.011 μM and 10 μM, and inhibit Bcl-2 with IC50 values between 0.017 μM and 10 μM.
IT 22106-33-8, 4-(1-Pyrrolyl)benzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N-aryl- and heteroarylcarbonyl benzenesulfonamide inhibitors of Bcl-Xl and Bcl-2 as promoters of apoptosis)
RN 22106-33-8 CAPLUS
CN Benzoic acid, 4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 103 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:503335 CAPLUS
DN 137:68177
TI Compositions comprising cyclodextrins and NO-releasing drugs
IN Naggi, Annamaria; Torri, Gian Giacomo; Trespidi, Laura
PA Nicox S.A., Fr.
SO Eur. Pat. Appl., 48 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1219306	A1	20020703	EP 2000-403719	20001229
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	WO 2002053188	A1	20020711	WO 2001-EP15340	20011227
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1347782	A1	20031001	EP 2001-272672	20011227
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004517116	T2	20040610	JP 2002-554137	20011227
	US 2004072798	A1	20040415	US 2003-450847	20031015
PRAI	EP 2000-403719	A	20001229		
	WO 2001-EP15340	W	20011227		

OS MARPAT 137:68177
AB The present invention relates to composition comprising cyclodextrins and a NO-releasing drug of formula A-X-L-NOn (A = radical deriving from a drug; X = divalent radical connecting A with the NO-releasing group L-NOn; L = O, S, NH; n = 1, 2). Cyclodextrins (CDs) are selected from α-CD, β-CD, γ-CD, dimethyl-α-CD, dimethyl-b-CD, dimethyl-γ-CD, etc., and the drug is selected from NSAIDs, analgesics, antibacterials, antivirals, steroids, antineoplastics, β-adrenergic agonists and blockers, antihyperlipoproteinemics, and bone resorption inhibitors. For example, three compns. containing 2-(acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester (I) was were prepared: F1 contained 1.470 g of α-CD and 0.500 g of I mixed in water and then dried; F2 contained 1.470 g of α-CD and 0.500 g of I mixed in ethanol/water and then dried; and F3 contained 2.000 g of dimethyl-β-CD and 0.500 g of I mixed in water and then dried; F0 represents the comparative formula containing I alone. Inhibition of contraction of aortic rings obtained was 54% for F1, 59% for F2, 61% for F3, and 19% for F0.
IT 53597-27-6, Fendosal
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. comprising cyclodextrins and NO-releasing drugs)
RN 53597-27-6 CAPLUS
CN Benzoic acid, 5-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)

L9 ANSWER 103 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 104 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:487387 CAPLUS
DN 137:63257
TI Preparation of benzamides as inhibitors of production and release of inflammatory cytokines
IN Muto, Susumu; Nagano, Tatsuo; Saotome, Tomomi; Itai, Akiko
PA Institute of Medicinal Molecular Design Inc., Japan
SO PCT Int. Appl., 313 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002049632	A1	20020627	WO 2001-JP11084	20011218
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2431083	AA	20020627	CA 2001-2431083	20011218
	AU 2002022683	A5	20020701	AU 2002-22683	20011218
	EP 1352650	A1	20031015	EP 2001-271124	20011218
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2004259877	A1	20041223	US 2004-433619	20040219
PRAI	JP 2000-383202	A	20001218		
	WO 2001-JP11084	W	20011218		

OS MARPAT 137:63257
GI



AB The title compds. I (wherein X is a connecting group; A is hydrogen or acetyl; E is aryl or heteroaryl; and Z is arene or heteroarene) are prepared
In an in vitro test using cells, 5-chloro-2-hydroxy-N-(4-methoxynaphthalen-2-yl)benzamide at 1 μg/mL gave 95.1% inhibition of NF-κB activation.
IT 53242-70-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of benzamides as inhibitors of production and release of

L9 ANSWER 104 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
inflammatory cytokines)
RN 53242-70-9 CAPLUS
CN Benzoic acid, 2-hydroxy-5-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 105 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:449627 CAPLUS
DN 137:33319
TI Preparation of N-aryl, N-arylalkyl, and N-heterocyclylnonanamide and -octanamide derivatives and related compounds as inhibitors of histone deacetylase
IN Curtin, Michael L.; Dai, Yujia; Davidsen, Steven K.; Frey, Robin R.; Guo, Yan; Heyman, Howard R.; Holms, James H.; Ji, Zhiqin; Michaelides, Michael R.; Vasudevan, Anil; Wada, Carol K.
PA Abbott Laboratories, USA
SO PCT Int. Appl., 111 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002046129	A2	20020613	WO 2001-US50931	20011026
	WO 2002046129	A3	20030116		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002103192	A1	20020801	US 2001-808389	20010314
	AU 2002043402	A5	20020618	AU 2002-43402	20011026
PRAI	US 2000-697387	A	20001026		
	US 2001-808389	A	20010314		
	WO 2001-US50931	W	20011026		

OS MARPAT 137:33319
AB Compds. having the formula (R4-L2)nL1-CR1R2R3 or therapeutically acceptable salts thereof [wherein n = 1, 2; L1 = alkenylene, alkylene, alkynylene, cycloalkylene, heteroalkylene, (alkylene)-C(O)N(R5)-(alkylene), (alkylene)-O-(alkylene) (wherein each group is drawn with its left-hand end being the end which attaches to L2, and its right-hand end being the end which attaches to the carbon substituted with R1, R2, and R3); L2 =, C2 alkenylene, O, S, SO2, OC(O)NR5, N(R6)C(O), C(O)N(R6), SO2N(R6), N(R6)SO2, C:N-O, N(R6)C(O)N(R6), and C(O)N(R6)N(R6)C(O) (wherein each group is drawn with its left-hand end being the end which attaches to R4, and its right-hand end being the end which attaches to L1); R1 is selected from the group consisting of alkanoyl, alkoxycarbonyl, CONH2, CO2H, haloalkyl, heterocyclyl (wherein the heterocycle is selected from the group consisting of oxazolyl, dihydrooxazolyl, oxadiazolyl, and tetrazolyl); R2 = R3 = HO; or R2 and R3 together are oxo; R4 = alkoxyalkyl, alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocyclylalkyl; R5, R6 = H, alkyl, aryl, arylalkyl; or R5 and R6, together with the nitrogen atom to which they are attached, form a heterocycle selected from the group consisting of (un)substituted morpholinyl, piperazinyl, piperidinyl, and thiomorpholinyl], which are histone deacetylase (HDAC) inhibitors (no data), are prepared These compds. are used for the treatment of diseases, possibly e.g. several human cancers associated with malfunction in histone deacetylases. Thus, a mixture

L9 ANSWER 105 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
of 9,9,9-trifluoro-8-oxononanoic acid (50 mg, 0.22 mmol), HOBt (30 mg, 0.22 mmol), carbodiimide PS resin (720 mg), and 4-phenyl-1,3-thiazol-2-amine (0.27 mmol) in DMF (5 mL) at room temp. was agitated in a Quest 210 parallel synthesizer for 18 h, treated with trisamine PS resin (220 mg), and agitated for 2 h. The soln. was decanted, the resin was rinsed with dichloromethane, and the combined solns. were concd., followed by purifn. using preparative HPLC with a gradient system of 0 to 95 % over 10 min of MeCN (contg. 0.1% CF3CO2H) in water to give 9,9,9-trifluoro-8-oxo-N-(4-phenyl-1,3-thiazol-2-yl)nonanamide.
IT 22106-33-8, 4-(1H-Pyrrol-1-yl)benzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of N-aryl, N-arylalkyl, and N-heterocyclylnonanamide and -octanamide derivs. and related compds. as inhibitors of histone deacetylase)
RN 22106-33-8 CAPLUS
CN Benzoic acid, 4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)

L9 ANSWER 106 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:429204 CAPLUS
DN 137:687
TI Method for screening bacterial transcription modulators
IN Pau, Bernard; Leonetti, Jean-Paul; Rouby, Joeelle
PA Centre National De La Recherche Scientifique, Fr.
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002044735	A1	20020606	WO 2001-FR3749	20011127
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	FR 2817349	A1	20020531	FR 2000-15332	20001128
	FR 2817349	B1	20030620		
	CA 2430174	AA	20020606	CA 2001-2430174	20011127
	AU 2002052774	A5	20020611	AU 2002-52774	20011127
	EP 1337857	A1	20030827	EP 2001-998834	20011127
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004523218	T2	20040805	JP 2002-546226	20011127
	US 2004048283	A1	20040311	US 2003-432987	20030910
PRAI	FR 2000-15332	A	20001128		
	WO 2001-FR3749	W	20011127		

AB The invention discloses a method for detecting a compound modulating complex formation between RNA polymerase and a transcription factor. The method comprises: incubating a mixture comprising RNA polymerase, transcription factor, and a test compound; detecting, by a complex formation test, the difference in the amount of complex formed between RNA polymerase and the transcription factor, relative to a control value corresponding to the amount of complex formed between RNA polymerase and the transcription factor in the absence of any modulator; deducing therefrom, when there is a significant change, that there has been formation of a bond between the compound and RNA polymerase and/or the transcription factor, which results in a modulation of complex formation between RNA polymerase and the transcription factor. The methodol. of the invention s useful for the discovery of antibiotics, antiviral agents, and antitumor drugs.
IT 15898-26-7 26180-28-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bacterial transcription modulator screening)
RN 15898-26-7 CAPLUS
CN Benzoic acid, 4-(2,5-dimethyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)

L9 ANSWER 106 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 26180-28-9 CAPLUS
CN Benzoic acid, 3-(2,5-dimethyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 107 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:408517 CAPLUS
DN 137:741
TI Inhibitors of ABC drug transporters at the blood-brain barrier for increasing brain concns. of central nervous system-active agents
IN Schoenhard, Grant L.
PA Pain Therapeutics, Inc., USA
SO PCT Int. Appl., 143 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002041884	A2	20020530	WO 2001-US45367	20011030
	WO 2002041884	C1	20031211		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 6011004	A	20000104	US 1996-768221	19961217
	AU 9947399	A1	19991028	AU 1999-47399	19990906
	CA 2427330	AA	20020530	CA 2001-2427330	20011030
	AU 2002039427	A5	20020603	AU 2002-39427	20011030
	US 2003073713	A1	20030417	US 2001-113	20011030
	US 7034036	B2	20060425		
	EP 1392265	A2	20040303	EP 2001-987187	20011030
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004528273	T2	20040916	JP 2002-544063	20011030
	AU 2002042422	A5	20020704	AU 2002-42422	20020521
	AU 782475	B2	20050804		
	AU 2002042423	A5	20020704	AU 2002-42423	20020521
	AU 782665	B2	20050818		
	AU 2005229765	A1	20060105	AU 2005-229765	20051108
PRAI	US 2000-244482P	P	20001030		
	US 2000-245110P	P	20001101		
	US 2000-246235P	P	20001102		
	US 1990-612847	B1	19901113		
	US 1993-153796	A1	19931117		
	AU 1995-32769	A3	19950718		
	AU 1999-41135	A3	19990726		
	AU 1999-47399	A3	19990906		
	WO 2001-US45367	W	20011030		
	AU 2002-42423	A3	20020521		

OS MARPAT 137:741
AB The invention relates to inhibitors of drug transporters of the ABC protein superfamily, particularly transporters present at the blood brain barrier. ABC transporter inhibitors identified according to the invention increase brain concns. of CNS-active agents. Such inhibitors increase the influx into the brain and/or reduce the efflux from the brain of such CNS-active agents.
IT 432492-45-0

L9 ANSWER 107 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ABC drug transporter inhibitors for increasing brain concns. of CNS-active agents)
RN 432492-45-0 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-(3-carboxy-2,4,6-trimethylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



L9 ANSWER 108 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:391703 CAPLUS
DN 136:402022
TI Preparation of (S)-α-methyltryptophan amide derivatives as bombesin receptor antagonists
IN Higginbottom, Michael; Pritchard, Martin Clive; Stock, Herman Thijs
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002040469	A1	20020523	WO 2001-EP14401	20011116
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	GB 2369117	A1	20020522	GB 2000-28104	20001117
	CA 2426089	AA	20020523	CA 2001-2426089	20011116
	AU 2002016079	A5	20020527	AU 2002-16079	20011116
	EP 1334100	A1	20030813	EP 2001-996536	20011116
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001015414	A	20030909	BR 2001-15414	20011116
	JP 2004513945	T2	20040513	JP 2002-543480	20011116
	US 2004116440	A1	20040617	US 2003-416779	20031204
PRAI	GB 2000-28104	A	20001117		
	WO 2001-EP14401	W	20011116		

OS CASREACT 136:402022; MARPAT 136:402022
GI



II

L9 ANSWER 108 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
AB This invention discloses the preparation of title compds. Ar-(CH2)k-X-NR3-CR5(CH2Ar1)-CO-NR4-(CH2)l-(CR1R6)m-(CH2)n-R2 (I) and their pharmaceutically acceptable salts as bombesin receptor antagonists [wherein: k = 0, 1, 2; l = 0, 1, 2, 3; m = 0, 1; n = 0, 1, 2; X = CO, OCO, SO, SO2; Ar = (un)substituted benzimidazolyl, benzofuryl, indanyl, indolyl, naphthyl, Ph, pyridyl, pyrimidyl, thienyl, furyl, imidazolyl, pyrrolyl, thiazolyl, etc.; Ar1 = groups given for Ar, plus pyridyl N-oxide; R1 = H, alkyl, (oxa- or aza)cycloalkyl; R2 = groups given for Ar, H, OH, alkoxy, NMe2, CONR12R13, certain substituted rings; R3-R5 = H, alkyl; R6 = H, Me, or together with R1 forms carbonyl or a C3-7 ring which can contain an oxygen or nitrogen atom; provided that when X = OCO, then l = 1-3 and m = 1]. Approx. 140 specific examples of I were prepared and/or claimed. For example, HBTU-mediated coupling of 1H-indole-2-carboxylic acid with the corresponding intermediate amine provided the claimed α-methyltryptophan amide II in 60% yield. In binding studies to cloned human BB1 and BB2 bombesin receptor subtypes, compound II had IC50 values of 11 nM and 119 nM, resp.
IT 10333-68-3, 2-Pyrrol-1-ylbenzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of α-methyltryptophan amide derivs. as bombesin receptor antagonists)
RN 10333-68-3 CAPLUS
CN Benzoic acid, 2-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 109 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:391535 CAPLUS
DN 136:380143
TI Treatment of sexual dysfunction using bombesin antagonist
IN Gonzalez, Maria Isabel; Higginbottom, Michael; Pinnock, Robert Denham; Pritchard, Martyn Clive; Stock, Herman Thijs
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 151 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002040022	A1	20020523	WO 2000-GB4380	20001117
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2426521	AA	20020523	CA 2000-2426521	20001117
	AU 2001014046	A5	20020527	AU 2001-14046	20001117
	EP 1333829	A1	20030813	EP 2000-976165	20001117
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2000017374	A	20030930	BR 2000-17374	20001117
	JP 2004525864	T2	20040826	JP 2002-542395	20001117
	CA 2429106	AA	20020523	CA 2001-2429106	20011114
	WO 2002040008	A2	20020523	WO 2001-GB5018	20011114
	WO 2002040008	A3	20020822		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002023802	A5	20020527	AU 2002-23802	20011114
	EP 1333824	A2	20030813	EP 2001-994552	20011114
	EP 1333824	B1	20050907		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001015364	A	20030923	BR 2001-15364	20011114
	JP 2004522710	T2	20040729	JP 2002-542382	20011114
	CN 1518445	A	20040804	CN 2001-821951	20011114
	NZ 525415	A	20041126	NZ 2001-525415	20011114
	AT 303804	E	20050915	AT 2001-994552	20011114
	TW 220650	B1	20040901	TW 2001-90128451	20011116
	ZA 2003003250	A	20040426	ZA 2003-3250	20030425
	US 2004087561	A1	20040506	US 2003-416934	20031204
PRAI	WO 2000-GB4380	W	20001117		
	GB 2001-9910	A	20010423		
	GB 2001-11037	A	20010504		
	WO 2001-GB5018	W	20011114		

AB Bombesin receptor antagonists have been found to be useful in the

L9 ANSWER 109 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
treatment of sexual dysfunction in both males and females. Prepn. of compds. of the invention is included.
IT **10333-68-3**, 2-Pyrrol-1-yl benzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction; bombesin antagonists for treatment of sexual dysfunction)
RN 10333-68-3 CAPLUS
CN Benzoic acid, 2-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 110 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:391522 CAPLUS
DN 136:395983
TI Bombesin receptor antagonists, and combinations with other agents, for the
treatment of sexual dysfunction
IN Gonzalez, Maria Isabel; Stock, Herman Thijs; Pinnock, Robert Denham; Pritchard, Martyn Clive; Wayman, Christopher Peter; Van der Graaf, Pieter Hadewijn; Naylor, Alisdair Mark; Higginbottom, Michael
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 225 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002040008	A2	20020523	WO 2001-GB5018	20011114
	WO 2002040008	A3	20020822		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	WO 2002040022	A1	20020523	WO 2000-GB4380	20001117
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2429106	AA	20020523	CA 2001-2429106	20011114
	AU 2002023802	A5	20020527	AU 2002-23802	20011114
	EP 1333824	A2	20030813	EP 2001-994552	20011114
	EP 1333824	B1	20050907		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001015364	A	20030923	BR 2001-15364	20011114
	JP 2004522710	T2	20040729	JP 2002-542382	20011114
	NZ 525415	A	20041126	NZ 2001-525415	20011114
	AT 303804	E	20050915	AT 2001-994552	20011114
	US 2004087561	A1	20040506	US 2003-416934	20031204
PRAI	WO 2000-GB4380	W	20001117		
	GB 2001-9910	A	20010423		
	GB 2001-11037	A	20010504		
	WO 2001-GB5018	W	20011114		

OS MARPAT 136:395983
AB Bombesin receptor antagonists have been found to be useful in the treatment of sexual dysfunction in both males and females. They may be selective BB1 antagonists or mixed BB1/BB2 antagonists. Combinations are

L9 ANSWER 110 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
disclosed of bombesin receptor antagonists with a range of other active compds., for example phosphodiesterase V inhibitors, neutral endopeptidase
inhibitors, and lasofoxifene. Prepn. of compds. of the invention is described.
IT **10333-68-3**, 2-Pyrrol-1-ylbenzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction; bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)
RN 10333-68-3 CAPLUS
CN Benzoic acid, 2-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



L9 ANSWER 111 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:368981 CAPLUS
DN 136:380137
TI Bombesin receptor antagonists, and preparation thereof, for the treatment of sexual dysfunction
IN Gonzalez, Maria Isabel; Pinnock, Robert Denham; Pritchard, Martyn Clive
PA UK
SO U.S. Pat. Appl. Publ., 72 pp., Cont.-in-part of U. S. Ser. No. 700,165.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002058606	A1	20020516	US 2001-759777	20010112
	US 2002169101	A1	20021114	US 2001-999284	20011115
	ZA 2003003249	A	20040623	ZA 2003-3249	20030425
PRAI	US 1999-133355P	P	19990510		
	WO 2000-GB1787	W	20000510		
	US 2000-700165	A2	20001109		
	US 2001-759777	A2	20010112		
	GB 2001-9910	A	20010423		
	GB 2001-11037	A	20010504		

AB Bombesin receptor antagonists have been found to be useful in the treatment of sexual dysfunction in both males and females.
IT **10333-68-3**, 2-Pyrrol-1-yl-benzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction; bombesin receptor antagonists, preparation, and use for sexual
dysfunction treatment, alone or with other agents)
RN 10333-68-3 CAPLUS
CN Benzoic acid, 2-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



L9 ANSWER 112 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:354097 CAPLUS

DN 136:355074

TI Preparation of N-arylcarbonyl- and heteroarylcarbonyl benzenesulfonamide inhibitors of Bcl-Xl and Bcl-2 as promoters of apoptosis

IN Augeri, David J.; Baumeister, Steven A.; Bruncko, Milan; Dickman, Daniel A.; Ding, Hong; Dinges, Jurgen; Fesik, Stephen W.; Hajduk, Philip J.; Kunzer, Aaron R.; McClellan, William; Nettesheim, David G.; Oost, Thorsten; Petros, Andrew M.; Rosenberg, Saul H.; Shen, Wang; Thomas, Sheela A.; Wang, Xilu; Wendt, Michael D.

PA USA

SO U.S. Pat. Appl. Publ., 126 pp., Cont.-in-part of U.S. Ser. No. 666,508.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002055631	A1	20020509	US 2001-935581	20010824
	CA 2423103	AA	20020328	CA 2001-2423103	20010920
	WO 2002024636	A2	20020328	WO 2001-US29432	20010920
	WO 2002024636	A3	20020926		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001091151	A5	20020402	AU 2001-91151	20010920
	EP 1318978	A2	20030618	EP 2001-971244	20010920
	EP 1318978	B1	20060208		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004529852	T2	20040930	JP 2002-529049	20010920
	BR 2001010101	A	20050607	BR 2001-10101	20010920
PRAI	US 2000-666508	A2	20000920		
	US 2001-935581	A	20010824		
	WO 2001-US29432	W	20010920		

OS MARPAT 136:355074

GI

L9 ANSWER 112 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB N-aryl- and N-heteroarylcarbonyl benzenesulfonamides I [A = (un)substituted Ph, 5- or 6-membered heterocyclic ring with 1-3 N, O, or S atoms; R1 = alkyl, haloalkyl, NO2, NR6R7; R2, R3 = H, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, etc.; R4 = aryl, arylalkenyl, arylalkoxy, cycloalkenyl, cycloalkyl, halo, heterocyclyl, heterocyclyloxy; R5 = H, alkyl, halo; R6, R7 = H, alkenyl, alkoxyalkyl, alkoxycarbonylalkyl, alkyl, heterocyclyl, etc.; R6R7N = imidazolyl, morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, etc.] are prepared Over 500 I are prepared E.g., N-biphenylcarbonyl benzenesulfonamide II was prepared by Pd-catalyzed coupling of 4-FC6H4B(OH)2 and 4-BrC6H4CO2Me, hydrolysis of the ester with LiOH, acylation of 4-chloro-3-nitrobenzenesulfonamide with the resulting acid in the presence of EDCI and DMAP, and nucleophilic aromatic substitution of the chlorobenzenesulfonamide with 2,2-dimethylcyclopentylamine. Compds. of the invention inhibit Bcl-Xl with IC50 values between 0.011 μM and 10 μM, and inhibit Bcl-2 with IC50 values between 0.017 μM and 10 μM.

IT 22106-33-8, 4-(1-Pyrrolyl)benzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N-aryl- and heteroarylcarbonyl benzenesulfonamide inhibitors of Bcl-Xl and Bcl-2 as promoters of apoptosis)

RN 22106-33-8 CAPLUS

CN Benzoic acid, 4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)

L9 ANSWER 112 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 113 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:240717 CAPLUS

DN 136:279215

TI Preparation of N-arylcarbonyl- and heteroarylcarbonyl benzenesulfonamide inhibitors of Bcl-Xl and Bcl-2 as promoters of apoptosis

IN McClellan, William; Oost, Thorsten; Bruncko, Milan; Wang, Xilu; Augeri, David J.; Baumeister, Steven A.; Dickman, Daniel A.; Ding, Hong; Dinges, Jurgen; Fesik, Stephen W.; Hajduk, Philip J.; Kunzer, Aaron R.; Nettesheim, David G.; Petros, Andrew M.; Rosenberg, Saul H.; Shen, Wang; Thomas, Sheela A.; Wendt, Michael D.

PA Abbott Laboratories, USA

SO PCT Int. Appl., 292 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002024636	A2	20020328	WO 2001-US29432	20010920
	WO 2002024636	A3	20020926		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002055631	A1	20020509	US 2001-935581	20010824
	CA 2423103	AA	20020328	CA 2001-2423103	20010920
	AU 2001091151	A5	20020402	AU 2001-91151	20010920
	EP 1318978	A2	20030618	EP 2001-971244	20010920
	EP 1318978	B1	20060208		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004529852	T2	20040930	JP 2002-529049	20010920
	BR 2001010101	A	20050607	BR 2001-10101	20010920
PRAI	US 2000-666508	A	20000920		
	US 2001-935581	A	20010824		
	WO 2001-US29432	W	20010920		

OS MARPAT 136:279215

GI

L9 ANSWER 113 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)





II

AB N-aryl- and N-heteroarylcarbonyl benzenesulfonamides I [A = (un)substituted Ph, 5- or 6-membered heterocyclic ring with 1-3 N, O, or S atoms; R1 = alkyl, haloalkyl, NO2, NR6R7; R2, R3 = H, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, etc.; R4 = aryl, arylalkenyl, arylalkoxy, cycloalkenyl, cycloalkyl, halo, heterocyclyl, heterocyclyloxy; R5 = H, alkyl, halo; R6, R7 = H, alkenyl, alkoxyalkyl, alkoxycarbonylalkyl, alkyl, heterocyclyl, etc.; R6R7N = imidazolyl, morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, etc.] are prepared Over 500 I are prepared E.g., N-biphenylcarbonyl benzenesulfonamide II was prepared by Pd-catalyzed coupling of 4-FC6H4B(OH)2 and 4-BrC6H4CO2Me, hydrolysis of the ester with LiOH, acylation of 4-chloro-3-nitrobenzenesulfonamide with the resulting acid in the presence of EDCI and DMAP, and nucleophilic aromatic substitution of the chlorobenzenesulfonamide with 2,2-dimethylcyclopentylamine. Compds. of the invention inhibit Bcl-Xl with IC50 values between 0.011 μM and 10 μM, and inhibit Bcl-2 with IC50 values between 0.017 μM and 10 μM.

IT 22106-33-8, 4-(1-Pyrrolyl)benzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N-aryl- and heteroarylcarbonyl benzenesulfonamide inhibitors of Bcl-Xl and Bcl-2 as promoters of apoptosis)

RN 22106-33-8 CAPLUS

CN Benzoic acid, 4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)

L9 ANSWER 113 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 114 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:107167 CAPLUS

DN 136:156464

TI Therapeutic polyesters and polyamides

IN Uhrich, Kathryn E.

PA Rutgers, the State University of New Jersey, USA

SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002009768	A2	20020207	WO 2001-US23747	20010727
	WO 2002009768	A3	20021107		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2417389	AA	20020207	CA 2001-2417389	20010727
	AU 2001078055	A5	20020213	AU 2001-78055	20010727
	US 2002071822	A1	20020613	US 2001-917194	20010727
	US 6689350	B2	20040210		
	EP 1309354	A2	20030514	EP 2001-956013	20010727
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004505063	T2	20040219	JP 2002-515320	20010727
	US 2005031577	A1	20050210	US 2004-753048	20040106
	AU 2005242165	A1	20060105	AU 2005-242165	20051208
PRAI	US 2000-220707P	P	20000727		
	US 2001-261337P	P	20010112		
	AU 2001-78055	A3	20010727		
	US 2001-917194	A3	20010727		
	WO 2001-US23747	W	20010727		

AB Polymers (i.e. polyesters, polyamides, and polythioesters or a mixture thereof) which degrade hydrolytically into biol. active compds. are provided. Methods of producing these polymers, intermediates useful for preparing these polymers, and methods of using these polymers to deliver biol. active compds. to a host are also provided. The biol. active compound is a non-steroidal anti-inflammatory drug, antibacterial, antifungal, anticancer, antithrombotic, immunosuppressant, or analgesic. For example, morphine was copolymd. with a diacid chloride to provide a polyester.

IT 53597-27-6, Fendosal
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of drug-containing polyamides, polyesters and polythioesters as prodrugs)

RN 53597-27-6 CAPLUS

CN Benzoic acid, 5-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)

L9 ANSWER 114 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 115 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:935407 CAPLUS
DN 136:53768
TI Preparation of N-[(piperazino or piperidino)phenyl] benzamides as microsomal triglyceride transfer protein (MTP) inhibitors
IN Daugan, Alain Claude-Marie
PA Glaxo Group Limited, UK; Kirilovsky, Jorge Eduardo
SO PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001097810	A2	20011227	WO 2001-EP6242	20010601
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1286670	A2	20030305	EP 2001-947331	20010601
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003535900	T2	20031202	JP 2002-503294	20010601
	US 2004044008	A1	20040304	US 2003-296794	20030711
PRAI	GB 2000-13378	A	20000601		
	WO 2001-EP6242	W	20010601		

OS MARPAT 136:53768
GI

L9 ANSWER 115 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB The title compds. [I; A = N, CH; X = alkylene, O, S, SO, etc.; Z = a bond, (un)substituted alkylene, optionally containing one double bond; R1 = H, perfluoroalkyl, aryl, etc.; Y = a bond, O, alkylene, etc.; R2 = (un)substituted Ph, cycloalkyl, heterocyclyl; R3 = H, halo, alkyl, etc.], useful as microsomal triglyceride transfer protein (MTP) inhibitors for treating obesity and post-prandial hyperlipemia, were prepared and formulated. Thus, amidation of 4-[4-(3-cyanobenzyl)-piperazin-1-yl]phenylamine with 4'-trifluoromethylbiphenyl-2-carboxylic acid (prepns. of both reactants were given) in the presence of HOBt, EDCl and Et3N in CH2Cl2 afforded II which showed IC50 of 0.9 nM in human MTP assay.
IT 10333-68-3, 2-(Pyrrol-1-yl)benzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N-[(piperazino or piperidino)phenyl] benzamides as microsomal triglyceride transfer protein (MTP) inhibitors)
RN 10333-68-3 CAPLUS
CN Benzoic acid, 2-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



L9 ANSWER 115 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L9 ANSWER 116 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:868447 CAPLUS
DN 136:5917
TI Preparation of (hetero)arylacyl-piperidinyl-benzylamines for use as tryptase inhibitors
IN Astles, Peter C.; Eastwood, Paul R.; Houille, Olivier; Levell, Julian; Pauls, Heinz; Czekaj, Mark; Liang, Guyan; Gong, Yong; Pribish, James; Neuenschwander, Kent
PA Aventis Pharmaceuticals Products Inc., USA
SO PCT Int. Appl., 267 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001090101	A1	20011129	WO 2001-US13811	20010427
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2003187020	A1	20031002	US 2001-843126	20010426
	US 6977263	B2	20051220		
	CA 2409827	AA	20011129	CA 2001-2409827	20010427
	EP 1296972	A1	20030402	EP 2001-930925	20010427
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001011206	A	20030415	BR 2001-11206	20010427
	JP 2004510697	T2	20040408	JP 2001-586288	20010427
	CN 1740169	A	20060301	CN 2005-10106304	20010427
	NO 2002005601	A	20030106	NO 2002-5601	20021121
	ZA 2002009484	A	20040223	ZA 2002-9484	20021121
	US 2005228018	A1	20051013	US 2005-57809	20050214
PRAI	GB 2000-12362	A	20000522		
	US 2001-843126	A	20010426		
	CN 2001-811952	A3	20010427		
	WO 2001-US13811	W	20010427		

OS MARPAT 136:5917
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [Ar = (hetero)aryl, where the two groups on the Ar ring are β to each other; R1-2 = H, alkyl; R3 = (un)substituted(hetero)aryl, arylalkenyl, cycloalkenyl, cycloalkyl, etc.; R4 = H, acyl, alkoxy, alkyloxycarbonyl, carboxy, CN, halo, etc.; n = 0 - 4] were prepared Over 300 synthetic examples were disclosed. For instance, 3-bromobenzylbromide was converted in two steps to boronate II. II was coupled to the triflate ester derivative of the enol of 4-oxo-N-benzyloxycarbonylpiperidine (DMF, K2CO3, PdCl2(dppf)•CH2Cl2, 80°C, 18 h) to give the corresponding bicyclic intermediate. This intermediate was deprotected and reduced to the piperidine (EtOH, 10%

L9 ANSWER 116 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Pd-C/H2, room temp., 5 h) and coupled to 5-phenethylthiophene-2-carboxylic acid (DMF, HAPyU, iPr2NEt, room temp., 18 h) to give III. III had Ki = 50 nM for tryptase. I are useful in the treatment of e.g., asthma and inflammatory diseases.
IT 22106-33-8, 4-(1H-Pyrrol-1-yl)benzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of (hetero)arylacyl-piperidinyl-benzylamines for use as tryptase inhibitors)
RN 22106-33-8 CAPLUS
CN Benzoic acid, 4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 117 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:726388 CAPLUS
DN 135:272871
TI Preparation of 3-phenyl-4,5-dihydrobenz[e]indoles as thrombolytics
IN Ries, Uwe; Stassen, Jean Marie; Wienen, Wolfgang
PA Boehringer Ingelheim Pharma KG, Germany
SO Ger. Offen., 8 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 10015939	A1	20011004	DE 2000-10015939	20000330
PRAI DE 2000-10015939		20000330		

OS MARPAT 135:272871
GI



AB Title compds. [I; R = H, alkyl, thienyl, (substituted) Ph; R1 = CO2H, alkoxycarbonyl, carbamoyl, N-alkylcarbamoyl, etc.; R2 = H, halo, OH, SH, CF3, alkyl, alkoxy, alkanoyloxy, etc.; R3 = H, alkanoyl, Ph; D = H, halo, alkyl, alkoxy, alkanoyloxy, alkanoylamino, amino, NO2, CF3; n = 1, 2], were prepared Thus, 1-phenacyl-2-tetralone and 5-aminosalicylic acid in glacial AcOH were stirred for 90 min at 140° to give 57% 3-(3-carboxy-4-hydroxyphenyl)-4,5-dihydro-2-phenylbenz[e]indole. The latter inhibited endogenous plasminogen activator inhibitor PAI-1 with IC50 = 17.2 μM.
IT 53597-27-6P, 3-(3-Carboxy-4-hydroxyphenyl)-4,5-dihydro-2-phenylbenz[e]indole 363607-41-4P 363607-43-6P 363607-44-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenyldihydrobenzindoles as thrombolytics)
RN 53597-27-6 CAPLUS
CN Benzoic acid, 5-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)

L9 ANSWER 117 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 363607-41-4 CAPLUS
CN Benzoic acid, 3-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)- (9CI) (CA INDEX NAME)



RN 363607-43-6 CAPLUS
CN Benzoic acid, 4-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)- (9CI) (CA INDEX NAME)



RN 363607-44-7 CAPLUS
CN Benzoic acid, 4-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)



L9 ANSWER 118 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:507732 CAPLUS
DN 135:103458
TI Novel bacterial genes and proteins that are essential for cell viability and their uses
IN Dougherty, Thomas J.; Pucci, Michael J.; Dougherty, Brian A.; Davison, Daniel B.; Bruccoleri, Robert E.; Thanassi, Jane A.
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 380 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001049721	A2	20010712	WO 2000-US35604	20001229
WO 2001049721	A3	20020912		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2396040	AA	20010712	CA 2000-2396040	20001229
EP 1261630	A2	20021204	EP 2000-992297	20001229
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI US 1999-174089P	P	19991230		
WO 2000-US35604	W	20001229		

AB The present invention provides novel bacterial genes and their encoded polypeptides thereof which are essential for bacterial cell viability, and their uses. Conserved essential gene (ceg) nucleotide sequences of the invention were obtained by large-scale computational comparisons of multiple genome sequences to identify conserved protein coding regions, followed by gene disruption to identify cegs. The conservation of protein sequences in many cases is believed to reflect the higher level conservation of common biochem. pathways essential for bacterial function and viability. A procedure is provided to generate recombinant vectors of pEVP-3 having inserts of candidate ceg nucleotide sequences. Knockout primers are used to generate DNA fragments comprising candidate ceg sequences. The high throughput gene disruption procedure used in Streptococcus pneumoniae identified 113 candidate genes and their encoded protein sequences. Bacterial gene sequences that encode gene products essential for bacterial cell viability are useful in strategies for developing new antimicrobial agents.
IT 54669-65-7
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(ligand; bacterial genes and proteins that are essential for cell viability and their uses)
RN 54669-65-7 CAPLUS
CN Benzoic acid, 2-hydroxy-5-(4,5,6,7-tetrahydro-2-phenyl-1H-indol-1-yl)- (9CI) (CA INDEX NAME)

L9 ANSWER 118 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 119 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:489366 CAPLUS

DN 135:92541

TI Preparation of a substance library from iminium salts and naphthalene, pyrrole, and/or indole compounds and use of the library in discovery of active compounds.

IN Gerlach, Matthias; Maul, Corinna

PA Gruenenthal G.m.b.H., Germany

SO PCT Int. Appl., 80 pp.
CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001047882	A2	20010705	WO 2000-EP12973	20001220
WO 2001047882	A3	20020530		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19963177	A1	20010712	DE 1999-19963177	19991227
PRAI DE 1999-19963177	A	19991227		

OS MARPAT 135:92541

AB A substance library was prepared by (1) reaction of aldehydes with secondary amines in the presence of base to give aminals, (2) treatment of the aminals with acid chlorides to give iminium salts, (3) reaction of the iminium salts with naphthalene, pyrrole, or indole compds. Thus, reaction of 1H-indole with benzylidenedimethylammonium chloride gave [(1H-indol-3-yl)phenylmethyl]dimethylamine. The latter gave 41% inhibition of phenylquinone-induced writhing in mice.

IT **347897-66-9**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(preparation of a substance library from iminium salts and naphthalene, pyrrole, and/or indole compds. and use of the library in discovery of active compds)

RN 347897-66-9 CAPLUS

CN Benzoic acid, 2-[2-[(5-bromo-2-fluorophenyl)-1-pyrrolidinylmethyl]-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 119 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 120 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:489365 CAPLUS

DN 135:92537

TI Preparation of novel pyrroles as cyclic AMP-specific phosphodiesterase inhibitors

IN Martins, Timothy J.; Fowler, Kerry W.; Oliver, Amy; Hertel, Carmen C.

PA Icos Corp., USA

SO PCT Int. Appl., 151 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001047880	A1	20010705	WO 2000-US28496	20001013
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6372777	B1	20020416	US 2000-686054	20001011
CA 2395543	AA	20010705	CA 2000-2395543	20001013
EP 1244620	A1	20021002	EP 2000-972173	20001013
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003519123	T2	20030617	JP 2001-549353	20001013
AU 781063	B2	20050505	AU 2001-10871	20001013
US 2003013754	A1	20030116	US 2002-54273	20020122
US 6569890	B2	20030527		
PRAI US 1999-171954P	P	19991223		
US 2000-686054	A3	20001011		
WO 2000-US28496	W	20001013		

OS MARPAT 135:92537

GI



AB The title compds. [I or II; R1 = alkyl, cycloalkyl, aryl, etc.; R2 = H, alkyl; R3 = alkyl, alkoxy, alkoxyalkyl, etc.; n = 0-3] that are potent and selective inhibitors of PDE4, and useful in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, were prepared Thus, reacting m-chloroaniline with 3-oxo-2-(2-oxo-2-phenylethyl)butyric acid Et

L9 ANSWER 120 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
ester in the presence of tosic acid in EtOH afforded I [R1 = 3-ClC6H4; R2 = Et; R3 = H] which showed IC50 of 0.20 μM against PDE4 and EC50 of 1.50 μM against TNFα release.
IT **347885-05-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel pyrroles as cAMP-specific phosphodiesterase inhibitors)
RN 347885-05-6 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-(3-carboxyphenyl)-5-methyl-2-phenyl-, 3-ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 121 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:489363 CAPLUS
DN 135:76789
TI Preparation of 2-[amino(aryl)methyl]pyrroles as analgesics
IN Gerlach, Matthias; Maul, Corinna
PA Gruenenthal G.m.b.H., Germany
SO PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001047878	A1	20010705	WO 2000-EP12976	20001220
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	DE 19963174	A1	20010712	DE 1999-19963174	19991227
	CA 2396502	AA	20010705	CA 2000-2396502	20001220
	BR 2000016814	A	20020910	BR 2000-16814	20001220
	EP 1246799	A1	20021009	EP 2000-991220	20001220
	EP 1246799	B1	20031015		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003527350	T2	20030916	JP 2001-549351	20001220
	AT 252077	E	20031115	AT 2000-991220	20001220
	NZ 519975	A	20040227	NZ 2000-519975	20001220
	PT 1246799	T	20040331	PT 2000-991220	20001220
	ES 2208466	T3	20040616	ES 2000-991220	20001220
	AU 782909	B2	20050908	AU 2001-31611	20001220
	ZA 2002004199	A	20040210	ZA 2002-4199	20020527
	NO 2002003028	A	20020820	NO 2002-3028	20020621
	US 2003023100	A1	20030130	US 2002-168964	20020625
	US 7034018	B2	20060425		
	HK 1051855	A1	20040723	HK 2003-102525	20030409
PRAI	DE 1999-19963174	A	19991227		
	WO 2000-EP12976	W	20001220		
OS	MARPAT 135:76789				

GI



I

AB Title compds. [I; R1 = H, alkyl, aryl, heteroaryl, etc.; R2 = CHR6NR7R8;

L9 ANSWER 121 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
R3-R5 = H, F, Cl, Br, CF3, cyano, NO2, etc.; R6 = (substituted) Ph; R7, R8
= (substituted) alkyl, Ph, PhCH2, PhEt; R7R8 = (CH2)2O(CH2)2, (CH2)n; n = 3-6] were prepd. Thus, 4-(2-methoxybenzylidene)morpholin-4-ium chloride (prepn. given) was stirred with 1-phenyl-1H-pyrrole at 18° for 16 h in a Zymark device to give 4-[(2-methoxyphenyl)-(1-phenyl-1H-pyrrol-2-yl)methyl]morpholine. Several I inhibited serotonin reuptake by 39-83% and inhibited phenylquinone-induced writhing in mice by 17-87%.
IT **347897-66-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-[amino(aryl)methyl]pyrroles as analgesics)
RN 347897-66-9 CAPLUS
CN Benzoic acid, 2-[2-[(5-bromo-2-fluorophenyl)-1-pyrrolidinylmethyl]-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



IT **10333-68-3**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 2-[amino(aryl)methyl]pyrroles as analgesics)
RN 10333-68-3 CAPLUS
CN Benzoic acid, 2-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 122 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:453076 CAPLUS
DN 135:46047
TI Preparation of pyrimidine heterocycles with a phosphorus containing moiety
for pharmaceutical use in the treatment of bone disorders
IN Weigele, Manfred; Dalgarno, David C.; Luke, George P.; Sawyer, Tomi K.; Bohacek, Regine; Shakespeare, William C.; Sundaramoorthi, Rajeswari; Wang,
Yihan; Metcalf, Chester A., III; Vu, Chi B.; Kawahata, Noriyuki H.
PA Ariad Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 186 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001044258	A1	20010621	WO 2000-US34487	20001218
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2394650	AA	20010621	CA 2000-2394650	20001218
	AU 2001024397	A5	20010625	AU 2001-24397	20001218
	US 2002132819	A1	20020919	US 2000-740653	20001218
	EP 1246829	A1	20021009	EP 2000-988160	20001218
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003532632	T2	20031105	JP 2001-544748	20001218
	US 2005096298	A1	20050505	US 2004-994962	20041122
PRAI	US 1999-172161P	P	19991217		
	US 1999-172510P	P	19991217		
	US 2000-240788P	P	20001016		
	US 2000-740653	A	20001218		
	US 2000-741619	A	20001218		
	US 2000-740619	A	20001218		
	WO 2000-US34487	W	20001218		
OS	MARPAT 135:46047				

GI



I

AB Heterocycles with a pyrimidine subunit and a phosphorus containing moiety,

L9 ANSWER 122 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
such as Hc-X-M-Y-M-Cy-M-Y-M-Z-Tb [Cy = aryl, heterocyclyl, heteroaryl, cycloalkyl; Hc = heterocycle contg. a pyrimidine subunit; M = (CH2)n; Tb = phosphorus contg. moiety; X, Y, Z = NR, O, S; R = H, alkyl, alkenyl, aryl, heterocyclyl, heteroaryl, etc.; n = 1 - 10], were prepd. for pharmaceutical use in the treatment of debilitating bone disorders, such as osteoporosis, Paget's disease, hyperparathyroidism, various cancers where bone tissue resorption is increased, and rheumatoid arthritis. Thus, pyrido[2,3-d]pyrimidine I was prepd. in 41% yield by condensation of Br-4-C6H4CH[P(O)(OEt)2]2 with 2-amino-6-(2,6-dichlorophenyl)-8-methyl-pyrido[2,3-d]pyrimidin-7(8H)-one using Pd(OAc)2, Cs2CO3, and (S)-BINAP in toluene. The prepd. phosphorus contg. purines were tested for anti-resorption activity, Src kinase inhibition, and inhibition of tumor growth.

IT **344891-90-3 344891-91-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrimidine heterocycles with a phosphorus containing moiety for pharmaceutical use in the treatment of bone disorders)

RN 344891-90-3 CAPLUS
CN Benzoic acid, 4-[4-amino-5-(3-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 344891-91-4 CAPLUS
CN Benzoic acid, 3-[4-amino-5-(3-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 122 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 123 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:434854 CAPLUS
DN 135:51045
TI Therapeutic compositions containing anti-inflammatory agents and biodegradable polyanhydrides
IN Uhrich, Kathryn; Macedo, Braz
PA Rutgers, the State University of New Jersey, USA; University of Medicine and Dentistry
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001041753	A2	20010614	WO 2000-US33378	20001207
	WO 2001041753	A3	20020912		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2393676	AA	20010614	CA 2000-2393676	20001207
	EP 1261347	A1	20021204	EP 2000-982544	20001207
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003528044	T2	20030924	JP 2001-543098	20001207
	US 2004038948	A1	20040226	US 2003-368288	20030218
PRAI	US 1999-455861	A	19991207		
	US 1999-304190P	P	19991207		
	WO 2000-US33378	W	20001207		
	US 2002-165220	B1	20020607		

AB Methods of promoting healing through enhanced regeneration of tissue (e.g. hard tissue or soft tissue) by contacting the tissue or the surrounding tissue with an antiinflammatory agent are useful in a variety of dental and orthopedic applications. Thus, poly[1,6-bis(o-carboxyphenoxy)hexane] was prepared in a series of steps by the treatment of salicylic acid with 1,6-dibromohexane, and polymerization of the resulting 1,6-bis(o-carboxyphenoxy)hexane. The polymer was characterized by glass transition temperature measurements and then subjected to compression molding.

IT **53597-27-6**, Fendosal
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic compns. containing antiinflammatory agents and biodegradable polyanhydrides)

RN 53597-27-6 CAPLUS
CN Benzoic acid, 5-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)

L9 ANSWER 123 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 124 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:416939 CAPLUS

DN 135:46203

TI Preparation and effect of triazaspiro[5.5]undecane derivatives as active ingredients in remedy for inflammatory diseases

IN Habashita, Hiromu; Hamano, Shinichi; Shibayam, Shiro; Takaoka, Yoshikazu

PA Ono Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 1149 pp.
CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001040227	A1	20010607	WO 2000-JP8517	20001201
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2394679	AA	20010607	CA 2000-2394679	20001201
	AU 2001016506	A5	20010612	AU 2001-16506	20001201
	AU 780419	B2	20050317		
	EP 1236726	A1	20020904	EP 2000-979050	20001201
	EP 1236726	B1	20041201		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2000016111	A	20030325	BR 2000-16111	20001201
	TW 224597	B1	20041201	TW 2000-89125555	20001201
	AT 283854	E	20041215	AT 2000-979050	20001201
	NZ 519183	A	20050225	NZ 2000-519183	20001201
	PT 1236726	T	20050429	PT 2000-979050	20001201
	ES 2233479	T3	20050616	ES 2000-979050	20001201
	RU 2265021	C2	20051127	RU 2002-117652	20001201
	ZA 2002004203	A	20030827	ZA 2002-4203	20020527
	NO 2002002609	A	20020726	NO 2002-2609	20020531
	US 2004097511	A1	20040520	US 2003-148382	20030508
PRAI	JP 1999-344967	A	19991203		
	JP 2000-18673	A	20000127		
	JP 2000-27968	A	20000204		
	JP 2000-147882	A	20000519		
	WO 2000-JP8517	W	20001201		

OS MARPAT 135:46203

GI



I



II

AB Title compds. [I; R1 = H, aryl, arylalkyloxycarbonyl, alkenyloxycarbonyl, heterocyclylalkyl, alkyl, alkenyl, alkynyl; R2 = alkyl, alkynyl; R3 = H; R4 = alkyl; R5 = H, alkyl], stereoisomers, quaternary ammonium salts thereof, N-oxides thereof and nontoxic salts thereof, are prepared via solid phase synthesis using divinylbenzene-polystyrene or divinylbenzene-Rink resin. Title compds. I, having controlling effects of chemokines/chemokine receptors, are useful in preventing and/or treating various inflammatory diseases, asthma, atopic dermatitis, urticaria, allergic diseases, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, etc. Thus, the title compound II·HCl was prepared and biol. tested.

IT **343835-56-3P 343836-34-0P 343837-17-2P**
343840-29-9P 343841-17-8P 343842-09-1P
343843-02-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and effect of triazaspiro[5.5]undecane derivs. as active ingredients in inflammatory disease therapy)

RN 343835-56-3 CAPLUS

CN Benzoic acid, 4-[3-[[1-ethyl-3-(2-methylpropyl)-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-2,5-dimethyl-1H-pyrrol-1-yl]-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 343835-55-2

L9 ANSWER 124 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CMF C28 H38 N4 O4



CM 2

CRN 64-19-7
CMF C2 H4 O2

RN 343836-34-0 CAPLUS

CN Benzoic acid, 4-[2,5-dimethyl-3-[[3-(2-methylpropyl)-2,5-dioxo-1-propyl-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-1H-pyrrol-1-yl]-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 343836-33-9
CMF C29 H40 N4 O4



CM 2

CRN 64-19-7
CMF C2 H4 O2

RN 343837-17-2 CAPLUS

CN Benzoic acid, 4-[3-[[1-butyl-3-(2-methylpropyl)-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-2,5-dimethyl-1H-pyrrol-1-yl]-, monoacetate (9CI) (CA INDEX NAME)

L9 ANSWER 124 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 1

CRN 343837-16-1
CMF C30 H42 N4 O4



CM 2

CRN 64-19-7
CMF C2 H4 O2

RN 343840-29-9 CAPLUS

CN Benzoic acid, 4-[3-[[3-(cyclohexylmethyl)-2,5-dioxo-1-propyl-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-2,5-dimethyl-1H-pyrrol-1-yl]-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 343840-28-8
CMF C32 H44 N4 O4



CM 2

CRN 64-19-7
CMF C2 H4 O2

L9 ANSWER 124 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 343841-17-8 CAPLUS
CN Benzoic acid, 4-[3-[[1-butyl-3-(cyclohexylmethyl)-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-2,5-dimethyl-1H-pyrrol-1-yl]-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 343841-16-7
CMF C33 H46 N4 O4



CM 2

CRN 64-19-7
CMF C2 H4 O2

RN 343842-09-1 CAPLUS
CN Benzoic acid, 4-[3-[[3-(cyclohexylmethyl)-1-(2-methoxyethyl)-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-2,5-dimethyl-1H-pyrrol-1-yl]-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 343842-08-0
CMF C32 H44 N4 O5



CM 2

L9 ANSWER 124 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CRN 64-19-7
CMF C2 H4 O2

RN 343843-02-7 CAPLUS
CN Benzoic acid,
4-[3-[[3-(cyclohexylmethyl)-2,5-dioxo-1-(phenylmethyl)-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]-2,5-dimethyl-1H-pyrrol-1-yl]-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 343843-01-6
CMF C36 H44 N4 O4



CM 2

CRN 64-19-7
CMF C2 H4 O2

RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 125 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:232516 CAPLUS
DN 134:275760
TI Medicine compositions for treatment of integrin α4-mediated cell adhesion-associated diseases
IN Sircar, Ila; Gudmundsson, Kristjan S.; Martin, Richard
PA Tanabe Seiyaku Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 88 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2001089368	A2	20010403	JP 2000-216898	20000718
PRAI JP 1999-204581	A	19990719		

OS MARPAT 134:275760
GI



I

AB The medicine compns. (I; A = aromatic hydrocarbon ring; Q = binding linkage; N = 0, 1, 2; W = O, S, -CH=CH-, -N=CH-; Z = O, S; R1, R2, R3 = H, halogen, (substituted)low alkyl; R4 = tetrazolyl, carboxyl, etc.; R5 = H, nitro, (substituted)amino, OH low alkanoyl, etc.; R6 = (substituted)phenyl, etc.) and their pharmacol. acceptable salts are claimed for treatment of integrin 4-mediated cell adhesion-associated diseases, including asthma, diabetes, rheumatoid arthritis, inflammatory bowel disease, and digestive tract and other diseases associated with leukocyte infiltration in the epithelium (e.g. skin, urethra, bronchiole, synovial membrane and transplanted kidney, liver, heart, blood vessel, and nerve tissues, and pancreas and other diseases including psoriasis, atopic dermatitis, contact dermatitis, systemic lupus erythematosus, etc.). I were prepared, and their inhibitory effects on cell adhesion were tested in vitro.
IT **232275-65-9P 232275-67-1P 232275-69-3P**
232275-71-7P 332394-46-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(phenylalanine analogs as medicine compns. for treatment of integrin α4-mediated cell adhesion-associated diseases)
RN 232275-65-9 CAPLUS
CN Benzoic acid, 2-chloro-4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)

L9 ANSWER 125 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 232275-67-1 CAPLUS
CN Benzoic acid, 2-chloro-4-[2-(trifluoroacetyl)-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 232275-69-3 CAPLUS
CN Benzoic acid, 2-chloro-4-(2,5-dichloro-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 232275-71-7 CAPLUS
CN Benzoic acid, 2-chloro-4-(2-formyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)

L9 ANSWER 125 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 332394-46-4 CAPLUS
CN Benzoic acid, 2-chloro-4-(2-methyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



L9 ANSWER 126 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 126 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:167849 CAPLUS
DN 134:217194
TI Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
IN Ridker, Paul; Hennekens, Charles H.
PA The Brigham and Women's Hospital, Inc., USA
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001015744	A1	20010308	WO 2000-US24251	20000831
	WO 2001015744	C2	20020926		
	W: AU, CA, JP				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 7030152	B1	20060418	US 1999-387028	19990831
	CA 2381926	AA	20010308	CA 2000-2381926	20000831
	AU 2000071103	A5	20010326	AU 2000-71103	20000831
	AU 782386	B2	20050721		
	EP 1212101	A1	20020612	EP 2000-959851	20000831
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	JP 2003508453	T2	20030304	JP 2001-520155	20000831
	AU 2005225101	A1	20051117	AU 2005-225101	20051021
PRAI	US 1999-387028	A	19990831		
	US 1997-41950P	P	19970402		
	US 1997-43039P	P	19970402		
	US 1998-70894P	P	19980109		
	US 1998-54212	A2	19980402		
	WO 2000-US24251	W	20000831		

AB The invention involves methods for characterizing an individual's risk profile of developing a future cardiovascular disorder such as atherosclerosis, stroke, and myocardial infarction by assessing the level of systemic inflammation marker (such as sICAM or C-reactive protein) in an individual. The invention also involves methods for evaluating the likelihood that an individual will benefit from treatment with an agent for reducing the risk of future cardiovascular disorders; and of drug combinations (anti-inflammatory agents, lipid-reducing agents, angiotensisin system inhibitors, calcium channel blockers, β-adrenergic receptor blockers) suitable for prevention future cardiovascular disease.
IT **53597-27-6**, Fendosal
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(use of agents and systemic inflammatory markers to predict and inhibit cardiovascular diorders in humans)
RN 53597-27-6 CAPLUS
CN Benzoic acid, 5-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)

L9 ANSWER 127 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:142150 CAPLUS
DN 134:193213
TI Preparation of carboxydiarylamines for pharmaceuticals
IN Tecle, Haile
PA Warner Lambert Co., USA
SO Jpn. Kokai Tokkyo Koho, 68 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2001055376	A2	20010227	JP 1999-53567	19990302
PRAI	US 1999-115650P	P	19990113		

OS MARPAT 134:193213
GI



I

AB Title compds. I (W = ORB, NR2OR1, NRARB, NR2NRARB, O(CH2)nNRARB, NR2(CH2)mNRARB; n = 2-4; m = 1-4; R1, RA, RB = H, C1-8 alkyl, C3-8 alkenyl, C3-8 alkynyl, C3-8 cycloalkyl; R2 = H, C1-4 alkyl, Ph, C3-6 cycloalkyl; one of R3 and R4 = H, F, the other = C2-6 heterocyclyl, C3-7 cycloalkyl, C2-6 heterocyclyl C1-4 alkyl; R5 = H, Me, Cl; R6 = H, F). The compds. are useful for treatment of psoriasis, restenosis, autoimmune disease, atherosclerosis, cancers, heart failure, symptoms of xenograft rejection, osteoarthritis, rheumatoid arthritis, asthma, cystic fibrosis, hepatomegaly, cardiomegaly, Alzheimer,s disease, diabetes, septic shock, and HIV. 2-Fluoro-4-aminobenzoic acid was cyclized with 2,5-dimethoxytetrahydrofuran in the presence of NaOAc in AcOH under reflux for 3 h 76% 2-fluoro-4-(pyrrol-1-yl)benzoic acid, which was condensed with 2-methylfluoroaniline in the presence of LDA in THF at room temperature for 16 h to give 93% I (W = OH, R3, R6 = H, R4 = pyrrol-1-ly, R5 = Me).
IT **326926-64-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of carboxydiarylamines for pharmaceuticals)
RN 326926-64-1 CAPLUS
CN Benzoic acid, 2-fluoro-4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)

L9 ANSWER 127 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT **326926-65-2P**
RL: SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of carboxydiarylamines for pharmaceuticals)
RN 326926-65-2 CAPLUS
CN Benzoic acid, 2-[(4-iodo-2-methylphenyl)amino]-4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



L9 ANSWER 128 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:137173 CAPLUS
DN 134:178396
TI Synthesis, activity and formulations of pharmaceutical compounds for treatment of oxidative stress and/or endothelial dysfunction
IN Del Soldato, Piero
PA Nicox S.A., Fr.
SO PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001012584	A2	20010222	WO 2000-EP7225	20000727
	WO 2001012584	A3	20020829		
	W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2381409	AA	20010222	CA 2000-2381409	20000727
	BR 2000013264	A	20020416	BR 2000-13264	20000727
	EP 1252133	A2	20021030	EP 2000-953102	20000727
	EP 1252133	B1	20050608		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003515526	T2	20030507	JP 2001-516885	20000727
	NZ 516889	A	20041029	NZ 2000-516889	20000727
	AU 781643	B2	20050602	AU 2000-65670	20000727
	AT 297375	E	20050615	AT 2000-953102	20000727
	EP 1593664	A1	20051109	EP 2005-104064	20000727
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY				
	RU 2264383	C2	20051120	RU 2002-103509	20000727
	ES 2243292	T3	20051201	ES 2000-953102	20000727
	NZ 535559	A	20051223	NZ 2000-535559	20000727
	ZA 2002000628	A	20030423	ZA 2002-628	20020123
	NO 2002000623	A	20020409	NO 2002-623	20020208
	AU 2005202824	A1	20050721	AU 2005-202824	20050628
PRAI	IT 1999-MI1817	A	19990812		
	EP 2000-953102	A3	20000727		
	WO 2000-EP7225	W	20000727		

OS MARPAT 134:178396
AB Compds. or their salts of general formula (I): A-B-N(O)s wherein: s is an integer equal to 1 or 2; A = R-T1-, wherein R is the drug radical and T1 =
(CO)t or (X)t', wherein X = O, S, NR1c, R1c is H or a linear or branched alkyl or a free valence, t and t' are integers and equal to zero or 1, with the proviso that t = 1 when t' = 0; t = 0 when t' = 1; B = -TB -X2-O-
wherein TB = (CO) when t = 0, TB = X when t' = 0, X being as above defined; X2, bivalent radical, is such that the precursor drug of A and the precursor of B meet resp. the pharmacol. tests described in the description. Synthesis, activity and formulations of pharmaceutical

L9 ANSWER 128 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
compds. for treatment of oxidative stress and/or endothelial dysfunction are disclosed. The precursors are such as to meet the pharmacol. test reported in the description.
IT **53597-27-6**, Fendosal
RL: RCT (Reactant); RACT (Reactant or reagent)
(antiinflammatory; synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial dysfunction)
RN 53597-27-6 CAPLUS
CN Benzoic acid, 5-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)



L9 ANSWER 129 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:62381 CAPLUS
DN 134:115960
TI Triazole and imidazole derivatives, methods of preparation and use in treatment or prophylaxis of diseases caused by overactivation of respective NMDA receptor subtypes
IN Alanine, Alexander; Buettelmann, Bernd; Heitz, Neidhart Marie-Paule; Jaeschke, Georg; Pinard, Emmanuel; Wyler, Rene
PA F. Hoffmann-La Roche A.-G., Switz.
SO Eur. Pat. Appl., 66 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1070708	A1	20010124	EP 2000-114183	20000713
	EP 1070708	B1	20040114		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	AT 257827	E	20040115	AT 2000-114183	20000713
	PT 1070708	T	20040531	PT 2000-114183	20000713
	ES 2211420	T3	20040716	ES 2000-114183	20000713
	CA 2314009	AA	20010121	CA 2000-2314009	20000717
	AU 773463	B2	20040527	AU 2000-48651	20000717
	SG 98422	A1	20030919	SG 2000-3981	20000718
	TR 200002097	A2	20010221	TR 2000-2097	20000719
	US 6265426	B1	20010724	US 2000-619518	20000719
	NO 2000003723	A	20010122	NO 2000-3723	20000720
	ZA 2000003680	A	20010122	ZA 2000-3680	20000720
	CN 1281852	A	20010131	CN 2000-120181	20000720
	HR 2000000482	A1	20010630	HR 2000-482	20000720
	BR 2000003075	A	20010313	BR 2000-3075	20000721
	JP 2001064263	A2	20010313	JP 2000-220748	20000721
	JP 3628946	B2	20050316		
PRAI	EP 1999-114313	A	19990721		

OS MARPAT 134:115960
GI



I



II

L9 ANSWER 129 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

AB The present invention relates to I wherein R1-R4 = H, CF3, OCF3, OCHF2, lower alkyl, lower alkoxy, halogen, hydroxy, Ph, benzyl, amino, nitro, pyrrol-1-yl, lower alkylsulfonyl, lower alkylthio, cyano or benzyloxy; or R2 and R3 may be together = O-(CH2)2-O-, -O-CH2-O-, -O-(CH2)2-, -(CH2)3- or CH:CH-CH:CH-; X = N:, imino with N possibly substituted, CH:; Y = -N:, :N-, imino with N possibly substituted, CH:; wherein one of X or Y has to be N; R5 = aminomethyl with N possibly substituted and to their pharmaceutically acceptable acid addition salts. The methods of preparation comprise cyclizing a carboxylic acid hydrazide with a benzenecarboximidamide hydrochloride or benzenecarboximidic acid ester to give a triazole; arylating a 4-iodo-2-phenylimidazole with a phenylboronic acid in the presence of Pd(PPh3)4 to give an imidazole; reducing II to the aminomethyl analog followed by di-N-alkylation using acyl chlorides and LiAlH4. These compds. may be used for the treatment or prophylaxis of diseases related to the N-methyl-D-aspartate (NMDA)-receptor-subtype selective blockers. Such diseases include acute forms of neurodegeneration caused, e.g., by stroke or brain trauma; chronic forms of neurodegeneration such as Alzheimer's disease, Parkinson's disease, Huntington's disease or ALS (amyotrophic lateral sclerosis); neurodegeneration associated with bacterial or viral infections, and diseases such as schizophrenia, anxiety, depression and acute/chronic pain.

IT **22106-33-8**, 4-Pyrrol-1-ylbenzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; triazole and imidazole derivs., methods of preparation and use in treatment or prophylaxis of diseases caused by overactivation of resp. NMDA receptor subtypes)

RN 22106-33-8 CAPLUS

CN Benzoic acid, 4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 130 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

iodo; R2 = H) with ClSO3H to give II (R1 = Cl, Br, iodo; R2 = SO2Cl), (2) redn. of the latter to give II [R1 = Cl, Br, iodo; R2 = S(O)OH], (3) treatment of the sulfinic acid with a salt of ClCH2CO2H under decarboxylation to give II (R1 = Cl, Br, iodo; R2 = SO2Me), (4) introduction of the pyrrole group via nucleophilic halogen-pyrrole exchange to give (III; A = H), (5) esterification to give III (A = alkyl, PhCH2), (6) reaction of the ester with guanidine, and (7) salification with MeSO3H. In comparison to the procedure of M. Baumgarth, the current procedure features 28% higher yields, is more reproducible, may be scaled up without loss of material, has a 7-fold greater space/time yield, is one step shorter, and does not require product recrystn.

IT **294204-22-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-(diaminomethylene)-2-methyl-5-methylsulfonyl-4-(pyrrol-1-yl)benzamide methanesulfonate (eniporide) from 4-halo-2-methylbenzoic acids)

RN 294204-22-1 CAPLUS

CN Benzoic acid, 2-methyl-5-(methylsulfonyl)-4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



L9 ANSWER 130 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:12124 CAPLUS

DN 134:71489

TI Preparation of N-(diaminomethylene)-2-methyl-5-methylsulfonyl-4-(pyrrol-1-yl)benzamide methanesulfonate (eniporide) from 4-halo-2-methylbenzoic acids.

IN Stein, Ingeborg; Bathe, Andreas; Bartmann, Ekkehard

PA Merck Patent G.m.b.H., Germany

SO Ger. Offen., 8 pp.
CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19929857	A1	20010104	DE 1999-19929857	19990629
	WO 2001002353	A1	20010111	WO 2000-EP5276	20000607
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	DE 1999-19929857	A	19990629		

OS CASREACT 134:71489; MARPAT 134:71489

GI



I



II



III

AB Title compound (I) was prepared by (1) treatment of benzoate (II; R1 = Cl, Br,

L9 ANSWER 131 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:10086 CAPLUS

DN 134:86277

TI 1,3-Diazines with platelet-derived growth factor receptor inhibitory activity

IN Matsuno, Kenji; Ichimura, Michio; Nomoto, Yuji; Fujiwara, Shigeki; Ide, Shinichi; Tsukuda, Eiji; Irie, Junko; Oda, Shoji

PA Kyowa Hakko Kogyo Co., Ltd., Japan

SO U.S., 127 pp., Cont.-in-part of PCT 9814431.
CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6169088	B1	20010102	US 1998-88199	19980601
	WO 9814431	A1	19980409	WO 1997-JP3510	19971001
	W: AU, BG, BR, CA, CN, CZ, HU, JP, KR, MX, NO, NZ, PL, RO, SG, SI, SK, UA, US, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 6207667	B1	20010327	US 2000-481544	20000112
	US 2002068734	A1	20020606	US 2000-734918	20001213
	US 6472391	B2	20021029		
PRAI	JP 1996-260743	A	19960110		
	WO 1997-JP3510	A2	19971001		
	US 1998-88199	A3	19980601		
	US 2000-481544	A3	20000112		

OS MARPAT 134:86277

GI



I



II



AB 1,3-Diazines and related N heterocycles [I; wherein V = O or S; W = 1,4-piperazinediyl or 1,4-homopiperazinediyl which may be substituted with unsubstituted alkyl on the ring; X = N or CR9; Y = N or CR8; Z = N or CR7,

L9 ANSWER 131 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
with at least one of X, Y and Z being N; R1 = H, (un)substituted alkyl, cycloalkyl, aryl, heterocyclyl, etc.; R2 = substituted alkyl, (un)substituted cycloalkyl, aryl, heterocyclyl, etc.; R3, R4, R5, R6 = H, halo, (un)substituted alkyl, NO2, cyano, (un)substituted OH or NH2, etc.; R7, R8 = R1 groups, halo, etc.; R9 = H, CO2H or derivs.] and their pharmacol. acceptable salts are prepd. These compds. inhibit the phosphorylation of PDGF receptors and the abnormal proliferation or migration of cells, and so are effective in preventing or treating cell proliferative diseases such as arteriosclerosis, vascular reocclusion diseases, cancer, and glomerulosclerosis. Thus, 6,7-dimethoxy-4-(1-piperazinyl)quinazoline reacted with Ph isocyanate in refluxing EtOH to give invention compd. II [R = CONHPh] in 44% isolated yield. The analog II [R = Q] showed an IC50 of 0.03 μM for inhibiting the phosphorylation of PDGF receptor in vitro. Pharmaceutical formulations, e.g. tablets contg. II [R = N-(p-nitrophenyl)carbamoyl], were prepd.
IT 22106-33-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 1,3-diazines with platelet-derived growth factor receptor
inhibitory activity)
RN 22106-33-8 CAPLUS
CN Benzoic acid, 4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 132 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:900448 CAPLUS
DN 134:56665
TI Preparation of amide substituted imidazoquinolines as immune response modifiers
IN Coleman, Patrick L.; Crooks, Stephen L.; Lindstrom, Kyle J.; Merrill, Bryon A.; Rice, Michael J.
PA 3M Innovative Properties Company, USA
SO PCT Int. Appl., 170 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000076505	A1	20001221	WO 2000-US15702	20000608
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6451810	B1	20020917	US 2000-589580	20000607
	CA 2376304	AA	20001221	CA 2000-2376304	20000608
	EP 1187613	A1	20020320	EP 2000-950215	20000608
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TR 200103574	T2	20020821	TR 2001-3574	20000608
	JP 2003501466	T2	20030114	JP 2001-502838	20000608
	EE 200100670	A	20030217	EE 2001-670	20000608
	AU 773113	B2	20040520	AU 2000-63349	20000608
	EP 1438958	A1	20040721	EP 2004-4588	20000608
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, CY				
	NZ 515639	A	20041029	NZ 2000-515639	20000608
	BR 2000011448	A	20041214	BR 2000-11448	20000608
	EP 1642580	A1	20060405	EP 2005-21837	20000608
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	NO 2001005503	A	20020208	NO 2001-5503	20011109
	ZA 2001009854	A	20030228	ZA 2001-9854	20011129
	ZA 2001009857	A	20030228	ZA 2001-9857	20011129
	ZA 2001009861	A	20030228	ZA 2001-9861	20011129
	HR 2001000888	A1	20030831	HR 2001-888	20011129
	US 2004029877	A1	20040212	US 2001-27272	20011221
	US 6800624	B2	20041005		
	US 2004204438	A1	20041014	US 2004-826836	20040416
	US 7030131	B2	20060418		
	US 2006106052	A1	20060518	US 2006-275699	20060125
PRAI	US 1999-138365P	P	19990610		
	US 2000-589580	A	20000607		
	US 2000-589216	A	20000607		
	US 2000-589236	A	20000607		
	EP 2000-938205	A3	20000608		

L9 ANSWER 132 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
EP 2000-938211 A3 20000608
WO 2000-US15702 W 20000608
US 2001-166321 A1 20010615
US 2001-27272 A1 20011221
US 2004-826836 A3 20040416
OS MARPAT 134:56665
GI



AB The title compds. [I; R1 = alkylNR3COR4, alkenylNR3COR4 (wherein R4 = (un)substituted aryl, heteroaryl, alkyl, etc.); R2 = H, alkyl, alkenyl, etc.; R = alkyl, alkoxy, halo, CF3; n = 0-4] and their pharmaceutically acceptable salts, useful as immune response modifiers, were prepared
Thus,
reacting 1-(4-aminobutyl)-1H-imidazo[4,5-c]quinolin-4-amine with benzoyl chloride in pyridine afforded the benzamide II which showed the lowest concentration of 0.37 μM to induce interferon in human cells. The compds. I
can induce the biosynthesis of various cytokines (data given for interferon α and TNFα) and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
IT 22106-33-8, 4-(1-Pyrrolyl)benzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of amide substituted imidazoquinolines as immune response modifiers)
RN 22106-33-8 CAPLUS
CN Benzoic acid, 4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 132 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L9 ANSWER 133 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2000:900433 CAPLUS

DN 134:56480

TI Method of inhibiting amyloid protein aggregation, treating Alzheimer's disease, and imaging amyloid deposits using [[(phenylalkyl)phenyl]amino]benzoic acids and analogs

IN Augelli-Szafran, Corinne Elizabeth; Barvian, Mark Robert; Bigge, Christopher Franklin; Glase, Shelly Ann; Hachiya, Shunichiro; Keily, John Steven; Kimura, Takenori; Lai, Yingjie; Sakkab, Annette Theresa; Suto, Mark James; Walker, Lary Craswell; Yasunaga, Tomoyuki; Zhuang, Nian

PA Warner-Lambert Company, USA; Yamanouchi Pharmaceutical Company, Ltd.; et al.

SO PCT Int. Appl., 135 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000076489	A2	20001221	WO 2000-US15071	20000531
WO 2000076489	A3	20020530		
W: AE, AG, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2375551	AA	20001221	CA 2000-2375551	20000531
BR 2000011728	A	20020226	BR 2000-11728	20000531
EP 1225886	A2	20020731	EP 2000-939471	20000531
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
TR 200103551	T2	20021223	TR 2001-3551	20000531
JP 2003504310	T2	20030204	JP 2001-502823	20000531
EE 200100673	A	20030217	EE 2001-673	20000531
NZ 515621	A	20040528	NZ 2000-515621	20000531
AU 775157	B2	20040722	AU 2000-54553	20000531
ZA 2001009794	A	20030701	ZA 2001-9794	20011128
NO 2001005995	A	20020204	NO 2001-5995	20011207
BG 106293	A	20020628	BG 2002-106293	20020109
HR 2002000026	A1	20030831	HR 2002-26	20020110
US 6972287	B1	20051206	US 2002-9611	20020520
US 2004220235	A1	20041104	US 2004-858912	20040602
PRAI US 1999-138550P	P	19990610		
WO 2000-US15071	W	20000531		
US 2002-9611	A3	20020520		

OS MARPAT 134:56480

GI



I



II

AB The invention provides a method of treating Alzheimer's disease using compds. I and their pharmaceutically acceptable salts [wherein: R = H, alkyl, alkanoyl; n = 0-5; R1-R7 = H, halo, OH, (un)substituted NH2 or cyclic amino, CO2H or derivs., NO2, alkoxy, CF3, cyano, (un)substituted OPh, etc.; or R1R2 = OCH2O; R8 = CO2H, tetrazolyl, SO2R9, CONHSO2R9; R9 = H, alkyl, CF3, or Ph; A = CH or N]. Also provided is a method of inhibiting the aggregation of amyloid proteins using I, and a method of imaging amyloid deposits, as well as new compds. Claims further include pharmaceutical formulations containing I. Examples include 163 synthetic examples and 4 bioassays. For instance, title compound II was prepared by a sequence of: (1) reaction of 4-(bromomethyl)-1,2-dichlorobenzene with PPh3 to give a bromophosphorane (i.e., phosphonium salt) (78%); (2) Swern oxidation of 4-(4-nitrophenyl)butan-1-ol to the aldehyde (65%); (3) Wittig reaction of the above 2 products to give an alkene (99%); (4) hydrogenation of the alkene and nitro functions (46%); and (5) lithiation and coupling of the amine with 2-fluoro-5-nitrobenzoic acid (75%). In an assay for inhibition of self-seeded amyloid fibril growth, II had an IC50 of 0.9 μM. A combinatorial methodol. for preparation of I is also described.

IT **313675-38-6P**, 2-[[4-[2-(3,4-Dichlorophenyl)ethyl]phenyl]amino]-5-pyrrol-1-ylbenzoic acid
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation and use of [[(phenylalkyl)phenyl]amino]benzoic acids and analogs as amyloid protein aggregation inhibitors)

RN 313675-38-6 CAPLUS

CN Benzoic acid, 2-[[4-[2-(3,4-dichlorophenyl)ethyl]phenyl]amino]-5-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)

L9 ANSWER 133 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

L9 ANSWER 133 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

I

II

AB The invention provides a method of treating Alzheimer's disease using compds. I and their pharmaceutically acceptable salts [wherein: R = H, alkyl, alkanoyl; n = 0-5; R1-R7 = H, halo, OH, (un)substituted NH2 or cyclic amino, CO2H or derivs., NO2, alkoxy, CF3, cyano, (un)substituted OPh, etc.; or R1R2 = OCH2O; R8 = CO2H, tetrazolyl, SO2R9, CONHSO2R9; R9 = H, alkyl, CF3, or Ph; A = CH or N]. Also provided is a method of inhibiting the aggregation of amyloid proteins using I, and a method of imaging amyloid deposits, as well as new compds. Claims further include pharmaceutical formulations containing I. Examples include 163 synthetic examples and 4 bioassays. For instance, title compound II was prepared by a sequence of: (1) reaction of 4-(bromomethyl)-1,2-dichlorobenzene with PPh3 to give a bromophosphorane (i.e., phosphonium salt) (78%); (2) Swern oxidation of 4-(4-nitrophenyl)butan-1-ol to the aldehyde (65%); (3) Wittig reaction of the above 2 products to give an alkene (99%); (4) hydrogenation of the alkene and nitro functions (46%); and (5) lithiation and coupling of the amine with 2-fluoro-5-nitrobenzoic acid (75%). In an assay for inhibition of self-seeded amyloid fibril growth, II had an IC50 of 0.9 μM. A combinatorial methodol. for preparation of I is also described.

IT **313675-38-6P**, 2-[[4-[2-(3,4-Dichlorophenyl)ethyl]phenyl]amino]-5-pyrrol-1-ylbenzoic acid
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation and use of [[(phenylalkyl)phenyl]amino]benzoic acids and analogs as amyloid protein aggregation inhibitors)

RN 313675-38-6 CAPLUS

CN Benzoic acid, 2-[[4-[2-(3,4-dichlorophenyl)ethyl]phenyl]amino]-5-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)

L9 ANSWER 134 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2000:742057 CAPLUS

DN 133:309791

TI Synthesis, activity and formulations of pharmaceutical compounds for treatment of oxidative stress and/or endothelial dysfunction

IN Del Soldato, Piero

PA Nicox S.A., Fr.

SO PCT Int. Appl., 140 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000061541	A2	20001019	WO 2000-EP3239	20000411
WO 2000061541	A3	20010927		
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, DM, EE, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
IT 1311923	B1	20020320	IT 1999-MI752	19990413
CA 2370425	AA	20001019	CA 2000-2370425	20000411
BR 2000009703	A	20020108	BR 2000-9703	20000411
EP 1169298	A2	20020109	EP 2000-926870	20000411
EP 1169298	B1	20060104		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
JP 2002541236	T2	20021203	JP 2000-610818	20000411
TR 200102928	T2	20021223	TR 2001-2928	20000411
NZ 514270	A	20040227	NZ 2000-514270	20000411
RU 2237057	C2	20040927	RU 2001-127574	20000411
AU 777579	B2	20041021	AU 2000-45474	20000411
AT 315021	E	20060215	AT 2000-926870	20000411
ZA 2001008126	A	20030403	ZA 2001-8126	20011003
NO 2001004928	A	20011213	NO 2001-4928	20011010
US 6987120	B1	20060117	US 2001-926322	20011015
US 2006030605	A1	20060209	US 2005-234084	20050926
PRAI IT 1999-MI752	A	19990413		
WO 2000-EP3239	W	20000411		
US 2001-926322	A3	20011015		

OS MARPAT 133:309791

AB Synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial dysfunction are disclosed. The precursors are such as to meet the pharmacol. test reported in the description.

IT **53597-27-6**, Fendosal
RL: RCT (Reactant); RACT (Reactant or reagent)
(antiinflammatory; synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial dysfunction)

RN 53597-27-6 CAPLUS

CN Benzoic acid, 5-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)

L9 ANSWER 134 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 135 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:742053 CAPLUS
DN 133:310142
TI Synthesis, activity and formulations of pharmaceutical compounds for treatment of oxidative stress and/or endothelial dysfunction
IN Del Soldato, Piero
PA Nicox S.A., Fr.
SO PCT Int. Appl., 159 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000061537	A2	20001019	WO 2000-EP3234	20000411
WO 2000061537	A3	20010927		
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, DM, EE, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
IT 1311924	B1	20020320	IT 1999-MI753	19990413
CA 2370412	AA	20001019	CA 2000-2370412	20000411
BR 2000009702	A	20020108	BR 2000-9702	20000411
EP 1169294	A2	20020109	EP 2000-925203	20000411
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002541233	T2	20021203	JP 2000-610814	20000411
NZ 514267	A	20040625	NZ 2000-514267	20000411
RU 2237657	C2	20041010	RU 2001-127576	20000411
AU 778989	B2	20041223	AU 2000-44001	20000411
ZA 2001008127	A	20030103	ZA 2001-8127	20011003
NO 2001004927	A	20011213	NO 2001-4927	20011010
US 6869974	B1	20050322	US 2001-926326	20011015
US 2005261242	A1	20051124	US 2004-24857	20041230
PRAI IT 1999-MI753	A	19990413		
WO 2000-EP3234	W	20000411		
US 2001-926326	A3	20011015		

OS MARPAT 133:310142
AB Compds. A-B-C-N(O)s and A-C1[N(O)s]-B1 or their salts [s is an integer 1 or 2, preferably s = 2; A is the radical of a drug and is such as to meet the pharmacol. tests reported in the description; C and C1 are two bivalent radicals; the precursors of the radicals B and B1 are such as to meet the pharmacol. test reported in the description] were prepared for use as pharmaceuticals. Thus, (S,S)-N-acetyl-S-(6-methoxy-α-methyl-2-naphthalenylacetyl)cysteine 4-nitroxybutyl ester was prepared (NCX 2101) from naproxene and N-acetylcysteine in the first of 28 synthetic examples given. Pharmacol. test examples and tabular data are also given.
IT 53597-27-6, Fendosal
RL: RCT (Reactant); RACT (Reactant or reagent)
(drug precursor)
RN 53597-27-6 CAPLUS
CN Benzoic acid, 5-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)

L9 ANSWER 135 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 136 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:441768 CAPLUS
DN 133:74324
TI Preparation of amino acid sulfonamide hydroxamates as inhibitors of procollagen C-proteinase.
IN Billedeau, Roland Joseph; Broka, Chris Allen; Campbell, Jeffrey Allen; Chen, Jian Jeffrey; Dankwardt, Sharon Marie; Delaet, Nancy; Robinson, Leslie Ann; Walker, Keith Adrian Murray
PA F. Hoffmann-La Roche A.-G., Switz.
SO PCT Int. Appl., 133 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000037436	A1	20000629	WO 1999-EP9920	19991214
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2355902	AA	20000629	CA 1999-2355902	19991214
BR 9916504	A	20010911	BR 1999-16504	19991214
EP 1149072	A1	20011031	EP 1999-963530	19991214
EP 1149072	B1	20040630		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200101868	T2	20011121	TR 2001-200101868	19991214
JP 2002533322	T2	20021008	JP 2000-589508	19991214
AU 769319	B2	20040122	AU 2000-19792	19991214
NZ 512292	A	20040326	NZ 1999-512292	19991214
AT 270271	E	20040715	AT 1999-963530	19991214
RU 2232751	C2	20040720	RU 2001-119461	19991214
US 6492394	B1	20021210	US 1999-469660	19991222
HR 2001000443	A1	20020630	HR 2001-443	20010614
ZA 2001005014	A	20020919	ZA 2001-5014	20010619
NO 2001003100	A	20010821	NO 2001-3100	20010621
US 2003199520	A1	20031023	US 2002-267292	20021009
US 6844366	B2	20050118		
US 2003216405	A1	20031120	US 2002-267727	20021009
US 6787559	B2	20040907		
PRAI US 1998-113311P	P	19981222		
US 1999-147053P	P	19990803		
US 1999-164138P	P	19991108		
WO 1999-EP9920	W	19991214		
US 1999-469660	A3	19991222		

OS MARPAT 133:74324
AB HOHNCOCHR1NRSO2Ar2 [R1 = alkyl, haloalkyl, heteroalkyl, cycloalkyl, aryl, aralkyl, aralkenyl, heteroaryl, heteroaralkyl, aminl, aryl, aralkyl, etc.; R = CHR2Ar1, CHR2CH:CHAr1; Ar2 = specified (substituted) Ph, naphthyl; R2 = H, alkyl; with provisos], were prepared Thus, N-hydroxy-2(R)-[(3,4-methylenedioxybenzyl)(4-methoxy-2,3,6-trimethylbenzenesulfonyl)amino]-3-methylbutyramide was prepared by solution phase synthesis from BOC-D-Val-OH.
Title compds. inhibited procollagen C-proteinase with IC50 0.01-2 μM.
IT 10333-68-3

L9 ANSWER 136 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of amino acid sulfonamide hydroxamates as inhibitors of procollagen C-proteinase)
RN 10333-68-3 CAPLUS
CN Benzoic acid, 2-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 137 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB H2NCR1R2ZCH2CHR3CHR4NR8COR5 [R1,R2 = H; R1R2 = NR9; R3 = H, COR6, CO2R6, CON(R6)2, CH2OR7, CH2SR7; R4 = H, (hydroxy)alkyl, aminoalkyl, (CH2CH2)nR, (CH:CH)nR, CH2R; R = (un)substituted (hetero)aryl; R5 = (ar)alk(en)yl, heterocyclyl, (hetero)aryl, etc.; R6,R8 = H or alkyl; R7 = H, alkyl, acyl, (hetero)aryl, etc.; R9 = H, OH, alkoxy(carbonyl), alkanoyl, etc.; Z = phenylene; n = 0-2] were prepared as factor Xa inhibitors (no data). Thus, 4-(NC)C6H4CH:CHCO2Me was cyclocondensed with 4-(MeO)C6H4N:CHCH:CHPh (preparation each given) to give, after N-deprotection, β-lactam I. The latter was N-acylated by 4-PhC6H4COCl and the product hydrolyzed to give, after amination/esterification, title compound II.
IT 22106-33-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of α-amidinobenzyl-β-(aroylamino)alkanoates and analogs as factor Xa inhibitors)
RN 22106-33-8 CAPLUS
CN Benzoic acid, 4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 137 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:433346 CAPLUS
DN 133:73861
TI Preparation of α-amidinobenzyl-β-(aroylamino)alkanoates and analogs as factor Xa inhibitors
IN Klein, Scott I.; Guertin, Kevin R.; Spada, Alfred P.
PA Aventis Pharmaceuticals Products, Inc., USA
SO U.S., 118 pp., Cont.-in-part of U.S. 9724118.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6080767	A	20000627	US 1997-884405	19970627
	WO 9724118	A1	19970710	WO 1996-US20770	19961223
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2264556	AA	19990107	CA 1998-2264556	19980626
	WO 9900356	A1	19990107	WO 1998-US13550	19980626
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9881771	A1	19990119	AU 1998-81771	19980626
	AU 741173	B2	20011122		
	EP 931060	A1	19990728	EP 1998-931728	19980626
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				
	BR 9806060	A	19990831	BR 1998-6060	19980626
	JP 2001500532	T2	20010116	JP 1999-505870	19980626
	AP 1061	A	20020424	AP 1999-1467	19980626
	W: GH, GM, KE, LS, MW, SD, SZ, UG, ZW				
	PL 191115	B1	20060331	PL 1998-331985	19980626
	ZA 9805664	A	19990113	ZA 1998-5664	19980629
	NO 9900854	A	19990423	NO 1999-854	19990223
	NO 314758	B1	20030519		
	US 6323227	B1	20011127	US 1999-259528	19990226
	US 6277865	B1	20010821	US 1999-273618	19990322
	HK 1022685	A1	20060127	HK 2000-101706	20000321
PRAI	US 1996-9485P	P	19960102		
	WO 1996-US20770	A2	19961223		
	US 1997-884405	A	19970627		
	US 1998-79002P	P	19980323		
	WO 1998-US13550	W	19980626		

OS MARPAT 133:73861
GI

L9 ANSWER 138 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:421138 CAPLUS
DN 133:58814
TI Preparation of piperazines for treating or preventing tachykinin-mediated diseases
IN Take, Kazuhiko; Konishi, Nobukiyo; Shigenaga, Shinji; Kayakiri, Natsuko; Azami, Hidenori; Eikyu, Yoshiteru; Nakai, Kazuo; Ishida, Junya; Morita, Masataka
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 245 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000035915	A1	20000622	WO 1999-JP6943	19991210
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2354875	AA	20000622	CA 1999-2354875	19991210
	EP 1140924	A1	20011010	EP 1999-959751	19991210
	EP 1140924	B1	20060322		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
	TR 200101649	T2	20011022	TR 2001-200101649	19991210
	BR 9917047	A	20020730	BR 1999-17047	19991210
	JP 2002532499	T2	20021002	JP 2000-588175	19991210
	JP 3454427	B2	20031006		
	JP 2003238563	A2	20030827	JP 2003-23481	19991210
	AU 768652	B2	20031218	AU 2000-16837	19991210
	RU 2258068	C2	20050810	RU 2001-119451	19991210
	TW 509688	B	20021111	TW 1999-88121878	19991214
	ZA 2001004597	A	20020905	ZA 2001-4597	20010605
	HK 1043998	A1	20050318	HK 2002-105609	20020730
	AU 2004201111	A1	20040422	AU 2004-201111	20040316
	US 2006014948	A1	20060119	US 2004-968473	20041020
PRAI	AU 1998-7706	A	19981214		
	AU 1999-3568	A	19991021		
	AU 1999-568	A	19991021		
	JP 2000-588175	A3	19991210		
	WO 1999-JP6943	W	19991210		
	US 2001-857869	B1	20010612		

OS MARPAT 133:58814
GI

L9 ANSWER 138 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I II

AB The title compds. [I; Y = bond, alkylene; R1 = (un)substituted aryl; R2 = (un)substituted aryl; R3 = H, alkyl; R4 = (3-pyridyl)alkyl, (3-pyridyl)alkenyl; thiazolylalkyl, etc.] and their pharmaceutically acceptable salts, useful for treating or preventing tachykinin-mediated diseases in human being or animals, were prepared E.g., the piperazine cis-II.2HCl showed more than 80% inhibition of 125I-BH-Substance P binding to h-NK1 receptors at 1 mg/kg, and 100% inhibition of emesis in the dog at 0.32 mg/kg.

IT **276861-97-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of piperazines for treating or preventing tachykinin-mediated diseases)

RN 276861-97-3 CAPLUS

CN Benzoic acid, 3-(1H-pyrrol-1-yl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 139 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2000:384166 CAPLUS

DN 133:30740

TI Preparation of benzamides as ApoB-100 secretion inhibitors

IN Daugan, Alain Claude-marie

PA Glaxo Group Limited, UK

SO PCT Int. Appl., 94 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000032582	A1	20000608	WO 1999-EP9320	19991201
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2353394	AA	20000608	CA 1999-2353394	19991201
	BR 9915895	A	20010821	BR 1999-15895	19991201
	EP 1135378	A1	20010926	EP 1999-959369	19991201
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI				
	TR 200101513	T2	20011022	TR 2001-200101513	19991201
	AU 750259	B2	20020711	AU 2000-16566	19991201
	JP 2002531444	T2	20020924	JP 2000-585224	19991201
	NZ 511481	A	20031128	NZ 1999-511481	19991201
	CN 1131222	B	20031217	CN 1999-815925	19991201
	TW 515796	B	20030101	TW 1999-88121321	19991206
	ZA 2001003680	A	20020614	ZA 2001-3680	20010507
	US 6552022	B1	20030422	US 2001-831844	20010515
	NO 2001002688	A	20010531	NO 2001-2688	20010531
PRAI	GB 1998-26412	A	19981203		
	WO 1999-EP9320	W	19991201		

OS MARPAT 133:30740

GI

L9 ANSWER 139 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB The title compds. [I; A = N, CH; X = (un)substituted alkylene (optionally containing one or two double bonds), O, SO2, etc.; Z = a direct link, (un)substituted alkylene (optionally containing one double bond); R1 = H, perfluoroalkyl, aryl, etc.; Y = a direct or oxy link, alkylene, etc.; R2 = (un)substituted Ph, cycloalkyl, heterocyclyl; R3 = H, halo, alkyl, etc.}, useful in the treatment of conditions mediated by ApoB-100 regulation, were prepared and formulated. Thus, reacting 4-[4-(3-cyanobenzyl)piperazin-1-yl]phenylamine with 4'-trifluoromethylbiphenyl-2-carboxylic acid (prepns. given) in the presence of HOBt, Et3N and EDCl in CH2Cl2 afforded benzamide II which showed IC50 of 13 nM against ApoB-100 and ApoA-1 secretion.

IT **10333-68-3**, 2-Pyrrol-1-ylbenzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of benzamides as ApoB-100 secretion inhibitors)

RN 10333-68-3 CAPLUS

CN Benzoic acid, 2-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 140 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:356164 CAPLUS
DN 133:805
TI Benzimidazole derivatives as neovascularization inhibitors and pharmaceutical compositions containing them
IN Kubo, Keiji; Hori, Akira; Kusaka, Masami
PA Takeda Chemical Industries, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 77 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2000143635	A2	20000526	JP 1999-158035	19990604
PRAI	JP 1998-162489	A	19980610		
	JP 1998-246689	A	19980901		

OS MARPAT 133:805
GI



I

AB Neovascularization inhibitors contain the derivs. I [ring A = (un)substituted phenyl; ring B = (un)substituted cyclyl; R4, R6 = (1) H, (ii) C1-6 alkyl which may have substituents selected from mono- or di(C1-6 alkyl)amino, 5-7-membered cyclic amino, CO2H, or C2-7 alkoxycarbonyl, (iii) C2-6 alkenyl, (iv) C3-7 cycloalkyl, (v) C7-13 aralkyl which may have 1-5 substituents selected from halo, C1-6 alkoxy, C1-6 alkyl, mono- or di(C1-6 alkyl)amino, (vi) C2-7 alkoxycarbonyl; R5 = (i) H, (ii) halo, (iii) C1-6 alkyl which may have substituents selected from mono- or di(C1-6 alkyl)amino and halo, (iv) C1-6 alkoxy, (v) C2-7 alkoxycarbonyl, (vi) mono- or di(C1-6 alkyl)amino, (vii) carbamoyl which may be substituted with C1-6 alkyl or C7-13 aralkyl; X = (i) direct bond, (ii) C1-6 alkylene, (iii) C2-6 alkenylene, (iv) C1-6 alkylene-aminocarbonyl, (v) C1-6 alkylene-oxycarbonylamino; Y = CO, SO2, NHCO, C1-6 alkylenecarbonyl, C2-6 alkenylenecarbonyl, C1-6 alkylene] or their pharmaceutically acceptable salts. Also claimed are pharmaceutical compns. containing I or their salts for treatment of neoplasm, inflammatory diseases, diabetic retinopathy, etc. IC50 of 2-(4-methoxyphenyl)-5-[3-methoxy-4-(4-pyridyl)methoxybenzoyl]aminobenzimidazole (preparation given) against recombinant VEGF-induced proliferation of HUVEC was 0.012 μM.
IT 22106-33-8, 4-(Pyrrol-1-yl)benzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of benzimidazole compds. as neovascularization inhibitors)
RN 22106-33-8 CAPLUS

L9 ANSWER 140 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzoic acid, 4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



L9 ANSWER 141 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:335406 CAPLUS
DN 132:347492
TI Preparation of 2-aminopyridine derivatives as nitric oxide synthase inhibitors
IN Cook, Anthony; Hamley, Peter; Tinker, Alan
PA Astrazeneca UK Limited, UK; Astrazeneca AB
SO PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000027842	A1	20000518	WO 1999-SE1988	19991103
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1124821	A1	20010822	EP 1999-971807	19991103
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002529463	T2	20020910	JP 2000-581020	19991103
PRAI	SE 1998-3773	A	19981105		
	WO 1999-SE1988	W	19991103		

OS MARPAT 132:347492
GI



I



II

L9 ANSWER 141 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

AB The title compds. [I; X = (CR6R7)n; R1 = H, alkyl, alkoxy, etc.; R2-R7 = H, alkyl; R2 and R4 joined together = (CH2)m; Y = H, alkyl; R2 and Y joined together = (CH2)p; R4 and Y joined together = (CH2)p; Y is joined to the ortho position of ring A and represents (CH2)r; Z = a bond, CH2; Q = H, alkyl, alkoxy, etc.; A = Ph, naphthyl, 5-membered heteroaryl containing 1-3 heteroatoms selected from O, S or N, etc.; m = 0-5; n = 0-3; p = 0-4; r = 0-3] and their pharmaceutically acceptable salts, useful in the treatment or prophylaxis of inflammatory disease and pain, were prepared E.g., a 3-step synthesis of II.HCl which showed IC50 of < 25 μM against nitric oxide synthase, was given.
IT 22106-33-8, 4-(1H-Pyrrol-1-yl)benzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 2-aminopyridine derivs. as nitric oxide synthase inhibitors)
RN 22106-33-8 CAPLUS
CN Benzoic acid, 4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 142 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:214835 CAPLUS
DN 132:265201
TI Preparation of imidazole derivatives as gonadotropin-releasing hormone antagonists
IN Suzuki, Nobuhiro; Takekawa, Shiro; Kubo, Keiji; Imaeda, Yasuhiro
PA Takeda Chemical Industries, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 79 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2000095767	A2	20000404	JP 1998-273013	19980928
PRAI JP 1998-273013		19980928		

OS MARPAT 132:265201
GI



I

AB Claimed are gonadotropin-releasing hormone (GnRH) antagonists containing the title compds. [I; ring A = (un)substituted Ph; ring B = (un)substituted cyclic group; R4 , R6 = H, (un)substituted C1-6 alkyl, C2-6 alkenyl, C3-7 cycloalkyl, (un)substituted C7-13 aralkyl, C2-7 alkoxycarbonyl; R5 = H, halo, (un)substituted C1-6 alkyl, C1-6 alkoxy, C2-7 alkoxycarbonyl, etc.; X = bond, C1-6 alkylene, C2-6 alkenylene, C1-6 alkylene-NHCO, C1-6 alkylene-O2NH; Y = CO, SO2, NHCO, C1-6 alkylene-CO, C2-6 alkylene-CO, C1-6 alkylene] or pharmacol. acceptable salts thereof. These compds. are useful for the treatment or prevention of gonadotropin-releasing hormone-related diseases such as sex hormone-dependent cancer, prostate cancer, uterine cancer, breast cancer, prostatic hypertrophy, true precocious puberty, endometriosis, hysteromyoma, pregnancy regulators, and menstruation regulators. Thus, 5-amino-2-(4-methoxyphenyl)benzimidazole was condensed with 4-pyrrolidinobenzoic acid using di-Et cyanophosphate in the presence of Et3N and 4-dimethylaminopyridine in DMF at room temperature for 1 h to give 41% 2-(4-methoxyphenyl)-5-((4-pyrrolidinobenzoyl)amino)benzimidazole (II). II in vitro showed IC50 of μg/mL for inhibiting the binding of [125I]leuprolelin to a membrane sample of CHO cell expressing human GnRH receptor.
IT **22106-33-8**, 4-(Pyrrol-1-yl)benzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of imidazole derivs. as gonadotropin-releasing hormone

L9 ANSWER 142 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
antagonists for drugs)
RN 22106-33-8 CAPLUS
CN Benzoic acid, 4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



L9 ANSWER 143 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:464267 CAPLUS
DN 131:116517
TI Preparation of N-acyl-phenylalanine derivatives as inhibitors of α4-mediated cell adhesion
IN Sircar, Ila; Gudmundsson, Kristjan S.; Martin, Richard
PA Tanabe Seiyaku Co., Ltd., Japan
SO PCT Int. Appl., 243 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9936393	A1	19990722	WO 1999-US993	19990119
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2318527	AA	19990722	CA 1999-2318527	19990119
AU 9924584	A1	19990802	AU 1999-24584	19990119
AU 749568	B2	20020627		
BR 9907040	A	20001017	BR 1999-7040	19990119
EP 1049662	A1	20001108	EP 1999-904115	19990119
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002509131	T2	20020326	JP 2000-540111	19990119
JP 3634749	B2	20050330		
NZ 506081	A	20030228	NZ 1999-506081	19990119
TW 591007	B	20040611	TW 1999-88100776	19990119
SG 118147	A1	20060127	SG 2002-200204434	19990119
US 6521666	B1	20030218	US 2000-619712	20000719
US 2003191118	A1	20031009	US 2002-286777	20021104
US 6855843	B2	20050215		
JP 2005002116	A2	20050106	JP 2004-202046	20040708
PRAI US 1998-71840P	P	19980120		
JP 2000-540111	A3	19990119		
WO 1999-US993	W	19990119		
US 2000-619712	A3	20000719		

OS MARPAT 131:116517
GI For diagram(s), see printed CA Issue.
AB The present invention relates to a pharmaceutical composition comprising as an active ingredient a compound of formula [I; wherein ring A is an aromatic or a heterocyclic ring; Q is a bond, carbonyl, lower alkylene optionally substituted by HO or Ph, lower alkenylene, or -O-(lower alkylene)-; n is 0, 1 or 2; Z is oxygen or sulfur; W is oxygen, sulfur, -CH:CH-, -NH- or -N:CH-; R1, R2 and R3 are the same or different and are hydrogen, halogen, hydroxyl, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted lower alkoxy group, a substituted or unsubstituted amino group, CO2H or an amide or an ester thereof, cyano, lower alkylthio, lower alkanesulfonyl, substituted or unsubstituted SO2NH2, etc.; R4 is tetrazolyl, carboxyl group, amide or ester; R5 is hydrogen, nitro, amino, hydroxyl, lower alkanoyl, lower alkyl, etc.; R6 is selected from (a) a

L9 ANSWER 143 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
substituted or unsubstituted Ph group, (b) a substituted or unsubstituted pyridyl group, (c) a substituted or unsubstituted thienyl group, (d) a substituted or unsubstituted benzofuranyl group, etc.; or a pharmaceutically acceptable salt thereof]. These phenylalanine derivs. are useful for treating or preventing conditions caused by α4-mediated cell adhesion such as rheumatoid arthritis, asthma, psoriasis, eczema, contact dermatitis and other skin inflammatory diseases, diabetes, multiple sclerosis, systemic lupus erythematosus (SLE), inflammatory bowel disease including ulcerative colitis and Crohn's disease, and other diseases involving leukocyte infiltration of the gastrointestinal tract, or other epithelial lined tissues, such as skin, urinary tract, respiratory airway, and joint synovium. N-(tert-butoxycarbonyl)-O-(trifluoromethanesulfonyl)-L-tyrosine Me ester (prepn. given) was coupled with 2-methoxybenzene boronic acid in toluene/DMF in the presence of K2CO3 and Pd(PPh3)4 at 80 °C for 24 h to give N-(tert-butoxycarbonyl)-4-(2-methoxyphenyl)-L-phenylalanine Me ester. The latter compd. was treated with CF3CO2H in CH2Cl2 for 1.5 h to remove the Boc group and then condensed with 2,6-dichlorobenzoyl chloride in the presence of diisopropylethylamine at room temp. for 24 h to give N-(2,6-dichlorobenzoyl)-4-(2-methoxyphenyl)-L-phenylalanine Me ester (II) which was sapond. with LiOH in THF/MeOH at room temp. for 3 h, evapd., treated with H2O, adjusted Ph 2, and extd. with EtOAc to give N-(2,6-dichlorobenzoyl)-4-(2-methoxyphenyl)-L-phenylalanine (III). II and III in vitro inhibited at IC50 of 1≥ and 0.3≥ μM, resp., β7-mediated cell adhesion which measured the adhesive interactions of a B-cell line, RPMI, known to express α4β7, to the alternatively spliced region of fibronectin referred to as CS-1, in the presence of test compds.
IT **232275-65-9P 232275-67-1P 232275-69-3P 232275-71-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-acyl-phenylalanine derivs. as inhibitors of α4-mediated cell adhesion for prevention and treatment of diseases caused by α4-mediated cell adhesion)
RN 232275-65-9 CAPLUS
CN Benzoic acid, 2-chloro-4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 232275-67-1 CAPLUS
CN Benzoic acid, 2-chloro-4-[2-(trifluoroacetyl)-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 143 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 232275-69-3 CAPLUS
CN Benzoic acid, 2-chloro-4-(2,5-dichloro-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 232275-71-7 CAPLUS
CN Benzoic acid, 2-chloro-4-(2-formyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 144 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
NO2 or they are combined together to form a 3- to 6-membered ring; and Ar represents a (un)substituted 5- to 6-membered heteroaryl group] are prepd.
having NOS inhibitory activities, and being useful as medicines such as a remedy for cerebrovascular disorder,. Also claimed are (a) therapeutics for brain vascular disorders such as cerebral hemorrhage, sub-arachnoid hemorrhage, cerebral infarction, atherothrombotic infarction, lacunar infarction, embolism, transient ischemic attack (TIA), cerebral edema, and
cerebral trauma, spinal injury, Parkinson's disease, Alzheimer's disease, and morphine resistance and dependence, (b) anticonvulsants, and (c) analgesics for headache, migraine, tension-type headache, cluster headache, and chronic paroxysmal headache contg. I as the active ingredients. Thus,
N-[3-[bis(tert-butoxycarbonyl)aminomethyl]-4-(pyrrol-1-yl)phenyl]thiourea was heated with Et iodide in acetone under reflux for 14 h followed by treatment with 4 N aq. HCl to give N-(3-aminomethyl-4-(pyrrol-1-yl)phenyl]-S-ethylisothiourea dihydrochloride (II). II showed IC50 of 3.7, 1,920, and 7,930 nM against NOS isoforms, i.e. nNOS (type 1),
eNOS (type 2), and iNOS (type 3), resp.
IT 55540-36-8P, 5-Nitro-2-(pyrrol-1-yl)benzoic acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-(heterocyclylphenyl)isothiourea and -isoureas having nitric oxide synthase (NOS) inhibitory activities as therapeutics)
RN 55540-36-8 CAPLUS
CN Benzoic acid, 5-nitro-2-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 144 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:311182 CAPLUS
DN 130:338112
TI Preparation of N-(heterocyclylphenyl)isothiourea and -isoureas having nitric oxide synthase (NOS) inhibitory activities
IN Makino, Toshihiko
PA Chugai Seiyaku Kabushiki Kaisha, Japan
SO PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9923069	A1	19990514	WO 1998-JP4967	19981104
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	TW 460460	B	20011021	TW 1998-87118206	19981102
	CA 2307581	AA	19990514	CA 1998-2307581	19981104
	CA 2307581	C	20051018		
	AU 9897614	A1	19990524	AU 1998-97614	19981104
	AU 737967	B2	20010906		
	EP 1043312	A1	20001011	EP 1998-951681	19981104
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	US 6414005	B1	20020702	US 2000-530752	20000504
	HK 1034511	A1	20060224	HK 2001-104945	20010716
PRAI	JP 1997-339267	A	19971104		
	JP 1998-146492	A	19980420		
	WO 1998-JP4967	W	19981104		

OS MARPAT 130:338112
GI



AB Compds. represented by general formula [I; wherein R1 represents (un)substituted aminoalkyl; R2 represents hydrogen, lower alkyl, or halo; R3 represents SR4 OR4, or NR5R6; wherein R4 represents lower alkyl or (un)substituted lower alkyl; R5 and R6 represent hydrogen, lower alkyl, or

L9 ANSWER 145 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:222935 CAPLUS
DN 130:267423
TI Preparation of N-(2-thiazolyl)indole-2-carboxamides and analogs as CCK-A receptor agonists
IN Brodin, Roger; Boigegrain, Robert; Bignon, Eric; Molimard, Jean-Charles; Olliero, Dominique
PA Sanofi, Fr.
SO PCT Int. Appl., 121 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9915525	A1	19990401	WO 1998-FR2007	19980918
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	FR 2768737	A1	19990326	FR 1997-11718	19970919
	FR 2768737	B1	20000519		
	FR 2777887	A1	19991029	FR 1998-5106	19980423
	FR 2777887	B3	20000707		
	ZA 9807961	A	19990407	ZA 1998-7961	19980901
	CA 2304397	AA	19990401	CA 1998-2304397	19980918
	AU 9891705	A1	19990412	AU 1998-91705	19980918
	AU 746707	B2	20020502		
	EP 1017693	A1	20000712	EP 1998-944024	19980918
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9812653	A	20000822	BR 1998-12653	19980918
	EE 200000168	A	20010416	EE 2000-168	19980918
	TW 430664	B	20010421	TW 1998-87115602	19980918
	TR 200001218	T2	20010521	TR 2000-200001218	19980918
	JP 2001517667	T2	20011009	JP 2000-512830	19980918
	JP 3456970	B2	20031014		
	NZ 503339	A	20020328	NZ 1998-503339	19980918
	IL 134961	A1	20020725	IL 1998-134961	19980918
	NO 2000001409	A	20000516	NO 2000-1409	20000317
	NO 314455	B1	20030324		
	HR 2000000153	A1	20010430	HR 2000-153	20000317
	BG 104254	A	20010831	BG 2000-104254	20000317
	US 6380230	B1	20020430	US 2000-508830	20000602
PRAI	FR 1997-11718	A	19970919		
	FR 1998-5106	A	19980423		
	WO 1998-FR2007	W	19980918		

OS MARPAT 130:267423
GI



L9 ANSWER 145 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

AB Title compds. (I; R = NHCOR3; R1 = MeO2; R2 = R7CH2, R7CH2S, R7SCH2, etc.; R3 = e.g., Z1(CH2)nR15 or Z1(CH2)mC6H4R15; R7 = (di)(methyl)cycloalkyl; R15 = CO2H or alkoxycarbonyl; Z = (un)substituted 1,2-phenylene; Z1 = (un)substituted indole-2,1-diyl; m = 0 or 1; n = 1-5] were prepared Thus, I (R1 = 2,5-dimethoxy-4-methylphenyl, R2 = 2-cyclohexylethyl)(II; R = NH2) was amidated by 1-tert-butoxycarbonylmethyl-5-methylindole-2-carboxylic acid (preparation each given) to give, after saponification, II (R = NHCOZ1CH2CO2H, Z1 = 5-methylindole-2,1-diyl). Data for biol. activity of I were given.

IT **221671-71-2P 221671-73-4P 221671-74-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(2-thiazolyl)indole-2-carboxamides and analogs as CCK-A receptor agonists)

RN 221671-71-2 CAPLUS
CN Benzoic acid, 3-[2-[[[5-(2-cyclohexylethyl)-4-(2,5-dimethoxy-4-methylphenyl)-2-thiazolyl]amino]carbonyl]-1H-indol-1-yl]- (9CI) (CA INDEX NAME)



RN 221671-73-4 CAPLUS
CN Benzoic acid, 2-[2-[[[5-(2-cyclohexylethyl)-4-(2,5-dimethoxy-4-methylphenyl)-2-thiazolyl]amino]carbonyl]-1H-indol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 145 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 221671-74-5 CAPLUS
CN Benzoic acid, 2-[2-[[[5-(2-cyclohexylethyl)-4-(2,5-dimethoxy-4-methylphenyl)-2-thiazolyl]amino]carbonyl]-1H-indol-1-yl]-, monosodium salt (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 146 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:682113 CAPLUS
DN 129:299893
TI Means of ascertaining an individual's risk profile for atherosclerotic disease based on systemic inflammation marker levels
IN Ridker, Paul; Hennekens, Charles H.
PA Brigham and Women's Hospital, Inc., USA
SO PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9843630	A1	19981008	WO 1998-US6613	19980402
	W: AU, CA, JP				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2285091	AA	19981008	CA 1998-2285091	19980402
	AU 9871008	A1	19981022	AU 1998-71008	19980402
	EP 1003501	A1	20000531	EP 1998-917992	19980402
	EP 1003501	B1	20050309		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2001525058	T2	20011204	JP 1998-542023	19980402
	JP 2003128582	A2	20030508	JP 2002-220353	19980402
	EP 1493439	A1	20050105	EP 2004-10424	19980402
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	AT 290375	E	20050315	AT 1998-917992	19980402
	PT 1003501	T	20050729	PT 1998-917992	19980402
	ES 2239801	T3	20051001	ES 1998-917992	19980402
PRAI	US 1997-41950P	P	19970402		
	US 1997-43039P	P	19970402		
	US 1998-70894P	P	19980109		
	EP 1998-917992	A3	19980402		
	JP 1998-542023	A3	19980402		
	WO 1998-US6613	W	19980402		

AB The invention involves methods for characterizing an individual's risk profile of developing a future cardiovascular disorder by obtaining a level of the marker of systemic inflammation in the individual. The invention also involves methods for evaluating the likelihood that an individual will benefit from treatment with an agent for reducing the risk of future cardiovascular disorder. The primary basis for this invention is evidence from the Physicians' Health Study, a large scale, randomized, double-blind, placebo-controlled trial of aspirin and β-carotene in the primary prevention of cardiovascular disease conducted among 22,000 apparently healthy men. In that trial, baseline level of C-reactive protein, a marker for underlying systemic inflammation, was found to determine the future risk of myocardial infarction and stroke, independent of a large series of lipid and non-lipid risk factors. Baseline C-reactive protein level was not associated with venous thrombosis, a vascular event generally not associated with atherosclerosis. Further, the data indicate that the magnitude of benefit that apparently healthy individuals can expect from prophylactic aspirin is dependent in large part upon baseline level of C-reactive protein.

IT **53597-27-6**, Fendosal
RL: BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(systemic inflammation marker level in evaluation of cardiovascular disorder risk redn. by)

L9 ANSWER 146 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 53597-27-6 CAPLUS
CN Benzoic acid, 5-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 147 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:604906 CAPLUS
DN 129:216422
TI Preparation of N-(ar)alkyl-4-(hetero)arylbenzamides and analogs as class III antiarrhythmic agents
IN Lloyd, John; Rovnyak, George C.; Stein, Philip D.; Ahmad, Saleem; Atwal, Karnail S.; Caulfield, Thomas J.; Poss, Michael A.
PA Bristol-Myers Squibb Co., USA
SO PCT Int. Appl., 143 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9837068	A1	19980827	WO 1998-US2364	19980206
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9863209	A1	19980909	AU 1998-63209	19980206
	US 2002137968	A1	20020926	US 2001-973826	20011010
	US 6624309	B1	20030923	US 2002-254398	20020925
PRAI	US 1997-38811P	P	19970221		
	US 1998-8825	B1	19980120		
	WO 1998-US2364	W	19980206		
	US 1999-468648	A1	19991221		
	US 2001-973826	B1	20011010		

OS MARPAT 129:216422
AB R2ZC(:X)NHR1 [R1 = (cyclo)alkyl, heterocyclyl, aryl, etc.; R2 = heterocyclyl, aryl; X = O, S, (alkyl)imino, NCN, etc.; Z = bond, C:C (sic), NH] were prepared as class III antiarrhythmic agents (no data). Thus, 2,2-dimethylcyclopentanone was treated with 4-MeC6H4SO2CH2NC and the reduced product amidated by 4-(BuCH2CH2O)C6H4COCl to give 4-(BuCH2CH2O)C6H4CONHR1 (R1 = 2,2-dimethylcyclopentylmethyl).
IT 71935-16-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-(ar)alkyl-4-(hetero)arylbenzamides and analogs as class III antiarrhythmic agents)
RN 71935-16-5 CAPLUS
CN Benzoic acid, 4-(1H-indol-1-yl)- (9CI) (CA INDEX NAME)

L9 ANSWER 147 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 148 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:527297 CAPLUS
DN 129:161184
TI Preparation of fatty acyl and alkyl derivatives of drugs and agrochemicals
IN Myhren, Finn; Borretzen, Bernt; Dalen, Are; Sandvold, Marit Liland
PA Norsk Hydro Asa, Norway
SO PCT Int. Appl., 128 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9832718	A1	19980730	WO 1998-NO21	19980123
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	GB 2321455	A1	19980729	GB 1997-1441	19970124
	ZA 9800579	A	19980723	ZA 1998-579	19980123
	CA 2276694	AA	19980730	CA 1998-2276694	19980123
	AU 9857828	A1	19980818	AU 1998-57828	19980123
	AU 733370	B2	20010510		
	EP 977725	A1	20000209	EP 1998-901593	19980123
	EP 977725	B1	20040616		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
	NZ 336724	A	20010629	NZ 1998-336724	19980123
	JP 2001522351	T2	20011113	JP 1998-531863	19980123
	RU 2227794	C2	20040427	RU 1999-118313	19980123
	AT 269292	E	20040715	AT 1998-901593	19980123
	ES 2224356	T3	20050301	ES 1998-901593	19980123
	IL 130853	A1	20050320	IL 1998-130853	19980123
	SK 284803	B6	20051103	SK 1999-1003	19980123
	TW 231209	B1	20050421	TW 1998-87103693	19980313
	NO 9903563	A	19990917	NO 1999-3563	19990721
	US 2001006962	A1	20010705	US 1999-355111	19990927
	US 2003153544	A1	20030814	US 2002-116358	20020405
	US 6762175	B2	20040713		
	US 2004063677	A1	20040401	US 2003-662441	20030916
PRAI	GB 1997-1441	A	19970124		
	WO 1998-NO21	W	19980123		
	US 1999-355111	B1	19990927		
	US 2002-116358	A1	20020405		

AB The properties of biol. active compds., for example drugs and agrochems. which contain in their mol. structure ≥1 functional groups selected from alc., ether, Ph, amino, amido, thiol, carboxylic acid, and carboxylic acid ester groups are modified by replacing one or more of these functional groups by a lipophilic group selected from those of the formula RCOO-, RCONH-, RCOS-, RCH2O-, RCH2NH-, -COOCH2R, -CONHCH2R and -SCH2R, (R = a lipophilic moiety selected from cis-8-heptadecenyl, trans-8-heptadecenyl, cis-10-nonadecenyl and trans-10-nonadecenyl). Data for biol. activity of title compds. were given.
IT 53597-27-6DP, Fendosal, lipophilic derivative
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of fatty acyl and alkyl derivs. of drugs and agrochems.)
RN 53597-27-6 CAPLUS
CN Benzoic acid, 5-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)

L9 ANSWER 148 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 53597-27-6, Fendosal
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of fatty acyl and alkyl derivs. of drugs and agrochems.)
RN 53597-27-6 CAPLUS
CN Benzoic acid, 5-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 149 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:509180 CAPLUS
DN 129:161414
TI Preparation of benzamidine derivatives as anticoagulants
IN Takayanagi, Masaru; Sagi, Kazuyuki; Nakagawa, Tadakiyo; Yamanashi, Masahiro; Kayahara, Takashi; Takehana, Shunji; et al.
PA Ajinomoto Co., Inc., Japan
SO PCT Int. Appl., 453 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9831661	A1	19980723	WO 1998-JP176	19980119
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	TW 542822	B	20030721	TW 1998-87100603	19980117
	CA 2278180	AA	19980723	CA 1998-2278180	19980119
	AU 9854975	A1	19980807	AU 1998-54975	19980119
	AU 731819	B2	20010405		
	EP 976722	A1	20000202	EP 1998-900422	19980119
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
PRAI	JP 1997-6783	A	19970117		
	JP 1997-194602	A	19970718		
	JP 1997-331887	A	19971202		
	WO 1998-JP176	W	19980119		

OS MARPAT 129:161414
GI



I

AB The title compds. I [L = CH2CH2, NWCOCH2, etc.; W = H, alkyl, etc.; Y = CH:CH, CONH, etc.; Z = H, alkyl, halo, etc.; when L is CH2CH2, V is benzoyl, cinnamoyl, etc., having substituents; further details on V are given] are prepared These compds. show anticoagulant effects based on their excellent effects of inhibiting activated blood coagulation factor X,

L9 ANSWER 149 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
which makes them useful as anticoagulants. In in vitro tests for the inhibition of activated blood coagulation factor X, compds. of this invention showed pIC50 values of 5.5 to 8.1.
IT 22106-33-8, 4-(1H-Pyrrol-1-yl)benzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of benzamidine deriva. as anticoagulants)
RN 22106-33-8 CAPLUS
CN Benzoic acid, 4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 150 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:338114 CAPLUS
DN 129:12755
TI Use of selected nonsteroidal antiinflammatory compounds for the prevention and the treatment of neurodegenerative diseases
IN Grilli, Mariagrazia; Pizzi, Marina; Memo, Maurizio; Spano, Pierfranco
PA Universita' Degli Studi di Brescia - Dipartimento di Scienze Biomediche, Italy
SO PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9820864	A2	19980522	WO 1997-EP6323	19971113
	WO 9820864	A3	19981015		
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI	IT 1996-MI2356	A	19961113		

OS MARPAT 129:12755
AB Nonsteroidal antiinflammatory compds. are used for the prevention and the treatment of neurodegenerative diseases, e.g. Alzheimer's disease and Parkinson's disease.
IT 53597-27-6, Fendosal
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)
RN 53597-27-6 CAPLUS
CN Benzoic acid, 5-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)



L9 ANSWER 151 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:324820 CAPLUS
DN 129:16148
TI Preparation of tricyclic benzodiazepines as vasopressin antagonists
IN Albright, Jay Donald; Venkatesan, Aranapakam M.; Dusza, John P.; Sum, Fuk-wah
PA American Cyanamid Co., USA
SO U.S., 119 pp., Cont.-in-part of U.S. 5,536,718.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5753648	A	19980519	US 1996-672150	19960627
	US 5536718	A	19960716	US 1995-373132	19950117
	CA 2258885	AA	19971231	CA 1997-2258885	19970620
	WO 9749707	A1	19971231	WO 1997-US10736	19970620
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9734063	A1	19980114	AU 1997-34063	19970620
	AU 731925	B2	20010405		
	EP 915876	A1	19990519	EP 1997-930167	19970620
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
	BR 9710087	A	19990810	BR 1997-10087	19970620
	CN 1231666	A	19991013	CN 1997-197413	19970620
	JP 2000510154	T2	20000808	JP 1998-503379	19970620
	NZ 332605	A	20000929	NZ 1997-332605	19970620
	KR 2000022297	A	20000425	KR 1998-710719	19981228
PRAI	US 1995-373132	A2	19950117		
	US 1996-672150	A	19960627		
	WO 1997-US10736	W	19970620		

OS MARPAT 129:16148
GI



I II

AB Title compds. [I; D,E,F = N or (un)substituted CH; R1R2 = atoms to complete an(un)substituted (hetero)aromatic ring; Y = bond, CH2, CH2CH2, CO, alkylidene; Z = (CH2)mNR3 or NR3(CH2)m; R3 = CO2lR6; R6 = acylamino, etc.;

L9 ANSWER 151 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Z1 = (un)substituted 1,4-phenylene or -3,6-pyridinediyl; m = 1 or 2] were prepd. Thus, 1-(2-nitrobenzyl)pyrrole-2-carboxaldehyde (prepn. given) was
reductively cyclized and the product N-acylated by 2-PhC6H4CONHC6H4(OMe)(CO2H)-3,4 (prepn. given) to give, after condensation with HCHO/CH2(NMe2)2, title compd. II. Data for biol. activity of I were given.
IT **10333-68-3**, 2-(1-Pyrrolyl)benzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of tricyclic benzodiazepines as vasopressin antagonists)
RN 10333-68-3 CAPLUS
CN Benzoic acid, 2-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 152 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:219795 CAPLUS
DN 128:257447
TI Preparation of nitrogenous heterocyclic compounds inhibiting phosphorylation of platelet-derived growth factors (PDGF) receptors
IN Matsuno, Kenji; Ichimura, Michio; Nomoto, Yuji; Fujiwara, Shigeki; Ide, Shinichi; Tsukuda, Eiji; Irie, Junko; Oda, Shoji
PA Kyowa Hakko Kogyo Co., Ltd., Japan
SO PCT Int. Appl., 312 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9814431	A1	19980409	WO 1997-JP3510	19971001
	W: AU, BG, BR, CA, CN, CZ, HU, JP, KR, MX, NO, NZ, PL, RO, SG, SI, SK, UA, US, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2239227	AA	19980409	CA 1997-2239227	19971001
	AU 9744708	A1	19980424	AU 1997-44708	19971001
	AU 719392	B2	20000511		
	EP 882717	A1	19981209	EP 1997-943133	19971001
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1208404	A	19990217	CN 1997-191741	19971001
	MX 9804356	A	20000831	MX 1998-4356	19980601
	US 6169088	B1	20010102	US 1998-88199	19980601
	US 6207667	B1	20010327	US 2000-481544	20000112
	US 2002068734	A1	20020606	US 2000-734918	20001213
	US 6472391	B2	20021029		
	US 2003229077	A1	20031211	US 2002-227302	20020826
	US 6750218	B2	20040615		
PRAI	JP 1996-260743	A	19961001		
	WO 1997-JP3510	W	19971001		
	US 1998-88199	A3	19980601		
	US 2000-481544	A3	20000112		
	US 2000-734918	A3	20001213		

OS MARPAT 128:257447
GI

L9 ANSWER 152 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Nitrogenous heterocyclic compds. of general formula [I; wherein V is oxygen or sulfur; W is 1,4-piperazinediyl or 1,4-homopiperazinediyl which may be substituted with unsubstituted alkyl on the ring; X is nitrogen or C-R9; Y is nitrogen or C-R8; Z is nitrogen or C-R7, with at least one of X, Y and Z being nitrogen; R1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl or the like; R2 is substituted alkyl, substituted or unsubstituted cycloalkyl or the like; R3, R4, R5 and R6 are each independently hydrogen, halogeno, substituted or unsubstituted alkyl, nitro, cyano, (un)substituted OH or NH2 or the like; R7, R8 = R1, halogeno or the like; R9 is hydrogen or acyl] and pharmacol. acceptable salts thereof are prepared These compds. inhibit the
phosphorylation of PDGF acceptors and the abnormal proliferation or migration of cells and so are effective in preventing or treating cell proliferative diseases such as arterial sclerosis, vascular reocclusion diseases, cancer, and glomerulosclerosis. Thus, 6,7-dimethoxy-4-piperazinylquinazoline was dissolved in ethanol, followed by adding Ph isocyanate, and the resulting mixture was heated at reflux for 10 min to give 4(4-quinazolinyl)piperazine derivative (II; R = CONHPh). II (R = Q) in
vitro showed IC50 of 0.03 μM for inhibiting the phosphorylation of PDGF receptor. Pharmaceutical formulations, e.g. tablet containing II (R = N-p-nitrophenylcarbamoyl), were prepared
IT **22106-33-8**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of nitrogenous heterocyclic compds. inhibiting phosphorylation
of platelet-derived growth factors (PDGF) receptors)
RN 22106-33-8 CAPLUS
CN Benzoic acid, 4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)

L9 ANSWER 152 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 153 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:154786 CAPLUS
DN 128:180344
TI Preparation of 9-arylacridine-1,8-diones and analogs as herpes simplex virus thymidine kinase inhibitors
IN Martin, Joseph Armstrong; Sherborne, Bradley Stuart; Taylor, Gareth Mark
PA F. Hoffmann-La Roche A.-G., Switz.
SO Eur. Pat. Appl., 23 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 823426	A1	19980211	EP 1997-113085	19970730
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	CA 2210415	AA	19980207	CA 1997-2210415	19970714
	JP 10067749	A2	19980310	JP 1997-209149	19970804
	BR 9704271	A	19981103	BR 1997-4271	19970806
	US 5969139	A	19991019	US 1997-906929	19970806
	CN 1100759	B	20030205	CN 1997-116160	19970806
	US 6162918	A	20001219	US 1999-342013	19990628
PRAI	GB 1996-16565	A	19960807		
	GB 1997-7695	A	19970418		
	US 1997-906929	A3	19970806		

OS MARPAT 128:180344
GI



I

AB Title compds. [I; R = (un)substituted (hetero)aryl; R1 = H or alkyl; R2 = alkyl; Z = O or NR3; R3 = H, alkyl, alkoxycarbonyl(alkyl)] were prepared Thus, 3-amino-5,5-dimethyl-2-cyclohexenone was cyclocondensed with 3,4-ClFC6H3CHO to give I (R = C6H3ClF-3,4, R1 = R2 = Me, Z = NH). Data for biol. activity of I were given.
IT 203179-04-8, 4-Chloro-3-(1-pyrrolyl)benzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 9-arylacridine-1,8-diones and analogs as herpes simplex virus thymidine kinase inhibitors)
RN 203179-04-8 CAPLUS
CN Benzoic acid, 4-cyano-3-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)

L9 ANSWER 153 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 154 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:42402 CAPLUS
DN 128:114970
TI Preparation of tricyclic benzazepine as vasopressin antagonists
IN Albright, Jay Donald; Venkatesan, Aranapakam Mudumbai; Dusza, John Paul; Sum, Fuk-wah
PA American Cyanamid Co., USA
SO PCT Int. Appl., 411 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9749707	A1	19971231	WO 1997-US10736	19970620
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5753648	A	19980519	US 1996-672150	19960627
	AU 9734063	A1	19980114	AU 1997-34063	19970620
	AU 731925	B2	20010405		
	EP 915876	A1	19990519	EP 1997-930167	19970620
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
	BR 9710087	A	19990810	BR 1997-10087	19970620
	JP 2000510154	T2	20000808	JP 1998-503379	19970620
PRAI	US 1996-672150	A	19960627		
	US 1995-373132	A2	19950117		
	WO 1997-US10736	W	19970620		

OS MARPAT 128:114970
GI

L9 ANSWER 154 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB The title compds. I [AB = CH2NR3, R3NCH2; R3 = (un)substituted arylcarbonyl; DEF ring = 5-member N-containing (un)substituted heterocyclic ring; Y = σ-bond, CH2; R = alkyl, NH2, halogen,etc; R1 = alkyl, OH, Cl, OMe, etc.], which exhibit antagonist activity at V1 and/or V2 receptors and exhibit in vivo vasopressin antagonist activity would be useful in treating diseases characterized by excess renal reabsorption of water (e.g., brain edema, cirrhosis, hyponatremia, brain edema, congestive heart failure, etc.), are prepared Thus, 2-chloro-4-[(4'-trifluoromethyl)(1,1'-biphenyl-2-carbonyl]amino]benzoyl chloride was reacted with 10,11-dihydro-5H-pyrrolo[2,1-c][1,4-]benzodiazepine, producing benzodiazepine II which demonstrated a rat kidney-derived V1 receptor IC50 of 41% at 1 μM and 92% for the V2 receptor at 10 μM.
IT 10333-68-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of tricyclic benzazepines as vasopressin antagonists)
RN 10333-68-3 CAPLUS
CN Benzoic acid, 2-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



L9 ANSWER 155 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:640655 CAPLUS
DN 127:307398
TI New piperidinyl- and piperazinyl-substituted 1,2,3,4-tetrahydronaphthalene derivatives useful as 5-HT antagonists
IN Berg, Stefan; Florvall, Lennart; Ross, Svante; Thorberg, Seth-Olov
PA Astra AB, Swed.
SO PCT Int. Appl., 137 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9734883	A1	19970925	WO 1997-SE469	19970320
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	ZA 9702056	A	19970922	ZA 1997-2056	19970310
	CA 2247940	AA	19970925	CA 1997-2247940	19970320
	AU 9721865	A1	19971010	AU 1997-21865	19970320
	AU 709856	B2	19990909		
	EP 888319	A1	19990107	EP 1997-914727	19970320
	EP 888319	B1	20030129		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	CN 1219170	A	19990609	CN 1997-194726	19970320
	CN 1073101	B	20011017		
	BR 9708093	A	19990727	BR 1997-8093	19970320
	NZ 331613	A	20000327	NZ 1997-331613	19970320
	JP 2000506883	T2	20000606	JP 1997-533410	19970320
	SK 282359	B6	20020107	SK 1998-1188	19970320
	AT 231847	E	20030215	AT 1997-914727	19970320
	US 6124283	A	20000926	US 1997-836004	19970425
	NO 9804385	A	19981123	NO 1998-4385	19980921
	NO 311803	B1	20020128		
	US 6410530	B1	20020625	US 2000-653427	20000831
PRAI	SE 1996-1110	A	19960322		
	WO 1997-SE469	W	19970320		
	US 1997-836004	A3	19970425		

OS MARPAT 127:307398
GI



I



II

AB New piperidinyl- and piperazinyl-substituted 1,2,3,4-tetrahydronaphthalene derivs. I [X = N or CH; Y = NR2CH2, CH2NR2, NR2CO, CONR2, or NR2SO2; R1 = H, C1-6 alkyl, or C3-6 cycloalkyl; R2 = H or C1-6 alkyl; R3 = C1-6 alkyl, C3-6 cycloalkyl, or (CH2)n-aryl where aryl = Ph or heteroarom. ring containing 1 or 2 N/O/S atoms and which may be mono- or di-substituted; n = 0-4], as enantiomers, racemates, free bases, or pharmaceutically acceptable salts or hydrates, are disclosed. Also disclosed are pharmaceutical formulations containing I, use of I in the treatment of disorders mediated by 5-hydroxytryptamine (5-HT), and processes and intermediates for the preparation of I. The compds. are primarily selective antagonists of the 5-HT1D receptor (no data). A variety of preferred compds., mostly (R)-isomers, are specifically claimed. Synthetic examples (138) include preparation of both I and their intermediates. For instance, (R)-8-methoxy-2-amino-1,2,3,4-tetrahydronaphthalene-HCl was converted in 8 steps to (R)-2-amino-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthalene, which was condensed with 4-morpholinobenzoic acid using 1,1'-carbonyldiimidazole in DMF to give title compound II.

IT **22106-33-8**, 4-(1H-Pyrrol-1-yl)benzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of piperidinyl- and piperazinyl-substituted tetrahydronaphthalenes as 5-HT1D antagonists)

RN 22106-33-8 CAPLUS
CN Benzoic acid, 4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)

L9 ANSWER 155 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 156 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:613834 CAPLUS
DN 127:278149
TI Preparation of heterocyclyl-substituted benzoylguanidines as antiarrhythmics
IN Lang, Hans-Jochen; Kleeman, Heinz-Werner; Scholz, Wolfgang; Albus, Udo
PA Hoechst A.-G., Germany
SO U.S., 9 pp., Cont.-in-part of U.S. Ser. No. 334,008, abandoned
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5665739	A	19970909	US 1995-440619	19950515
PRAI	DE 1992-4242191	A	19921215		
	DE 1993-4311800	A	19930409		
	US 1993-165649	B1	19931213		
	US 1994-334008	B2	19941102		

OS MARPAT 127:278149
GI



I

AB The title compds. [I; R1 = H, halo, NO2, etc.; R2 = C1-9 heteroaryl linked via C or N, S-CaH2a-C1-9 heteroaryl (wherein a = 0-2), etc.; R3 = R1, C1-6 alkyl, etc.], outstandingly suitable as antiarrhythmic pharmaceuticals with a cardioprotective component for the prophylaxis and treatment of infarctions and for the treatment of angina pectoris, and they also preventively inhibit, or greatly reduce, the pathophysiol. processes in the formation of ischemia-induced damage, in particular in the triggering of ischemia-induced cardiac arrhythmias, were prepared Thus, reaction of Me 4-fluoro-3-trifluoromethylbenzoate with 3-hydroxypyridine in the presence of K2CO3 in DMF followed by treatment of the resulting Me 4-(3-pyridyloxy)-3-trifluoromethylbenzoate with guanidine afforded I [R1 = H; R2 = 3-pyridyloxy; R3 = CF3] which showed IC50 of 0.03 μM/L against Na+/H+ exchange.

IT **157069-51-7P 157069-53-9P 196707-35-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclyl-substituted benzoylguanidines as antiarrhythmics)

RN 157069-51-7 CAPLUS
CN Benzoic acid, 3-chloro-5-methyl-4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)

L9 ANSWER 156 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 157069-53-9 CAPLUS
CN Benzoic acid, 3,5-dimethyl-4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 196707-35-4 CAPLUS
CN Benzoic acid, 3,5-dichloro-4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



L9 ANSWER 157 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
in blood pressure in rats.
IT 175153-00-1P 175153-01-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzazepine derivs. and analogs as pharmaceuticals with
affinity for vasopressin receptors)
RN 175153-00-1 CAPLUS
CN Benzoic acid, 4-(2,5-dimethyl-1H-pyrrol-1-yl)-2-methoxy- (9CI) (CA INDEX NAME)



RN 175153-01-2 CAPLUS
CN Benzoic acid, 4-(2,5-dimethyl-1H-pyrrol-1-yl)-3-methoxy- (9CI) (CA INDEX NAME)



L9 ANSWER 157 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:594560 CAPLUS
DN 127:248027
TI Preparation and formulation of benzazepine derivatives and analogs as pharmaceuticals with affinity for vasopressin receptors
IN Ogawa, Hidenori; Kondo, Kazumi; Yamashita, Hiroshi; Suga, Keizo; Matsuzaki, Noriyuki; Shinohara, Tomokazu; Tanada, Yoshihisa; Kurimura, Muneaki; Tominaga, Michiaki; Yabuuchi, Yoichi
PA Otsuka Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 646 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 09221476	A2	19970826	JP 1996-354761	19961216
PRAI JP 1995-348123	A	19951215		

OS MARPAT 127:248027
GI



I



II

AB The title compds. I [G = CR2R3X, etc.; X = CH2, etc.; R1 = H, halo, etc.; R2 = H, etc.; R3 = H, CH2CO2R15, etc.; R15 = H, alkyl, etc.; R = adamantylcarbonyl, etc.], useful as pharmaceuticals with affinity for the vasopressin receptors and as oxytocin antagonists, are prepared The title
compound II showed oral ED50 of 1 mg/kg against vasopressin-induced increase

L9 ANSWER 158 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:189938 CAPLUS
DN 126:186111
TI Preparation of heterocyclic carboxylic acid derivatives as retinoid receptor agonists
IN Kikuchi, Kouichi; Tagami, Katsuya; Yoshimura, Hiroyuki; Hibi, Shigeki; Nagai, Mitsuo; Abe, Shinya; Okita, Makoto; Hida, Takayuki; Higashi, Seiko;
Tokuhara, Naoki; Kobayashi, Seiichi; et al.
PA Eisai Co., Ltd., Japan
SO PCT Int. Appl., 160 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9702244	A1	19970123	WO 1996-JP1782	19960627
W: AU, CA, CN, HU, KR, MX, NO, NZ, RU, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 09071566	A2	19970318	JP 1996-141433	19960604
AU 9662422	A1	19970205	AU 1996-62422	19960627
EP 838453	A1	19980429	EP 1996-921104	19960627
EP 838453	B1	20050427		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
AT 294160	E	20050515	AT 1996-921104	19960627
EP 1559709	A1	20050803	EP 2005-1823	19960627
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
US 5977108	A	19991102	US 1997-981770	19971230
US 6329402	B1	20011211	US 1999-313087	19990517
US 2002032202	A1	20020314	US 2001-910012	20010723
US 6541474	B2	20030401		
US 2002103234	A1	20020801	US 2001-910068	20010723
US 6630463	B2	20031007		
US 2003144276	A1	20030731	US 2003-336756	20030106
US 6884808	B2	20050426		
PRAI JP 1995-166004	A	19950630		
JP 1996-141433	A	19960604		
EP 1996-921104	A3	19960627		
WO 1996-JP1782	W	19960627		
US 1997-981770	A3	19971230		
US 1999-313087	XX	19990517		
US 2001-910068	A3	20010723		

OS MARPAT 126:186111
GI



I

AB Heterocyclic carboxylic acid derivs. AB(D)nCOM [A is a heteroaryl group

L9 ANSWER 158 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
which has at least one nitrogen atom and may be substituted, or the like; B is heteroarylene, CONH, CR6:CR7 (R6 and R7 being each H, lower alkyl or the like) or the like; D is arylene, heteroarylene or the like; n is 0 or 1; and M is hydroxyl, lower alkoxy or the like] are prepd. In an in vitro
retinoid receptor binding assay, tetrahydroquinoxaline deriv. I showed IC50 of 1.6 nM, vs. IC50 of 1.1 nM shown by all-trans-retinoic acid.
IT **187400-36-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic carboxylic acid derivs. as retinoid receptor
agonists)
RN 187400-36-8 CAPLUS
CN Benzoic acid, 4-[2-[1,2,3,4-tetrahydro-1-(1-methylethyl)-6-quinolinyl]-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



L9 ANSWER 159 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of fused five-membered heterocycloazepine compds. as vasopressin antagonists)
RN 10333-68-3 CAPLUS
CN Benzoic acid, 2-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



L9 ANSWER 159 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:148847 CAPLUS
DN 126:186116
TI Preparation of fused five-membered heterocycloazepine compounds as vasopressin antagonists
IN Cho, Hidetsura; Wakitani, Yukikyo
PA Nippon Tobacco Sangyo, Japan
SO Jpn. Kokai Tokkyo Koho, 106 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 09020779	A2	19970121	JP 1995-351538	19951225
PRAI JP 1995-107485	A	19950501		

OS MARPAT 126:186116
GI



AB The title compds. (I; dotted line = single or double bond; A1 = O, S, NR9;
A2 = CH2, NH, etc. when dotted line = single bond; A2 = CH when dotted line = double bond; A3, A4 = CH or one of them represents N; R1, R2, R9 = H, lower alkyl, etc.; R3, R4 = H, lower alkyl or alkoxy, etc.; R5 = H, lower alkyl, aryl, etc.; R6 = cycloalkyl, aryl, etc.) are prepared I, possessing vasopressin and oxycotin antagonism, are useful for prevention and treatment of corgeotive heart failure, cerebral edema, hypertension, and oversecret exaggerated secretion of arginine vasopressin and as diuretics. Thus, 4-(4-nitrobenzoyl)-5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepine (preparation given) was hydrogenated over platinum oxide and then
reacted with 2-phenylbenzoyl chloride in the presence of Et3N to give the title compound (II), which showed IC50 of 5 X 10-8 and 3 X 10-7 M against vasopressin (V1) and vasopressin (V2) receptors resp. when tested on rats in vitro.
IT **10333-68-3**

L9 ANSWER 160 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1996:485727 CAPLUS
DN 125:142700
TI Tricyclic oxime ethers process for their preparation and pharmaceutical compositions containing them
IN Rault, Sylvain; Robba, Max; Lancelot, Jean-Charles; Prunier, Herve; Renard, Pierre; Pfeiffer, Bruno; Guardiola-Lemaitre, Beatrice; Rettori, Marie-Claire
PA Adir Et Compagnie, Fr.
SO Eur. Pat. Appl., 45 pp.
CODEN: EPXXDW
DT Patent
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 718299	A1	19960626	EP 1995-402865	19951219
EP 718299	B1	20000405		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
FR 2728571	A1	19960628	FR 1994-15431	19941222
FR 2728571	B1	19970131		
CA 2165618	AA	19960623	CA 1995-2165618	19951219
CA 2165618	C	20010410		
AT 191483	E	20000415	AT 1995-402865	19951219
PT 718299	T	20000731	PT 1995-402865	19951219
ES 2147271	T3	20000901	ES 1995-402865	19951219
FI 9506136	A	19960623	FI 1995-6136	19951220
AU 9540593	A1	19960627	AU 1995-40593	19951220
AU 693615	B2	19980702		
NO 9505215	A	19960624	NO 1995-5215	19951221
ZA 9510901	A	19960624	ZA 1995-10901	19951221
JP 08231554	A2	19960910	JP 1995-333347	19951221
JP 2937837	B2	19990823		
US 5627203	A	19970506	US 1995-576678	19951221
CN 1131155	A	19960918	CN 1995-120144	19951222
CN 1066449	B	20010530		
CN 1261073	A	20000726	CN 1999-120993	19991203
GR 3033507	T3	20000929	GR 2000-401198	20000525
PRAI FR 1994-15431	A	19941222		

OS MARPAT 125:142700
GI



AB The present invention concerns compds. I, in which A represents a thieno group, x and y are independently 0-4, R1 is H, alkyl, alkenyl, cycloalkyl,
OH, alkoxy, substituted Ph, phenylalkyl, substituted phenoxy, R2 and R3 are H, alkyl, alkenyl, cycloalkyl, substituted indanyl, substituted Ph,

L9 ANSWER 160 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
phenylalkyl, or R2 and R3 form azacycloalkyl rings, and their oxalates or fumarates. I, e.g. II (X = NOCHPhCH2CH2NMe2) are prepd. from the ketone, e.g II (X = O), via hydroxyimination followed by O-alkylation, e.g with PhCHClCH2CH2NMe2·HCl. I were tested as serotoninergic receptor antagonists (IC50 1.1 x 10 -10 to 10-4 M), anxiolytics and antidepressants.
IT **10333-68-3P 55540-33-5P 55540-34-6P 133662-26-7P**
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tricyclic oxime ethers as serotoninergic receptor antagonists)
RN 10333-68-3 CAPLUS
CN Benzoic acid, 2-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 55540-33-5 CAPLUS
CN Benzoic acid, 5-chloro-2-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 55540-34-6 CAPLUS
CN Benzoic acid, 4-chloro-2-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



L9 ANSWER 160 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 133662-26-7 CAPLUS
CN Benzoic acid, 5-methyl-2-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



L9 ANSWER 161 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1996:455768 CAPLUS
DN 125:114322
TI Preparation of urea derivatives as cholesterol acyltransferase inhibitors
IN Terasawa, Takeshi; Tanaka, Akira; Chiba, Toshiyuki; Takasugi, Hisashi
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 228 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9610559	A1	19960411	WO 1995-JP1982	19950929
	W: AU, CA, CN, HU, JP, KR, MX, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2200981	AA	19960411	CA 1995-2200981	19950929
	AU 9535779	A1	19960426	AU 1995-35779	19950929
	EP 784612	A1	19970723	EP 1995-932934	19950929
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	JP 10510512	T2	19981013	JP 1995-511616	19950929
	ZA 9508365	A	19960508	ZA 1995-8365	19951004
PRAI	GB 1994-19970	A	19941004		
	GB 1995-6720	A	19950331		
	GB 1995-14021	A	19950710		
	WO 1995-JP1982	W	19950929		

OS MARPAT 125:114322
AB R4YC6H4(CH2)nNR2CONHR3 [R2 = (ar)alkyl, heterocyclyl(alkyl), alkoxyalkyl, etc.; R3,R4 = (un)substituted aryl, heterocyclyl; Y = bond, alkylene, O, CO, CONH, etc.; n = 0 or 1] were prepare Thus, 1-cycloheptyl-1-(4-phenoxyphenylmethyl)-3-(2,4,6-trifluorophenyl)urea had IC50 of 1.1x10-8M against cholesterol acyltransferase in vitro.
IT **22106-33-8**, Benzoic acid, 4-(1H-pyrrol-1-yl)- **61471-45-2**, 3-(1-Pyrrolyl)benzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of urea derivs. as cholesterol acyltransferase inhibitors)
RN 22106-33-8 CAPLUS
CN Benzoic acid, 4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 61471-45-2 CAPLUS
CN Benzoic acid, 3-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)

L9 ANSWER 161 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 162 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1996:443907 CAPLUS
DN 125:86670
TI Preparation of 4-aminopyrrolo[2,3-d]pyrimidines as inhibitors of the protein tyrosine kinase pp60c-src
IN Missbach, Martin
PA Ciba-Geigy A.-G., Switz.
SO PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9610028	A1	19960404	WO 1995-EP3536	19950908
	W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SN, TD, TG				
	CA 2200210	AA	19960404	CA 1995-2200210	19950908
	AU 9535643	A1	19960419	AU 1995-35643	19950908
	AU 694801	B2	19980730		
	EP 783505	A1	19970716	EP 1995-932693	19950908
	EP 783505	B1	20010307		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	CN 1164234	A	19971105	CN 1995-196308	19950908
	CN 1046731	B	19991124		
	HU 76785	A2	19971128	HU 1997-1333	19950908
	BR 9509048	A	19980106	BR 1995-9048	19950908
	JP 10506624	T2	19980630	JP 1995-511312	19950908
	AT 199553	E	20010315	AT 1995-932693	19950908
	ES 2157344	T3	20010816	ES 1995-932693	19950908
	PT 783505	T	20010830	PT 1995-932693	19950908
	US 5869485	A	19990209	US 1997-793313	19970319
	NO 9701342	A	19970321	NO 1997-1342	19970321
	NO 308108	B1	20000724		
	FI 9701225	A	19970514	FI 1997-1225	19970324
	FI 112867	B1	20040130		
	GR 3035996	T3	20010928	GR 2001-400849	20010606
PRAI	CH 1994-2953	A	19940929		
	WO 1995-EP3536	W	19950908		

OS CASREACT 125:86670; MARPAT 125:86670
GI

L9 ANSWER 162 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I II

AB The title compds. [I; R1, R3 = (substituted) aryl; R2 = H, alkyl, halo], useful for the treatment of osteoporosis, breast cancer and cardiovascular disorders, e.g. thrombosis, were prepared by e.g. treatment of substituted 2-amino-3-cyano-pyrrole with (EtO)3CH followed by treatment of II (X = EtO) with NH3/EtOH and cyclization of II (X = NH2) with NH3/EtOH at 130° in an autoclave. Tablets formulations containing I are given. In general, compds. I showed IC50 of 0.001-10 μM against protein tyrosine kinase pp60c-src.
IT 178909-37-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 4-aminopyrrolo[2,3-d]pyrimidines as inhibitors of the protein tyrosine kinase pp60c-src)
RN 178909-37-0 CAPLUS
CN Benzoic acid, 3-(4-amino-5-phenyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)- (9CI) (CA INDEX NAME)



IT 178910-30-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 4-aminopyrrolo[2,3-d]pyrimidines as inhibitors of the protein tyrosine kinase pp60c-src)
RN 178910-30-0 CAPLUS
CN Benzoic acid, 3-(2-amino-3-cyano-4-phenyl-1H-pyrrol-1-yl)-, monosodium salt (9CI) (CA INDEX NAME)

L9 ANSWER 162 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na

L9 ANSWER 163 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1996:211765 CAPLUS
DN 124:260869
TI Preparation of benzazepine and benzodiazepine derivatives as vasopressin antagonists and agonists or oxytocin antagonists
IN Ogawa, Hidenori; Kondo, Kazumi; Yamashita, Hiroshi; Kan, Keizo; Matsuzaki, Takayuki; Shinohara, Tomoichi; Tanada, Yoshihisa; Kurimura, Muneaki; Tominaga, Michiaki; Yabuuchi, Yoichi
PA Otsuka Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 678 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9534540	A1	19951221	WO 1995-JP1124	19950607
	W: AU, CA, CN, KR, MX, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2192928	AA	19951221	CA 1995-2192928	19950607
	AU 9526293	A1	19960105	AU 1995-26293	19950607
	AU 690283	B2	19980423		
	EP 765314	A1	19970402	EP 1995-921112	19950607
	EP 765314	B1	20030507		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	CN 1150799	A	19970528	CN 1995-193642	19950607
	CN 1104418	B	20030402		
	EP 1221440	A1	20020710	EP 2002-7987	19950607
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
	AT 239710	E	20030515	AT 1995-921112	19950607
	PT 765314	T	20030930	PT 1995-921112	19950607
	ES 2199251	T3	20040216	ES 1995-921112	19950607
	TW 467899	B	20011211	TW 1995-84105805	19950608
	JP 08301848	A2	19961119	JP 1995-177127	19950615
	JP 3215910	B2	20011009		
	JP 11349570	A2	19991221	JP 1999-111038	19950615
	JP 2000351768	A2	20001219	JP 2000-155830	19950615
	US 6096735	A	20000801	US 1996-737432	19961113
	US 6335327	B1	20020101	US 1999-431635	19991101
	CN 1313280	A	20010919	CN 2000-131787	20001018
	US 2002049194	A1	20020425	US 2001-874452	20010606
	US 6642223	B2	20031104		
PRAI	JP 1994-132355	A	19940615		
	JP 1995-70727	A	19950303		
	EP 1995-921112	A3	19950607		
	WO 1995-JP1124	W	19950607		
	JP 1995-177127	A3	19950615		
	US 1996-737432	A3	19961113		
	US 1999-431635	A3	19991101		

OS MARPAT 124:260869
GI

L9 ANSWER 163 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Title compds. I and II [R1 = H, halo, alkyl, etc.; R2 = H, OH, (substituted) amino, etc.; R3 = H, hydroxy-substituted alkyl; R2R3 = O, (substituted) alkylidene; R4 = H, alkoxy, (substituted) benzoyl, etc.; X = CH2, a single bond, (substituted) imino, etc.; Y = (substituted) imino], useful as antihypertensives, diuretics and antidiuretics, were prepared and formulated. Treatment of 4-ethoxy-2-methoxybenzoic acid with SOCl2 followed by addition of I [R1 = 7-Cl; R2 = Et2NCH2CH2N(Me)COCH2; R3 = R4 = H; X = CH2] in the presence of Et3N in CH2Cl2 and treatment of the base with concentrate HCl afforded I.HCl [R1 = 7-Cl; R2 = Et2NCH2CH2N(Me)COCH2; R3 = H; R4 = 4,2-(EtO)(MeO)C6H3CO; X = CH2] which showed IC50 of 0.021 μM in a vasopressin V1 receptor binding assay and IC50 of 0.15 μM in a vasopressin V2 receptor binding assay.

IT **15898-26-7P 175153-00-1P 175153-01-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzazepine and benzodiazepine derivs. as vasopressin antagonists and agonists or oxytocin antagonists)

RN 15898-26-7 CAPLUS
CN Benzoic acid, 4-(2,5-dimethyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 175153-00-1 CAPLUS
CN Benzoic acid, 4-(2,5-dimethyl-1H-pyrrol-1-yl)-2-methoxy- (9CI) (CA INDEX NAME)

L9 ANSWER 163 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 175153-01-2 CAPLUS
CN Benzoic acid, 4-(2,5-dimethyl-1H-pyrrol-1-yl)-3-methoxy- (9CI) (CA INDEX NAME)



L9 ANSWER 164 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1995:998395 CAPLUS
DN 124:176153
TI Preparation of DC-89 derivatives as antitumor agents
IN Amishiro, Nobuyoshi; Nagamura, Satoru; Saito, Hiromitsu; Kobayashi, Eiji; Okamoto, Akihiko; Gomi, Katsushige
PA Kyowa Hakko Kogyo Co., Ltd., Japan
SO PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9529179	A1	19951102	WO 1995-JP779	19950420
	W: AU, CA, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2165819	AA	19951102	CA 1995-2165819	19950420
	CA 2165819	C	20051227		
	AU 9522671	A1	19951116	AU 1995-22671	19950420
	AU 685939	B2	19980129		
	EP 705833	A1	19960410	EP 1995-916020	19950420
	EP 705833	B1	20040721		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	AT 271557	E	20040815	AT 1995-916020	19950420
	PT 705833	T	20041130	PT 1995-916020	19950420
	ES 2220927	T3	20041216	ES 1995-916020	19950420
	US 5641780	A	19970624	US 1995-564178	19951215
PRAI	JP 1994-84714	A	19940422		
	WO 1995-JP779	W	19950420		

OS MARPAT 124:176153
GI



AB DC-89 derivs. [I; X = Cl or Br; R = (un)substituted alkyl, (un)substituted aralkyl, COR1, OR2, SR2, NR3R4, Q, Q1, SO2R8; wherein R1 = H, (un)substituted alkyl, aryl, or heterocyclyl; R2 = (un)substituted alkyl, aryl; R3, R4 = H, (un)substituted alkyl, NH2, mono- or dialkylamino; provided that R3 = R4 = H; R5 = NR7, O ; R6, R7 = H, (un)substituted

L9 ANSWER 164 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

alkyl; R8 = (un)substituted alkyl or aryl; Y = Q2, Q3] or pharmacol. acceptable salts thereof are prepd. Thus, the tert-butyldimethylsilyl ether I (R = Me3CSiMe2, X = Br, Y = Q2) (50 mg) was dissolved in THF, treated with 0.11 mL 1.0 M Bu4NF/THF, and stirred at room temp. for 1 h to give, after workup, the alc. I (R = H, X = Br, Y = Q2) which was dissolved in MeCN, treated with 48% aq. HBr, stirred at room temp. for 1 h, treated with 1 N aq. HBr, and extd. with CHCl3. The CHCl3 ext. was dried over anhyd. Na2SO4 and evapd. to dryness to give the crude product which was dissolved in CH2Cl2, treated with 0.027 mL Ph chloroformate and 0.030 mL Et3N, and stirred at -78° to 0° for 1 h to give, after workup and silica gel chromatog., the title pyrroloindoline I (R = CO2Ph, X = Br, Y = Q2). The latter compd. in vitro showed IC50 of 0.051 nM for inhibiting the proliferation of HeLaS3 cells and in vivo exhibited T/C of 0.090 (tumor vol. of the treated animal/tumor vol. of the control) in mice transplanted with sarcoma 180.

IT **22106-33-8**, 4-(1H-Pyrrol-1-yl)benzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of DC-89 (pyrroloindoline) derivs. as antitumor agents)

RN 22106-33-8 CAPLUS
CN Benzoic acid, 4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



L9 ANSWER 165 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:938557 CAPLUS
DN 124:21782
TI Preparation of 2-(arylmethyl)-1-naphthols and 5-lipoxygenase inhibitors containing them
IN Kobori, Takeo; Fujita, Mikako; Kondo, Sei; Higuchi, Shohei
PA Sagami Chem Res, Japan; Taisho Pharma Co Ltd
SO Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 07233052	A2	19950905	JP 1994-43395	19940218
PRAI	JP 1994-43395		19940218		

OS MARPAT 124:21782
GI



AB 5-Lipoxygenase inhibitors containing the title compds. I [R1 = (un)substituted aryl; R2-4 = H, halo, alkyl, alkoxy, alkylthio, NO2] as active ingredients are claimed. The inhibitors are useful for treatment of airway disorders, e.g. allergic asthma, bronchitis, inflammation, rheumatism, thrombosis, ischemia, angina pectoris, arteriosclerosis, skin diseases, e.g. psoriasis, inflammatory skin disease, and as cytoprotective agents for gastrointestinal tracts. IC50 value of 2-[(4-biphenyl)methyl]-1-naphthol (II; preparation given) against 5-lipoxygenase (prepared from rat basophilic leukemia cell RBL-1) was 0.14 μM. Tablets containing I were also formulated.

IT 22106-33-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(reaction with tetralone; 5-lipoxygenase inhibitors containing [(arylphenyl)methyl]naphthols for treatment of airway disorders, inflammation, vascular diseases, skin diseases, and for protection of gastrointestinal cells)

RN 22106-33-8 CAPLUS
CN Benzoic acid, 4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)

L9 ANSWER 165 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 166 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:875004 CAPLUS
DN 124:117091
TI Preparation of benzopyranylpropenamides for treatment of ischemia and arrhythmia.
IN Atwal, Karnail S.; Ahmed, Syed Z.; Santafianos, Dinos P.
PA E. R. Squibb and Sons, Inc., USA
SO U.S., 10 pp. Cont.-in-part of U.S. Ser. No. 944,137, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5453421	A	19950926	US 1993-103053	19930812
	CA 2105958	AA	19940312	CA 1993-2105958	19930910
	AU 9346241	A1	19940317	AU 1993-46241	19930910
	JP 06211761	A2	19940802	JP 1993-225585	19930910
PRAI	US 1992-944137	B2	19920911		

OS MARPAT 124:117091
GI



AB Title compds. (I; X = O, S; R1 = aryl; R2 = H, OH, O2CR3; R3, R4 = H, alkyl, aralkyl; R3R4 = atoms to form a 5-7 membered ring; R5 = H, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, cycloalkylalkyl, cyano, NO2, alkylthio, alkylsulfinyl, alkylsulfonyl, halo, alkoxy, OCF3, OCH2CF3, alkoxycarbonyl, etc.; R6 = H, alkyl, halo, OH, alkoxy, amino, alkoxy, alkoxycarbonyl, etc.; R7 = H, alkyl, aralkyl; R8 = H, alkyl, aryl, alkoxy; R9 = H, alkyl, aryl, alkoxycarbonyl, alkylcarbonyl; Y = O), were prepared as potassium channel activators (no data). Thus, 6-cyano-2,2-dimethyl-2H-1-benzopyran was treated with Na2HPO4- and NaOH-treated household bleach (pH 11.3) and Mn(III) salen complex to give 99% (1aR)-cis-1a,7b-dihydro-2,2-dimethyl-2H-oxireno[c][1]benzopyran-6-carbonitrile. This was heated with aqueous NH3 in EtOH/THF at 50° for 16 h to give 86% (3S-trans)-4-amino-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-6-carbonitrile. The latter in THF was treated with cinnamoyl chloride in THF and aqueous Na2CO3 ti give 62.6% [3S-[3α,4β(E)]]-N-(6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl)-3-phenyl-2-propenamide.

IT 53242-70-9, Benzoic acid, 2-hydroxy-5-(1H-pyrrol-1-yl)-

L9 ANSWER 166 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of benzopyranylpropenamides for treatment of ischemia and arrhythmia)

RN 53242-70-9 CAPLUS
CN Benzoic acid, 2-hydroxy-5-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



L9 ANSWER 167 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:858578 CAPLUS
DN 123:256508
TI Preparation of pyrrole derivatives as ACAT inhibitors
IN Ito, Yoshikuni; Oone, Kazuhiko; Tanaka, Hirokazu
PA Fujisawa Pharmaceutical Co, Japan
SO Jpn. Kokai Tokkyo Koho, 18 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 07118229	A2	19950509	JP 1993-284471	19931019
PRAI	JP 1993-284471		19931019		

OS MARPAT 123:256508
GI



I

AB The title compds. I [R1 = (un)substituted aryl; R2 = alkyl, etc. ; R3 = (un)substituted aryl; R4 = H, halo, etc.; A = single bond, alkylene] are prepared In an in vitro test for acyl-CoA:cholesterol acyltransferase (ACAT) inhibiting activity, N-[1-(4-Chlorophenyl)pyrrol-2-ylmethyl]-N-heptyl-N'-(2,4,6-trifluorophenyl)urea showed IC50 of 5.7 x 10-8 M.
IT 22106-33-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrrole derivs. as ACAT inhibitors)
RN 22106-33-8 CAPLUS
CN Benzoic acid, 4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



L9 ANSWER 168 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:835463 CAPLUS
DN 123:256771
TI Guanidine derivatives as inhibitors of Na+/H+ exchange in cells
IN Kuno, Atsushi; Inoue, Yoshikazu; Takasugi, Hisashi; Mizuno, Hiroaki; Yamasaki, Kumi
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 212 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9426709	A1	19941124	WO 1994-JP786	19940512
	W: AU, CA, CN, HU, JP, KR, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	TW 393487	B	20000611	TW 1994-83104223	19940510
	CA 2163004	AA	19941124	CA 1994-2163004	19940512
	AU 9466912	A1	19941212	AU 1994-66912	19940512
	AU 685457	B2	19980122		
	HU 70206	A2	19950928	HU 1994-3233	19940512
	EP 699185	A1	19960306	EP 1994-914623	19940512
	EP 699185	B1	20010905		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CN 1123545	A	19960529	CN 1994-192121	19940512
	CN 1080257	B	20020306		
	JP 08511243	T2	19961126	JP 1994-525245	19940512
	RU 2141946	C1	19991127	RU 1995-122558	19940512
	AT 205191	E	20010915	AT 1994-914623	19940512
	ES 2159558	T3	20011016	ES 1994-914623	19940512
	PT 699185	T	20020130	PT 1994-914623	19940512
	ZA 9403388	A	19950123	ZA 1994-3388	19940517
	US 5824691	A	19981020	US 1995-532804	19951109
	GR 3036549	T3	20011231	GR 2001-401402	20010906
PRAI	GB 1993-10074	A	19930517		
	GB 1993-25268	A	19931210		
	WO 1994-JP786	W	19940512		

OS MARPAT 123:256771
GI



I II

L9 ANSWER 168 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
AB The N-benzoylguanidine derivs. or N-(heteroaroyl)guanidine derivs. I (X, Y, Z = nitrogen, methine; R2 = H, aryl, etc.; R3 = H, alkoxy, hydroxy, etc.) and pharmaceutically acceptable salts thereof were disclosed as pharmaceuticals. I inhibit the sodium/hydrogen exchange in cells and are hence useful for the treatment of cardiovascular diseases, cerebrovascular diseases, renal diseases, arteriosclerosis or shock. A claimed example compound is N-[3-(1H-pyrrol-1-yl)benzoyl]guanidine [i.e., N-(aminoiminomethyl)-3-(1H-pyrrol-1-yl)benzamide] (II).
IT 168618-81-3P 168618-82-4P 168618-83-5P
168618-84-6P 168619-50-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-(aroyl)guanidine derivs. as sodium exchange inhibitors)
RN 168618-81-3 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 1-(3-carboxyphenyl)-, 2-(phenylmethyl) ester (9CI) (CA INDEX NAME)



RN 168618-82-4 CAPLUS
CN Benzoic acid, 3-(3-cyano-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 168618-83-5 CAPLUS
CN Benzoic acid, 3-(2-cyano-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



L9 ANSWER 168 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 168618-84-6 CAPLUS
CN Benzoic acid, 3-cyano-5-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 168619-50-9 CAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-(1H-pyrrol-1-yl)-, monomethyl ester (9CI) (CA INDEX NAME)



IT 168620-28-8P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(aroyl)guanidine derivs. as sodium exchange inhibitors)
RN 168620-28-8 CAPLUS
CN Benzoic acid, 3-[[(aminoiminomethyl)amino]carbonyl]-5-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



L9 ANSWER 169 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:801426 CAPLUS
DN 123:199403
TI Preparation of drug conjugates incorporating amino acid spacers and fatty acid ester residues.
IN Whittaker, Robert George; Bender, Veronika Judith; Reilly, Wayne Gerrard
PA Commonwealth Scientific and Industrial Research Organization, Australia
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9504030	A1	19950209	WO 1994-AU440	19940802
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN				
	RW: KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2167818	AA	19950209	CA 1994-2167818	19940802
	AU 9473420	A1	19950228	AU 1994-73420	19940802
	AU 683289	B2	19971106		
	EP 712389	A1	19960522	EP 1994-922189	19940802
	EP 712389	B1	20010124		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	CN 1128531	A	19960807	CN 1994-192985	19940802
	CN 1125040	B	20031022		
	JP 09501655	T2	19970218	JP 1994-505456	19940802
	RU 2137755	C1	19990920	RU 1996-104379	19940802
	AT 198880	E	20010215	AT 1994-922189	19940802
	ES 2156156	T3	20010616	ES 1994-922189	19940802
	NO 9600389	A	19960130	NO 1996-389	19960130
	NO 313227	B1	20020902		
	FI 9600504	A	19960202	FI 1996-504	19960202
	US 5792786	A	19980811	US 1996-592399	19960412
	US 6353124	B1	20020305	US 1998-16633	19980130
PRAI	AU 1993-325	A	19930802		
	WO 1994-AU440	W	19940802		
	US 1996-592399	A1	19960412		

OS CASREACT 123:199403; MARPAT 123:199403
GI



I

L9 ANSWER 169 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

AB XYNHC(B)(CH2OR1)(CH2OR2) (X = residue of therapeutic compound; Y = null, 1-2 amino acids, peptide residue, spacer group; B = H, CH2OR3; R1, R2, R3 = H, Me, Et, OH, acyl group derived from a fatty acid; ≥1 of R1-R3 = acyl group derived from a fatty acid), were prepared Thus, ibuprofen was stirred with O-(N-succinimidyl)-N,N,N',N'-tetramethyluronium tetrafluoroborate in DMF at pH 8.5; ATP1 [ATP1 = alanine trismonopalmitate; tris = 2-amino-2-hydroxymethyl-1,3-propanediol] in CH2Cl2 was added to give ibuprofen-ATP1 (I). I applied topically had a much greater protective effect than ibuprofen itself on UVB-induced skin burns on mice.
IT **53597-27-6DP**, Fendosal, conjugates
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of drug conjugates incorporating amino acid spacers and fatty acid ester residues)
RN 53597-27-6 CAPLUS
CN Benzoic acid, 5-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)



L9 ANSWER 170 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:354655 CAPLUS
DN 123:256509
TI Substituted indole derivatives as angiotensin II antagonists
IN Clark, Robin D.; Clarke, David E.; Fisher, Lawrence E.; Jahangir, Alam
PA Syntex (U.S.A.) Inc., USA
SO U.S., 45 pp. Cont.-in-part of U.S. 5,212,195.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5380739	A	19950110	US 1993-4869	19930204
	US 5212195	A	19930518	US 1992-882390	19920513
	WO 9323391	A1	19931125	WO 1993-US1533	19930226
	W: AU, CA, FI, HU, JP, KR, NO, NZ				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9337274	A1	19931213	AU 1993-37274	19930226
	AU 672599	B2	19961010		
	EP 640080	A1	19950301	EP 1993-906123	19930226
	EP 640080	B1	19971022		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	HU 68056	A2	19950529	HU 1994-3238	19930226
	JP 07506826	T2	19950727	JP 1993-520179	19930226
	JP 3332234	B2	20021007		
	AT 159524	E	19971115	AT 1993-906123	19930226
	IL 104869	A1	19971120	IL 1993-104869	19930226
	ES 2110086	T3	19980201	ES 1993-906123	19930226
	CN 1039714	B	19980909	CN 1993-102401	19930226
	NZ 299146	A	20000623	NZ 1993-299146	19930226
	FI 9405319	A	19941111	FI 1994-5319	19941111
	NO 9404311	A	19941114	NO 1994-4311	19941111
	NO 308535	B1	20000925		
PRAI	US 1992-882390	A2	19920513		
	US 1993-4869	A	19930204		
	NZ 1993-249729	A1	19930226		
	WO 1993-US1533	A	19930226		

OS MARPAT 123:256509
GI



I

AB Indole derivs. I [wherein: R1 is lower alkyl, cycloalkyl, or cycloalkyl lower alkyl; R2 is 2''-(1H-tetrazol-5-yl)biphenyl-4'-ylmethyl; X is hydrogen, lower alkyl, halogen, C(O)CF3, CO2R4, or C(O)NR5R6 ; Y is hydrogen, lower alkyl, lower alkoxy, hydroxy, halogen, CO2R4 ; Z is hydrogen, lower alkyl, lower alkoxy, or halogen; wherein R4 is hydrogen or lower alkyl; R5 is hydrogen or lower alkyl; R6 is hydrogen or lower alkyl;

L9 ANSWER 170 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
or R5 and R6 taken together with the nitrogen to which they are attached represent a heterocycle; or a pharmaceutically acceptable salt thereof] exhibit useful pharmacol. properties, and are particularly useful as angiotensin II antagonists (no data). Thus, e.g., sapon. of Me 2-ethyl-1-[2''-(1H-tetrazol-5-yl)biphenyl-4'-ylmethyl]indole-7-carboxylate (prepn. given) in NaOH/MeOH/water afforded 2-ethyl-1-[2''-(1H-tetrazol-5-yl)biphenyl-4'-ylmethyl]indole-7-carboxylic acid. Pharmaceutical formulations were given.
IT **154287-04-4P**, 1-(4-Carboxyphenyl)-2-cyanoindole
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(indole derivs. as angiotensin II antagonists)
RN 154287-04-4 CAPLUS
CN Benzoic acid, 4-(2-cyano-1H-indol-1-yl)- (9CI) (CA INDEX NAME)



L9 ANSWER 171 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:330823 CAPLUS
DN 122:105922
TI Preparation of pyrrolopyrazines as 5-HT3 ligands
IN Lancelot, Jean-Charles; Prunier, Herve; Robba, Max; Delagrange, Philippe; Renard, Pierre; Adam, Gerard
PA Adir et Compagnie, Fr.
SO Eur. Pat. Appl., 32 pp.
CODEN: EPXXDW
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 623620	A1	19941109	EP 1994-400881	19940425
	EP 623620	B1	19980909		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	FR 2704547	A1	19941104	FR 1993-5109	19930430
	FR 2704547	B1	19950609		
	AT 170862	E	19980915	AT 1994-400881	19940425
	ES 2123728	T3	19990116	ES 1994-400881	19940425
	CA 2122290	AA	19941031	CA 1994-2122290	19940427
	AU 9461873	A1	19941103	AU 1994-61873	19940428
	AU 671199	B2	19960815		
	ZA 9402964	A	19950210	ZA 1994-2964	19940429
	US 5599812	A	19970204	US 1994-235426	19940429
	JP 06340666	A2	19941213	JP 1994-127963	19940502
PRAI	FR 1993-5109	A	19930430		

OS MARPAT 122:105922
GI



I II

AB Title compds. [I; A = atoms to complete an (un)substituted benzene, -pyridine, -pyrazine, or -pyrimidine ring; R1 = pyrrolidino, piperidino, morpholino, NH(CH2)kNH2, etc.; k = 2-4] were prepared Thus, 2-pyrroloaniline was cyclocondensed with COCl2 and the product converted in 2 steps to title compound II (R = H). II (R = Cl) had ED50 of 31.3μg/kg i.v. against serotonin-induced bradycardia in rats.
IT 10333-68-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrrolopyrazines as 5-HT3 ligands)
RN 10333-68-3 CAPLUS
CN Benzoic acid, 2-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)

L9 ANSWER 171 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 172 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:305882 CAPLUS
DN 123:228180
TI Antihypertensive indole- and benzimidazole-substituted imidazole and benzimidazole derivatives
IN Poss, Michael A.
PA E. R. Squibb and Sons, Inc., USA
SO U.S., 29 pp. Cont.-in-part of U.S. Ser. No. 739,126, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5374615	A	19941220	US 1992-838492	19920207
PRAI	US 1992-838492	B2	19920207		
	US 1991-739126	B2	19910731		
	US 1990-606631		19901031		

OS MARPAT 123:228180
GI



I

AB Novel compds. I [X = N; when X = :N, the double bond is always present; R1 = H, halo, NO2, haloalkyl, CN; R2 = e.g., H, CN, C1-10-alkyl; or R1 and R2 taken together with the carbon atoms of the imidazole nucleus to which they are attached form a benzimidazole; with the proviso that when R1 = H, R2 is other than H; R3 = e.g., C2-10-alkyl, alkenyl or alkynyl of 3-10 C atoms; R4 = e.g, H, halo, haloalkyl; R5 = e.g., H, COR9, NHSO2CF3 (R9 = e.g., H, C1-6-alkyl)]. I inhibit the action of angiotensin II (no data) and are useful, therefore, for example, as antihypertensive agents. Thus, e.g., saponification of 5-[[2-butyl-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]-1-[2-(ethoxycarbonyl)phenyl]-1H-indole-2-carboxylic acid, Et ester (preparation given) with aqueous LiOH afforded 5-[[2-butyl-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]-1-(2-carboxyphenyl)-1H-indole-2-carboxylic acid, dilithium salt. Pharmaceutical formulations were given.
IT 142999-86-8P 142999-87-9P 143017-74-7P

L9 ANSWER 172 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antihypertensive indole- and benzimidazole-substituted imidazole and benzimidazole derivs.)
RN 142999-86-8 CAPLUS
CN 1H-Indole-2-carboxylic acid, 5-[[2-butyl-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]-1-(2-carboxyphenyl)-, dilithium salt (9CI) (CA INDEX NAME)



●2 Li

RN 142999-87-9 CAPLUS
CN Benzoic acid, 2-[5-[[2-butyl-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]-1H-indol-1-yl]-, monolithium salt (9CI) (CA INDEX NAME)



● Li

RN 143017-74-7 CAPLUS
CN Benzoic acid, 2-[4-[[2-butyl-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]-1H-indol-1-yl]-, monolithium salt (9CI) (CA INDEX NAME)

L9 ANSWER 172 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Li

L9 ANSWER 173 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1994:534162 CAPLUS
DN 121:134162
TI Pyrrolopyrimidines as CRF antagonists
IN Chen, Yuhpyng L.
PA Pfizer Inc., USA
SO PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9413676	A1	19940623	WO 1993-US10715	19931112
	W: AU, BR, CA, CZ, JP, KR, NO, NZ, PL, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2150016	AA	19940623	CA 1993-2150016	19931112
	CA 2150016	C	20000208		
	AU 9456664	A1	19940704	AU 1994-56664	19931112
	AU 690090	B2	19980423		
	EP 674641	A1	19951004	EP 1994-902214	19931112
	EP 674641	B1	19990303		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	JP 07509726	T2	19951026	JP 1993-514157	19931112
	JP 2895961	B2	19990531		
	RU 2124015	C1	19981227	RU 1995-113862	19931112
	AT 177101	E	19990315	AT 1994-902214	19931112
	ES 2128544	T3	19990516	ES 1994-902214	19931112
	BR 9307646	A	19990525	BR 1993-7646	19931112
	PL 176526	B1	19990630	PL 1993-309357	19931112
	CZ 286892	B6	20000712	CZ 1995-1584	19931112
	IL 119461	A1	20000229	IL 1993-119461	19931206
	IL 119462	A1	20000229	IL 1993-119462	19931206
	IL 107897	A1	20010128	IL 1993-107897	19931206
	HU 70505	A2	19951030	HU 1993-3515	19931209
	HU 221587	B	20021128		
	ZA 9309271	A	19950612	ZA 1993-9271	19931210
	FI 9305585	A	19940618	FI 1993-5585	19931213
	CN 1097758	A	19950125	CN 1993-120179	19931213
	CN 1038131	B	19980422		
	US 6765008	B1	20040720	US 1995-448539	19950614
	NO 9502398	A	19950616	NO 1995-2398	19950616
	NO 306678	B1	19991206		
	CN 1189339	A	19980805	CN 1997-119551	19970916
	FI 2000000343	A	20000216	FI 2000-343	20000216
	FI 109799	B1	20021015		
PRAI	US 1992-991764	A	19921217		
	WO 1993-US10715	W	19931112		
	IL 1993-107897	A3	19931206		

OS MARPAT 121:134162
GI

L9 ANSWER 173 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I II

AB The title compds., 7H-pyrrolo[2,3-d]pyrimidines I (B = amino group, alkylthio, etc.; R3, R4 = H, alkyl, halo, etc.; R5 = Ph, naphthyl, heteroaryl, etc.; R6 = H, alkyl, halo, etc.) were disclosed. I are useful in the treatment of stress-related and other diseases. I have ACTH-releasing factor antagonist activity and as such are of use in the treatment of depression and anxiety related, and other disorders.3. A specifically claimed example compound is N-butyl-N-ethyl-2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (II).

IT **157285-55-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as ACTH-releasing factor antagonist)

RN 157285-55-7 CAPLUS

CN Benzoic acid, 4-[4-(butylethylamino)-2,5-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-3,5-dimethyl- (9CI) (CA INDEX NAME)



L9 ANSWER 174 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1994:270407 CAPLUS
DN 120:270407
TI Preparation of substituted indoles and azaindoles as angiotensin II antagonists
IN Fisher, Lawrence E.; Clarke, David E.; Jahangir, Alam; Clark, Robin D.
PA Syntex (U.S.A.), Inc., USA
SO PCT Int. Appl., 113 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9323391	A1	19931125	WO 1993-US1533	19930226
	W: AU, CA, FI, HU, JP, KR, NO, NZ				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5212195	A	19930518	US 1992-882390	19920513
	US 5380739	A	19950110	US 1993-4869	19930204
	AU 9337274	A1	19931213	AU 1993-37274	19930226
	AU 672599	B2	19961010		
	EP 640080	A1	19950301	EP 1993-906123	19930226
	EP 640080	B1	19971022		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 07506826	T2	19950727	JP 1993-520179	19930226
	JP 3332234	B2	20021007		
	FI 9405319	A	19941111	FI 1994-5319	19941111
	NO 9404311	A	19941114	NO 1994-4311	19941111
	NO 308535	B1	20000925		
PRAI	US 1992-882390	A	19920513		
	US 1993-4869	A	19930204		
	WO 1993-US1533	A	19930226		

OS MARPAT 120:270407
GI



I II III

AB Title compds. I, II, III (R = alkyl when R2 = V, R2 = alkyl when R1 = V wherein V = R,C6H4CH2 wherein R7 = substituted Ph, substituted furanyl, substituted thiophenyl, disubstituted thiophenyl, etc.; R3 = H, alkyl; X

L9 ANSWER 174 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
H, alkyl, halo, F3CCO, R4O2C wherein R4 = H, alkyl; (substituted) aminocarbonyl; Y = H, alkyl, alkoxy, HO, halo R4O2C; Z = H, alkyl, alkoxy,
halo) and a salt thereof, are prepd. 1-N-butyl-2-(2-cyanobiphenyl-4-ylmethyl)indole-3-carboxylic acid (prepn. given), xylene and Bu3SuN3 were refluxed for 20 h to give I [R1 = u-Bu, R2 = 2"-(1H-tetrazol-5-yl)biphenyl-
4'-ylmethyl; X = HO2C, Y = Z = H] (IV). In an assay for detn. of affinity
for angiotensin II receptors the pK; of IV was 7.7. Antihypertensive activity and cognitive enhancement assay were demonstrated for the title compds. Pharmaceutical formulations of I, II and III are given.
IT 154287-04-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of angiotensin II receptor
antagonists)
RN 154287-04-4 CAPLUS
CN Benzoic acid, 4-(2-cyano-1H-indol-1-yl)- (9CI) (CA INDEX NAME)



L9 ANSWER 175 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1993:517246 CAPLUS
DN 119:117246
TI Preparation and formulation of fused heterocyclic compounds as angiotensin
II antagonists
IN Naka, Takehiko; Inada, Yoshiyuki
PA Takeda Chemical Industries, Ltd., Japan
SO Can. Pat. Appl., 160 pp.
CODEN: CPXXEB
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CA 2066094	AA	19921017	CA 1992-2066094	19920415
	CA 2066094	C	20030624		
	JP 05163267	A2	19930629	JP 1992-137485	19920415
	JP 3260415	B2	20020225		
	JP 2001328988	A2	20011127	JP 2001-159745	19920415
	EP 518033	A1	19921216	EP 1992-106621	19920416
	EP 518033	B1	20030702		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, PT, SE				
	KR 217164	B1	19990901	KR 1992-6383	19920416
	AT 244240	E	20030715	AT 1992-106621	19920416
	EP 1327631	A2	20030716	EP 2003-6453	19920416
	EP 1327631	A3	20040211		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT				
	US 5389641	A	19950214	US 1993-127356	19930928
PRAI	JP 1991-173473	A	19910416		
	JP 1991-263341	A	19910705		
	JP 1991-315629	A	19910925		
	JP 1992-137485	A3	19920415		
	EP 1992-106621	A3	19920416		
	US 1992-868841	B1	19920416		

OS MARPAT 119:117246
GI

L9 ANSWER 175 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Title compds. (I R1 = an optionally substituted hydrocarbon residue which may be attached through a hetero atom; R2 = a group capable of forming an anion or a group convertible thereinto; R3 = an optionally substituted aromatic hydrocarbon or heterocyclic residue which contains at least one hetero atom; X = a direct bond or a spacer having an atomic length of two or
less between the R3 group and the ring W group; W = an optionally substituted aromatic hydrocarbon or heterocyclic residue which contains at
least one hetero atom; a, c and d are independently selected from the group consisting of one or two optionally substituted carbon atoms and one
or two optionally substituted hetero atoms; b and e are independently selected from the group consisting of one optionally substituted carbon atom and one optionally substituted nitrogen atom; the dotted line is a bond to form one double bond; n is an integer of 1 or 2 and when a, which is an optionally substituted carbon atom, is taken together with R1, R1c:a
may form a ring) were prepared Thus, 3-methyl-4,5-diaminopyridine was cyclocondensed with BuCO2H and the product converted in 3 steps to imidazopyridinecarboxylate II (R = H, R4 = Me) which was condensed with R5Br (R5 = biphenylylmethyl group Q, R6 = CPh3) to give, after deprotection and saponification, II (R = Q, R4 = R6 = H) which gave 63% inhibition
of angiotensin II binding at 10-7M in vitro.
IT 149323-68-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of angiotensin II inhibitors)
RN 149323-68-2 CAPLUS
CN Benzoic acid, 4-(2-formyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)

L9 ANSWER 175 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 176 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1990:571868 CAPLUS
DN 113:171868
TI Preparation of N-alkyl-N-alkenynylheterocyclylbenzyloxybenzylamines as anticholesteremics
IN Takezawa, Hiroshi; Hayashi, Masahiro; Iwasawa, Yoshikazu; Hosoi, Masaaki; Iida, Yoshiaki; Tsuchiya, Yoshimi; Horie, Masahiro; Kamei, Toshio
PA Banyu Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 135 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9005132	A1	19900517	WO 1989-JP522	19890525
	W: AU, DK, JP, KR, US				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	AU 8937328	A1	19900528	AU 1989-37328	19890525
	EP 395768	A1	19901107	EP 1989-906430	19890525
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	ZA 8908464	A	19910130	ZA 1989-8464	19891107
	ES 2018420	A6	19910401	ES 1989-3833	19891110
	JP 03173865	A2	19910729	JP 1989-291008	19891110
	CN 1042910	A	19900613	CN 1989-109196	19891111
	DK 9001665	A	19900907	DK 1990-1665	19900710
PRAI	JP 1988-285381	A	19881111		
	JP 1989-505699		19890525		
	WO 1989-JP522	A	19890525		

OS MARPAT 113:171868
GI



I

AB The title compds. I [A1, A2 = methine, N, O, S; Q1, Q2 may contain 1 or 2 heteroatoms and form a 5- or 6-membered aromatic ring together with adjacent C atoms and A1 or A2; X, Y = O, S, carbonyl, CHRa (Ra = H, alkyl), etc.; or XY may form a vinylene or ethynylene group; R1 = 5- or 6-membered heterocyclic ring containing 1-4 heteroatoms; R2 = alkyl, allyl, propargyl, cyclopropyl; R3, R4 = alkyl, or CR3R4 = cycloalkane; R5 = H, alkyl, alkoxy; R6, R7 = halo, OH, cyano, alkyl, alkoxy, provided that when one of X and Y is O, S, NRb (Rb = H, alkyl), the other is carbonyl or CHRa) were prepared for treatment of arteriosclerosis. A mixture of (E)-N-ethyl-N-(6-methoxy-6-methyl-2-hepten-4-ynyl)-3-hydroxybenzylamine and NaH in THF was stirred at room temperature for 10 min. After addition of a solution of

L9 ANSWER 176 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
3-(3-thienyl)benzyl methanesulfonate in DMF, the reaction mixt. was stirred overnight to give, after workup and treatment with HCl, (E)-N-ethyl-N-(6-methoxy-6-methyl-2-hepten-4-ynyl)-3-[3-(3-thienyl)benzyloxy]benzylamine hydrochloride (II). II in vitro exhibited an IC50 of 11 nM against cholesterol biosynthesis in human hepatoma (Hep-G2) cells.
IT 61471-45-2, 3-(1-Pyrrolyl)benzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of anticholesteremic)
RN 61471-45-2 CAPLUS
CN Benzoic acid, 3-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



L9 ANSWER 177 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1987:470649 CAPLUS
DN 107:70649
TI Preliminary studies on the analgesic activity of some phenylacetic acid derivatives and other structural analogs
AU Miguelez, J.; Teran, T.; Negro, A.; Serrano, J. M.; Cabanas, L. F.; Santiago, D.
CS Fac. Vet., Univ. Cordoba, Cordoba, Spain
SO Anales de la Facultad de Veterinaria de Leon (1985), 31, 125-32
CODEN: AFVLA5; ISSN: 0373-1170
DT Journal
LA Spanish
AB The analgesic activities of α-(N-pyrrolyl)phenylacetic acid, dibenzylamine α-(N-pyrrolyl)-p-hydroxyphenylacetate, 2-(N-pyrrolyl) benzoic acid, 4-(N-pyrrolyl)bengoic acid, α-(N-pyrrolyl)-p-hydroxyphenylpropionic acid, α-(N-pyrrolyl)-p-fluorophenylpropionic acid, and α-(N-pyrrolyl)-p-chlorophenylpropionic acid were studied in mice. All compds. tested exhibited stronger analgesic activity than aspirin, the standard The most active compound was dibenzylamine α-(N-pyrrolyl)-p-hydroxyphenylacetate.
IT **10333-68-3 22106-33-8**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(analgesic activity of)
RN 10333-68-3 CAPLUS
CN Benzoic acid, 2-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 22106-33-8 CAPLUS
CN Benzoic acid, 4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



L9 ANSWER 178 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1984:603899 CAPLUS
DN 101:203899
TI N-Arylpyrrole derivatives with analgesic and antiinflammatory activity. Part 2. Pharmacomodulation of a 1-arylpyrrole model
AU Thiault, G. A.; Le Guen, Y.; Boucherle, A.; Walrant, P.
CS PCAS, Longjumeau, 91611, Fr.
SO Farmaco, Edizione Scientifica (1984), 39(9), 765-80
CODEN: FRPSAX; ISSN: 0430-0920
DT Journal
LA French
OS CASREACT 101:203899
GI



I



II, R=Me
III, R=Et

AB Twenty N-arylpyrroles were prepared and 3 were extensively tested for pharmacol. activity. All 3 arylpyrroles, I [93078-56-9], II [93078-57-0], and III [93078-58-1] showed antiinflammatory activity, and 2 of them (I and II) also possessed analgesic activity. None showed anxiolytic or anticonvulsant, but all exhibited sedative activity. II appeared to be the most promising of the 3 arylpyrroles tested.
IT **93078-55-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and amidation of)
RN 93078-55-8 CAPLUS
CN Benzoic acid, 4-[2-(4-cyclohexylphenyl)-5-methyl-1H-pyrrol-1-yl]-2-methoxy- (9CI) (CA INDEX NAME)

L9 ANSWER 178 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L9 ANSWER 179 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1984:465552 CAPLUS
DN 101:65552
TI N-Arylpyrrole derivatives with analgesic and antiinflammatory activities. Part I. 4,5-Disubstituted 1-arylpyrroles
AU Thiault, G. A.; Le Guen, Y.; Boucherle, A.; Walrant, P.
CS PCAS, Longjumeau, 91611, Fr.
SO Farmaco, Edizione Scientifica (1984), 39(6), 524-37
CODEN: FRPSAX; ISSN: 0430-0920
DT Journal
LA French
GI



AB Thirty-nine pyrroles (I; R1 = 4-cyclohexylphenyl, tetrahydronaphthyl, di-Ph, etc.; R2 = Cl, F, CF3, Br, OMe, Me, etc.; R3 = Me, Et, p-ClC6H4, Ph) were prepared and tested for pharmacol. activity. All the compds. showed analgesic and antiinflammatory activity, but only at relatively high i.p. doses. For the series of compds. where R1 was 4-cyclohexylphenyl and R3 was Me, the relative order of analgesic activity with respect to the R2 substituent was: 3-CO2H > 4-Me > 3,4-Cl2 = 4-NO2 = 4-Br > 3-CF3 > H. The corresponding order for antiinflammatory activity was: 4-Me > 3-CO2H > 4-NO2 > H.
IT **91306-87-5P 91306-88-6P 91306-96-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and analgesic and antiinflammatory activity of)
RN 91306-87-5 CAPLUS
CN Benzoic acid, 4-[2-(4-cyclohexylphenyl)-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 179 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 91306-88-6 CAPLUS
CN Benzoic acid, 3-[2-(4-cyclohexylphenyl)-5-methyl-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



RN 91306-96-6 CAPLUS
CN Benzoic acid, 3-(2-[1,1'-biphenyl]-4-yl-5-methyl-1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



L9 ANSWER 180 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1979:611822 CAPLUS
DN 91:211822
TI Antihypertensive compositions containing an aryl-substituted alanine azo and an arylhydrazinopropionic acid
IN Stone, Clement A.
PA Merck and Co., Inc., USA
SO U.S., 28 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4156734	A	19790529	US 1978-877532	19780213
	US 4160835	A	19790710	US 1977-850755	19771111
	US 4170654	A	19791009	US 1978-922460	19780706
PRAI	US 1976-657822	A2	19760213		
	US 1976-743369	A1	19761119		
	US 1977-850755	A3	19771111		

OS MARPAT 91:211822
GI



AB 3-Arylalanines I (R = H, CO2H, CN, NCNH, CSNH2, H2NCH2CH2, guanidino, OH, MeSO2NH, NO2, NH2, MeSO3, H2OCCH2O, formyl, MeO; R1 = substituted or unsubstituted 5-membered heterocyclic ring containing 1 or more N atoms; R2 and R3 = H, C1-4 alkyl) and decarboxylase-inhibiting α-hydrazinodopa analogs II (R4, R5, R6, and R7 = H, C1-4 alkyl) were prepared as antihypertensives. Thus, 4-amino-α-methyl-DL-phenylalanine dihydrochloride was treated with BrCN in H2O containing NaOAc for 30 min to give a mixture which was treated with more BrCN for 16 h at room temperature to give 77% DL-I (R = R3 = H, R1 = NCNH, R2 = Me) (III). Sixty-nine other examples are given. III at 0.3 mg/kg exhibited a slightly active antihypertensive rating in rats.
IT **71935-21-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(hydride reduction of)
RN 71935-21-2 CAPLUS
CN Benzoic acid, 4-(9H-carbazol-9-yl)- (9CI) (CA INDEX NAME)

L9 ANSWER 180 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT **71935-16-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydride reduction of)
RN 71935-16-5 CAPLUS
CN Benzoic acid, 4-(1H-indol-1-yl)- (9CI) (CA INDEX NAME)



L9 ANSWER 181 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzoic acid, 2-hydroxy-5-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



L9 ANSWER 181 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1979:16188 CAPLUS
DN 90:16188
TI Synthesis and analgesic-antiinflammatory activity of some 4- and 5-substituted heteroarylsalicylic acids
AU Jones, Howard; Fordice, Michael W.; Greenwald, Ronald B.; Hannah, John; Jacobs, Arlene; Ruyle, William V.; Walford, G. Lyn; Shen, T. Y.
CS Merck Sharp and Dohme Res. Lab., Rahway, NJ, USA
SO Journal of Medicinal Chemistry (1978), 21(11), 1100-4
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
OS CASREACT 90:16188
GI



I

AB The title compds. I (R = heterocyclic group), prepared by different routes,
were tested for antiinflammatory-analgesic activities and were compared to
aspirin. The rat carageenan edema model and rat hyperesthesia analgesic assay were used. 5-N-pyrrylsalicylic acid [**53242-70-9**] prepared by the reaction of 5-aminosalicylic acid [89-57-6] with 2,5-dimethoxytetrahydrofuran [696-59-3] was the most active in both tests
with less gastric toxicity than aspirin.
IT **35580-52-0P 53242-70-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and analgesic and antiinflammatory activities of)
RN 35580-52-0 CAPLUS
CN Benzoic acid, 2-hydroxy-4-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 53242-70-9 CAPLUS

L9 ANSWER 182 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1978:83720 CAPLUS
DN 88:83720
TI Use of N-phenyl-substituted condensed pyrroles in the treatment of skin inflammations
IN Lassman, Howard B.; Novick, William J., Jr.
PA Hoechst A.-G., Fed. Rep. Ger.
SO Ger. Offen., 8 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 2721085	A1	19771201	DE 1977-2721085	19770511
US 4056624	A	19771101	US 1976-686525	19760514
PRAI US 1976-686525	A	19760514		

GI For diagram(s), see printed CA Issue.
AB The title compds. (I; R-R4 refer to a wide variety of substituents; X = various alkylenes on condensed hydrocarbon moieties) are antiinflammatory substances for local application in salves, creams, suspensions, etc., containing 0.05-20% active ingredient. Of special interest are I with R = Ph,
R1 = m-CO2H, R2 = p-OH or p-OAc, and R4 = H. Thus, the croton oil-induced
edema of the mouse ear was reduced 50% by the local application of 0.7 mg 3-(4-acetoxy-3-carboxyphenyl)-4,5-dihydro-2-phenylbenz[e]indole [**54669-70-4**].
IT **53597-27-6 54669-65-7 54669-70-4 54670-07-4 54670-22-3 54670-23-4**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(inflammation inhibition by)
RN 53597-27-6 CAPLUS
CN Benzoic acid, 5-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)



RN 54669-65-7 CAPLUS
CN Benzoic acid, 2-hydroxy-5-(4,5,6,7-tetrahydro-2-phenyl-1H-indol-1-yl)- (9CI) (CA INDEX NAME)

L9 ANSWER 182 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 54669-70-4 CAPLUS
CN Benzoic acid,
2-(acetyloxy)-5-(4,5-dihydro-2-phenyl-3H-benz[e]indol-3-yl)-
(9CI) (CA INDEX NAME)



RN 54670-07-4 CAPLUS
CN Benzoic acid, 2-hydroxy-5-(2-phenyl-1H-indol-1-yl)- (9CI) (CA INDEX NAME)



RN 54670-22-3 CAPLUS
CN Benzoic acid,
2-(acetyloxy)-5-(4,5,6,7-tetrahydro-2-phenyl-1H-indol-1-yl)-
(9CI) (CA INDEX NAME)

L9 ANSWER 182 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 54670-23-4 CAPLUS
CN Benzoic acid, 2-(acetyloxy)-5-(2-phenyl-1H-indol-1-yl)- (9CI) (CA INDEX NAME)



L9 ANSWER 183 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1975:86270 CAPLUS
DN 82:86270
TI N-Substituted pyrrole derivatives
IN Kawamatsu, Yutaka; Sugihara, Hirosada; Matsumoto, Norichika; Hamuro, Yukihiko
PA Takeda Chemical Industries, Ltd.
SO Jpn. Tokkyo Koho, 4 pp.
CODEN: JAXXAD
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 49024065	B4	19740620	JP 1970-71888	19700817
PRAI JP 1970-71888		19700817		

GI For diagram(s), see printed CA Issue.
AB o-Amino carboxylic acids (I) or their inorg. salts were treated with 2,5-dialkoxytetrahydrofurans (II) to give N-substituted pyrroles (III; ring A is benzene, pyridine, thiophene or benzothiophene, optionally substituted by lower alkyl, alkoxy, halogen, nitro or carboxyl; R1 and R2 = H, lower alkyl; OR3 and OR4 = etherified hydroxy). When R1 = R2 = H, X = CR5:CR6CR7:CH (R5, R6 and R7 = H, lower alkoxy, Cl, NO2 and at least one of them is not H R5, R6 and R7 are at positions 3, 4, and 5, resp.). III are antidiabetics (LD50 4 g/kg). Thus, 3.1 g Me 6-chloroanthranilate and 2.2 g II (R1 = R2 = H; R3 = R4 = Me) was refluxed in AcOH under N and the product hydrolyzed by refluxing with KOH-MeOH to give 84% 1-(3-chloro-2-carboxyphenyl)pyrrole.
IT **54779-76-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antidiabetic activity of)
RN 54779-76-9 CAPLUS
CN Benzoic acid, 2-chloro-6-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



L9 ANSWER 184 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1975:4227 CAPLUS
DN 82:4227
TI Analgesic and antiinflammatory 5-(1,4,6,7-tetrahydro-2-phenylthiopyrano[4,3-b]pyrrol-1-yl)salicylic acids
IN Allen, Richard C.; Taylor, Chandler R., Jr.
PA Farbwerke Hoechst A.-G.
SO Ger. Offen., 18 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 2407888	A1	19740912	DE 1974-2407888	19740219
US 3865839	A	19750211	US 1973-336920	19730301
NL 7402463	A	19740903	NL 1974-2463	19740222
FR 2219779	A1	19740927	FR 1974-6776	19740228
AT 7401655	A	19760115	AT 1974-1655	19740228
AT 332398	B	19760927		
BE 811786	A1	19740902	BE 1974-141570	19740301
JP 49134695	A2	19741225	JP 1974-23477	19740301
GB 1452203	A	19761013	GB 1974-9466	19740301
PRAI US 1973-336920	A	19730301		

GI For diagram(s), see printed CA Issue.
AB Ten acids I (n = 0, 1, or 2; R = H, Br-4, F-4, Cl-4, Ph-4, CF3-3, or MeO-3 or -4) were prepared by reaction of 2,3,5,6-tetrahydro-3-phenacylthiopyran-4-one (II) or its derivs. with 2,5-HO(H2N)C6H3CO2H (III), optionally followed by oxidation I had analgesic or antiinflammatory activity when tested in the mouse or rat, resp. Thus, tetrahydrothiopyran-4-one and pyrrolidine were refluxed in C6H6 to give 5,6-dihydro-4-(1-pyrrolidinyl)-2H-thiopyran, which was treated with PhCOCH2Br in DMF to give II. II and III were refluxed in AcOH to give 50% I (n = 0, R = H) (IV). Treatment of IV with NaIO4 in EtOH at 0° gave I (n = 1, R = H).
IT **54030-13-6P 54030-16-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and analgesic and antiinflammatory activity of)
RN 54030-13-6 CAPLUS
CN Benzoic acid, 5-(6,7-dihydro-2-phenylthiopyrano[4,3-b]pyrrol-1(4H)-yl)-2-hydroxy- (9CI) (CA INDEX NAME)



RN 54030-16-9 CAPLUS

L9 ANSWER 184 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzoic acid, 5-[6,7-dihydro-2-(4-methoxyphenyl)thiopyrano[4,3-b]pyrrol-1(4H)-yl]-2-hydroxy- (9CI) (CA INDEX NAME)



IT 54030-15-8P 54030-19-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antiinflammatory activity of)
RN 54030-15-8 CAPLUS
CN Benzoic acid, 5-[2-(4-fluorophenyl)-6,7-dihydrothiopyrano[4,3-b]pyrrol-1(4H)-yl]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 54030-19-2 CAPLUS
CN Benzoic acid, 5-[6,7-dihydro-2-(3-methoxyphenyl)thiopyrano[4,3-b]pyrrol-1(4H)-yl]-2-hydroxy- (9CI) (CA INDEX NAME)



L9 ANSWER 184 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzoic acid, 5-(2-[1,1'-biphenyl]-4-yl-6,7-dihydrothiopyrano[4,3-b]pyrrol-1(4H)-yl)-2-hydroxy- (9CI) (CA INDEX NAME)



RN 54030-21-6 CAPLUS
CN Benzoic acid, 5-(6,7-dihydro-5,5-dioxido-2-phenylthiopyrano[4,3-b]pyrrol-1(4H)-yl)-2-hydroxy- (9CI) (CA INDEX NAME)



RN 54030-22-7 CAPLUS
CN Benzoic acid, 5-(6,7-dihydro-5-oxido-2-phenylthiopyrano[4,3-b]pyrrol-1(4H)-yl)-2-hydroxy- (9CI) (CA INDEX NAME)



L9 ANSWER 184 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
IT 54030-14-7P 54030-17-0P 54030-18-1P 54030-20-5P 54030-21-6P 54030-22-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 54030-14-7 CAPLUS
CN Benzoic acid, 5-[2-(4-bromophenyl)-6,7-dihydrothiopyrano[4,3-b]pyrrol-1(4H)-yl]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 54030-17-0 CAPLUS
CN Benzoic acid, 5-[2-(4-chlorophenyl)-6,7-dihydrothiopyrano[4,3-b]pyrrol-1(4H)-yl]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 54030-18-1 CAPLUS
CN Benzoic acid, 5-[6,7-dihydro-2-[3-(trifluoromethyl)phenyl]thiopyrano[4,3-b]pyrrol-1(4H)-yl]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 54030-20-5 CAPLUS

L9 ANSWER 185 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1974:463478 CAPLUS
DN 81:63478
TI 5-N-Pyrrylsalicyclic acid
IN Sarett, Lewis H.; Ruyle, William V.
PA Merck and Co., Inc.
SO S. African, 34 pp.
CODEN: SFXXAB
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	ZA 7201129	A	19731031	ZA 1972-1129	19720221
PRAI	ZA 1972-1129	A	19720221		

GI For diagram(s), see printed CA Issue.
AB The title compound (I) was prepared by several methods. Thus, 2,5-HO(H2N)C6H3CO2H was treated with 2,5-dimethoxytetrahy-drofuran in presence of p-MeC6H4SO3H to give I. The antiinflammatory ED50 of I was 67 mg/kg. The antiinflammatory activity of I was compared with several heterocyclic salicylic acids.
IT 53242-70-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antiinflammatory activities of)
RN 53242-70-9 CAPLUS
CN Benzoic acid, 2-hydroxy-5-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



IT 53242-68-5P 53242-72-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 53242-68-5 CAPLUS
CN Benzoic acid, 2-chloro-5-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)

L9 ANSWER 185 OF 185 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 53242-72-1 CAPLUS
CN Benzoic acid, 2-methoxy-5-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



```
=> => d que l13 stat
L12             4 SEA FILE=REGISTRY ABB=ON  PLU=ON  (114067-97-9 OR 138907-81-0
                  OR 138907-82-1 OR 265986-57-0)/RN
L13             8 SEA FILE=CAPLUS ABB=ON  PLU=ON  L12

=> d 1-8 bib abs hitstr
```

L13 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:572591 CAPLUS
DN 143:78185
TI A preparation of (pyridin-4-ylethynyl)imidazole derivatives, useful for the treatment of mGluR5 receptor mediated disorders
IN Buettelmann, Bernd; Ceccarelli, Simona Maria; Jaeschke, Georg; Kolczewski, Sabine; Philip, Porter Richard Hugh; Vieira, Eric; Ford, Anthony P. D. W.; Zhong, Yu
PA Roche Palo Alto Llc, Germany
SO U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S. Ser. No. 858,969.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005143375	A1	20050630	US 2004-20451	20041222
	AU 2004245208	A1	20041216	AU 2004-245208	20040601
	CA 2527315	AA	20041216	CA 2004-2527315	20040601
	EP 1636206	A1	20060322	EP 2004-739484	20040601
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
	US 2004248888	A1	20041209	US 2004-858969	20040602
	NO 2005005465	A	20051118	NO 2005-5465	20051118
PRAI	EP 2003-12200	A	20030605		
	US 2004-858969	A2	20040602		
	WO 2004-EP5881	W	20040601		

OS MARPAT 143:78185
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a preparation of (pyridin-4-ylethynyl)imidazole derivs. of formula I [wherein: R1 = halo, CN; R2 = alkyl; R3 = (un)substituted (hetero)aryl; R4 = H, CHO, CH2OH, etc.], useful as mGluR5 receptor antagonists. These compds. can be used in the treatment or prevention of mGluR5 receptor mediated disorders. These compds. are useful in the treatment of urinary tract disease such as, but not limited to, reduced bladder capacity, urge incontinence and stress incontinence. For instance, (pyridin-4-ylethynyl)imidazole derivative II (Ki = 23 nM) was prepared from 2-fluoro-4-iodopyridine and 4-ethynyl-1-(4-fluorophenyl)-2-methyl-1H-imidazole. Pharmaceutical compns. comprising I are disclosed.
IT 114067-97-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (pyridinylethynyl)imidazole derivs. useful for the treatment of mGluR5 receptor mediated disorders)
RN 114067-97-9 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 1-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

L13 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L13 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:1060777 CAPLUS
DN 142:23285
TI A preparation of (pyridin-4-ylethynyl)imidazole derivatives, useful for the treatment of mGluR5 receptor mediated disorders
IN Buettelmann, Bernd; Ceccarelli, Simona Maria; Jaeschke, Georg; Kolczewski, Sabine; Porter, Richard Hugh Philip; Vieira, Eric
PA Germany
SO U.S. Pat. Appl. Publ., 28 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004248888	A1	20041209	US 2004-858969	20040602
	AU 2004245208	A1	20041216	AU 2004-245208	20040601
	CA 2527315	AA	20041216	CA 2004-2527315	20040601
	EP 1636206	A1	20060322	EP 2004-739484	20040601
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
	US 2005143375	A1	20050630	US 2004-20451	20041222
	NO 2005005465	A	20051118	NO 2005-5465	20051118
PRAI	EP 2003-12200	A	20030605		
	WO 2004-EP5881	W	20040601		
	US 2004-858969	A2	20040602		

OS MARPAT 142:23285
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a preparation of (pyridin-4-ylethynyl)imidazole derivs. of formula I [wherein: R1 is halo or CN; R2 is alkyl; R3 is (un)substituted (hetero)aryl; R4 is H, CHO, CH2OH, or Me, etc.], useful as mGluR5 receptor antagonists. These compds. can be used in the treatment or prevention of mGluR5 receptor mediated disorders. These compds. are useful in the treatment or prevention of acute and/or chronic neurol. disorders such as psychosis, epilepsy, schizophrenia, Alzheimer disease, and cognititve disorders, etc. For instance, (pyridin-4-ylethynyl)imidazole derivative II (Ki = 23 nM) was prepared from 2-fluoro-4-iodopyridine and 4-ethynyl-1-(4-fluorophenyl)-2-methyl-1H-imidazole.
IT 114067-97-9P, 1-(4-Fluorophenyl)-1H-imidazole-4-carboxylic acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (pyridinylethynyl)imidazole derivs. useful for treatment of mGluR5 receptor mediated disorders)
RN 114067-97-9 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 1-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

L13 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L13 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:817667 CAPLUS
DN 141:327646
TI Inhibitors of cathepsin S for use in pharmaceuticals
IN Liu, Hong; Alper, Phil; Chatterjee, Arnab; Tully, David; Bursulaya, Badry;
Woodmansee, David; Epple, Robert; Harris, Jennifer Leslie; Li, Jun
PA IRM LLC, Bermuda
SO PCT Int. Appl., 166 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004084843	A2	20041007	WO 2004-US9414	20040324
	WO 2004084843	A3	20050929		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004248887	A1	20041209	US 2004-807613	20040323
PRAI	US 2003-457848P	P	20030324		
	US 2004-807613	A	20040323		

OS MARPAT 141:327646
AB The present invention provides compds. R1-Y-X-NH-C(R2)(R3)-(CH)n(R4)-CO-NH-C(R5)(R6)-C(R7)(R8)-N(R9)-Ar [R1 = H, (substituted)C6-10-aryl, 5-6-membered monocyclic, 8-10-membered bicyclic heteroaryl, C3-8-cycloalkyl or C3-8-heterocycle; R2 = (substituted)phenyl, 5-6-membered heteroaryl, C2-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-7-cycloalkyl, C7-11-bicycloalkyl; R3 = H, C1-4-alkyl; n = 0, 1; R4 = H, C1-6-alkyl; R5 = H, C3-7-cycloalkyl, C2-6-alkenyl, C2-6-alkynyl, (substituted)phenyl, 5-6-membered heteroaryl, C1-6-alkyl; Y = bond, (CR20R21)mW(CR22R23)p; m = 0,1; p = 1,2; W = bond, O, S, SO, SO2, NR12; X = CO,OCO,NR24CO, SO2; R6-9 = H, C1-4-alkyl; Ar = substituted Ph or 5-6-membered heteroaryl; R20-23 = bond, H, F, OH, C1-4-alkyl, C1-3-alkylhydroxy; R12 = H, C1-4-alkyl] and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isoenzyme. The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S. Thus, (S)-3-cyclohexyl-N-[2-(5-fluoro-2,3-dihydroindol-1-yl)ethyl]-2-[5-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yl)thiophene-2-sulfonylamino]propionamide was synthesized. This compound displayed a Ki for cathepsin S of <0.1 μM and Ki's for cathepsins B, K, and L of > 10 μM.
IT 138907-82-1
RL: RCT (Reactant); RACT (Reactant or reagent)

L13 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(inhibitors of cathepsin S for use in pharmaceuticals)
RN 138907-82-1 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



L13 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:780691 CAPLUS
DN 141:296020
TI Preparation of (1H-imidazol-4-yl)ethynylpyridines as metabotropic glutamate 5 receptor antagonists for treating neurodegenerative diseases, in particular anxiety
IN Buettelmann, Bernd; Ceccarelli, Simona Maria; Jaeschke, Georg; Kolczewski,
Sabine; Porter, Richard Hugh Philip; Vieira, Eric
PA F. Hoffmann-La Roche A.-G., Switz.
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004080998	A1	20040923	WO 2004-EP2276	20040305
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004220382	A1	20040923	AU 2004-220382	20040305
	CA 2516682	AA	20040923	CA 2004-2516682	20040305
	EP 1606277	A1	20051221	EP 2004-717578	20040305
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004008093	A	20060214	BR 2004-8093	20040305
	CN 1759111	A	20060412	CN 2004-80006572	20040305
	US 2004229917	A1	20041118	US 2004-795619	20040308
	NO 2005004136	A	20050926	NO 2005-4136	20050906
PRAI	EP 2003-4952	A	20030310		
	WO 2004-EP2276	A	20040305		

OS MARPAT 141:296020
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB 4-(1-Aryl-1H-imidazol-4-ylethynyl)-2-alkylpyridine and 4-(1-heteroaryl-1H-imidazol-4-ylethynyl)-2-alkylpyridine derivs. of formula I [wherein R1 = alkyl; R2 = cyclo/alkyl; R3 = (un)substituted hetero/aryl; R4 = H, C(:O)H, CH2R5; R5 = H, OH, cyclo/alkyl; and their pharmaceutically acceptable salts] were prepared as metabotropic glutamate receptor 5 (mGluR 5), especially mGluR 5a, antagonists for treating neurodegenerative diseases, in particular anxiety. For example, II was prepared, in 2 steps, by reacting 4-iodo-2-methyl-1H-imidazole with 4-fluorophenylboronic acid in THF in the presence of Cu(OAc)2/TEA, followed by Sonogashira reaction of the iodide with 2-methyl-4-[(trimethylsilanyl)ethynyl]pyridine (preparation given). I displayed Ki < 150 nM in a radioligand binding assay. I are useful for treating acute, traumatic and chronic degenerative processes of the nervous system, such as Alzheimer's disease, senile dementia, Parkinson's disease, Huntington's chorea, amyotrophic lateral sclerosis and multiple sclerosis, psychiatric diseases such as schizophrenia and anxiety, depression, pain and drug dependency.
IT 114067-97-9P, 1-(4-Fluorophenyl)-1H-imidazole-4-carboxylic acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of (imidazol-4-yl)ethynylpyridines as metabotropic glutamate 5 receptor antagonists for treating neurodegenerative diseases, in particular anxiety)

L13 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 114067-97-9 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 1-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:573775 CAPLUS
DN 133:177164
TI Preparation of pyrazolecarboxamides and pyrrolecarboxamides as inhibitors of the proliferation of activated lymphocytes and as remedies for autoimmune disease.
IN Ushio, Hiroyuki; Ishibuchi, Seigo; Naito, Youichiro; Sugiyama, Naoki; Kawaguchi, Takafumi; Chiba, Kenji; Ohtsuki, Makio; Naka, Yoichi
PA Yoshitomi Pharmaceutical Industries, Ltd., Japan
SO PCT Int. Appl., 315 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000047558	A1	20000817	WO 2000-JP767	20000210
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2362381	AA	20000817	CA 2000-2362381	20000210
	NZ 514095	A	20010928	NZ 2000-514095	20000210
	EP 1176140	A1	20020130	EP 2000-902925	20000210
	EP 1176140	B1	20041229		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000008173	A	20021022	BR 2000-8173	20000210
	JP 3419395	B2	20030623	JP 2000-598479	20000210
	JP 2003176273	A2	20030624	JP 2002-375683	20000210
	AT 286026	E	20050115	AT 2000-902925	20000210
	ES 2234564	T3	20050701	ES 2000-902925	20000210
	US 7015218	B1	20060321	US 2001-913260	20011119
PRAI	JP 1999-33367	A	19990210		
	JP 1999-198473	A	19990713		
	JP 2000-598479	A3	20000210		
	WO 2000-JP767	W	20000210		

OS MARPAT 133:177164
GI

L13 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB The title compds. I (R1 represents substituted aryl, heteroaryl, etc.; R2 and R3 represent each hydrogen, alkyl, halogeno, hydroxy, etc.; Q represents N, CH, etc.; W represents hydrogen, alkyl, hydroxycarbonylalkyl, etc.; X represents halogeno, cyano, nitro, amino, etc.; X' represents hydrogen, halogeno, cyano or nitro; and Y represents alkyl, hydroxy, alkoxy, etc.) are prepared For example, pyrazolecarboxamide derivative II was prepared The title compds. are said to show significant inhibiting activity against the proliferation of activated lymphocytes in in vitro tests. A formulation is given.
IT 138907-81-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazolecarboxamides and pyrrolecarboxamides as inhibitors of the proliferation of activated lymphocytes and as remedies for autoimmune disease.)
RN 138907-81-0 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD

L13 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:176977 CAPLUS
DN 132:308284
TI Fluorine-sacrificial cyclizations as an access to 5-fluoropyrazoles
AU Volle, Jean-Noel; Schlosser, Manfred
CS Section de Chimie (BCh), Universite of Lausanne, Lausanne, CH-1015, Switz.
SO European Journal of Organic Chemistry (2000), (5), 823-828
CODEN: EJOCFK; ISSN: 1434-193X
PB Wiley-VCH Verlag GmbH
DT Journal
LA English
OS CASREACT 132:308284
AB Me 3-methoxy-2-trifluoromethylacrylate, readily prepared by Wittig reaction from Me 3,3,3-trifluoropyruvate, has been treated with a number of aryl(or heteroaryl)hydrazines. Under mild base catalysis, the resulting 3-hydrazinoacrylates undergo consecutive hydrogen fluoride elimination and intramol. nucleophilic addition to afford Me 1-(hetero)aryl-5-fluoropyrazole-4-carboxylates. 5-Aminopyrazoles have been obtained by direct reaction of Me 5-fluoro-1-phenylpyrazole-4-carboxylate with lithium amides, whereas 5-fluoro-1-phenylpyrazole-4-carboxamides have been formed by condensation of 5-fluoro-1-phenylpyrazole-4-carboxylic acid with amines.
IT 265986-57-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(fluorine-sacrificial cyclizations as access to 5-fluoropyrazoles)
RN 265986-57-0 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 5-fluoro-1-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 65 THERE ARE 65 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1992:83669 CAPLUS
DN 116:83669
TI Preparation of 3-(1-substituted-pyrazoyl)-2-oxindole derivatives as therapeutics
IN Goddard, Carl J.; Schulte, Gary R.
PA Pfizer Inc., USA
SO U.S., 14 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5064851	A	19911112	US 1990-557265	19900724
	WO 9201684	A1	19920206	WO 1991-US4043	19910612
	W: CA, FI, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
	EP 540614	A1	19930512	EP 1991-913692	19910612
	EP 540614	B1	19960821		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 05504773	T2	19930722	JP 1991-513041	19910612
	JP 2504659	B2	19960605		
	AT 141601	E	19960915	AT 1991-913692	19910612
	ES 2090345	T3	19961016	ES 1991-913692	19910612
	CA 2086432	C	19971216	CA 1991-2086432	19910612
	FI 107609	B1	20010914	FI 1993-263	19930122
PRAI	US 1990-557265	A	19900724		
	WO 1991-US4043	W	19910612		
OS	MARPAT 116:83669				
GI					

L13 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I





II

AB Title compds. I (R1 = H, C2-10 alkanoyl, C5-7 cycloalkylcarbonyl, C7-10 phenylalkanoyl, chlorobenzoyl, thenoyl, etc.; R2 = R13CO, R15R14NCO, C1-6 alkyl, wherein R13 = C1-6 alkyl, and R14, R15 = H, C1-6 alkyl; X1 = H, Br, Cl, F, F3C, O2N, etc.; Y1 = X1, etc; X2 = H, Br, Cl, F, C1-4 alkyl, O2N, CHO, C1-6 alkyl, etc.; Y2 = H, H2NCO, F3C, etc.) useful as analgesics and for treatment of rheumatoid arthritis, osteoporosis, etc. (no data), are prepared 1-Phenyl-4-pyrazolecarboxylic acid was combined with 1,1'-carbonyldiimidazole in DMF and stirred at room temperature under Ar for 2 h
after which it was added to a mixture of 5-chloro-2-oxindole-1-carboxamide and 4-(dimethylamino)pyridine in DMF at room temperature to give the title compound II.
IT **138907-81-0P 138907-82-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate in preparation of pyrazoyloxindole therapeutics)
RN 138907-81-0 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

L13 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 138907-82-1 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



L13 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1988:186744 CAPLUS
DN 108:186744
TI Preparation of arylimidazolecarboxylates as CNS agents
IN Biere, Helmut; Huth, Andreas; Rahtz, Dieter; Schmiechen, Ralph; Seidelmann, Dieter; Schneider, Herbert Hans; Stephens, David Norman
PA Schering A.-G., Fed. Rep. Ger.
SO Ger. Offen., 8 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3627155	A1	19880218	DE 1986-3627155	19860811
	WO 8801268	A1	19880225	WO 1987-DE342	19870730
	W: DK, JP, US				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	EP 282502	A1	19880921	EP 1987-904844	19870730
	EP 282502	B1	19910515		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	JP 01500521	T2	19890223	JP 1987-504627	19870730
	AT 63547	E	19910615	AT 1987-904844	19870730
	DK 8801384	A	19880314	DK 1988-1384	19880314
	DK 165951	B	19930215		
	DK 165951	C	19930705		
	US 4952698	A	19900828	US 1988-189511	19880411
PRAI	DE 1986-3627155	A	19860811		
	EP 1987-904844	A	19870730		
	WO 1987-DE342	W	19870730		
OS	CASREACT 108:186744; MARPAT 108:186744				
GI					



I

AB The title compds. [I; R1 = H, halo; R2 = H, C1-6 alkyl; R3 = (modified) carboxylate] were prepared as CNS agents (no data). Et 1,4-bis(dimethylamino)-2-aza-1,3-butadiene-3-carboxylate and 3-chloroaniline were stirred in HOAc at room temperature and then at 80° for 5 h to give 81% Et 1-(3-chlorophenyl)imidazole-4-carboxylate.
IT **114067-97-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as CNS agent)
RN 114067-97-9 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 1-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

L13 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



```
=> => d que l17 stat
L16             2 SEA FILE=REGISTRY ABB=ON  PLU=ON  (19749-51-0 OR 19749-55-4)/RN

L17             3 SEA FILE=CAPLUS ABB=ON  PLU=ON  L16


=> d 1-3 bib abs hitstr
```

L17 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1968:443835 CAPLUS
DN 69:43835
TI Benzonitrile oxide and nitrocinnamic acid derivatives
AU Monforte, Francesco; Lo Vecchio, Giacomo
CS Univ. Messina, Messina, Italy
SO Atti della Accademia Peloritana dei Pericolanti, Classe di Scienze Fisiche, Matematiche e Naturali (1966), 49, 169-81
CODEN: AAPFAO; ISSN: 0365-0359
DT Journal
LA Italian
GI For diagram(s), see printed CA Issue.
AB Compds. of the general formula I are prepared from the title oxide (II) and
nitrocinnamic acids. III is prepared from Et 3-phenyl-5-(o-nitrophenyl)-2-
isoxazoline-4-carboxylate (IV). Thus, a solution of II (prepared from PhCCl:NOH) and NaOH in ether is added to o-O2NC6H4CH:CHCO2Et and the mixture
kept in the dark 24-48 hrs. to give IV, m. 112°; a mixture of larger amts. of II, NaOH, and o-O2NC6H4CH:CHCO2Et is kept > 48 hrs. to give a mixture of IV, m. 112°, and a compound (V), m. 143-4°. It is suggested that V is the 4-(o-nitrophenyl)-5-carboxylate isomer of IV. A solution of IV in EtOH is exposed to sunlight 1 month at 45-55° to give III, m. 195-6°. IV is hydrolyzed (10% NaOH) to give I (R = CO2H, Ar = o-O2NC6H4) (VI), m. 165°. A solution of VI in EtOH is treated with a stream of HCl gas to give IV, m. 112°. A solution of II in ether is treated with o-O2NC6H2CH:CHCO2H in a small amount of Me2CO and the mixture heated 1.5 hrs. to give VI, m. 165°. VI is slowly heated to 165° to give I (R = H, Ar = o-O2NC6H4), m. 118°.
Similarly prepared are the following I (Ar = p-O2NC6H4) (R and m.p. given):
CO2Et, 94-5°; CO2H, 146°; H, 132-3°.
IT **19749-51-0P 19749-55-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 19749-51-0 CAPLUS
CN 2-Isoxazoline-4-carboxylic acid, 5-(p-nitrophenyl)-3-phenyl- (8CI) (CA INDEX NAME)



RN 19749-55-4 CAPLUS
CN 2-Isoxazoline-4-carboxylic acid, 5-(o-nitrophenyl)-3-phenyl- (8CI) (CA INDEX NAME)

L17 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L17 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1959:77767 CAPLUS
DN 53:77767
OREF 53:14088d-f
TI Relation between ethylene bond length and reactivity with benzonitrile oxide. II. Inductive effects of substituents in unsaturated carbonyl compounds
AU Vecchio, Giacomo Lo
CS Univ. Messina, Italy
SO Annali di Chimica (Rome, Italy) (1958), 48, 960-8
CODEN: ANCRAI; ISSN: 0003-4592
DT Journal
LA Unavailable
AB cf. C.A. 52, 14569e. Results of attempted reaction of XCH:CHCOZ with PhNCO to give isoxazolines are tabulated, and discussed in terms of the influence of substituents on the conjugation of the C:C and C:O bonds. An
increase in conjugation increases the length and decreases the reactivity of the C:C bond. The polarizing power of the substituents is calculated following Price (C.A. 35, 7379g), or, for substituted aryl groups, by calcn. of the charge distribution in the corresponding styrenes. The reactivity is highest if X is electropos. and Z electroneg. The anomalous
behavior of the nitrocinnamic acids, which may give 2- or 3-nitrophenyl-3-
or 2-isoxazolinecarboxylic acids, is explained in terms of the direction of polarization of the C:C bond to which 2 electron-attracting groups are attached.
IT **19749-51-0**, 2-Isoxazoline-4-carboxylic acid, 5-(p-nitrophenyl)-3-phenyl-
(and derivs., and related compds.)
RN 19749-51-0 CAPLUS
CN 2-Isoxazoline-4-carboxylic acid, 5-(p-nitrophenyl)-3-phenyl- (8CI) (CA INDEX NAME)



L17 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1955:1291 CAPLUS
DN 49:1291
OREF 49:296h-i,297a-i,298a-c
TI Benzonitrile oxide and nitrocinnamic derivatives
AU Monforte, Francesco; Vecchio, Giacomo Lo
CS Univ. Messina, Italy
SO Gazzetta Chimica Italiana (1953), 83, 416-30
CODEN: GCITA9; ISSN: 0016-5603
DT Journal
LA Unavailable
AB Application of the Quilico reaction by M. to the synthesis of isoxazolines
(C.A. 47, 4876h) was extended to nitrocinnamic derivs. for 2 reasons: (1) because the existence of 3 isomeric forms of the starting compound offered
the possibility of a still greater number of isomeric products, and (2) because the strongly electroneg. NO2 group would be expected to influence the course of the reaction. These predictions were confirmed by experiment
PhCN→O (I) and o-O2NC6H4CH:CHCO2Et (II) (equimolar amts.) in Et2O, allowed to stand 24 hrs. in darkness, evaporated, the yellowish oil allowed to
crystallize (24-48 hrs.), and the solid purified by hot EtOH, give Et3-phenyl-5-(o-nitrophenyl)-2-isoxazoline-4-carboxylate, o-O2NC6H4CH.O.N:CPh.CHCO2Et (III), m. 116°. Addition of a few drops of N NaOH (diluted with Me2CO) to III in Me2CO gives a yellow solution
Condensation of I and II, storage of the reaction mixture for a much longer
time than 48 hrs., and purification of the precipitate by EtOH yield Et 3-phenyl-4-(o-nitrophenyl)-2-isoxazoline-5-carboxylate (IV), m. 143-4°, giving in Me2CO with NaOH a violet-red solution The Et2O mother liquor of IV concentrated, the oil allowed to stand, and the crystalline
compound purified by EtOH gives III. When exposed to light, III turns successively yellow, dark red, and tobacco-brown. Microscopic examination
showed products of different colors, but attempts at separation by crystallization were
fruitless. However, saturated alc. III, exposed many days at 45-55° to sunlight, turned increasingly intense yellow, red, and ruby-red, with separation of an intensely ruby-red crystalline compound (V), which, purified by EtOH,
gave the azo compound, C36H32O6N4, probably [O.N:CPh.CH(CO2Et).CHC6H4N:]2,
m. 195-6°. The exposed solution after separation of V contained AcH and, when evaporated, yielded only an intensely colored pitch. Aqueous NaOH (10%) added
dropwise to III in Me2CO, the mixture allowed to stand, acidified with dilute
H2SO4, and the precipitate purified by EtOH gives free acid (VI), m. 165° (evolution of CO2). Dry HCl passed through a saturated solution of VI in anhydrous
EtOH, the mixture allowed to stand, and the precipitate washed with aqueous Na2CO3 and
water and purified by EtOH, yields III. Heated cautiously, VI fuses to a yellowish liquid which evolves CO2; the cooled and solidified residue washed free of undecompd. VI and purified by EtOH, gives 3-phenyl-5-o-nitrophenyl-2-isoxazoline, m. 118°. Prepared like III, the Me ester (VII), m. 149-50°, turns yellow under the same
conditions as does III, and by saponification gives VI. A secondary product,

L17 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
isolated by evapn. of the Et2O soln. from which VII was recovered and purified by MeOH, is Me 3-phenyl-4-(o-nitrophenyl)-2-isoxazoline-5-carboxylate (VIII), m. 115-16°, little affected by exposure to light, and giving with NaOH and Me2CO violet-red solns. Sapon. of VIII is
difficult, but by cautious operation at relatively low temps. it is possible to obtain, after purification by hot EtOH, the free acid, decomp.
above 250° (evolution of CO2). Condensation of I in Et2O with a suspension of o-O2NC6H4CH:CHCO2H in Me2CO by heating on a steam bath 90 min., evapg., allowing the yellow oil to crystallize, washing it free of diphenylfuroxan with aq. Na2CO3, neutralizing the alk. soln. with H2SO4, removing the viscous red-yellow solid mechanically, acidifying the filtered liquid, and purifying the ppt. by EtOH, gives VI. Under the conditions used in prepg. III, a notable proportion of p-O2NC6H4CH:CHCO2Et (IX) does not react with I, but removal of the unaltered IX, evapn., and purification by EtOH, gives Et 3-phenyl-5-(p-nitrophenyl)-2-isoxazoline-4-carboxylate (X), m. 94-5°, turns NaOH in Me2CO yellow; exposure to light turns it yellow. The alc. mother liquor, allowed to stand several days, ppts. Et 3-phenyl-4-(p-nitrophenyl)-2-isoxazoline-5-carboxylate, m. 90°, stable in light, turns NaOH in Me2CO an intense blue changing slowly to red. Attempts to saponify it were fruitless. Aq. NaOH (10%) added dropwise to the calcd. amt. of X in very cold Me2CO (the least excess of NaOH turns the soln. red because of secondary products, which are even more readily formed in alc. medium and at temps. above 0°), the yellow soln. neutralized with dil. H2SO4, the viscous yellow-red product sepd. mechanically and by filtration, the filtrate allowed to stand, and the ppt. purified by aq. Me2CO (1:1) yields
the free acid (XI), m. 146° (decompn.), giving with SOCl2 the acid chloride (XII), m. 101°. In anhyd. Et2O with dry NH3, XII gives, after purification by Me2CO, the amide (XIII), m. 236-7°, turns NaOH in Me2CO yellow. Condensation of I with p-O2NC6H4CH:CHCONH2 (XIV) was studied under various conditions because of the insoly. of XIV in Et2O. XIV added to I in Et2O, the mixt. treated successively with anhyd. EtOH and Me2CO with agitation, refluxed 90 min., decanted, the clear liquid again heated, and the ppt. purified by Me2CO gives XIII. On prolonged standing, the mother liquor ppts. a substance which, purified by
Me2CO, yields 3-phenyl-4-(p-nitrophenyl)-2-isoxazoline-5-carboxamide, m. 147°, turns NaOH in Me2CO blue, changing to red. Under the conditions used for prepg. X, I, and p-O2NC6H4CH:CHCO2Me give, from MeOH, Me 3-phenyl-5-(p-nitrophenyl)-2-isoxazoline-4-carboxylate (XV), m. 115-17°, turns NaOH in Me2CO yellow; sapond. like X, XV gives XI. The mother liquor of XV does not, either on long standing or by concn., yield the isomeric compd. p-O2NC6H4CH:CHCO2H, added in small portions to I
in Me2CO, the mixt. refluxed 2 hrs., filtered, the filtrate evapd. slowly,
the oil allowed to solidify, the product washed with aq. Na2CO3, the alk. soln. neutralized with H2SO4, the viscous reddish yellow substance removed, the soln. acidified, and the ppt. purified by aq. Me2CO, yields XI. Attempts to condense I with m-O2NC6H4CH:CHCO2Et (XVI) at different temps. and concns. left in all cases the XVI entirely unaltered. The exptl. results, in conjunction with the earlier expts. on compds. contg. no NO2 group (loc. cit.), show that the condensation compds. can be

L17 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
rationally classified in 2 groups: (1) those with the carboxyl group in the 4-position, and (2) those with this group in the 5-position. Group 1 represents the primary and chief products of the condensation, the esters of which can be sapond. with relative ease, the acids of which can easily be decarboxylated, and which turn even an extremely dil. soln. of NaOH in Me2CO yellow. Group 2 represent essentially secondary products of the condensation reaction, which are formed in relatively low yields, are difficult to saponify, do not yield the corresponding isoxazolines, and turn NaOH in Me2CO red.

IT **19749-51-0**, 2-Isoxazoline-4-carboxylic acid, 5-[p-nitrophenyl]-3-phenyl- **19749-55-4**, 2-Isoxazoline-4-carboxylic acid, 5-[o-nitrophenyl]-3-phenyl-
(and esters)

RN 19749-51-0 CAPLUS

CN 2-Isoxazoline-4-carboxylic acid, 5-(p-nitrophenyl)-3-phenyl- (8CI) (CA INDEX NAME)



RN 19749-55-4 CAPLUS

CN 2-Isoxazoline-4-carboxylic acid, 5-(o-nitrophenyl)-3-phenyl- (8CI) (CA INDEX NAME)



```
=> => d que l24
L19          112 SEA FILE=CAPLUS ABB=ON  PLU=ON  "JIANG SHIBO"/AU
L20           67 SEA FILE=CAPLUS ABB=ON  PLU=ON  ("DEBNATH ASIM K"/AU OR
                 "DEBNATH ASIM KUMAR"/AU)
L21          151 SEA FILE=CAPLUS ABB=ON  PLU=ON  L19 OR L20
L22           92 SEA FILE=CAPLUS ABB=ON  PLU=ON  L21 AND HIV
L24            2 SEA FILE=CAPLUS ABB=ON  PLU=ON  L22 AND (PYRROL?)


=> d 1-2 bib abs
```

L24 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:988741 CAPLUS
DN 142:85863
TI N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion
AU **Jiang, Shibo**; Lu, Hong; Liu, Shuwen; Zhao, Qian; He, Yuxian; **Debnath, Asim K.**
CS Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA
SO Antimicrobial Agents and Chemotherapy (2004), 48(11), 4349-4359
CODEN: AMACCQ; ISSN: 0066-4804
PB American Society for Microbiology
DT Journal
LA English
AB A recently approved peptidic human immunodeficiency virus type 1 (HIV-1) fusion inhibitor, T-20 (Fuzeon; Trimeris Inc.), has shown significant promise in clin. application for treating HIV -1-infected individuals who have failed to respond to the currently available antiretroviral drugs. However, T-20 must be injected twice daily and is too expensive. Therefore, it is essential to develop orally available small mol. HIV-1 fusion inhibitors. By screening a chemical library consisting of "drug-like" compds., the authors identified two N-substituted pyrroles, designated NB-2 and NB-64, that inhibited HIV-1 replication at a low micromolar range. The absence of the COOH group in NB-2 and NB-64 resulted in a loss of anti-HIV-1 activity, suggesting that this acid group plays an important role in mediating the antiviral activity. NB-2 and NB-64 inhibited HIV-1 fusion and entry by interfering with the gp41 six-helix bundle formation and disrupting the α-helical conformation. They blocked a D-peptide binding to the hydrophobic pocket on surface of the gp41 internal trimeric coiled-coil domain. Computer-aided mol. docking anal. has shown that they fit inside the hydrophobic pocket and that their COOH group interacts with a pos. charged residue (K574) around the pocket to form a salt bridge. These results suggest that NB-2 and NB-64 may bind to the gp41 hydrophobic pocket through hydrophobic and ionic interactions and block the formation of the fusion-active gp41 core, thereby inhibiting HIV-1-mediated membrane fusion and virus entry. Therefore, NB-2 and NB-64 can be used as lead compds. toward designing and developing more potent small mol. HIV-1 fusion inhibitors targeting gp41.
RE.CNT 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
HIV replication only when they were added to the cells less than one hour after virus addn.; (3) they did not block the gp120-CD4 binding; (4) they did not interact with the co-receptor CXCR4 since they failed to block anti-CXCR4 antibody binding to CXCR4-expressing cells; (5) they blocked the formation of the gp41 core that is detected by sandwich enzyme linked immunosorbent assay (ELISA) using a conformation-specific Mab NC-1; (6) they inhibited the formation of the gp41 six-helix bundle revealed by fluorescence native-polyacrylamide gel electrophoresis (FN-PAGE); and (7) they blocked binding of D-peptide to the hydrophobic cavity within gp41 coiled coil domain, modeled by peptide IQN17. These results suggested that NB-2 and NB-64 may interact with the hydrophobic cavity and block the formation of the fusion-active gp41 coiled coil domain, resulting in inhibition of HIV-1 mediated membrane fusion and virus entry.

L24 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:467690 CAPLUS
DN 141:17579
TI Substituted N-phenylpyrrole compounds for inhibition of HIV infection by blocking HIV entry
IN **Jiang, Shibo; Debnath, Asim Kumar**
PA New York Blood Center, USA
SO PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004047730	A2	20040610	WO 2003-US36359	20031112
	WO 2004047730	A3	20040916		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003294275	A1	20040618	AU 2003-294275	20031112
	EP 1567491	A2	20050831	EP 2003-789757	20031112
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2004116427	A1	20040617	US 2003-706027	20031113
PRAI	US 2002-428055P	P	20021121		
	WO 2003-US36359	W	20031112		

OS MARPAT 141:17579
GI



AB A group of compds. that inhibit HIV replication by blocking HIV entry was identified. Two representative compds., designated NB-2 (I) and NB-64 (II), inhibited HIV replication (p24 production) with IC50 values < 0.5 μg/mL. It was proved that NB-2 and NB-64 are HIV entry inhibitors by targeting the HIV gp41 since: (1) they inhibited HIV-mediated cell fusion; (2) they inhibited

=>